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Abstract 
The aim of this project was to investigate pharmacological methods of overcoming resistance 
in cancer. Novel compounds, targeted therapies and non-steroidal anti-inflammatory drugs 
(NSAIDs) were examined for their potential to modulate and manipulate specific forms of 
drug resistance.  
Sixty one novel compounds were tested in combination with chemotherapeutic drugs in 
proliferation assays for their ability to overcome MRP1 and P-gp-mediated drug resistance. 
Two compounds were successful P-gp modulators in the DLKP-A cell line; the 
ditrifluoroacetyl resveratrol derivative, RBM15, and the macrocycle derivative, KG104.  
A panel of nine therapeutic agents were evaluated for their potential to down-regulate 
multidrug resistant protein expression and thus, overcome P-gp, MRP1 or BCRP-mediated 
drug resistance, at and below pharmacologically-relevant concentrations. Two of these agents 
(indomethacin and 17-AAG) partially down-regulated the expression of P-gp in the A549-
Taxol cell line but did not overcome P-gp-mediated resistance when combined with docetaxel 
simultaneously or in pre-treated proliferation assays. Three agents (lapatinib, sulindac 
sulphide and 17-AAG) reduced the expression of MRP1 in the A549 cell line. Only sulindac 
sulphide overcame MRP1-mediated resistance in the combination proliferations assays; 
however, this was due to the inhibitory mechanism of sulindac sulphide and not due to the 
down-regulation of the MRP1 protein. Five agents (17-AAG, lapatinib, indomethacin, 
elacridar and gefitinib) down-regulated the expression of BCRP in the DLKP-SQ/mitox cell 
line.  Lapatinib, gefitinib, elacridar and 17-AAG overcame BCRP-mediated resistance in both 
the combination and pre-treatment proliferation assays. The data indicates that the amount of 
down-regulation resulting from treatment with these drugs was insufficient to overcome drug 
resistance. Up-regulation of the three MDR transporter proteins was observed with a variety 
of agents tested. This suggests that, long-term treatment with such agents could lead to the 
development and amplification of multidrug resistance, and therefore, reduce the 
effectiveness of substrate chemotherapies in patients.  
Targeted therapies, including tyrosine kinase inhibitors (TKIs, such as lapatinib), are the latest 
significant development in the treatment of cancer. Lapatinib sensitised HER2-expressing cell 
lines to chemotherapeutic agents in the presence or absence of EGFR expression. This agent 
was also found to be a more active sensitiser in P-gp-expressing cell lines, while erlotinib was 
more active in BCRP-expressing cell lines. Gefitinib was the least active of three TKIs at 
modulating P-gp, MRP1 or BCRP. Following a 48 hours treatment, lapatinib up-regulated the 
expression and function of COX-2. It also stimulated COX-2 activity directly. This lapatinib-
mediated COX-2 induction was independent of its TKI action on EGFR, and HER2 and could 
have serious therapeutic effects as COX-2 is known to increase cell growth, inhibit apoptosis, 
and enhance metastasis and angiogenesis.  
A COX-2-specific inhibitor, celecoxib, overcame P-gp, MRP1 and BCRP-mediated resistance. 
At pharmacologically relevant concentrations, celecoxib significantly overcame MRP1 and 
BCRP-mediated resistance. And to a much lesser extent celecoxib overcame P-gp mediated 
resistance above pharmacologically relevant concentrations. The combination of lapatinib 
with celecoxib could be of therapeutic benefit, as the combination of these agents could 
collectively inhibit COX-2, P-gp, MRP1, BCRP, HER2 and EGFR activity in tumours 
expressing multiple oncoproteins resistant pathways and enhanced signalling pathways.  
It is hoped that a novel treatment regimens, using these agents and TKI drugs with traditional 
chemotherapeutic agents, could improve current treatment strategies resulting in increased 
survival rates and decreased mortality.   
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Section 1. 
 
 
Introduction 
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1.1. Cancer: History and Treatment 
 
Cancer is a term used for a group of diseases, in which abnormal cells divide uncontrollably 
and are able to invade other tissues. More than a hundred types of cancers have been 
identified and are generally named after the organ in which they are found, i.e. lung cancer, 
colon cancer, breast cancer, etc. As cancer has a high mortality rate, intelligent ways to 
inhibit its progress and development and therefore, increase the survival and remission for 
cancer patients, have been researched for the past 70 years. Current treatments include 
surgical excision of the tumour, radiotherapy, chemotherapy, immunotherapy and 
combinations of all of the above.  
Research has identified a number of biological markers associated with the aggressive growth 
and drug resistance in cancer. Recent discoveries into the understanding of these biological 
markers or pro-oncoproteins, (such as; multi-drug resistant (MDR) proteins, epidermal 
growth factor receptors (EGFR), and cyclooxygenase enzymes (COX-2) (reviewed in 
sections 1.4, 1.5.1 and 1.6)) have led to a new approach in the anti-cancer strategy employed 
in the laboratory and clinic. Some recently developed drugs that were found to inhibit these 
oncoproteins include tyrosine kinase inhibitors (against EGFR family [1]), non-steroidal anti-
inflammatory drugs (against COX-2 [2]) and ERK/P13K/Hsp90 [3] signalling pathway 
inhibitors. It is hoped that pharmacodynamic information and an intrinsic mechanistic 
understanding of how these targeted therapies function in individual patients will improve 
current treatment strategies resulting in increased survival rates and decreased mortality.   
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1.2. Cancer Chemotherapy 
 
Conventional drug treatment of cancer involves treatment with cytotoxic chemotherapy drugs 
that directly cause cancer cell death. These cytotoxic drugs can damage cells in target organs 
in a variety of ways by causing cellular injury leading to a complex sequence of events. The 
eventual response may be reversible injury or an irreversible change leading to the death of 
the cell. These toxic compounds have proven very helpful in the reduction or cure of some 
cancers. Their action can be through interfering with cell growth, antagonising proteins 
associated with an aggressive phenotype, interfering with DNA repair mechanisms, 
preventing unzipping of the double helical strands of DNA, inhibiting mitosis and 
angiogenesis and by causing or promoting apoptosis (see table 1.2.1.). 
Chemotherapy is generally most useful against tumours with a high proportion of dividing 
cells, such as leukaemia. Some of the more common malignant tumours, i.e. solid tumours 
including colorectal, lung and breast tumours, usually have a lower proportion of dividing 
cells that in some cases are less susceptible to treatment by chemotherapy. However, some 
normal tissues, i.e. bone marrow and gastrointestinal tract (GIT) [4], also have a high 
proportion of dividing cells. The side effects of chemotherapy are different depending on the 
person, the drugs, and the drug doses, and can be acute (short-term), chronic (long-term) or 
permanent. A few of these side-effects include: neurotoxicity, cardiotoxicity, nausea, 
vomiting, anemia, infertility or respiratory problems. The clinical effectiveness of a 
chemotherapeutic drug necessitates that the dose administered must allow enough cells in a 
patient’s normal tissues (bone marrow, GIT etc) to survive and allow the patient to recover, 
while killing as many malignant tumour cells as possible [4].  
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1.2.1. Agents used in Cancer treatment. 
A variety of chemotherapeutic agents are used in the treatment of malignancies. They vary in their cellular targets, mechanism of action and 
types of cancer they are used to treat. The major compounds are classified in table 1.2.1.1., along with the diseases that the chemotherapeutic 
agents are used to treat: 
Table 1.2.1.1.: Below is a table that contains a list of chemotherapeutic drugs, their classes, names, primary mechanisms and types of 
cancers treated by them. 
Class Type of agent Name 1o Mechanism of action Cancer treated 
Natural products Antibiotics Daunorubicin intercalation of the planar ring with DNA and 
subsequent inhibition of DNA and RNA synthesis. 
Acute myeloid leukemia; acute 
lymphocytic leukemia  
  Doxorubicin Intercalation of the planar ring with DNA and 
subsequent inhibition of DNA and RNA synthesis. 
Osteogenic sarcoma, Hodgkin’s & non-
Hodgkin’s disease, breast, lung, thyroid and 
stomach cancer, neuroblastoma and 
genitourinary cancer. 
  Epirubicin Intercalation of the planar ring with DNA and 
subsequent inhibition of DNA and RNA synthesis. 
Breast; lung; lymph system; stomach; and 
ovaries 
 Vinca Alkaloids 
 
Vincristine Inhibits formation of microtubules Brain; breast; lung; leukaemia; melanoma 
and many more. 
  Vinblastine Inhibits formation of microtubules. Breast; bladder; Hodgkin’s; lung; testicular. 
 Taxanes Paclitaxel Render microtubules resistant to depolymerisation. Ovarian; non-small cell lung; prostate; and 
many more. 
  Docetaxel Render microtubules resistant to depolymerisation. Breast; non-small cell lung; prostate; and 
more 
 Epipodophyllotoxins Etoposide 
Teniposide 
Topoisomerase II inhibitors Testicular, lung, and breast cancer, 
Hodgkin’s and non-Hodgkin’s disease, 
acute granulocytis carcinoma, Kaposi’s 
sarcoma.  
 Camptothecins Topotecan 
Irinotecan 
Topoisomerase I inhibitors Ovarian, lung and colon cancer 
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Class Type of agent Name 1o Mechanism of action Cancer treated 
Miscellaneous Anthracenedione Mitoxantrone Topoisomerase II inhibitor Acute granulocytic carcinoma, pancreatic 
and breast cancer. 
 Platinum complexes Cisplatin 
Carboplatin 
Inhibit DNA through covalent binding leading to 
intra-strand, inter-strand, and protein cross-linking 
of DNA. 
Bladder; lung; breast; testicular; ovarian; 
brain and many more. 
 
 Alkylating agents Chlorambucil Binds to DNA double helix, preventing it from 
unzipping and thus replicating hence cells cannot 
reproduce. 
Immunosuppressive agent;  
Antimetabolites Folic acid analogue Methotrexate Folate synthase inhibitor Acute lymphocytic leukaemia, breast, lung, 
head and neck cancer, estrogenic sarcoma. 
 Pyrimidine analogue Fluorouracil 
(5-Fu) 
DNA destabilisation Breast, colon, stomach, pancreatic, ovarian, 
head and neck cancer 
  Gemcitabine DNA destabilisation Pancreatic and ovarian cancer. 
 
This table was derived from the following references: [5] [6] [7] [8] [9] [10] [11] [12] [13] [14].
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The Anthracycline, Epirubicin 
 
Different anthracycline derivatives have been used successfully in the treatment of a 
wide spectrum of cancers for over two decades. Epirubicin is the 4`-epi-isomer of 
doxorubicin which is an anti-neoplastic antibiotic originally obtained from 
Streptomyces peucetius (see figure 1.2.1.1 for the structure of epirubicin) [15].  
Intracellular production of free radicals along with intercalation with DNA and 
subsequent inhibition of topoisomerase II are generally accepted as the major 
mechanisms of anthracycline cytotoxicity [16] [17]. Anthracycline-produced free radicals 
can be generated by both enzymatic and non-enzymatic mechanisms [18] [19]. Free 
radicals may cause damage to biological molecules such as DNA. They can produce 
different kinds of DNA lesions, among which are free radical-modified DNA bases [20]. 
Base damage appears to be an important class of lesions because some of them may 
possess mutagenic properties and may lead to carcinogenesis [20] [21]. Thus, the 
observed mutagenicity of anthracyclines may be, at least in part, attributed to the 
generation of reactive oxygen species [16]. 
 
O
CH3
O
O OH
OH O
OH
O
O CH3
NH2
OH
OH
 
 
 Figure 1.2.1.1.: The chemical structure of epirubicin [15]. 
 
Anthracyclines are widely used and effective anti-neoplastic drugs. Although active 
against a wide variety of solid tumours and haematological malignancies, their 
clinical use is hindered by tumour resistance and toxicity to healthy tissues [22].  
Resistance to the three anthracyclines (daunorubicin, doxorubicin and epirubicin) is 
mainly established through over-expression of mdr1 and its protein, P-glycoprotein 
(P-gp), in cancer cells [15] [23] (Discussed later in section 1.4.2.) 
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The two major side effects of the anthracyclines are cardio-toxicity following long-
term treatment and haemo-toxicity experienced following acute exposure. Increased 
distribution in tumours, prolonged circulation and reduced free drug concentrations in 
plasma may increase anti-tumour activity and improve the tolerability of the 
anthracyclines [24]. Therefore, understanding the pharmacokinetics of epirubicin in 
patients is essential for treatment and management of side effects.  The plasma 
concentration of epirubicin varies depending on the dose and method of 
administration. The most common form of administering epirubicin is by intravenous 
delivery. This can result in an area under the curve (AUC) of between 1.6 and 4.2 
µg·h/mL and a Cmax of between 5.7 and 9.3 µg/ml with a half life of 30 to 35 hours 
[25]. All concentrations used in this project fall below the AUC values. 
 
Taxanes 
 
Paclitaxel and docetaxel are the most prominent members of the taxane family of 
cancer drugs. Paclitaxel is a natural product isolated from the bark of the Pacific yew 
tree, Taxus brevifolia. The anti-tumour activity of the yew bark extract was 
discovered through a plant screening program in the 1960s. Docetaxel is a semi-
synthetic product derived from the needles of the European yew, Taxus baccata. Both 
share the tricyclic taxane skeleton but have different substitutes at the c-10 and c-13 
side chains (Figure 1.2.1.2).  
 
Figure 1.2.1.2.: Docetaxel and paclitaxel structures [26]. 
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Despite similar structures, docetaxel and paclitaxel exhibit noticeable differences in 
pharmacological properties. Gligorov and Lotz [27], summarise the major differences. 
 
Docetaxel: 
 
• Exhibits greater uptake into, and slower efflux from, tumour cells (P388, 
murine leukaemia cell line). 
• Exhibits greater affinity to the β-tubulin subunit of microtubules. 
• Targets centrosome organisation. 
• Acts on cells in the S/G2/M stages of the cell cycle. 
• Demonstrates linear pharmacokinetics and no cardiotoxic effects in 
combination with anthracyclines. 
 
Paclitaxel: 
 
• Targets the mitotic spindle. 
• Acts on cells in the G2/M phase of the cell cycle. 
• Demonstrates non-linear pharmacokinetics and enhanced cardio-toxicity, 
especially in combination with the anthracyclines. 
 
Docetaxel and paclitaxel share a unique mechanism of cytotoxic action. Both agents 
promote assembly of tubulin proteins into microtubules, and render them resistant to 
depolymerisation. Treated cells are blocked in the G2/M phase of the cell cycle giving 
rise to mitotic arrest [28]. Both taxanes bind to the β-subunit of tubulins, but the 
microtubules produced by docetaxel are larger than those produced by paclitaxel. This 
may explain why docetaxel appears to be two to four times more potent than 
paclitaxel [26].  
 Both taxanes cause Bcl-2 phosphorylation leading to apoptosis but the concentration 
of docetaxel needed to cause apoptosis through Bcl-2 is 100 times less than paclitaxel 
[29]. Bcl-2 is an anti-apoptotic protein over-expressed in a number of tumours. 
Paclitaxel increases Raf 1, a serine/threonine protein kinase involved in the MAPK 
pathway and Bcl-x, leading to decreased levels of Bcl-2 [30]. Once activated, Raf-1 can 
phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which 
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in turn phosphorylate to activate the serine/threonine specific protein kinases ERK1 
and ERK2. 
To date, two main mechanisms of taxane resistance have been identified; through 
increased expression of P-glycoprotein [31] [32] (discussed later in section 1.4.2.) and 
tubulin mutations leading to alterations in microtubule binding activity [33]. 
Similar to epirubicin, the main method of taxane administration in the clinic is 
through intravenous delivery. This method results in an AUC of between 6300 and 
15007 µg.h/ml and a Cmax between 195 and 3650 µg/ml with a half life of 13 to 53 
hours [25].  
In 2008, data combined from eleven clinical trials showed that patients receiving 
taxanes (paclitaxel or docetaxel) for the treatment of newly diagnosed advanced 
breast cancer lived about as long as those receiving anthracyclines (epirubicin or 
doxorubicin). As single agents, however, the anthracyclines offered better 
progression-free survival. Combinations based on sensitising cancer cells to taxane 
treatment, by targeting epidermal growth factor receptor family or multidrug 
resistance, provided better response rates and also better progression-free survival 
than those based on anthracyclines [34]. 
 
1.3. Pharmacokinetics of cancer drugs  
 
Pharmacokinetics is a branch of pharmacology dedicated to the determination of the 
fate of substances administered to a living organism. Pharmacokinetics includes the 
study of the mechanisms of absorption and distribution of an administered drug, the 
rate at which a drug action begins and the duration of the effect, the chemical changes 
of the substance in the body and the effects and route of excretion of the metabolites 
of the drug.  
The majority of chemotherapeutic drugs are intravenously administered while many 
small molecule agents (discussed in section 1.4.5.) are orally administered. Biological 
factors that alter the distribution and elimination of intravenously administered drugs 
include plasma transport proteins (discussed in sections 1.3.4 and 1.3.5.), such as 
albumin and α1-acid glycoprotein and ABC transport pumps [35] (discussed in section 
1.4.) such as P-glycoprotein (P-gp), multidrug resistance protein-1 (MRP1) and breast 
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cancer resistance protein (BCRP) (see section 1.3.2.). The pharmacokinetics of orally 
administered drugs are influenced by tissue membranes [36], such as the 
gastrointestinal tract and liver, plasma transport proteins and ABC transport pumps. In 
relation to ABC transport pumps, it is clear that they are saturable, inducible, can be 
inhibited and display some degree of polymorphism – these are factors that need to be 
considered with respect to variability in drug disposition and response [37]. 
 
1.3.1. Role of the gastrointestinal tract in orally administered drug distribution 
 
Drug absorption across the gastrointestinal tract can be highly dependent upon ABC 
transport pump affinity as well as lipophilicity. ABC transport pumps can be involved 
in the active absorptive (influx) of compounds, such as amino acids, oligopeptides, 
monosaccharides, mono- and dicarboxylic acids, bile acids, and several water-soluble 
vitamins from the lumen into the portal bloodstream [38] [39]. They are also responsible 
for the reduced absorption of anti-cancer agents. For example, the expression of 
BCRP in the gastrointestinal tract reduces the bioavailability of irinotecan [40]. 
Similarly, cyclosporine absorption in man is decreased by intestinal P-gp. There is a 
greater decrease in its absorption from the colon due to P-gp expression resulting in 
variations of its levels found in the blood [41]. Therefore, preclinical and clinical 
studies clearly demonstrate that P-gp-mediated intestinal efflux not only limits 
absorption of anti-cancer drugs, but also can result in variable and non-linear oral 
pharmacokinetics [42].  
 
1.3.2. Role of the liver in cancer drug distribution 
 
The liver plays a key role in the clearance and excretion of many cancer drugs. 
Hepatobiliary excretion of these agents from the blood, through the hepatocyte, and 
into the bile can be considered a three-step process. 
The first step involves the uptake of anti-cancer drugs from blood into the hepatocyte. 
A significant number of anti-cancer drugs can be transported into hepatocytes via the 
sinusoidal (basolateral) membranes [43]. 
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Once inside the hepatocyte the anti-cancer drug is transferred to metabolic sites and 
/or the biliary canalicular membrane, which is mediated by intracellular transfer 
proteins and passive diffusion [44]. The degree of metabolic biotransformation of anti-
cancer drugs is highly dependent upon their physicochemical properties and structure-
metabolism relationship [45]. 
The third step of biliary excretion, at the canalicular membrane, can involve mainly 
unchanged drug, metabolites or a combination of both parent drug and metabolites. 
Many carrier proteins have been shown to be present on the canalicular membrane to 
mediate this process [46] [47].  
1.3.3. Transport of intravenous and orally administered anti-cancer agents via 
the blood system. 
Serum transport proteins, such as serum albumin and α1-acid glycoprotein (AAG), 
play a major role in the binding, distribution, and thus potency, of anti-cancer agents 
transported in the blood [48]. The average human has 5 litres of blood in his body. 55% 
of the blood is made up of plasma constituting the fluid part of the blood. The cells 
and platelets that are present in our blood make up the other 45%.  Plasma is made up 
of water (90%), proteins, (8%) inorganic ions (0.9%) and organic substances (1.1%).  
The plasma proteins include serum albumin, serum globulin (including α1-acid 
glycoprotein), fibrinogen, and prothrombin.  
These proteins are mainly involved in: 
• Transportation of substances with low solubility, such as drugs, around the 
body by allowing them to bind to protein molecules.  
• Blood clotting 
• Inflammatory response 
• Protection from infection via gamma globulin function  
• Balancing pH of the blood  
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1.3.5. The role of serum albumin in drug transport 
 
Serum albumin is a highly soluble single polypeptide that is manufactured in the liver 
and isn’t stored. It is present at approximately 40 mg/ml (600 µM) in the plasma. 
Serum albumin is important for the transport of drugs (including anti-cancer drugs), 
maintenance of colloidal osmotic pressure, free radical scavenging, platelet function 
inhibition and anti-thrombotic effects as well as control of vascular permeability. 
Serum levels of albumin can decrease due to decreased synthesis, increased 
catabolism, increased loss (nephrotic syndrome), exudative loss (in burns, 
haemorrhage), and redistribution (haemodilution, increased capillary permeability, 
decreased lymph clearance). Albumin has the highest affinity for drugs with acidic or 
strong electronegative functional groups and is less easily saturated than other 
transport proteins, such as AAG (see next section). 
To date, it has been demonstrated that serum albumin is crucial for the distribution, 
elimination and effectiveness via binding of drugs such as digoxin, NSAIDs [49], 
midazolam, warfarin, thiopentone, tamoxifen, digitoin, and cancer drugs such as the 
anthracyclines [50] and taxanes etc. [51] [52].  
 
1.3.6. The role of Alpha-1 acid glycoprotein (AAG) in drug transport 
 
AAG (or orosomucoid) is a major glycoprotein of human plasma. It is produced by 
the liver and is an acute-phase reactant - i.e. its concentration in the blood can 
increase by up to 280-fold following stress, inflammatory response [53], pregnancy, 
and neoplasia. AAG has been reported to be taken up avidly in rats by tumours and 
granulomas [54]. The possibility that AAG regulates immune responses has been 
suggested by several findings [55] [56]. There is a strong similarity between the amino 
acid sequences in AAG and immunoglobulin.  Detected on the surface of human 
lymphocytes, AAG inhibits proliferation of lymphocytes stimulated with the mitogen 
phytohemagglutinin or with allogeneic cells [57] and interferes with phagocytosis of 
bacteria by macrophages [58].  
AAG is a 40 kDa protein present in the plasma at an approximate concentration of 0.8 
mg/ml (20 µM).  Basic drugs are often selectively bound to AAG with high affinity. 
Chassany O., et al. [59], investigated the in vitro binding potential of AAG to a range 
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of anthracycline derivatives and found that the hydrophobicity of the anthracycline 
derivatives was directly related with the percentage binding. Iododoxorubicin was the 
most highly bound (94%) while epirubicin (31%) had the least affinity for AAG. The 
impact of this variation on anthracycline distribution, bioavailability and potency has 
yet to be investigated.  
Since a protein-bound drug is generally considered to be too large to pass through 
most cell membranes to exert pharmacological actions, protein binding can affect the 
potency of drugs that exert pharmacological actions intracellularly. Sham HL., et al, 
[60] found that the magnitude of this effect could be estimated by the reduction of in 
vitro potency of a compound in the presence or absence of exogenously added serum. 
 
1.4. MultiDrug Resistance in Cancer 
 
MultiDrug Resistance (MDR) is a major cause of chemotherapeutic treatment failure. 
MDR is a phenomenon whereby tumour cells, which have been exposed to one 
cytotoxic agent, develop cross-resistance to a range of structurally and functionally 
unrelated compounds. This resistance is often due to elevation in the expression of 
cellular proteins, such as cell membrane transporters, which can result in an increased 
efflux of cytotoxic drugs from the cancer cells [61]. One such family of proteins are the 
transport proteins belonging to the ATP-binding cassette (ABC) family. Other 
mechanisms that can mediate the development of MDR include decreased drug 
uptake into the cell, activation of detoxifying enzymes (ROS), and defective apoptotic 
pathways [61].  
Most of the drugs effluxed by MDR pump proteins are natural products derived from 
plants (taxanes) and micro-organisms; examination of their chemical structures 
reveals no common chemical features, but these drugs commonly display 
hydrophobic regions and are often positively charged at physiological pH [62].  
The cytotoxic drugs that are most frequently associated with MDR are hydrophobic, 
amphipatic natural products, such as taxanes (paclitaxel, docetaxel), vinca alkaloids 
(vinorelbine, vincristine, and vinblastine), anthracyclines (doxorubicin, daunorubicin, 
and epirubicin), epipodophyllotoxins (etoposide, teniposide), topotecan, dactinomycin, 
and mitomycin C [32] [63]. 
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1.4.1. ATP-binding-cassette (ABC) transport systems 
 
The ATP-binding cassette (ABC) transport proteins are a superfamily consisting of a 
broad range of intra-cellular and transmembrane proteins that transport solutes in and 
out of the cell. The ABC transporters comprise of an extremely diverse class of 
membrane transport proteins that couple the energy of ATP hydrolysis to 
translocation of solutes across biological membranes [64]. The sequence and 
organisation of their ATP-binding domain(s) (nucleotide-binding folds (NBFs)) is the 
method by which these ABC transporters are classified (see figure 1.4.1.1.A). All 
ATP-binding domains have a characteristic motif (walker A and B domains) 
separated by 90-120 amino acids (see figure 1.4.1.1.B). This NBF also contains a 
signature (C) motif located upstream of the Walker B site [65]. In eukaryotic cells, the 
ABC genes are organised into a full transporter; containing two NBFs and two 
transmembrane (TM) domains, or a half transporter (see figure 1.4.1.2.); the latter 
must form either homodimers or heterodimers to become a fully functioning 
transporter. The specificity of each MDR transporter is determined by the TM domain.  
This domain comprises of 6-11 membrane-spanning α-helices. The NBFs are located 
in the cytoplasm and transfer energy to transport the substrate across the membrane. 
ABC transporter pumps are predominantly unidirectional. Most of the known 
functions of eukaryotic ABC transporters involve the shuttling of hydrophobic 
compounds either within the cell as part of a metabolic process or outside the cell for 
transport to other organs or for secretion from the body. 
 
 
 
 
 
 
 
 
 
 
 15
 
Figure 1.4.1.1.: Diagram of a typical ABC transporter protein. A. A diagram of the 
structure of a representative ABC protein is shown with a lipid bilayer in yellow, the 
TM domains in blue, and the NBF in red. Although the most common arrangement is 
a full transporter with motifs arranged N-TM-NBF-TM-NBF-C, as shown, NBF-TM-
NBF-TM, TM-NBF, and NBF-TM arrangements are also found. B. The NBF of an 
ABC gene contains the Walker A and B motifs found in all ATP-binding proteins. In 
addition, a signature or C motif is also present [66]. 
 
 
 
Figure 1.4.1.2.: ABC gene structure. Above is a diagram of an ABC half transporter 
and a full transporter. The half transporter can form homo- or heterodimers, whereas 
the entire full transporter is found in one transcript [66]. 
 
ABC genes play an important role in MDR, and at least six genes are associated with 
drug transport. (For a recent review in this area refer to Lage H. [67]). Three ABC 
genes appear to account for a large majority of the MDR in tumour cells in both 
human and rodent cells. These are ABCB1/P-gp/MDR1, ABCC1/MRP1, and 
ABCG2/MXR/BCRP (see tables 1.4.1. to 1.4.3.). In vitro, scientists have been 
developing drug resistance variants in order to further study the mechanism by which 
these MDR pumps are over-expressed and how best to overcome this phenotype in 
the clinic [58]. The phylogenetic associations between each ABC transporter subfamily 
is illustrated in figure 1.4.1.3 below. 
N 
C 
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Figure 1.4.1.3.: The phylogenetic tree above illustrates the inter-relationship between 
each ABC transporter subfamily [68]. 
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1.4.2. MultiDrug Resistance 1 (MDR1) 
 
Multidrug resistance 1 (MDR1) or p-glycoprotein (P-gp) is a 170 kDa ATP-dependent 
membrane transporter that acts as a drug efflux pump (pumping drug out of the cell or 
into vesicles). Its gene, ABCB1/mdr1, maps to chromosome 7q21.1 and is the best 
characterised ABC drug pump. ABCB1 was the first transporter cloned and the first to 
be characterised for its ability to confer a multidrug resistant phenotype in cancer cells 
[69] [70].  
A component of P-gp-mediated multidrug resistance may be due to alterations in 
membrane potential. This feature of P-gp-expressing cells is caused by changes in 
lipid-protein interactions on the intra-membranous surface of the transporter, which 
may be brought about by changes in the distribution of types of lipids (i.e. 
glucosylceramide) between the inner and outer leaflets of the plasma membrane 
giving rise to altered dipole potentials [71] and altered alkalinisation of the acidic 
compartments (endosomes and lysosomes). However, it is argued that resistance to 
weakly basic chemotherapeutic agents used in cancer treatment cannot be explained 
by changes in membrane potential and therefore trans-membranous distribution of 
those drugs [72] [73].  
 
Several hypotheses have been developed to explain the mechanism by which this 
pump confers resistance to chemotherapy drugs. The classic model for drug transport 
by P-gp states that P-gp acts as a transmembrane pore-forming protein and interacts 
with anti-cancer drugs in the cytoplasm and expels them directly into the extracellular 
medium. According to the “hydrophobic vacuum cleaner” model, P-gp binds directly 
with substrates in the plasma membrane and pumps them out of the cell [74]. In the 
“flippase” model, P-gp encounters drugs in the inner leaflet of the plasma membrane 
and flips them to the other leaflet from which they diffuse into the extracellular 
medium [75]. In an alternative model, P-gp affects the intracellular pH and/or the 
plasma membrane electric potential of the cell by acting as a proton pump or a 
chloride channel [73], thereby indirectly reducing intracellular accumulation of weakly 
basic, cationic lipophilic anti-cancer drugs. However, this last model does not agree 
with studies done in the mid 90’s that demonstrated direct drug transport by purified 
P-gp [76] (see figure 1.4.2.1.). 
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Figure 1.4.2.1.: An image to illustrate how the membrane bound P-gp transporter 
protein which pumps drug out is inhibited and evaded [77]. Engaging agents inhibit and 
prevent the efflux activity of the MDR pump. Agents unaffected by the expression of 
MDR pumps are known as evaders, while agents that use MDR pumps to enter the 
cell are known as exploiters. 
  
Many of the first chemosensitisers identified were themselves substrates for P-gp and 
worked by competing with the cytotoxic substrate compounds for efflux by the P-gp 
pump; and high serum concentrations of the chemosensitisers were necessary to 
produce adequate intracellular concentrations of the cytotoxic drug [63] (see table  
1.4.1 below).  
Three generations of inhibitors have been developed and investigated but an effective 
and safe clinical P-gp inhibitor has yet to be described [61]. 
Many anti-cancer agents have been found to either have no effect on the function of 
the P-gp pump (work independently of P-gp), to be substrates (pumped by the 
transporter), or are inhibitors, (directly interfere with the mechanics of the pump 
preventing it from doing its job). These agents include a broad range of families; for 
example, the taxanes, vinca alkaloids and anthracyclines are P-gp substrates while 
some of the platinum drugs and 5-flourouracil operate independent of P-gp (see table 
1.4.2.1.) 
Some of these cytotoxic substrates include some epipodophyllotoxins, camptothecins 
and heavy metal anions [78] [79] [80] (see table 1.4.2.1.).  
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The ABCB1/P-gp protein is also expressed in normal tissue. It is highly expressed in 
haematopoietic stem cells, where it may serve to protect these cells from toxins [81]. 
The highest expression is found in secretory cell types such as kidney, pancreas, colon, 
liver, intestinal and adrenal glands, where the normal function is thought to involve 
the excretion of toxic metabolites [82] (discussed briefly in section 1.3.).  Cancerous 
tissues originating from these cells express the highest levels of P-gp. This over-
expression leads to the resistance of malignant tumours prior to treatment with 
chemotherapeutic drugs. However, cancer cells with low expression of P-gp can also 
develop an MDR phenotype following treatment with cytotoxic agents [62].  
 
The general up-regulation of P-gp protein expression has been studied both in vivo 
and in vitro. Results indicate that MDR1 expression can be up-regulated by many 
extracellular stimuli including UV irradiation [83], heat shock [84], osmotic shock, low 
external pH, xenobiotics, differentiating agents, hypoxia (via HIF-1) [85], hormones [86] 
[87], radiotherapy, and growth factors, and by a number of drugs [88] [89]. There are a 
number of different mechanisms known for down-regulating P-gp including, 
degradation of its protein [3] and reducing intracellular reactive oxygen species (ROS) 
(ROS causes DNA damage and oxidises amino acids in proteins) [90]. 
Transcriptional regulation resulting in increased mdr1 mRNA has been widely 
investigated and many studies provide evidence of complex mechanisms involving 
transcription factor recognition sites as MDR1 gene promoters [91]. SPI, NF-Y [83] and 
YB-1 [92] transcription factors have been shown to up-regulate MDR1 promoter 
activity. Also, inactivation of p53, by mutation, can cause resistance to doxorubicin in 
vivo and the mutational status of p53 might be associated with the up-regulation of P-
gp-mediated drug resistance in human tumours [93] [94]. 
Transcription regulation resulting in a decrease in mdr1 mRNA has also been 
investigated. A negative regulator of the MDR1 gene promoter was identified as a 
protein complex made-up of NF-kappaB/p63 and c-Fos that interacted with the 
CAAT region of the promoter [95]. Negative down-regulation can also be caused by 
the activation of the transcription factor, c-Jun [96].  
Apart from interfering with the MDR1 protein at the gene level, blocking the function 
of the pump by inhibiting post-translational modifications such as phosphorylation, is 
also an effective way of overcoming P-gp mediated drug resistance [97]. Agents known 
to modulate the function of P-gp include calcium channel blockers, calmodulin 
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antagonists, steroidal agents, protein kinase C inhibitors, immunosuppressive drugs, 
antibiotics, tyrosine kinase inhibitors, non-steroidal anti-inflammatory drugs and 
surfactants. Calcium channel blockers, such as verapamil, have been shown to reverse 
P-gp-mediated MDR by blocking drug-pumping function of P-gp. However, Sikic BI., 
[98], found that these agents exhibit dose-limiting side effects that severely restrict 
their clinical utility.  
 
Table 1.4.2.1: Below is a list of anti-cancer agents that have been shown to be 
substrates, inhibitors or to function independently of P-gp. 
MDR pump Substrate Inhibitor Non-substrates 
P-glycoprotein Actinomycin D Cyclosporine A Carboplatin 
 Bisantrene Elacridar 
(GF120918) 
Cisplatin 
 Cyclosporine A Indole-3-carbinol Cyclophosphamide 
 Daunorubicin Verapamil Fluorouracil (5FU) 
 Doxorubicin Valspodar Gemcitabine 
 Homourringtonine Zosuquidar Ifosfamide 
 Epirubicin PSC833 Melphalan 
 Etoposide GG918 Methotrexate 
 Imatinib Pluronic L61  
 Irinotecan   
 Mitomycin c   
 Mitoxantrone   
 Paclitaxel   
 Docetaxel   
 Teniposide   
 Topotecan   
 Vinblastine   
 Vincristine   
 Vinorelbine   
This was compiled using the following references: [79] [99] [100] [101] [102]. 
1.4.3. MultiDrug Resistance Protein 1 (MRP1)  
 
The first member of the MRP subfamily (MRP1) was identified in the NCI-H69 cell 
line [103]. Despite having a broad spectrum of drug resistance, this cell line did not 
express P-gp [103]. Although both MDR transporters share similar substrates, they have 
less than 15% identical amino acids [103]. Identification of MRP1 led to the discovery 
of 8 additional members (MRP2-9), with MRP1-6 being the best characterised to date 
[104].  
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Mature MRP1 protein has an apparent molecular weight of 190 kDa and its gene 
maps to chromosome 16p13.1. It is an organic anion transporter that couples ATP 
binding with hydrolysis to transport across the biological membrane. MRP1 transports 
a wide variety of anti cancer drugs [105].  
 
The MRP transporter protein family can be found in both normal and tumour cells. 
MRP1 is predominantly expressed in lung [106] [107] [108], gastrointestinal tract [109], 
blood brain barrier (BBB) [110] and blood-testis barrier [103] [111] and has been identified 
in liver [112], kidney and at varying levels in the placenta [113]. MRP2 has also been 
located in all of these tissues except lung and testis (see review [78]). The function of 
MRP1 in normal tissues appears to be protective and maintenance of cell health 
through regulation of absorption, distribution and excretion of xenobiotics, nutrients, 
hormones, etc (see review [78] and discussed briefly in section 1.3.).  
Because of the protective role MRP1 plays, over-expression is common in cancer 
cells and confers MDR. In general, MRP1 expression levels are found to be higher 
post-chemotherapy treatment compared to initial presentation of the tumour. For 
example, 62% of breast cancer patients presented MRP1 expression prior to treatment 
while 88% expressed it post-chemotherapy treatment [114]. MRP1 over-expression has 
been located in treated tumour types such as acute myeloid leukaemia, small cell lung 
cancer, T-cell leukaemia and neuroblastoma. Studies into MRP1 in breast cancer 
suggest no correlation exists between MRP1 expression and tumour size, lymph node 
status, histologic grade and type, hormone-receptor status, age, or menopausal status 
[114]. However, early expression of MRP1 correlates with a worse prognosis [114].  
The regulation of MRP1 expression is not fully understood but tenuous links between 
transcription factors, nrf2, n-myc and c-myc (important in P13K pathway), and MRP1 
transcriptional regulation have been suggested. Hypoxic conditions increase the 
phosphorylation of ERK/MAPK and increase HIF-1 activity. These factors cause the 
up-regulation of MRP1. 
MRP1 inhibition might be a clinically relevant target for improving patient outcome 
in cancer treatment. Regardless of the resistance profile similarities between MRP1 
and P-gp a whole new approach in developing and designing MRP1 inhibitors is 
called for. Also, unlike P-gp, MRP1 does not affect resistance to and/or transport of 
paclitaxel [80] [115] (see table 1.4.3.1.), mitoxantrone [100] (see table 1.4.3.1.), 
arabinofuranosylcytosine [116] or m-AMSA (amsacrine) [115]. Also membrane vesicle 
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assays [117] [118] (see figure 1.4.3.1.) of MRP1 transport demonstrated that MRP1 
require acidic ligands such as glutathione (GSH), glucuronide, or sulphates for 
efficient transport of its substrates across biological membranes [100] [115] [105] [119]. 
Whether these acidic ligands bind to the MRP1 protein or the drug is unclear at 
present. 
To date, competent MRP1 inhibitors include emtricitabine, MK571, probenecid, 
sulindac sulphide and indomethacin [78] [79] [99] [102] (see table 1.4.3.1.). 
 
 
Table 1.4.3.1.:  Below is a list of compounds associated with the functioning of the 
MRP1 pump. 
MDR pump Substrate Inhibitor Non-substrates 
MRP1 Actinomycin D Emtricitabine Bisantrene 
 Emtricitabine MK571 Carboplatin 
 Epirubicin Probenasid Cisplatin 
 Etoposide Sulindac sulphide Cyclophosphamide 
 Daunomycin Indomethacin Docetaxel 
 Doxorubicin Cyclosporine A Fluorouracil (5FU) 
 Methotrexate V-104 Gemcitabine 
 Menogaril  Ifosfamide 
 Vincristine  Melphalan 
 Vinorelbine  Methotmexate 
   Mitoxantrone 
   Paclitaxel 
   Verapamil 
   Vinblastine 
This table was compiled using the following reference: [78] [79] [120] [121].  
 23
1.4.4. Breast Cancer Resistance Protein (BCRP/ABCG2) 
 
BCRP (ABCG2; 72kDa membrane-protein) is the second member of the ABCG 
subfamily of ABC transporter proteins [122]. BCRP was first cloned from a breast cell 
line (MCF7/AdrVp) selected for its unique drug resistance in the presence of a P-gp 
inhibitor, verapamil [122]. Phylogenetic analysis of the relationship between BCRP and 
other members of the ABC transporter family revealed that it was more closely 
related to ABCG1 than MRP1 or P-gp. ABCG1 is also a member of the ABCG/white 
subfamily [123].  To date, there are 4 members of the G subfamily, ABCG1, ABCG2, 
ABCG5, and ABCG8.  
There are two unique features of the ABCG family that imply a different transport 
mechanism compared to that of other ABC transporters. Firstly, the ABCG proteins 
are half transporters. Half transporters are composed of only one ABC and one 
transmembrane domain (TMD) unit within one polypeptide, the ABC domain being 
N-terminally located from the TMD.  Increasing evidence suggests that ABCG 
proteins operate as either homodimer or heterodimers [124] [125]. The second unique 
characteristic is the configuration of the ABC and TMD domains to the N-terminal. In 
ABC transporter proteins such as MRP1 and P-gp, the TMD always precedes the 
ABC domain (ie. TMD is nearer the N-terminal than the ABC domain), whereas 
ABCGs’ configuration is the opposite [126]. 
 
Several cell lines, from breast cancer, colon and gastric carcinoma, and fibrosarcoma, 
selected with drugs such as mitoxantrone, topotecan, daunorubicin, or verapamil, 
display resistance to a range of anti-cancer drugs (anthracyclines, topotecans and 
mitoxantrone).  These resistant variants remain sensitive to cisplatin, taxanes, vinca 
alkaloids and other known P-gp/MRP1 substrates. This resistance profile is 
characteristic of BCRP. Inconsistencies in the resistance profile between wild and 
mutant/selected BCRP has been observed. The alteration to substrate specificity was 
found to be due to the conversion of arginine to threonine or glycine at position 482 
[127]. It appears this single amino acid change enhances the export of anthracyclines; 
however, it also causes loss in the protein’s ability to export methotrexate [128]. 
Extensive study has been carried out in amino acid substitution and authors speculate 
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that the intracellular change at position 482 is important for electrostatic interactions 
with some substrates at the membrane-cytosol interface [129] [130] [131] [132] [133].  
 
Similar to other ABC transporter protein such as MRP1 and P-gp, BCRP can be found 
distributed around the body. A study carried out by Doyle L.A. et al. [134], found that 
BCRP is not expressed in heart, lung, skeletal muscle, kidney, pancreas, spleen, 
thymus, or peripheral blood leukocytes. However, Scheffer GL., et al. [107], detected 
low levels of BCRP in small endothelial capillaries in the lung. ABCCG2 was found 
to be highly expressed in the placenta [134], liver [134], blood brain barrier [135] and small 
intestines [134] [136] [137]. Low levels were detected in the blood-testis barrier. The role 
of BCRP appears to be solely a protective one; reducing exposure to xenobiotics 
primarily under hypoxic conditions. Hypoxia up-regulates the expression of BCRP by 
the hypoxia-inducible transcription factor complex HIF-1 [138]. 
 
The implications BCRP has on prognosis, survival and response to treatment have yet 
to be examined in many cancer types. Compared to P-gp, BCRP expression was 
found in a smaller proportion of childhood acute lymphoblastic leukaemia (ALL) [139] 
or nasophoryngeal tumours. However, on average 30% of acute myeloid leukaemia 
(AML) patients express BCRP at significantly high levels [140] and an unfavourable 
prognosis has been linked with BCRP over-expression in adult acute myeloid 
leukaemia (AML) and ALL [141] [142]. Studies carried out by Diestra J.E. [143] [144], on 
140 untreated tumours found that more than 40% of tumours reacted to the 
immunoassay and that the digestive tract carcinomas (esophagus, colon, stomach) 
were the predominant expressers. Bladder carcinomas and osteosarcomas showed a 
low frequency of BCRP expression. Researchers have suggested that BCRP is 
predominantly expressed in a subpopulation and this may be the cause for treatment 
failure. Research by Hirschmann-Jax C., et al. [145], into BCRP expression in 
neuroblastomas suggests there is a highly expressing subpopulation which may 
represent the cancer stem cells and work carried out by Dean M. et al. [146], seconds 
this theory. They also revealed that neuroblastomas can be found in other solid 
tumours such as ovarian cancer, small-cell lung carcinoma, Ewing sarcoma, and 
prostate cancer. Therefore, despite the lack of clinical epidemiology the putative role 
BCRP plays in solid tumour resistance (hypoxic conditions promote BCRP 
expression [138] could still have prognostic value. 
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With BCRP’s possible prognostic value the necessity to develop effective inhibitors is 
imperative. To date, a number of inhibitors have been identified and despite the 
structural difference between BCRP and P-gp they share a number of functional 
inhibitors and expression reducers. These include AG1478, lapatinib [147], erlotinib 
[148], gefitinib [149] [150] [151] [152], imatinib [153], sunitinib, wortmannin, LY294002 [154], 
elacridar [130], PD98059, FTC [155], and Ko143 [130] (see table 1.4.4.1). Some of these 
drugs have already proven beneficial (extended survival period) in the fight against 
multidrug resistance in treated tumours. Some agents can be both substrates and 
inhibitors, i.e. imatinib mesylate. 
 
Table 1.4.4.1: A list of compounds associated with the functioning of the BCRP 
pump. 
MDR pump Substrate Inhibitor Non-substrates 
BCRP Aza-anthrapyrazole Cyclosporine A Carboplatin 
 9-Aminocamptothecin Elacridar/GF120928 Cisplatin 
 Bisantrene Flavonoids (chrysin, 
biochanin A) 
Cyclophosphamide
 Daunorubicin# Flavopiridol Docetaxel 
 Doxorubicin# Fumitremorgin C (FTC) Fluorouracil(5-FU)
 Epirubicin# Gefitinib Gemcitabine 
 Etoposide Imatinib mesylate Ifosfamide 
 Flavopiridol Iressa Melphalan 
 Idarubicinol# Ko143 Paclitaxel 
 Imatinib Novobiocin Vinblastine 
 Imatinib mesylate Tamoxifen Vincristine 
 Irinotecan VX-710 Verapamil 
 J107088   
 Methotrexate (glu2, glu3)Ψ   
 Mitoxantrone   
 Nb-506   
 parzocin   
 SN-38   
 statins   
 Topotecan   
Note: 
# symbol denotes the substrates transported by BCRP with the amino acid change at position 482. 
Ψ symbol denotes the substrate transported by wild-type BCRP. 
This table was compiled from the following references: [63] [99] [78] [80] [102] [156]. 
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1.4.5. Interactions of modern targeted therapies with multidrug resistance 
proteins 
The aim of modern therapies is to target overactive signalling pathways and growth 
factor receptors that are characteristic of aggressive tumours. Many of these targeted 
therapies interact with ABC transporter proteins, i.e. they are modulators, which mean 
they can be substrates, inhibitors of the function or expression of these proteins. Some 
of these P-gp, MRP1 and BCRP modulators, mentioned in table 1.4.5.1 below, will be 
briefly discussed in this section. The small molecule agents examined in the project 
range from a new class of targeted therapies as well as older drugs that are and were 
used for other diseases. These agents come from a range of families, such as, 
P13K/Akt inhibitor, ERK/Mek inhibitors, Hsp90 inhibitors, tyrosine kinase inhibitor 
and non-steroidal anti-inflammatory drugs (NSAIDs), and were selected for their 
MDR status and use in clinic.  More traditional anti-neoplastic agents such as 
epirubicin, docetaxel, cisplatin, vincristine, or 5FU are not discussed in this section as 
they have either been discussed previously or are solely used as MDR substrates or 
MDR-independent agents throughout this project. 
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Table 1.4.5.1.: A selection of modern targeted therapies and their relationship with three MDR pumps (P-gp, MRP1 and BCRP). 
Class Drugs P-gp MRP1 BCRP 
  Modulation Reference Modulation Reference Modulation Reference 
Growth factor TKI AG1478 Inhibit function  No effect N/A Inhibit function 157 
 Lapatinib Inhibitor 112 ? N/A Inhibitor 97 
 Erlotinib Inhibitor 157 No effect 157, 158 Inhibitor 148 
 Gefitinib Inhibitor 150 ? N/A Substrate, inhibitor 
& ↓expression 
150 
 Genistein ? N/A Inhibitor 159 ? N/A 
 Imatinib Substrate 160 ? N/A Substrate 153 
 Sorafenib ? N/A ? N/A ? N/A 
Src TKI Dasatinib substrate 161 ? N/A substrate 161 
Receptor TKI Sunitinib Inhibitor 162 ? N/A Inhibitor 163 
P13K/Akt LY294002 Inhibitor & 
↓expression 
163, 164 Inhibitor, 
↑expression?? 
163 ↓Expression 163, 165 
 Wortmannin Inhibitor 166 ↓expression 167 ↓expression 168 
 WO 04/007491 ? N/A ? N/A ? N/A 
ERK/MEK U0126 ↓expression 3 ↓expression, no 
effect 
169 ? N/A 
 PD98059 ↓expression 3 Inhibitor, no 
effect?? 
163 ↓expression 170 
 PD184161 ? N/A ? N/A ? N/A 
NSAID Sulindac Non-inhibitor 171 Inhibitor 172, 173 ? N/A 
 Celecoxib ↓expression 160 ↓expression 174 ? N/A 
 Naproxen ↔Expression 96 ? N/A ↑expression 96 
 Rofecoxib ↓Expression & 
inhibitor 
175 ? N/A ? N/A 
 Valdecoxib ? N/A ? N/A ? N/A 
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Class Drugs P-gp MRP1 BCRP 
  Modulation Reference Modulation Reference Modulation Reference 
NSAID Paracoxib ? N/A ? N/A ? N/A 
 Ketorolac ? N/A ? N/A ? N/A 
 NS-398 ↓Expression & 
inhibitor 
171 ? N/A ? N/A 
 Ibuprofen Inhibitor 171 ? N/A No inhibition 176 
 Nimesulide ↓Expression & 
inhibitor 
96 ? N/A No interaction 176 
 Indomethacin ↓Expression & 
inhibitor 
96 Inhibitor 177 ↑ expression 96 
Hsp90 Radicicol ? N/A ? N/A ? N/A 
 17-AAG ↓expression 3 ? N/A ? N/A 
 Geldamycin ? N/A ? N/A ? N/A 
 NVP-AUY922 ? N/A ? N/A ? N/A 
 17-DMAG ? N/A ? N/A ? N/A 
Fungal Toxin FTC Weak inhibitor 130 Weak inhibitor 130 Inhibitor 130 
 FTC analogue: 
Ko143 
Weak inhibitor 130 Weak inhibitor 130 Inhibitor 130 
Chelating agent FTI-277 ↓Expression 3 ? N/A ? N/A 
Quinoline-type 
reversal agent 
Dofequidar 
fumarate 
Substrate & 
competitive 
inhibitor 
 
178 Inhibitor 179 ? N/A 
Ca+ channel 
inhibitor 
Verapamil Inhibitor 180 No interaction 181 No interaction 182 
 Diltiazem Substrate & 
competitive 
inhibitor 
183 ? N/A No interaction 182 
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Class Drugs P-gp MRP1 BCRP 
  Modulation Reference Modulation Reference Modulation Reference 
Immunosuppressive Cyclosporine A Inhibitor 184 Modulator 185 Modulator/Inhibitor 185 
 Clycosporine 
analogue: PSC-
833 
Substrate, 
competitive 
inhibitor 
185 No interaction 185 No interaction 185 
 Tacrolimus 
(FK-506) 
Substrate 186 ? N/A Modulator 187 
 Sirolimus ? N/A ?  Modulator 187 
Anti-inflammatory MK-571 No interaction 188 Inhibitor 188 No interaction 188 
Taxane Orataxel Modulator 189 Modulator 189 Modulator 189 
Other Tariquidar Inhibitor 190 No interaction  Inhibitor 179 
 Elacridar Inhibitor 191 No interaction 192 Inhibitor 193 
 Indole-3-
carbinol 
↓Expression 194 ? N/A ↑expression 195 
Note: 
An agent where mechanism is that of overcoming MDR-mediated resistance is termed a modulator. 
Key: ?: status unknown ↓: down-regulation of protein expression ↑: up-regulation of protein expression ↔: no change in protein expression 
       N/A: not applicable 
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Tyrosine kinase inhibitors: 
The epidermal growth factor receptor (EGFR) family is composed of cell surface 
tyrosine kinase receptors that are involved in the regulation of cellular proliferation 
and survival of epithelial cells (this area is discussed further in section 1.5). EGFR 
and HER2 receptor activation leads to the phosphorylation of the intracellular 
catalytic domains, and ultimately activation of signal transduction pathways that 
promote proliferation and survival, including the phosphatidylinositol 3′-kinase 
(PI3K)/Akt/mTOR, the Erk1/2 mitogen-activated protein kinase (MAPK) and the 
Jak/Stat pathway [196]. As stated in table 1.4.4.1., most tyrosine kinase inhibitors 
interact with P-gp and BCRP. Three of these agents (lapatinib, erlotinib and gefitinib) 
are briefly discussed below. 
 
Lapatinib: 
At clinically relevant concentrations (below 3.77 µg/ml or 3.99 µM) lapatinib, the 
dual HER2/EGFR tyrosine kinase inhibitor, has been shown to increase P-gp 
expression [197] [112] while directly inhibiting the function of both the P-gp and BCRP 
transporter proteins (demonstrated using ATPase assays) [112] [97].  
Conversely, Dai C-L., et al. [147], showed that lapatinib does not affect the expression 
of the P-gp and BCRP mRNA and protein expression (0.3 – 5 µM for 48 hours) in 
doxorubicin and vincristine-selected MCF7 cells and SI-M1-80 cells induced with P-
gp and BCRP expression. However, they proved that lapatinib reverses P-gp and 
BCRP-mediated multidrug resistance by directly inhibiting their transport function 
(2.5 and 10 µM).   
 
Erlotinib: 
Erlotinib is a specific EGFR tyrosine kinase inhibitor. Erlotinib has been shown to be 
a substrate ([198] 1.3 and 15 µM of erlotinib used) and have direct inhibitory activity on 
both P-gp and BCRP ([157] [148] 2.5 and 10 µM of erlotinib used in Western blotting (36 
and 72 hours), combination assays and accumulation/efflux assays). It does not alter 
the expression BCRP [157]. Erlotinib has no interaction with MRP1 [157] [158]. 
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Gefitinib: 
Gefitinib is also a specific EGFR tyrosine kinase inhibitor. A number of researchers, 
using ATPase and pharmacokinetic assays, observed the direct inhibition of both P-gp 
and BCRP by gefitinib (in human myelogenous leukaemia cells transfected with 
BCRP: [150] 10 µM caused 80-90% BCRP function inhibition while 1 µM caused 
~10% inhibition [151] [199] [40]). No studies have been carried out to date with regard to 
effect on MRP1 activity. 
 
The P13K/Akt inhibitors: 
The P13K/Akt signal transduction cascade has been investigated extensively for its 
roles in oncogenic transformation. Initial studies implicated both P13K and Akt in 
prevention of apoptosis. More recent evidence has also associated this pathway with 
regulation of cell cycle progression. Uncovering the signalling network spanning from 
extracellular environment to the nucleus should illuminate biochemical events 
contributing to malignant transformation [200]. Therefore, by inhibiting the signal 
transduction, targeted anti-cancer agents such as wortmannin, and LY294002 could 
inhibit tumour progression. If these agents also have anti-MDR potential scheduling 
regimens could provide improved patient treatment while minimizing the number and 
dose of drugs necessary and therefore side-effects.  
 
LY294002: 
LY294002 is a potent P13K/Akt inhibitor. Abdul-Ghan R., et al. [163], showed that 20 
µM of this Akt inhibitor inhibited the function of MRP1, while 10 µM reduced P-gp-
mediated resistance and down-regulated the expression of BCRP at the protein level.  
Using murine lymphoma cell lines (vincristine & doxorubicin variant), Garcia MG., et 
al. [164], demonstrated that 10 µM LY294002 reduced the efflux of daunorubicin from 
the P-gp expressing cell line. No protein characterisation was carried out. In 2006, 
Mantovani I., et al. [201], proved that the cleavage of the membrane bound P-gp protein 
following exposure to 50 µM LY294002 (no effect at 10 and 25 µM but large effect at 
50 µM was observed in T-lymphoblastoid CEM cells and its vinblastine variant). The 
deactivation of functional protein is thought to be through the cleavage of 170kDa P-
gp by caspase 3 (as part of the process of apoptosis). Katayama K., et al. [3], carried 
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out Western blots for changes in P-gp expression following a 12 hour treatment with 
10 µM LY294002 in colon and breast cell lines. No change was observed. 
Nakanishi T., et al. [165], observed a down regulation in BCRP protein expression 
following exposure to 10 µM LY294002 (K562 & BCRP variant, MCF7/AdrVp and 
Igrov1/T8 (ovarian); no change occurred with 2 µM, 10-20% reduction with 10 µM 
following a 14 hour exposure). 
Therefore, LY294002 is either an inhibitor or competitive substrate for MRP1 and P-
gp while being a down-regulator of the BCRP protein. The exact mechanism by 
which LY294002 acts is unknown (see table 1.4.5.1.). There is no clinical or 
pharmacological data on this drug therefore it is unclear if the concentrations used are 
clinically relevant. 
 
ERK/Mek inhibitors: 
Growth factors and mitogens use the Ras/Raf/MEK/ERK signalling cascade to 
transmit signals from their receptors to regulate gene expression, control cell 
proliferation, differentiation and prevent apoptosis. Some components of these 
pathways are mutated or abnormally expressed in human cancer (i.e., Ras, B-Raf) [202], 
[203]. Mutations also occur at genes encoding upstream receptors (i.e., EGFR and Flt-3) 
and chimeric chromosomal translocations (i.e., BCR-ABL) which transmit their 
signals through these cascades [204]. The activation of this pathway can lead to the 
unrestrained growth of cancer cells. The Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt pathways have been shown to interact with each other to 
regulate growth and in some cases tumourigenesis. The ERK/Mek pathways have also 
been linked with a multidrug resistance phenotype [205]. Some anti-ERK/Mek 
inhibitors affect the expression of MDR transporter proteins (see table 1.4.5.1.). 
U0126 and PD98059 down-regulate P-gp. No research has been published on the 
newest ERK/Mek inhibitor, PD184161, in relation to MDR. 
 
U0126: 
This drug is an ERK/Mek inhibitor. In 2006, Abdul-Ghani R., et al. [163], 
demonstrated no interaction between this ERK/Mek inhibitor and MRP1 (at 20 µM). 
However, a year later, using Western and RT-PCR techniques, Zhu H., et al. [106],  
found that, in hepatocellular carcinoma cell lines, a 12 hour treatment down regulated 
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both MRP1 and P-gp protein and RNA levels but did not affect BCRP. No data 
regarding concentrations or magnitude of effect is available as the article is in Chinese. 
Katayama K., et al. [3], carried out Western blots for changes in P-gp expression 
following a 12 hour treatment with 10 µM U0126 in colon and breast cell lines. An 
80-100% reduction was observed and in some cases this reduction was better than 17-
AAG (a Hsp90 inhibitor derivative of geldamycin, described later in this section). 
Therefore, U0126 down-regulates both P-gp and MRP1 but does not affect BCRP 
protein expression. U0126 affects MRP1 at the transcriptional level (see table 
1.4.5.1.). However, the mechanism by which U0126 down-regulates P-gp protein 
expression is unknown. There is no clinical or pharmacological data on this drug. 
 
Non-steroidal anti-inflammatory drugs (NSAIDs): 
NSAIDs are drugs commonly used in the treatment of pain and inflammation. Their 
primary mode of action is the blockage of one or both of the cyclooxygenase enzymes, 
COX-1 and COX-2.  These enzymes play an intrinsic role in the synthesis of 
prostaglandins (see section 1.6.2. for further details). COX expression has been 
directly related with tumour initiation, progression and metastasis (see section 1.6.3.). 
To date, substantial evidence suggests that COX-2 could contribute to the 
development of resistance to the pharmacological treatment of tumour cells (see 
section 1.6.3.: COX expression and Multidrug resistance). A number of NSAIDs have 
proven to be effective modulators of P-gp and MRP1. See table 1.4.5.1 for a selected 
list of NSAIDs and their known interactions with P-gp, MRP1 and BCRP.  
 
Sulindac: 
Sulindac is a non-specific COX-1/COX-2 inhibitor. Tatebe S., et al. [207], investigated 
the effect of sulindac exposure on the MRP gene family. They found that 24 hour 
treatment with 100-1200 µM sulindac increased the gene expression levels. O’Connor 
R., et al. [172], suggested that sulindac would be a good therapeutic MRP1 inhibitor. 
Sulindac does not reverse P-gp-mediated resistance in the human doxorubicin-
resistant uterine sarcoma cells [171]. No studies with regard to sulindac’s effect on 
BCRP have been published to date. There are no publications with regard to 
sulindac’s active form, sulindac sulphide, and MDR [25].  
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With a 300 mg dose the peak plasma concentration for this drug is about 2 µg/ml and 
it has a half life ranging from 7 hours to 16 hours depending on health and diet of the 
patient [25]. 
 
Celecoxib: 
Celecoxib is a COX-2 specific inhibitor that has been shown to down-regulate the 
expression of MRP1 and P-gp. Arunasree KM., et al. [160], demonstrated a 50% down 
regulation in P-gp protein expression (imatinib resistance) with 10 µM celecoxib 
following a 24 hour exposure time. Kang H-K., et al. [174], showed no change in 
MRP1 expression with 5 µM celecoxib for 24 hours but a 50 µM exposure for 24 
hours caused an 80% down regulation of MRP1 expression.  However, this 
concentration is exorbitant compared to achievable plasma concentrations (a 
maximum of 2 µg/ml). 
No data has been published on celecoxib relationship with BCRP. 
Therefore, celecoxib down-regulates P-gp at pharmacological concentration but its 
mechanism is unknown. It only affects the expression of MRP1 at extremely high, 
non-clinically relevant concentrations, and has not been linked with BCRP transport 
or function (see table 1.4.5.1.).  
For a dose of 200 mgs, the peak plasma concentration can reach 0.705 µg/ml with a 
half life of 11 hours [25]. Higher doses have caused an increase in plasma 
concentrations of up to 2 µg/ml.  
 
Ibuprofen: 
This non-selective COX inhibitor was found to overcome P-gp mediated resistance 
below its therapeutic plasma concentration by Angelini A., et al. [171]. Nozaki Y., et al. 
[176], found that concentrations ranging from 1 to 100 µM did not inhibit the function 
of BCRP in human kidney slices. Neither authors examined the mechanism by which 
it modulates P-gp. (See table 1.4.5.1.) 
The dosage for ibuprofen is between 1.2 g and 3.2 g. The peak plasma concentration 
reached with this dosage is 10 µg/ml with a half life of 1.8 hours to 2 hours [25]. 
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Naproxen: 
This NSAID is a COX-1 and COX-2 inhibitor. It has been shown not to affect the 
function of BCRP (in human kidney splices, at 1-100 µM [176]) but instead cause an 
increase in BCRP protein (6 µM exposure for 24, 48 and 72 hours resulted in an 
increase of 30%, 70% and 100% respectively) and mRNA levels (a 150% increase 
with 6 µM for 24 hours [96]) at clinically relevant concentrations. Zrieki A., et al. [96], 
observed no change in the expression of P-gp protein or levels of mRNA with the 
same treatments. No data was located for MRP1. (See table 1.4.5.1.) 
The peak plasma concentration obtained with a typical dose is between 90 µg/ml and 
98 µg/ml with a half life of 12 to 17 hours [25].  
 
Nimesulide: 
This preferential COX-2 inhibitor has been shown to decrease P-gp at the 
transcriptional level. No change in BCRP was observed and no data for MRP1 has 
been published. (See table 1.4.5.1.) 
Zrieki A., et al. [96], studied the effect of 10 µM nimesulide on P-gp and BCRP protein 
expression and levels of mRNA in a colorectal cell line (CaCo-2). With 10 µM 
exposure for 24 hours they observed no change in P-gp protein expression but a 40% 
decrease in mRNA levels. However, by increasing the exposure time by 24 or 48 
hours a 20% decrease in protein expression was observed. Using the same treatment 
times and concentration, no change was observed in BCRP mRNA levels and protein 
expression.   
The peak plasma concentration for nimesulide is 1.93 µg/ml [25]. 
 
Indomethacin: 
Indomethacin (non-selective COX inhibitor) has been shown to inhibit both MRP1 
and BCRP but not P-gp. However, this only occurs at concentrations exceeding the 
peak plasma concentration (1 µg/ml to 2 µg/ml) [25]. It has been shown to decrease the 
expression of P-gp transporter protein and mRNA level at clinically relevant 
concentrations. (See table 1.4.5.1.) 
Zrieki A., et al. [96], studied the effect of 0.4 µM indomethacin on P-gp and BCRP 
protein expression and levels of mRNA in a colorectal cell line (CaCo-2). 24, 48 and 
72 hour exposures resulted in a 10%, 30% and 40-50% down-regulation of P-gp 
expression. While a 24 hour exposure reduced the P-gp mRNA level by 40%. The 
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same exposure saw a 10-40% increase in BCRP protein expression but no change in 
mRNA level. Nozaki Y., et al. [176], found that 1 µM had no inhibitory effect on 
BCRP function, but 10 µM caused a 30% decrease in activity in human kidney splices. 
Draper MP., et al. [177], showed that 10 µM indomethacin inhibited MRP1 but not P-
gp. Gedeon C., et al. [208], also demonstrated this.  
 
NS-398: 
NS-398 is a selective COX-2 inhibitor. To date, no work has been carried out on its 
interaction with MRP1 and BCRP. Kim SK., et al. [209], indicated that NS-398 could 
impede the function of P-gp (using efflux assays/combination assays) and down 
regulate P-gp protein expression (by Western blot) (see table 1.4.5.1.).  Zatelli M.C. et 
al. [175], showed that 1 µM NS-398 prevents the development of P-gp resistance due to 
doxorubicin exposure over a 10 day period. And also, that this concentration could, to 
a small extent, down-regulate doxorubicin induced P-gp expression. Combination and 
efflux assays further demonstrated the drugs ability to inhibit the function of P-gp at 
this concentration in MCF7-doxorubicin selected breast cells. 
No clinical toxicological data is available but in vitro toxicological data would 
suggest its IC50 values lies between 100-200 µM. No clinical or pharmacological data 
is available for this NSAID.  
Heat shock protein 90 (Hsp90) inhibitors:  
Heat shock protein 90 (Hsp90) is a molecular chaperone required for the stability and 
function of several conditionally activated and/or expressed signalling proteins. Many 
of these client proteins such as Akt, HER2, Bcr-Abl, c-Kit, EGFR and PDGFR-α are 
oncoproteins and important cell-signalling proteins [210]. As signal transducers and 
molecular switches, these client proteins are inherently unstable. Hsp90 keeps 
unstable signalling proteins poised for activation until they are stabilised by 
conformational changes associated with the formation of signal transduction 
complexes. As such, it is a single molecular target that is a central integrator of 
multiple pathways important to cancer. 
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17-AAG: 
17-AAG is a derivative of geldamycin that retains its Hsp90 inhibitory function. 
Katayama K., et al. [3], demonstrated the potent ability of 0.1 µM 17-AAG to down-
regulate the expression of P-gp (~80% after a 12 hour treatment in colon (SW620 
MDR selected) and breast cell lines (MCF7 and MDA-MB-231 MDR induced)). 
Zhang H., et al. [211], presented in vitro and in vivo work to show that 17-AAG is a P-
gp and MRP1 substrate. No information has been published to suggest 17-AAG 
modulates BCRP. The pharmacologically achievable levels of 17-AAG range from 
0.15 - 17 µM depending on dosage [212]. 
Therefore, 17-AAG is a substrate of both P-gp and  MRP1 and is also potent down-
regulator of P-gp protein expression (mechanism of down-regulation is unknown). For 
details of other Hsp90 inhibitors see table 1.4.5.1.  
 
Other: 
 
Indole-3-Carbinol: 
This drug is a natural elastase enzymatic inhibitor that also down regulates vinblastine 
induced P-gp [194] and up-regulates BCRP expression (1 µM had no effect while 10 
µM doubled the expression of BCRP after a 72 hour treatment [195]).  The authors [194] 
used 10 mM for 24 hours to reduce the P-gp expression by ~50%. 
 
Elacridar: 
This lipophilic compound has proven to be a potent inhibitor of both P-gp and BCRP. 
No effect was observed on function or expression of MRP1. Den Ouden D., et al. [191], 
demonstrated that elacridar could reverse P-gp-mediated resistance in AML cells. 
Elacridar was found to directly inhibit the function of BCRP at 2 µM and 10 µM [193] 
[213]. Evers R., et al. [192], established that 5 µM elacridar had no effect on MRP1- 
mediated resistance. 
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1.5. Tyrosine kinase inhibitors 
 
1.5.1. Epidermal growth factor receptor family 
The epidermal growth factor receptor (EGFR) family is composed of cell surface 
tyrosine kinase receptors that are involved in the regulation of cellular proliferation, 
survival and differentiation during development, tissue homeostasis, and 
tumourigenesis of epithelial cells. The EGFR family includes four receptors: 
EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. Each receptor has an 
extracellular domain (ECD), a transmembrane region and an intracellular domain with 
tyrosine kinase activity. The binding of receptor-specific ligands to the ectodomain of 
EGFR, HER3 and HER4 results in the formation of homodimeric and heterodimeric 
kinase-active complexes. HER2 signalling is potentiated by HER2-containing 
heterodimers, and/or increases in the binding affinity of receptor ligands to EGFR and 
HER3/4 [214]. HER2 receptor activation leads to the phosphorylation of the 
intracellular catalytic domains, and ultimately activation of signal transduction 
pathways that promote proliferation and survival, including the phosphatidylinositol 
3′-kinase (PI3K)/Akt/mTOR, the Erk1/2 mitogen-activated protein kinase (MAPK) 
and the Jak/Stat pathway [196]. 
HER2 is over-expressed and/or amplified in one-fourth of breast tumours and confers 
a more aggressive clinical course and a worse survival [215]. The clinical outcome for 
these highly aggressive tumours has markedly improved with the development of anti-
HER2 therapies, i.e. trastuzumab (see table 1.5.2.1 below). Recently a number of 
these therapies, alone and in combination with more conventional chemotherapeutic 
agents, have been evaluated in randomised trials.  Results from these trials indicate 
activity with the single agent and also improved survival in patients with advanced 
disease [216] [217] [218] [219]]. 
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1.5.2. ErbB inhibitors 
 
Inhibition of the EGFR family can be at their extracellular and intracellular domains. 
Small molecule targeted antibodies target the extracellular domain while tyrosine 
kinase inhibitors (TKIs) target the intracellular domain (refer to table 1.5.2.1 for 
examples of both antibodies and TKIs). These types of inhibitors are less toxic then 
commonly used chemotherapeutic drugs. They target a number of cell surface and 
intracellular markers, such as, EGFR, HER2, PDGFR, VEGF etc., which are found to 
be over-expressed in malignancies. A number of these inhibitors also have anti-
multidrug resistance properties. Three TKIs (lapatinib, erlotinib and gefitinib) were 
found to directly inhibit the function of both P-gp [112] [157] [151] and BCRP [112] [157] [151] 
(for further information refer to sections 1.3 and 1.4.). Figure 1.5.2.1 below is a 
diagrammatical representation of the activation EGFR and the signal transduction 
pathways that lead to increased cell growth and reduced apoptosis. The legend for this 
figure discusses the site of action of tyrosine kinase inhibitor and the signal 
transduction cascades affected. 
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Figure 1.5.2.1.: This diagram represents the activation of EGFR and its down-stream 
signal transduction pathways. Tyrosine kinase phosphorylation occurs at intracellular 
docking sites. Tyrosine kinase inhibitors, such as lapatinib, erlotinib and gefitinib, 
prevent phosphorylation at these sites. This prevents EGFR tyrosine and protein 
binding and thus prevents the activation of pathways such as Ras/Raf/MEK/ERK. 
STAT protein activation is also inhibited by this method. The combined activation of 
ERK 1/2 and STAT leads to increased proliferation. Heterodimerisation with HER3 
recruits PI3K, which activates a cascade that results in Akt phosphorylation. 
Inhibiting this dimerisation prevents the activation of downstream components of Akt 
that lead to decreased apoptosis. This image was obtained from medscape [220]. Table 
1.5.2.1 below provides a list of tyrosine kinase inhibitors and antibodies targeted at 
members of the EGFR family. 
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Table 1.5.2.1.: The table below contains a list of targeted therapy antibodies and 
tyrosine kinase inhibitors for cell surface proteins, including their category, target and 
multidrug resistance status.  
Inhibitor Category Targets MDR status 
Lapatinib (Tykerb) TKI- Reversible EGFR & HER2 Inhibits P-gp transport 
function. 
Erlotinib TKI- Reversible EGFR P-gp/BCRP substrate. 
P-gp/BCRP pump 
function inhibitor 
Imatinib (Gleevec)  EGFR BCRP & P-gp substrate 
Imatinib mesylate  EGFR BCRP substrate & 
functional inhibitor 
Trastuzumab Antibody HER2 N/A 
Gefitinib TKI EGFR Inhibits P-gp/BCRP 
function. 
Key:  
N/A:  unknown 
This table was compiled from: [40] [147] [148] [150] [151] [157] [198] [199] [221].  
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1.6. Non-Steroidal anti-inflammatory drugs (NSAIDs) 
 
Early in the nineteenth century, the active component of white willow bark 
(commonly used for the relief of inflammation and fever) was determined and acetyl 
salicylate (aspirin) was synthesised on an industrial scale for the first time. What 
evolved from this event was a new class of treatment for inflammation and pain, 
known as non-steroidal anti-inflammatory drugs (NSAIDs) (some of these agents 
have previously been discussed in relation to their MDR status in section 1.4.5). 
Modern NSAIDs include drugs such as sulindac and ibuprofen, and have become the 
most commonly used pharmaceutical compounds worldwide, especially for the 
outpatient management of pain and inflammation in a wide spectrum of diseases. 
Over 70,000 tons of aspirin are produced a year, reflecting the importance of this drug. 
In the US alone, 50 million people per year use NSAIDs for the treatment of a number 
of patho-physical conditions from the prophylaxis of cardiovascular disease or 
rheumatoid/osteoarthritis, to the relief of discomfort from minor injuries and headache 
(reviewed in reference [222]). Numerous clinical trials have taken place using a 
combination of chemotherapy with an NSAID in cancer treatment.  
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1.6.1. Classification and side-effects of NSAIDs 
 
Classification: 
 
NSAIDs primary mode of action is the blockage of one or both of the cyclooxygenase 
enzymes, COX-1 and COX-2, activity. These enzymes play an intrinsic role in the 
synthesis of prostaglandins. These prostaglandins (PGs or prostanoids) are ubiquitous 
lipid mediators that coordinate a wide variety of physiological and pathological 
processes via membrane receptors on the surface of target cells [223]. Prostanoids play 
an important biological function in the: 
1. Activation and reduction of the inflammatory response, depending on their 
type, 
2. Production of pain and fever, 
3. Stimulation of blood vessel constriction or dilation, 
4. Clotting of platelets or inhibition of blood clotting, 
5. Regulation of the secretion of digestive juices and hormones, 
6. Regulation of temperature and blood pressure, 
7. Controlling cell division and growth, 
8. Aiding in the introduction of labour and other reproductive processes 
including fertility, as well as, 
9. Cytoprotection of the gastric mucosa, hemostasis, and renal hemodynamics 
Prostanoid biosynthesis is induced in different pathological conditions, including 
inflammation and cancer [223] [224]. A broad spectrum of COX specific and non-specific 
inhibitors have been developed over the last 100 years. Table 1.6.1.1 below provides a 
comprehensive list of NSAIDs including their family subtype and COX selectivity. 
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Table 1.6.1.1.: The table below contains a list of the chemical classification, 
biological action of each drug, and specificity of a broad range of NSAIDs. 
NSAID Family Drug COX-1, COX-2 selectivity 
Salicylates Acetylsalicylic acid (aspirin) Non-selective COX. 
 Benorylate/benorilate Not specified 
 Diflunisal Non-selective COX 
 Magnesium salicylate Not specified 
 Salicyl salicylate Not specified 
 Salicylamide Not specified 
Arylalkanoic acids   
 Diclofenac Non-selective COX 
 Aceclofenac  Non-selective COX 
 Etodolac Not specified 
 Indomethacin Non-selective COX. 
 Nabumetone  Not specified 
 Sulindac Non-selective COX. 
 Tolmetin Not specified 
2-Arylpropionic acids 
(profens) 
Ibuprofen Non-selective COX 
 Dexketoprofen Not specified 
 Fenoprofen Not specified 
 Flurbiprofen Not specified 
 Ketoprofen Non-selective COX 
 Ketorolac COX-1 
 Loxoprofen Non-selective COX 
 Naproxen Cox-1 and Cox-2. 
 Oxaprozin Not specified 
 Tiaprofenic Not specified 
N-Arylanthranilic acids 
(fenamic acids) 
Mefenamic acid Non-selective COX 
 Flufenamic acid Not specified 
 Meclofenamic acid Not specified 
 Tolfenamic acid Not specified 
Pyrazolidine derivatives Ampyrone Not specified 
 Metamizole Not specified 
 Phenazone Not specified 
Oxicams Piroxicam Non-selective COX 
 Lornoxicam Not specified 
 Meloxicam Cox-2 preference 
 Tenoxicam Not specified 
COX-2 inhibitors Celecoxib Cox-2 
 Etoricoxib Cox-2 
 Lumiracoxib Cox-2 
 Parecoxib Cox-2 
 Rofecoxib Cox-2 
 Valdecoxib Cox-2 
This list was compiled using google, pubmed and sciencedirect searches. 
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Side-effects of NSAIDs: 
Given the important role of prostanoids in the body, one can imagine preventing their 
synthesis may result in some significant side effects. The most common adverse effect 
of NSAID-use are respiratory problems, cutaneous [225], gastrointestinal (GI) [226] [227] 
[228] [229] and cardiovascular [230] complications. Typically these manifest as: 
• asthma attacks,      ●  urticaria,  
• heart attacks,       ●  strokes,  
• increased mucosal permeability,    ●  mucosal inflammation,  
• anemia and acute blood loss,     ●  malabsorption,  
• protein loss,       ●  illeal dysfunction,  
• active bleeding, GI/stomach perforations  ●  diarrhoea,   
• mucosal ulceration,  
• stricture due to diaphragm disease   
 
The therapeutic effects of NSAIDs are primarily related to their ability to inhibit 
COX-2, whereas some of their most frequent adverse effects may be caused by COX-
1 inhibition. In contrast to most “classic” NSAIDs which block both isoforms, the so-
called coxibs preferentially inhibit COX-2. These coxibs (such as celecoxib, rofecoxib, 
valdecoxib, etoricoxib, etc.) were developed in the hopes of overcoming some of the 
undesirable side-effects of non-selective COX inhibitors. To date, these coxibs have 
been associated with reduced gastrointestinal toxicity from the upper and lower GI 
tract compared to that of non-selective COX inhibitors. COX-2 inhibitors selectively 
reduce vascular prostacyclin synthesis without disrupting COX-1-derived 
thromboxane synthesis in platelets. However, removal of prostacyclin’s capacity to 
restrain endogenous compounds contributing to platelet activation and 
vasoconstriction is a well-recognised mechanism for coxib action in the 
cardiovascular system [231]. The severity of this side-effect appears to depend on the 
drug, dose and duration of use.  
Capone ML., et al. [231], performed an etoricoxib (coxib) versus diclofenac (old 
NSAID) gastrointestinal evaluation study in patients with OA (osteoarthritis) and 
showed that etoricoxib significantly reduced the rate of discontinuation by 50% due to 
adverse gastrointestinal events versus diclofenac. Rates of discontinuation due to 
hypertension-related adverse effects were higher on etoricoxib than diclofenac. 
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Similar to other COX-2 inhibitors, etoricoxib is contradicted in patients with ischaeme 
heart disease or stroke and should be used with caution in patients with risk factors for 
heart disease. 
Graham DJ., et al. [230], suggested that coxibs may confer an elevated risk for acute 
myocardial infarction and sudden cardiac death after long-term therapy. As a result 
the Food and Drug Administration (FDA) met to discuss the future of 
cyclooxygenase-2 inhibitors in April of 2005 and controversially approved rofecoxib, 
celecoxib, and valdecoxib use but placed a black-box warnings on their labels [232].  
Around the same time as this meeting, randomised clinical trials and observational 
studies showed an increased risk of myocardial infarction, stroke, hypertension and 
heart failure during treatment of patients with coxibs [231], leading to the withdrawal of 
rofecoxib and valdecoxib from the market. Furthermore, several cases of severe liver-
toxicity led to a halt in the approval of lumiracoxib in the EU in November 2007. 
Rofecoxib has subsequently been removed from by market by Merck. 
 
However, short term treatment with NSAIDs have little side-effects. Therefore, the 
availability of coxibs would be advantageous for non-COX selective intolerant 
patients, patients with risk of heart disease and for osteoarthritis or rheumatoid 
arthritis patients who are unable to tolerate the gastrointestinal side effects of other 
drugs. 
 
1.6.2. PGE pathway and COX proteins 
 
1.6.2.1. PGE pathway 
Prostaglandins were first discovered and isolated from human semen in the 1930’s by 
Ulf von Euler of Sweden. Thinking they had come from the prostate gland he named 
them prostaglandins (PG’s).  
Prostaglandin and thromboxane production from arachidonic acid (AA) is mediated 
by two cyclooxygenase (COX) enzymes, also referred to as prostaglandin H synthases, 
or prostaglandin endoperoxide synthases. AA is a 20 carbon polyunsaturated fatty 
acid that is released from membrane-bound phospholipids, usually by the action of 
phospholipase enzyme A2, prior to oxygenation by the COX enzymes. 
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Both of these enzymes possess two activities, cyclooxygenase and peroxidase, that act 
sequentially, thus converting AA to an unstable intermediate prostaglandin G2 (PGG2) 
and then the product prostaglandin H2 (PGH2). PGH2 is subsequently converted to 
other prostaglandins (PGs: PGD2, PGE2, PGF2alpha, PGI2) or thromboxanes (TXAs). 
The array of PGs produced varies according to the downstream enzymatic machinery 
present in particular cell type. See figure 1.6.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.2.1.: The Arachidonic acid pathway. 
 
In the last 10 years, studies have suggested that PGEs and tissue specific isomerases 
(prostaglandin receptors (EP)) 1-4 types may play a role in tumourigenesis. For 
example, increased mPGES-1 expression has been associated with human cancers of 
the lung [233], uterus [234], stomach [235], colon [236], penis [237], and head and neck [238], 
whereas studies using EP-knockout mice have suggested a role for each receptor 
subtype in murine intestinal tumour formation [239] [240]. 
COX-2 derived prostaglandins were demonstrated to promote tumour growth by 
accelerating the cellular proliferation rate, inhibiting apoptosis and enhancing 
metastasis and angiogenesis [241] [193].  
Based on knowledge of the pathway of PGE2 generation, a number of targets for 
selective inhibition come to light. For example, PGE2 is formed by the isomerisation 
of PGH2 by the action of three specific PGE2 synthases (PGEs), after which it is able 
Tissue-specific isomerases
Diverse physiological stimuli 
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to signal through any one of four G protein-coupled E-prostanoid receptors, and 
ultimately, four different signal transduction pathways [242] (figure 1.6.2.1. previous). 
PGE2 is also cleared from the extracellular environment by a specific prostaglandin 
transporter [243] and metabolised to ligands with diminished biological activity by 
further catabolic enzymes [244] which lead to the rapid attenuation of stimulated 
response. Such stimulated responses are suggested to include the transactivation of 
growth factor receptors such as EGF receptor [245] and nuclear receptors such as 
NR4A2 [246] and PPARs [247].  
Non-steroidal anti-inflammatory drugs (NSAIDs), which are widely prescribed as 
analgesics and anti-inflammatory agents, inhibit the biosynthesis of PGs. Their 
mechanism of action includes inhibition of both COX-1 and COX-2 isoenzymes [224] 
[248] [249]. COX-2, but not COX-1, is characterised by an accessible side pocket that is 
an extension to the hydrophobic channel [250] thus allowing for drugs to have 
selectivity.  
There are still a number of targets yet to be evaluated for selectively inhibiting the 
functions of PGE2 that may prove less harmful to the individual than inhibiting all 
prostaglandin production. Through COX-2 inhibition targeting such differences may 
be a more suitable approach for long term applications, such as cancer chemo-
prevention.  
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1.6.2.2. COX proteins   
 
As discussed in section 1.6.2.1., cyclooxygenase (COX) enzymes (COX-1, COX-2 
and COX-3) catalyze prostaglandin synthesis from arachidonic acid. The two 
isoforms that have been almost fully characterised to date are COX-1 and COX-2. 
COX-1 is a homeostasis protein constitutively expressed in a variety of tissues. The 
COX-2 protein is induced by growth factors, cytokines and oncogenes (for review see 
[251]).  
 
 
 
 
 
 
 
 
 
 
 
COX enzymes are proteins with a molecular weight of about 68 kDa in an unmodified 
condition, which increases to 72-74 kDa after post-translation glycosylation [252]. The 
structure of COX enzymes consists of three distinct domains: an N-terminal domain 
with a conformation that is highly similar to that of epidermal growth factor, a domain 
containing a series of amphipathic helices, which comprise the membrane attachment 
site, and a C-terminal catalytic domain, which contains the cyclooxygenase and 
peroxidase active sites. Although the two enzymes are highly similar in structure and 
enzymatic activity they have different genomic structures and different gene 
regulations and expressions.  
 
COX-1: 
COX-1 was first purified and characterised in the 1970s and the gene was isolated in 
1988 [253], COX-1 and COX-2 are encoded by separate genes located on different 
human chromosomes. The gene encoding for COX-1 enzyme is located on 
Figure 1.6.2.2.: The structure of the 
COX-1 enzyme. 
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chromosome 9 (9q32-9q33.3) and is approximately 40 kilobase (kb) pairs, contains 11 
exons and its mRNA is 2.8 kb [254]. This gene exhibits the features of a housekeeping 
gene, it lacks a TATA box [255], and is generally not subject to transcriptional 
induction, but it is constitutively expressed with near-constant levels and activity in 
most tissues and cell types. 
 
COX-2: 
The COX-2 gene was cloned in 1993 [256]. The gene encoding for COX-2 is located on 
chromosome 1 (1q25.2-25.3), contains 10 exons and is approximately 8.3 kb with a 
4.5 kb transcript [257]. COX-2 is an inducible or early-response gene, whose expression 
is undetectable in most normal tissues. COX-2 is highly induced in response to a 
broad spectrum of stimuli such as bacterial lipopolysaccharide (LPS) [258], cytokines 
[259], and growth factors [260].  
Transcriptional control of the COX-2 gene is cell-specific, and it is evident that more 
than one pathway may co-operate to regulate COX-2 expression.  
 
COX-3: 
It has been suggested that there is another COX enzyme formed as a splice variant of 
COX-1 [261], referred to as COX-3. COX-3 is made from the COX-1 gene but retains 
intron 1 in its mRNA. Its expression was initially reported in the canine cerebral 
cortex and in lesser amounts in other analyzed tissues [261]. Recent molecular biology 
studies revealed that indeed three distinct COX-1 splicing variants exist in human 
tissues [262]. The most prevalent of these variants, called COX-1b1, would make the 
expression of a full-length protein impossible; therefore a catalytically active form of 
the enzyme might not exist in humans. However, the other two variant types, called 
COX-1b2 and COX-1b3, encode predicted full-length and probably COX-active 
proteins, as suggested by functional studies, which revealed that COX-1b2 is able to 
catalyse the synthesis of PGF2a from AA [262]. 
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1.6.3. Relationship between COX expression and cancer 
 
COX-1, COX-2 and their major metabolites involved in tumour progression are 
frequently up-regulated in many cancer types. The homeostasic protein COX-1, which 
is constitutively expressed in a variety of tissues, is over-expressed in human breast 
[263], prostate [264], cervical [265], hepatocellular carcinoma (HCC) [266] and ovarian 
cancer [267] [268], but not in colorectal adenocarcinoma. Chulada PC., et al. [269], showed 
that a loss of the COX-1 gene reduced intestinal tumourigenesis in mice. It has been 
suggested that COX-1 may be involved in the early stages of HCC tumour growth, as 
expression levels are significantly higher in well-differentiated HCC compared to 
poorly-differentiated tissues [269] [270] [271]. Sugimoto T., et al. [272], found that COX-1 
expression levels in endometrial cancer patient samples were significantly up-
regulated compared to mRNA levels. They also found that levels of COX-2 
expression differed among cell lines, although no COX-2 mRNA elevation was found 
in their patients samples. These results indicate that the up-regulation of COX-1 rather 
than COX-2 may have an important role in tumour development in endometrial 
cancer. 
COX-2 protein, which cannot be detected in the majority of normal tissues, is not only 
up-regulated in 80-90% of colorectal cancer [273], but is also up-regulated in gastric 
[274], lung [275], prostate [264], breast, ovarian [276] [277], liver, bladder, osteosarcoma, 
melanoma [278] and bone cancer. Several lines of evidence suggest the critical role of 
COX-2 in tumourigenesis [279] [280]. COX-2 has been demonstrated to promote cell 
growth, inhibit apoptosis, increase angiogenesis and enhance cell motility and 
adhesion [279] [281] [282].  
In addition, it is known that PGE2 (a COX-2 derived product) can have 
immunosuppressive properties allowing tumour to escape host surveillance 
mechanisms [280]. It has been reported that COX-2 inhibition reverses the tumour-
induced increase in the immunosuppressive cytokine IL-10 from lymphocytes and 
macrophage and the suppression of the production of macrophage immune activator 
cytokine IL-12 [283].  
Also, it is predominantly PGE2 that is thought to be responsible for promoting 
colorectal tumourigenesis, with elevated levels reported in benign and malignant 
human and rodent colorectal tumours in vivo [284] [285].  
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COX-2 over-expression has been tentatively linked with poor prognosis, decreased 
survival and increase risk of re-occurrence in colorectal [286], ovarian [277] [287] and 
breast cancers [288]. In breast cancer, COX-2 up-regulation is associated with a high 
histological grade, a negative hormone receptor status, a high proliferation rate, high 
p53 expression, and the presence of HER-2 oncogene amplification, along with 
auxiliary node metastasis and a ductal type of histology (i.e. a poor prognosis) [286] 
[289].  
Steffensen KD., et al. [276], revealed that COX-2 expression in epithelial ovarian 
cancer is only seen in a subset of ovarian carcinomas and that negative COX-2 
expression is an independent prognostic factor for poor overall survival, however, 
others found that COX-2 expression was associated with significantly reduced median 
survival time [277] and levels were significantly higher in non-responding patients than 
patients responding to chemotherapy [287].  
Elevated COX-2 expression in breast and colorectal cancer is associated with the 
more advanced stages and larger tumours. However, HCC and ovarian carcinoma 
portray a different expression pattern (high COX-2 expressed at pre-malignant and 
malignant lesions and well-differentiated carcinoma) [290]. 
In mouse and human adenomatous polyps of the colon, the earliest expression of 
COX-2 is detected in stromal cells, but in several types of cancers, COX-2 is found in 
multiple cells, i.e., epithelial, endothelial, stromal, and inflammatory cells [280]. 
1.6.3.1. Regulation of COX 
 
A number of factors influence COX expression. The extracellular stimuli that induce 
COX-2 include growth factors, cytokines, tumour promoters, hypoxia (HIF-1 and NF-
KappaB p65 transcription factor) [292] [293], ionizing radiation, carcinogens and 
chemotherapeutic drugs (cisplatin and taxanes up-regulate mRNA and protein) [294] 
[295] [296]. Hepatitis B (HBV) and hepatitis C (HCV) viral infections are risk factors 
associated with hepatocellular carcinoma (HCC). Studies have shown that both 
viruses promote COX-2 expression through activation of NF-KappaB and p38 MAPK 
pathways through the endoplasmic reticulum and reactivated oxygen species (ROS) 
[297]. Increased COX-2 expression has been noted in the presence of IFN-gamma [298], 
but to date, evidence to confirm its relationship has not been established. NF-kappaB 
co-regulates IL-4 while IFN-gamma inhibits the biological function of IL-4. Peng H., 
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et al. [299], showed that endothelin-1 (ET-1) caused an increase in COX-2 protein 
expression as well as increased production of PGE2. It also increased the production 
of IL-8 in A549 cells. Other factors influencing the expression of COX-2 mRNA and 
protein expression may include the combined de-regulation of Wnt and Ras pathways. 
Inhibition of COX-2 expression is caused by glucocorticoids [221], IL-4 [300], IL-13 [300], 
the anti-inflammatory cytokine IL-10 [301] and targeted therapies, such as erlotinib and 
gefitinib. 
COX-2 expression can be regulated at the post-transcriptional level in tumours. This 
can occur through the binding of RAW [302a] or HuR [302b] to its RNA. 
1.6.3.2. Relationship between COX expression and Angiogenesis  
 
Angiogenesis, the development of new blood vessels, is an essential step in the 
growth of tumours, since the growth of malignant cells is limited by the availability of 
nutrients. Vascular endothelial growth factor (VEGF) is a well-characterised 
tumourigenic molecule and is known to potentiate tumour angiogenesis and invasion. 
A substantial body of evidence supports the role of COX-2 in angiogenesis, the 
“sprouting” of capillaries from pre-existing vasculature, in a variety of human 
malignancies [303]  [304] [305] [306]. COX-2-expressing cells produce high levels of 
angiogenic factors that promote angiogenesis, mainly through the synthesis of 
prostanoids. These factors can induce tumour angiogenesis in an autocrine and/or 
paracrine fashion by stimulating the expression of pro-angiogenic factors [2].  
COX-1 expression has been found to correlate with VEGF expression in ovarian [305] 
and endometrial cancer [272]. COX-2 expression has been linked with an angiogenic 
phenotype in colorectal carcinoma [280], bone [280], liver [307], intestinal epithelial cells 
[308] [309], pancreatic, cervical [305] [287] [310] and in patients with HVC- and HBV- 
associated HCC [311] [292] [312]. 
 
In vitro studies carried out by Kim MH., et al. [305], and Ferrandina G., et al. [287], 
demonstrate an association between COX-2 production, increasing VEGF, and 
subsequent angiogenesis. While Howe LR., et al. [264], showed that genetic abolition 
of the COX-2 gene product in HER2/nue knockout mice caused a decrease in tumour 
size, number and significantly reduced vascularisation as well as the expression of 
pro-angiogenic genes. 
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Lindstrom AK., et al. [310], reported that high COX-2 expression related to locally 
advanced disease, distant metastases, and decreased survival in cervical cancer 
patients. Multiple studies have shown that high COX-2 expression in conjunction with 
vascular endothelial growth factor (VEGF) or EGFR in cervical cancer correlates with 
poor prognosis and outcome [287]. Dai Y., et al. [313], confirmed over-expression of 
COX-2 and prostaglandins by immunohistochemistry and RT-PCR of pre-invasive 
cervical intraepithelial neoplasia [314] and invasive cervical cancer tissue compared to 
normal and inflamed cervical tissue (HPV negative) [313]. Head and neck squamous 
cell tumours show a similar pattern of co-existing COX-2 and VEGF over-expression 
as cervical disease [312]. Findings by Cervello M. et al. [311], suggest the hypothesis that 
selective inhibition of COX-2 by treatment with coxibs may contribute to inhibit 
HCC-associated angiogenesis. 
 
To date, COX-2 inhibitors have been shown to induce apoptosis of transformed 
intestinal epithelial cells, inhibit angiogenesis in vitro [308] [310] [307], and inhibit 
invasion, growth and metastasis in vivo [2] [315] [316]. Other selective COX-2 inhibitors, 
including celecoxib, have anti-angiogenic activity in a variety of in vitro [299] and in 
vivo [317] [318] [319] models. 
 
1.6.3.3. Relationship between COX expression and Invasion 
 
A number of studies have shown that the expression of COX-1 and COX-2 is 
involved in VEGF [312] and metalloproteinase (MMP) activation [219] [320] [321]. MMPs 
play an important role in the control of cellular interactions with, and response to, 
their environment in conditions that promote tissue turnover be they physiological, 
such as normal development, or pathological, such as inflammation and cancer 
including invasion. Physiologically, MMP2 and MMP9 in coordination with other 
MMPs, play a role in normal tissue re-modeling events such as embryonic 
development, angiogenesis, ovulation, mammary gland involution and wound healing. 
In ovarian [305] and endometrial cancer [272], VEGF expression correlates with COX-1 
expression and invasiveness. The COX-2/PGE2 pathway plays a key role not only in 
bone, liver, breast, colon and ovarian metastasis but also in provoking angiogenesis 
and therefore progression of the tumour growth and survival. PGE2 has been found to 
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stimulate growth, modulate apoptosis and enhance cell motility in colon carcinoma 
cell lines in vitro [322] [245].  
Both COX-1 and COX-2 play a role in the activation of MMP2 by way of membrane-
type 1 MMP induction in human breast cancer cell lines. In 2002, Dohadwala., et al. 
[323], showed that blockage of MMP expression by anti-sense oligonucleotides 
produced significant inhibition of PGE1-mediated CD44 expression. Singh B., et al. 
[324], showed that COX-2 over-expression correlated with increased production of IL-
11 and increased bone metastasis. 
 
In vitro and in vivo studies have proven that metastasis due to over-expression of 
COX-2 can be reversed by administering NSAIDs [241]. Diclofenac, nimesulide, 
celecoxib, valdecoxib, rofecoxib and sulindac sulphide all inhibited the expression 
and activation of MMP2 and MMP9 [241] [325]. Sulindac sulphide reduced MMP2-
related invasion in COX-2 induced human colon cancer cells (Caco-2) [210]. 
Diclofenac sodium, nimesulide, celecoxib, valdecoxib, rofecoxib and etoricoxib 
down-regulated the expression of gelatinases (matrix metalloproteinase (MMP)-2 and 
MMP-9) in samples from early knee osteoarthritis (OA) of humans [325]. 
1.6.3.4. Relationship between COX expression and MultiDrug Resistance  
 
Induction of COX-2 expression has been linked with the expression of multi-drug 
resistance proteins, such as P-gp, BCRP, MRP1, MRP2 and MRP3. Growing 
evidence indicates that COX-2 over-expression can up-regulate the expression of the 
multidrug resistance 1 (mdr1) gene and its protein, the multidrug resistance pump p-
glycoprotein (P-gp) [326] [327] but this can be reversed by using NSAIDs and coxibs, 
such as celecoxib (for review see Sorokin A., [327]).  
Using immunohistochemical analyses, a strong correlation between expression of 
COX-2 and P-gp was found in human breast tumour specimens [328]. Surowiak P., et 
al. [329], found a positive correlation between COX-2 and MDR1/P-gp expression and 
demonstrated that COX-2 and MDR/P-gp are unfavourable prognostic factors in 
breast cancers and unfavourable predictive factors in chemotherapy-treated breast 
cancer cases. In the P-gp-induced drug resistant cell line, MCF7, there was significant 
up-regulation of COX-2 expression as well as the up-regulation of transcription 
factors; protein kinase C (PKC) and activator protein 1 (AP1) subunits c-Jun and c-
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Fos were also upregulated [328]. The inhibition of prostaglandin synthesis by COX-
inhibitors could block this cascade resulting in a negative modulation of MDR1. This 
[329] and other evidence [326] [327] suggest that COX-2 could contribute to the 
development of resistance to pharmacological treatment by tumour cells. Zatelli MC., 
et al. [175], provided data to support the hypothesis that the COX-2 selective inhibitor, 
NS-398, can prevent and reduce the development of the chemo-resistance phenotype 
in breast cancer cells by inhibiting P-gp and function. Also using NS-398, Kim SK., et 
al. [209], suppressed the expression and function of P-gp and induced apoptosis in 
ependymomas (cancer derived from the ependyma, a tissue of the central nervous 
system). Patel VA., et al. [326], suggests that the up-regulation of COX-2 leads to 
increased P-gp expression and activity in RMC cells.  
Puhlmann U., et al. [330], showed that doxorubicin-induced MDR1 over-expression 
was down-regulated by the COX-2-preferential inhibitor, meloxicam, in both HL-60 
and primary AML blasts with subsequent improvement of cytostatic efficacy of 
doxorubicin. Arunasree KM., et al. [160], provided evidence that COX-2 and MDR-1 
over-expression are responsible for the development of resistance to imatinib in IR-
K564 cells. They showed that celecoxib, a selective COX-2 inhibitor, induced 
apoptosis by down-regulating the expression of COX-2 and MDR-1 via a mechanism 
involving the Akt pathway. Many other studies provide evidence that the non-
steroidal anti-inflammatory drug, celecoxib, can increase the efficacy of 
chemotherapeutic [331] [332] [333] and neurotropic drugs [334]. Many of these drugs are 
substrates of P-gp, such as, doxorubicin, vincristine, etoposide, irinotecan, risperidone 
and reboxetine. Therefore, by acting on the expression of P-gp, it could be speculated 
that a selective inhibition of COX-2 activity could reinforce the anti-tumour act of 
conventional chemotherapy. The rationale behind the possible combination of 
traditional chemotherapy and selective COX-2 inhibitors is further supported by the 
fact that chemotherapy itself induces COX-2 expression [335]. 
Kang HK., et al. [174], examined the possibility that COX-2 expression is not only 
related to P-gp expression but also MRP1 expression. When the model chosen, A549 
(a human epithelial lung cell line that highly expresses COX-2 and MRP1), was 
exposed to high levels of celecoxib (50 and 100 µM), MRP1 expression and function 
was down-regulated. They proved that MRP1 expression is not necessarily due to 
COX-2 expression as forced expression by transfection did not up-regulate MRP1. 
Incidentally, they also showed that induced COX-2 expression did not increase P-gp 
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expression, suggesting that the P-gp up-regulation observed  by Patel VA., et al. [326], 
Puhlmann U., et al. [330], and Arunasree KM., et al. [160], may be carcinoma specific or 
it may not have happened as the cell line already expresses MRP1. 
On the other hand, work carried out by Takaoka K., et al. [336], demonstrated that 
COX-2-transfected human epidermoid KB carcinoma cells, showed increased 
expression of MRP1 and MRP2 (shown by Western blot) which gave a 2.5-fold 
resistance to cisplatin, while maintaining sensitivity to vincristine, bleomycin and 
5FU. 
Using MRP1 expressing lung cell lines (A549, DLKP, HL60/Adr, COR L23P, COR 
L23R), Duffy CP. et al. [337], revealed that a specific subset of NSAIDs significantly 
increased the cytotoxicity of MRP1 substrates (anthracyclines, temiposide, VP-16 and 
vincristine), but not other vinca alkaloid (vinblastine and vinorelbine) or P-gp 
substrates (methotrexate, cytarabine, hydroxyurea, chlorambucil, cyclophosphamide, 
mitoxantrone, actinomycin D, bleomycin, paclitaxel and camptotecan). This 
demonstrates that some NSAID, such as, indomethacin and sulindac, are MRP1 
inhibitors.  
NSAIDs are currently being investigated for potential influences on multidrug 
resistant mechanisms. Ibuprofen overcame resistance in the human doxorubicin (doxo) 
resistant uterine sarcoma cells (MES-SA/Dx-5) expressing high levels of P-gp [171]. 
Similarly, NS-398 impeded the function and protein expression of P-gp in two 
primary cultured ependymoma cell lines [209]. However, sulindac, a non-specific 
COX-inhibitor, increased MRP1 and MRP3 expression levels while having no effect 
on MRP2, MRP4, MRP5 and MRP6 [207]. Tatebe S., et al. [207], suggested the 
mechanism was via the induction of ROS (and γ-glutamylcysteine synthetase heavy 
subunit gene which is a rate-limiting enzyme in glutathione biosynthesis), this was 
proven using down-regulation by NAC (N-acetylcysteine), a ROS suppression anti-
oxidant. 
COX-2-specific inhibitors, celecoxib [160], NS-398 [209], indomethacin [96] and 
nimesulide [96] reduce the expression and function of P-gp protein. Puhlmann U., et al. 
[330], down-regulated the expression and function of P-gp in doxorubicin-resistant cells, 
using meloxicam (COX-2 selective inhibitor), and suggested the mechanism is 
through the modulation of NF-KappaB.   
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1.6.3.5. Relationship between COX expression and Epidermal Growth Factor 
Receptors expression 
 
Receptor tyrosine kinases, such as members of the EGFR family (i.e. HER2) via their 
over-expression and/or over-activation, mediate many of the characteristics of the 
malignant phenotype, such as decreased apoptosis, increased cell proliferation, 
metastasis, and resistance to chemotherapy and radiotherapy [338]. These receptors 
play a crucial role for the growth of both normal tissue and malignant tumours. The 
debate as to whether the expression of COX-2 is regulated or effected by 
EGFR/HER2 activation has been investigated since 1997 and remains a hot subject.  
Several studies reported that the epidermal growth factor receptor family can increase 
COX-2 protein expression and activity levels. This increase is suggested to occur 
through EGFR activation which increases COX-2 protein expression [339], 
paracrine/autocrine activation of HER2/HER3 heterodimers which leads to activation 
of the COX-2 promoter [340] [341], and a HER2/COX-2 promoter complex which 
stimulates COX-2 transcription [342]. 
 
HER2: 
The correlation between COX-2 and HER2 co-expression with prognosis has been 
investigated in breast [343] [344] [345] ovarian [340], bladder [346], prostate [347] and 
endometrial cancer patients [348].  
COX-2 expression is associated with increased angiogenesis, lymph node metastasis, 
and HER2-nue expression. Howe LR., et al. [349], found that tumour size, 
vascularisation, and expression of pro-angiogenic genes were down-regulated in 
COX-2 knockout mice that expressed HER2/neu compared to COX-2 and HER2/neu 
expressing mice. 
COX-2 and HER2 co-expression is a poor prognostic marker in breast cancer. Dillon 
MF., et al. [343], found a link between membrane HER2, nuclear HER2 and COX-2 
expression predicted a poor disease-free survival in breast cancer patients on 
endocrine treatment and had adverse side effects to tamoxifen treatment. Nassar A., et 
al. [344], found that the same co-expression also correlated with large tumour size and 
high tumour grade but not with outcome [350]. Zerkowski MP., et al. [345], showed that 
COX-2 expression was up-regulated in invasive breast tumours and that these patients 
had significantly worse disease-specific and overall survival. This was independent of 
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tumour size, nodal status, grade and ER levels. Despite this correlation, the 
combination of celecoxib and trastuzumab (an anti-HER2/neu monoclonal antibody) 
produced no change in response compared to trastuzumab treatment only [351]. 
However, in vitro research showed that 5 and 10 µM lapatinib (a dual EGFR/HER2 
tyrosine kinase inhibitor (TKI)) reduced protein expression and function of TNFα, IL-
1B and EGF stimulated COX-2 [352].  
Using immunohistochemical analysis no prognostic significance was found with the 
expression of COX-2 and HER2 in ovarian [340] [353], bladder, prostate cancer [347] or 
NSCLC [354].  COX-2 and HER2 was co-expressed in 33% of invasive bladder cancer 
patients but this was independent of tumour stage, lymph node status and histological 
grade [346].  
 
EGFR: 
A link between COX-2 expression and EGFR expression and activation has been 
identified. A number of publications suggest that EGFR ligands potentiate and are 
required for COX-2 induction [355] [356]. Some of these ligands identified include, 
epidermal growth factor (EGF) and transforming growth factor-  (TGFα). These have 
been linked with ERK and Ras-Raf / Rac-PAKI-MEK signalling [357]. ERK interacts 
with the p38MAPK pathway which leads to the phosphorylation of CREB and 
transcriptional activation of the COX-2 promoter [357] [358].  EGF-induced 
transcriptional activation of COX-2 and COX-2 mRNA was found to result from 
increased activator protein-1 (AP-1; c-Jun) activity, although some question exists as 
to whether this involves receptor signalling to JNK [356].  
On the other hand, COX-2 activation has also been shown to lead to the 
transactivation of EGFR. The presence of PGE2 leads to rapid EGFR phosphorylation 
and triggers the extracellular signal-regulated kinase 2 (ERK2) [245]. This PGE2-
induced EGFR transactivation involves signal transduction via TGF-alpha (likely 
released by c-Src-activated MMP(s)) [358] [281]. Al-Salihi MA., et al. [359], provided data 
demonstrating that COX-2 potentiates tumourigenesis in colon epithelial cells. They 
showed that COX-2 is not involved in initiation but instead, activation, of EGFR and 
the Akt signalling pathway, which may be responsible for the increase in tumour 
number and volume and in changes in morphological architecture and organisation. 
Despite this cycle of regulation and activation, no significant correlation between 
COX-2/EGFR co-expression and survival has been identified. Brattstrom D., et al. 
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[360], demonstrated this in NSCLC while van Dyke AL., et al. [362], observed the same 
lack of trend in tumour status, prognosis and outcome in women with adenocarcinoma 
of the lung. 
The combination of COX-2 inhibitors (celecoxib/NS-398) with erlotinib or gefitinib 
(EGFR tyrosine kinase inhibitors) increased apoptosis and decreased cell number in 
vitro [281] [362], while decreasing tumour size and number in vivo [363] [364]. Gadgeel SM., 
et al. [365], combined erlotinib/gefitinib with celecoxib in EGFR-wild and -mutant 
(moderate and high) expressing NSCLC cell lines. Both combinations had the greatest 
effect on the highly expressing EGFR-mutant-expressing cell line. This cell line also 
expressed high levels of COX-2. These results indicate that the combination would 
not be beneficial in EGFR-wild type-expressing NSCLC tumours.  
Both erlotinib and gefitinib (EGFR-specific TKI’s) down-regulate COX-2 expression 
and reduce its function in a non-small cell lung carcinoma cell line (H3255). A 
clinical trial investigating the efficacy of combined therapy with a COX-2 inhibitor 
with an EGFR inhibitor (erlotinib and gefitinib) found no additional benefit of 
combined treatment in platinum therapy unresponsive or chemotherapy-naïve patients 
in comparison with results from previous studies involving treatment with the TKI’s 
alone [365] [366] [367]. 
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1.7. In vitro assessment of anti-cancer agents’ activity 
 
As stated by Putnam KP., et al. [368], cytotoxicity is an important factor in 
understanding the mechanisms of action of chemicals on cells and tissues. 
Cytotoxicity is thought to play an important role in a number of pathological 
processes, including carcinogenesis and inflammation. It may also modulate the 
activity of other agents, including free radicals, irritants and genotoxins.  
When testing a compound for cytotoxicity there are many biological endpoints that 
can be examined. These may be general mechanisms common to all cells or 
mechanisms specific to particular cell type. The use of cell culture systems has 
become common in the toxicological assessment of chemicals and chemical mixtures. 
Several large research groups have evaluated various in vitro assays and have 
recommended the use of cytotoxicity assays in toxicology. 
 
There are many different types of cytotoxicity assays that suit various cell lines or 
toxic effects. Some use the breakdown of various tetrazolium salts to formazan by 
mitochondrial dehydrogenase in viable cells. Such assays include MTT, MTS, MTT-
A, XTT, XTT-A, XTT (PMS) and WST-1.  
Other assays that take advantage of the cell damage, which may be manifested by a 
loss of plasma membrane integrity or changes in influx and efflux systems through the 
cell membrane caused by toxins or drugs include; the neutral red assay (NR), Trypan 
blue exclusion assay, Lactate dehydrogenase assay (LDH), crystal violet dye elution 
(CVDE), kenacid blue and the resazurin system. Some of the above can determine the 
health of the cell by quantifying the amount of cellular protein. During normal cell 
growth, in an ideal environment, the protein levels within the cell will be constant. 
Once these standards are known, any change in cellular protein concentration can be 
directly related to the addition of drugs or toxins. ATP based assays, sulforhodamine 
B and the Acid Phosphatase (AP) assay are the only three that do not fall into the 
above categories. The ATP based assay determines changes in ATP levels within the 
cells at a given time, the sulforhodamine assay measures the amount of cellular 
protein, but does not require alterations in the structure or permeability of the cell 
membrane to do so. The AP assay is based on the amount of acid phosphatase enzyme 
on the cell membrane or on the lysosome. The AP assay requires lysis of the cell to 
release the acid phosphatase enzyme. The activity of acid phosphatase is quantified by 
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the catalysis of a substrate, p-nitrophenol (PNP), to p-nitrophenolate in the presence 
of NaOH producing as easily detectable colour change.  
This highly sensitive, easy and direct colorimetric method of determining changes in 
cell proliferation, compared to the control wells, caused by small molecule and 
chemotherapeutic agents was employed throughout this project.  
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1.8. Aims of the thesis 
 
The aims of this project were to: 
 
1. Evaluate the anti-MDR and cytotoxicity of novel compounds in MRP1 or P-gp 
expressing cell models. 
 
2. Identify a panel of MDR modulators that down-regulate the expression of 
MDR proteins while targeting other important signalling pathways and 
oncoproteins. To determine whether these agents cause the greatest anti-cancer 
effects in concurrent combination with traditional chemotherapeutic drugs or 
as a pre-treatment to the chemotherapeutic drugs.  
 
3. Investigate the role of serum transport proteins, serum albumin and α1-acid 
glycoprotein, may play in the availability and thus efficacy of epirubicin in 
normal versus cancer cells. 
 
 
Focusing on two types of small molecule agents that modulate multidrug resistance: 
 
4. Characterise the ability of three tyrosine kinase inhibitors (lapatinib, erlotinib 
and gefitinib) to sensitise EGFR/HER2-amplified breast cancer cell models 
and multidrug resistant cell lines to the chemotherapeutic drugs.  
 
5. Determine the affect of lapatinib on COX-2 protein expression and activity. 
 
6. Identify the relationship between the COX-2 inhibitor, celecoxib, and 
expression and function of multidrug resistant proteins. 
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Section 2. 
 
 
Materials and Methods 
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2.1. Ultrapure water 
 
Ultapure water (UHP) was used in the preparation of all media and solutions. This 
water was purified to a standard of 12-18 MΩ/cm resistance by a reverse osmosis 
system (Millipore Mill-RO 10 Plus, Elastat UHP). 
 
2.2. Glassware 
 
The solutions used in the various stages of cell culture were stored in sterile glass 
bottles. All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% RBS-
25 (AGB Scientific) for 1 hour. After this time, they were cleansed and washed in an 
industrial dishwasher, using Neodisher detergent and rinsed twice with UHP. The 
resulting materials were sterilised by autoclaving. 
 
2.3. Sterilisation procedures 
 
All thermostable solutions, water and glassware were sterilised by autoclaving at 
121oC for 20 minutes at 15 p.s.i. Thermolabile solutions were filtered through 0.22 
µm sterile filters (Millipore, Millex-GV SLGV025BS). Larger volumes (up to 10 
litres) of thermolabile solutions were filter sterilised through a micro-culture bell filter 
(Gelman, 12158). 
 
2.4. Preparation of cell culture media 
 
Basal media used during cell culture was prepared as followed: 10X media was added 
to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2-
ethanesulfonic acid) and NaHCO3 as required and adjusted through sterile 0.22µm 
bell filters (Gelman, 12158) and stored in sterile 500 ml bottles at 4oC. Sterility 
checks were performed on all bottles of media by inoculation of media samples on to 
Colombia blood agar (Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and 
Thioglycolate broth (Oxoid, CM173). All sterility checks were then incubated at both 
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25oC and 37oC. These tests facilitated the detection of bacterial, yeast and fungal 
contamination. Basal media were stored at 4oC for up to three months. The HEPES 
buffer was prepared by dissolving 23.8 g of HEPES in 80 ml UHP water and this 
solution was then sterilised by autoclaving. Then 5 ml sterile 5 N NaOH was added to 
give a final volume autoclaving. Complete media was then prepared as follows: 
supplements of 2 mM l-glutamine (Gibco, 11140-0350) for all basal media and 1 ml 
100X non-essential amino acids (Gibco, 11140-035) and 100 mM sodium pyruvate 
(Gibco, 11360-035) were added to MEM. Other components were added as described 
in Table 2.1. Complete media was stored at 4oC for a maximum of one month. 
 
Sources of other types of media: 
DMEM/Ham’s F12 1:1 = represented by ATCC in this project and produced in house 
RPMI-1640 (made in house) 
McCoy5A (Lonza; 12-688F) 
MEGM (Lonza; CC-3151 and CC-4136).  
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Table 2.4.1.: This table is a list of cell lines used during the life of this project. 
Including their basal media, percentage foetal calf serum and any additional 
requirements for growth. 
Cell Line Basel media FBS (%) Additions 
DLKP ATCC 5 None 
DLKP-A ATCC 5 None 
A549 ATCC 5 None 
A549-Taxol ATCC 5 None 
MDA-MB-453 RPMI-1640 10 None 
MDA-MB-231 RPMI-1640 10 None 
MCF7 RPMI-1640 10 None 
NCI/Adr-res RPMI-1640 10 None 
BT20 RPMI-1640 10 None 
HL60/s RPMI (sigma;R8758) 10 None 
HL60/adr RPMI (sigma;R8758) 10 None 
HL60/Mdr1 RPMI (sigma;R8758) 10 None 
HL60/mxr RPMI (sigma;R8758) 10 None 
H1299 RPMI-1640 5 Sodium pyruvate 
H1299-Taxol RPMI-1640 5 Sodium pyruvate 
2008/MRP1 RPMI-1640 10 None 
M14 RPMI-1640 10 None 
DLKP-SQ/mitox ATCC 5 None 
HMEC MEGM N/A Lonza formula 
 
 
2.5. Cells and cell culture 
 
All cell culture work was carried out in a class II laminar airflow cabinet (Holten 
LaminAir). All experiments involving cytotoxic compounds were conducted in a 
cytoguard laminar airflow cabinet (Holten LaminAir Maxisafe). Before and after use 
the laminar airflow cabinet was cleaned with 70% industrial methylated spirits (IMS). 
Any items brought into the cabinet were also swabbed with IMS. Only one cell line 
was used in the laminar airflow cabinet at a time and upon completion of work with 
any given cell line the laminar airflow cabinet was allowed to clear for at least 15 
minutes before use. This was to eliminate any possibility of cross-contamination 
between cell lines. The cabinets were cleaned weekly with industrial disinfectants 
(Virkon or TEGO). These disinfectants were alternated fortnightly. Details pertaining 
to the cell lines used for the experiments detailed in this thesis are provided in Table 
2.5.1. All cells were incubated at 37oC with an atmosphere of 5% CO2. Cell lines such 
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as, DLKP, DLKP-A, AsPC1, BxPC3 and HT1299-Taxol, did not have any CO2 
requirement. Cell were fed with fresh media or subcultured every 2-3 days in order to 
maintain active cell growth. All cell lines listed in Table 2.5.1. are anchorage 
dependent cell lines.  
 
Table 2.5.1.: This table is a list of cell lines used during the life of this project, 
including the cancer type and where they were obtained.  
Cell Line Details Source 
DLKP Non-small cell lung carcinoma 
(NSCLC) 
NICB 
DLKP-A NSCLC, adriamycin-selected. NICB [369] 
DLKP-SQ/mitox NSCLC, mitoxantrone-selected NICB derived by Helena 
Joyce [unpublished] 
A549 Lung ECACC 
A549-Taxol Lung, paclitaxel-selected ECACC derived by Dr. 
Laura Breen [370] 
MDA-MB-453 Breast ATCC 
MDA-MB-231 Breast ATCC 
MCF7 breast ATCC 
NCI/Adr-res Ovarian; Adriamycin-selected NCI USA 
HL60/S Acute myeloid leukemia cells, non-
MDR 
ECACC 
HL60/Adr Acute myeloid leukemia cells, 
adriamycin-selected. 
Melvin Center, Kansas 
State University [371] 
HL60/Mdr1 Acute myeloid leukemia cells; 
Mdr1-transfected 
Balazs Sarkadi, Hungary 
[371] 
HL60/mxr Acute myeloid leukemia cells; 
BCRP-transfected 
Balazs Sarkadi, Hungary 
[372] 
H1299-Taxol Lung; paclitaxel-selected NCTCC, derived by Dr. 
Laura Breen [370] 
M14 Melanoma NCI USA 
2008/MRP1 Ovarian; MRP1-transfected P. Borst, University 
Hospital, Amsterdam [373] 
HMEC Normal mammary Lonza 
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2.5.1. Sub-culturing of cell lines 
 
The cell culture medium was removed from the tissue culture flask and discarded into 
a sterile bottle. The flask was then rinsed out with 5 ml of PBS solution (Oxoid, 
BR14a) to ensure the removal of any residual media. Trypsin/EDTA solution (0.25% 
trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, E9884) solution in PBS (Oxoid, 
BRI4a)) was then added to the flask and was incubated at 37oC for the required period 
of time (dependant of each cell line) until all cells were detached from the inside 
surface of the tissue culture flask. The amount of trypsin used varies depending on 
flask size, i.e., 0.5 ml for T25cm2, 1 ml for T75cm2 and 2 - 4 ml for T175cm2. The 
trypsin was deactivated by adding an equal volume of complete media to the flask. 
The cell suspension was removed from the flask and placed in a sterile universal 
container (Sterilin, 128a) and centrifuged at 160 x g for 3 minutes. The supernatant 
was then discarded from the universal and the pellet was suspended in complete 
medium. A cell count was performed. An aliquot of cells was then used to re-seed a 
flask at the required density, topping the flask up with fresh medium. 
 
2.5.2. Assessment of cell number and viability 
 
Cells were trypsinised, pelleted and resuspended in media. An aliquot of the cell 
suspension was then added to trypan blue (Gibco, 525) at a ratio of 5:1. The mixture 
was incubated for 3 minutes at room temperature. A 10µl aliquot of the mixture was 
then applied to the chamber of a glass coverslip enclosed haemocytometer. Cells in 
the 16 squares of the four grids of the chamber were counted. The average cell 
number, per 16 squares, was multiplied by a factor of 104 and the relevant dilution 
factor to determine the number of cells per ml in the original cell suspension. Non-
viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained. On this basis, percentage 
viability was calculated. 
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2.5.3. Cryopreservation of cells 
 
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in section (above). Cell pellets were resuspended in a suitable volume of 
FCS. An equal volume of a 10-20% DMSO/FCS solution was added dropwise to the 
cell suspension. A total volume of 1ml of this suspension was then placed in a 
cryovial (Greiner, 122278). These vials were then placed in the -20oC freezer for 20 
minutes and then in the -80oC freezer overnight. Following this period the vials were 
removed from the -80oC freezer and transferred to the liquid nitrogen tanks for storage 
(-196oC). 
 
2.5.4. Thawing of cryopreserved cells 
 
A volume of 5 ml of fresh warmed growth media was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen tank and thawed rapidly at 
37oC. The cells were removed from the vials and transferred to the aliquoted media. 
The resulting cell suspension was centrifuged at 160 x g for 3 minutes. The 
supernatant was removed and the pellet resuspended in fresh culture medium. An 
assessment of cell viability on thawing was then carried out (see section: 2.5.2.). 
Thawed cells were then added to an appropriately sized tissue culture flask with a 
suitable volume of fresh growth media. 
 
2.5.5. Monitoring of sterility of cell culture solutions 
 
Sterility testing was performed on all cell culture media and related culturing 
solutions. Samples of prepared basal media were incubated at 37oC for a period of 
seven days. This ensured that no bacterial or fungal contamination was present in the 
media. 
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2.5.6. Serum Batch Testing 
 
Batch to batch variation is a major problem associated with the use of FCS in cell 
culture. In extreme cases this variation may result in a lack of cell growth, whereas in 
more moderate cases growth may be retarded. To avoid the effects of the above 
variations, a range of FCS batches were screened for growth of each cell line. A 
suitable FCS batch was then purchased in bulk for a block of work with each 
particular cell line in use. Screening involved seeding cells into a 96 well plate and 
determining growth as a percentage of serum with known acceptance growth rate. 
Logarithmically growing cells were seeded into a 96 well plate (Costar; 3599) from a 
single cell suspension at a density of 103 cells/well in 100 µl of medium without FCS. 
100 µl volumes of medium containing 10%  or 20% FCS was added to respective 
wells on the 96 well plate, resulting in final dilutions of FCS to 5% or 10% 
respectively. The first column of each plate was maintained as a blank and the last 
column was maintained as a control where FCS resulting in known acceptance growth 
rate was used. Plates were placed at 37oC in 5% CO2, for 5 days, after which growth 
was assessed (see section: 2.7.2.). 
 
2.6. Mycoplasma analysis of cell lines 
 
Cell lines were tested for possible mycoplasma contamination in house by Mr. 
Michael Henry. The protocol is detailed in the following section. 
 
2.6.1. Indirect staining procedure for Mycoplasma analysis. 
 
Mycoplasma-negative NRK (Normal rat kidney fibroblast) cells were used as 
indicator cells for this analysis. The cells were incubated with a sample volume of 
supernatant from the cell lines in question and the examined for mycoplasma 
contamination. A fluorescent Hoechst stain was used in the analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cells in addition to any 
mycoplasma present. Mycoplasma infection was indicated by fluorescent bodies in the 
cytoplasm of the NRK cells. 
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2.7. In vitro proliferation assays 
 
Adherent cells in the exponential phase were harvested by trypsinisation as described 
in Section: 2.5.1. Cell suspensions containing 1 x 104 cell/ml were prepared in cell 
culture medium. Volumes of 100 µl/well of these cell suspensions were added to 96-
well plates (Costar; 3599) using a multichannel pipette. Plates were agitated gently in 
order to ensure even dispersion of cells over a given well. Cells were then incubated 
overnight at 37oC in an atmosphere containing 5% CO2. Cytotoxic drug dilutions were 
prepared at 2X their final concentration in cell culture medium. Volumes of the drug 
dilutions (100 µl) were then added to each well using a multichannel pipette. Plates 
were then mixed gently as above. Cells were incubated for a further 6-7 days at 37oC 
and 5% CO2 until the control wells had reached approximately 80-90% confluency. 
Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (see section: 2.7.2.). The concentration of each drug which caused 
50% cell kill (IC50 for that drug) was determined from a plot of the percentage cell 
proliferation (relative to the control cells) versus cytotoxic drug concentration using 
Calcusyn software.  
 
2.7.1. Combination proliferation assays 
 
Cells were harvested in the exponential phase of growth as described in Section: 2.5.1. 
The 96-well plates were seeded as described above and incubated overnight at 37oC 
with 5% CO2. Dilutions of cytotoxic drugs and other agents were prepared at 4X their 
final concentration in media. Volumes of 50 µl of the drug dilution and 50 µl of the 
combination drug dilution were then added to each relevant well so that each well had 
a final volume of 200 µl. All potential toxicity-enhancing agents were dissolved in 
DMSO, ethanol or media. Stock solutions were prepared at approximately 15 mg / 10 
ml media; filter sterilised with a 0.22 µm filter (Millex-GV, SLGV025BS) and then 
used to prepare all subsequent dilutions. Cells were incubated for a further 6-7 days at 
37oC in an atmosphere of 5% CO2. At this point the control wells would have reached 
approximately 80-90% confluency. Cell number was assessed using acid phosphatase 
assay (section: 2.7.3.).  
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2.7.2. Scheduled/pre-treated proliferation assays 
 
Cells were harvested in the exponential phase of growth as described in Section: 2.5.1. 
The 96-well plates were seeded as described above and incubated overnight at 37oC 
with 5% CO2. Dilutions of test agents were prepared at 2X their final concentration in 
media. Volumes of 100 µl of the agent dilution was added to each relevant well so 
that each well had a final volume of 200 µl. All potential toxicity-enhancing agents 
were dissolved in DMSO, ethanol or media. Stock solutions were prepared at 
approximately 15 mg / 10 ml media; filter sterilised with a 0.22 µm filter (Millex-GV, 
SLGV025BS) and then used to prepare all subsequent dilutions. Cells were incubated 
for 24 hours at 37oC in an atmosphere of 5% CO2. At this point all media was 
removed from each well using a 12-channel multichannel pipette and 100 µl of 
warmed fresh media was added to each well. A 2X toxicity curve of the 
chemotherapeutic drug was prepared and 100 µl of each concentration was added to 
the appropriate wells. The plates were incubated at 37 oC for 4 days.  At this point the 
control wells would have reached approximately 80-90% confluency. Cell number 
was assessed using acid phosphatase assay (section: 2.7.3.).  
 
2.7.3. Assessment of cell proliferation by the acid phosphatase assay 
 
Following the incubation period of 6-7 days, media was removed from the plates. 
Each well was washed twice with 100 µl PBS. This was then removed and 100 µl of 
freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma; 104-
0) in 0.1 M sodium acetate (pH 5.5) (Sigma; S8625), 0.1%% triton X-100 (BDH; 
30632)) was added to each well. The plates were then incubated in the dark at 37oC 
for 2 hours. The enzymatic reaction was stopped by the addition of 50 µl of 1 N 
NaOH. The plate was read in a dual beam plate reader (spectrophotometer, Synergy 
HT, Bio-Tek, USA) at 450 nm with a reference wavelength of 620 nm. 
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2.8. Safe handling of cytotoxic drugs 
 
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due 
to the potential risks in handling them. Disposable nitrile gloves (Medical Supply 
Company Ltd) were worn at all times and all work was carried out in cytotoxic 
cabinets (Holten LaminAir Maxisafe). All drugs were stored in a safety cabinet at 
room temperature or in designated areas at 4oC. The storage and means of disposal of 
the cytotoxic drugs used in this work are outlined in Table 2.8.1. 
 
Table 2.8.1.: This table contains a list of chemotherapeutic drugs and other drugs 
used in this project. All drugs were disposed of by incineration. 
Cytotoxic Agent Storage of liquid stock 
Adriamycin 4oC in dark 
Epirubicin 4oC in dark 
Paclitaxel Room temperature in the dark 
Docetaxel Room temperature in the dark 
5-Fluorouracil Room temperature in the dark 
SN-38 -20oC 
Vincristine Room temperature in the dark 
Vinblastine Room temperature in the dark 
Cisplatin Room temperature in the dark 
Celecoxib 4oC 
Sulindac sulfide 4oC 
Valdecoxib Room temperature 
Rofecoxib Room temperature 
Lapatinib Room temperature in the dark 
Elacridar/ GF 4oC 
Tarceva/ Erlotinib Room temperature in the dark 
Iressa/Gefitinib Room temperature in the dark 
 
2.9. Safe handling and stock make-up of all novel compounds 
 
All compounds were handled with extreme caution at all times in the laboratory, due 
to the potential risks of the unknown agents. Disposable nitrile gloves (Medical 
Supply Company Ltd) were worn at all times and all work was carried out in 
cytotoxic cabinets (Holten LaminAir Maxisafe).  
All compounds were weighed in a fume hood and dissolved in media, DMSO or 
ethanol depending on their solubility. All compounds dissolved in media or ethanols 
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were stored in a safety cabinet at room temperature. All compounds in the DMSO 
suspension were stored in designated areas at 4oC. The storage and means of disposal 
of the non-characterised agents used in this work are outlined in Table 2.9.1. 
 
Table 2.9.1.: A list of the novel chemistry compounds entered into the biological 
testing panel. The molecular weight (M.W.), solvent they were dissolved in, solubility, 
and storage. All drugs were disposed of by incineration. 
Novel 
Compound 
M.W. 
(g) 
Vehicle Solubility in Culture 
media with vehicle 
Stock 
storage 
PA1 464 DMSO Soluble -20oC 
PA2 565 DMSO Soluble -20oC 
PA3 202 DMSO Not soluble -20oC 
PA4 218 Water Soluble -20oC 
PA5 356 DMSO Soluble -20oC 
PA6 272 DMSO Soluble -20oC 
RF1 274 DMSO Soluble 4oC 
RF2 314 DMSO Soluble 4oC 
RF3 232 DMSO Soluble 4oC 
RF4 272 DMSO Soluble 4oC 
BM1 324 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
BM2 324 DMSO/Ethanol 
(50:50) 
Soluble 20oC 
BM3 306 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
BM4 306 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
BM5 444 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
RBM2 225 DMSO/Ethanol 
(50:50) 
Soluble 20oC 
RBM3 261 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
RBM4 231 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
RBM5 261 DMSO/Ethanol 
(50:50) 
Not soluble 20oC 
RBM6 231 DMSO Soluble 20oC 
RBM7 302 DMSO Soluble 20oC 
RBM8 344 DMSO Soluble 20oC 
RBM9 288 DMSO Appeared soluble but may 
have had impurities 
20oC 
RBM10 233 DMSO Soluble 20oC 
RBM11 388 DMSO/Ethanol 
(50:50) & salts 
Insoluble 20oC 
RBM12 228 DMSO Soluble 20oC 
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Novel 
Compound 
M.W. 
(g) 
Vehicle Solubility in Culture 
media 
Storage 
RBM13 273 DMSO Soluble 20oC 
RBM14 312 DMSO Soluble 20oC 
RBM15 420 DMSO Soluble 20oC 
RBM16 288 Water Soluble 20oC 
RBM17 342 Water Soluble 20oC 
KG1 568 DMSO Soluble, limitations 4oC 
KG2 568 DMSO Soluble, limitations 4oC 
KG3 504 DMSO Soluble 4oC 
KG4 500 Ethanol Soluble 4oC 
KG5 568 DMSO Soluble, limitations 4oC 
KG6 568 DMSO Soluble, limitations 4oC 
KG100 170 Ethanol Soluble 4oC 
KG101 142 Water Soluble 4oC 
KG102 288 Water Soluble 4oC 
KG103 446 Ethanol Soluble 4oC 
KG104 446 Ethanol Soluble 4oC 
KG105 386 Ethanol Soluble 4oC 
KG200 162 N/A Soluble 4oC 
KG201 210 N/A Soluble 4oC 
KG202 258 N/A Soluble 4oC 
KG203 305 N/A Soluble 4oC 
KG204 240 N/A Soluble 4oC 
KG205 296 Water Insoluble 4oC 
KG206 344 Water Soluble 4oC 
KG207 400 Water & Salt Insoluble 4oC 
KG401 418 Ethanol Not soluble 4oC 
KG402 466 Ethanol Soluble 4oC 
KG403 457 Ethanol Not soluble 4oC 
KG404 458 Ethanol Not soluble 4oC 
KG405 459 Ethanol Soluble 4oC 
KG406 455 Ethanol Soluble 4oC 
KG408 418 Ethanol Soluble, limitations 4oC 
KG411 457 Ethanol Soluble, limitations 4oC 
KG413 455 Ethanol Soluble 4oC 
Titanocene Y 482 Provided in 
solution 
Soluble 4oC 
N/A: not applicable as the compounds are glycols and received in liquid form. 
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2.10. Chemistry compound screening 
 
2.10.1. Compound solubilisation 
 
Test compound (2 mg) was weighed out in a cryovial using the fine balance. DMSO, 
ethanol or water (1 ml) was added and the cryovial was shaken vigorously. The vial 
was then sonicated at 37oC for 1 hour. 
If the compound was dissolved at this stage it was tested for its solubility in cell 
culture complete media (10 µl of the test solution in 40 µl of complete media or a 
dilution to make up 100 µM was carried out). 
If the compound was found not to be soluble in media or if it didn’t fully dissolve 
following sonication then another ml of DMSO, ethanol or water was added and the 
procedure was repeated. 
Some compounds could not be fully dissolved and hence were not tested. 
 
2.10.2. Compound combination proliferations with MDR substrates 
 
The 96-well plates were prepared as described in section 2.7.1. Each novel compound 
was diluted to concentrations of 5 µM, 25 µM, and 50 µM. The first double 
combination to be carried out was with epirubicin and if an interesting result was 
found the double combinations was repeated with docetaxel and 5FU.  
The plates were incubated for a further 6 days, at which time the acid phosphatase 
assay (see section 2.7.2.) was carried out in order to determine the cell density. 
Results from this method gave information on the compounds short term stability in 
culture conditions, of its general toxicity and whether a synergistic combination with 
epirubicin was possible on either the DLKP or DLKP-A cell lines. 
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2.11. Protein investigations 
 
2.11.1. Protein extraction 
 
The tissue culture 10 mm2 petri-dishes were seeded with 1x105 cells in 10 mls of fresh 
complete media. The cells were allowed to grow at 37oC with 5% CO5 until an 80% 
confluency was achieved. Media was removed and the petri dish was rinsed twice 
with cold PBS. Cold RIPA buffer (500 µl, Sigma; R0278) with 5µl 10X Protease 
Inhibitors (Sigma; P2714) and 50 µl 200 mM PMSF (348 mg in 10 ml 100% ethanol) 
was added to the cells and incubated on ice for 20 minutes. Following this period the 
lysed cells were removed, using a cell scraper, and transferred to a sterile eppendorf. 
The sample was passed through a 21-gauge needle (with a 1ml syringe) to shear and 
then centrifuged at 16100 x g for 5 minutes at 4oC. The supernatant was transferred to 
a new sterile eppendorf and stored at -20oC.  
2.11.2. Protein quantification by bicinchoninic acid protein assay 
 
The protein samples were diluted by 1 in 10 in cold PBS. Diluted sample (of 25 µl 
each) was added to the 96 well plate (in duplicate). Part A and part B of the 
bicinchoninic acid (BCA) kit (Pierce; # 23225) were mixed (1:50) when the 96 well 
plate was fully loaded. 200 µl of the part A/B mixture was added to each well. The 
plate was covered with tin-foil to block out the light and incubated for 20 mins at 
37oC. The plate was gently swirled to ensure even mixture before reading on the plate 
reader. The protein concentrations were calculated on the plate reading using software. 
 
2.11.3. Gel Electrophoresis 
 
Proteins for Western blotting analysis were resolved using Sodium Dodecyl Sulphate-
Polyacrylamide Gel Eletrophoresis (SDS-PAGE) gel electrophoresis (SDS-PAGE). The 
stacking and resolving gels were prepared as illustrated in Table 2.11.3.1. The gels 
were set in clean 9 cm x 8 cm gel cassettes, which consisted of 2 glass plates 
separated by a rubber gasket to a width of 1 mm. The resolving gel was added to the 
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gel cassette and allowed to set. Once the resolving gel had set, the stacking gel was 
poured on top. A comb was placed into the stacking gel after pouring, in order to 
create wells for sample loading (maximum sample loading volume of 20 µl for a 12 
well gel and 25-30 µl for a 10 well gel). Some pre-gels were also purchased from 
Lonza (7.5% PAGEr gels, 12well, # 58501) 
 
Table 2.11.3.1.: Preparation protocol for SDS-PAGE gels (2 x 0.75 mm gels) 
Components 7.5% Gel 10%  Gel 5% Stacking Gel 
Acrylamide/bis-acrylamide 30% 
solution (Sigma A-3574) 
3.8 ml 5.07 ml 840 µl 
Ultrapure  water 7.3 ml 5.94 ml 2.84 ml 
1.5 M Tris-HCL pH 8.8 3.75 ml 3.75 ml - 
0.5 M Tris-HCL pH 6.8 - - 1.25 ml 
SDS solution 10% (w/v) 150 µl 150 µl 50 µl 
Ammonium persulphate 10% 
solution (Sigma A-3678) 
60 µl 60 µl 20 µl 
TEMED (Sigma T-9281) 10 µl 10 µl 5 µl 
 
In advance of samples being loaded into the relevant samples wells, 8-40µg of protein 
was diluted in 5X loading buffer and stored on ice. Molecular weight markers (Lonza; 
Prosieve color protein marker, # 50550) were loaded alongside the samples. The gels 
were run at 250V and 20mA (per gel) until the bromophenol blue dye front reached 
the end of the gel, at which time sufficient resolution of the molecular weight markers 
was achieved.  
 
2.11.4. Western Blotting 
 
Western blotting was performed by the method of Towbin H., et al. [374]. Once 
electrophoresis had been completed, the SDS-PAGE gel was equilibrated in transfer 
buffer (25mM Tris (Sigma; T8404), 192 mM gylcine (Sigma; G7126), pH 8.3-8.5) for 
approximately 15 minutes. Ten sheets of Whatman 3 mm filter paper and a 
nitrocellulose membrane (GE Healthcare; cat #: RPN303 2D) were soaked in freshly 
prepared transfer buffer for up to 15 minutes. Five of the filter papers were placed on 
top of each other on the plate of a semi-dry blotting apparatus (Bio-rad) followed by 
the nitrocellulose membrane and the air bubbles were removed. The SDS-PAGE gel 
was then placed on top and the air bubbles were removed again. Finally the last five 
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sheets of wetted filter paper were placed on top and air bubbles were removed. The 
proteins were transferred from the gel to the membrane at a current of 300 mA at 15 V 
for 60 - 75 minutes, until all colour markers had transferred. 
Membranes were blocked for 2 hours with 5% blocking agent in PBS. Then they were 
treated with primary antibody overnight at 4oC. All antibodies were prepared in 3% 
blocking powder in PBS and are listed in Table 2.11.4.1. Primary antibody was 
removed after this period and the membranes were rinsed 3 times with PBS 
containing 0.5% Tween 20 (Sigma; P1379) for a total 15 - 30 minutes.  
The secondary antibody (anti-mouse IgG, Sigma; A6782, used 1:1000) was then 
added for 1 - 1.5 hours at room temperature. The membranes were washed thoroughly 
in PBS containing 0.5% Tween for 15 minutes and finally washed in PBS for another 
5 minutes. 
 
 
Table 2.11.4.1.: Primary antibodies, including the company they were purchased 
from and the dilution used for probing. 
Primary Antibody Company Catalogue # Dilution 
P-glycoprotein Alexis ALX-801-002-C100 1:250 
MRP1 Santa Cruz Sc-18835 1:100 
BCRP Alexis ALX-801-029-C250 1:250 
COX-1 Santa Cruz Sc-52971 1:500 
COX-2 Santa Cruz Sc-19999 1:500 
 
2.11.5. Enhanced chemiluminescence (ECL) detection 
 
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109), which facilitated the detection of bound peroxidase-conjugated secondary 
antibody. Following the final washing membranes were subjected to ECL. A volume 
of 2 ml of a 50:50 mixture of ECL reagents was used to cover the membrane. The 
ECL reagent mixture was removed after a period of one minute and the membrane 
placed between two plastic sheets, air bubbles were carefully removed. The 
membrane was then exposed to autoradiographic (Kodak, X-OMATS) for various 
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times (from 10 seconds to 10 minutes depending on the signal). The exposed 
autoradiographic film was developed in developer (Kodak; LX-24). The film was then 
briefly washed in water and transferred to a fixative (Kodak; FX-40) until clear. After 
another 5-10 minute wash in water, the film was left to dry at room temperature. 
 
2.11.6. ELISAs 
 
Samples were extracted and quantified as in Section 2.11.1. and 2.11.2.  EGFR, 
pEGFR, HER2 and pHER2 levels were examined using developmental sandwich 
ELISA assay kits, DYC1854, DYC1095, DYC1129 and DYC1768 were purchased 
from R&D systems. 
2.11.6.1. EGFR and HER2 
 
The capture antibody was diluted to a working concentration of 0.8 µg/ml (EGFR) 
and 4.0 µg/ml (HER2) with PBS. The 96-well plates were coated with 100 µl of the 
diluted capture antibody. The plate was sealed and incubated overnight at room 
temperature. The capture antibody was aspirated vigorously and washed three times 
with wash buffer (0.05% Tween 20 in PBS, pH 7.2 – 7.4). The plate was blotted dry 
on clean paper towel then blocked for 1 – 2 hours at room temperature by adding 300 
µl of block buffer (1% BSA, 0.05% NaN3 in PBS, pH 7.2 – 7.4). The plate was 
aspirated and washed three times with wash buffer. A volume of 100 µl of each 
sample or standard, diluted in Diluent #12 (1% NP-40, 20 mM Tris (pH 8.0), 137 mM 
NaCl, 10% glycerol, 2 mM EDTA, 1mM activated sodium orthovanadate), was added 
to each well, sealed and incubated at room temperature for 2 hours. The plates were 
aspirated and washed three times with wash buffer. A volume of 100 µl of the diluted 
detection antibody (200 ng/ml) was added to each well, sealed and incubated for 2 
hours at room temperature. The plates were aspirated and washed three times with 
wash buffer. The plates were incubated in darkness for 20 minutes at room 
temperature in the presence of 100 µl diluted Streptavidin-HRP (diluted in Diluent 
#14: 20 mM Tris, 137 mM NaCl, 0.05% Tween 20, 0.1% BSA, pH 7.2- 7.4). The 
plates were aspirated and washed three times. Substrate solution (100 µl) was added 
to each well and incubated in the dark for 20 minutes at room temperature. Stop 
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solution (50 µl) was added to each well. To mix, the plate was gently tapped. The 
plate was read at a wavelength of 450 nm.  
2.11.6.2. Phospho-EGFR and Phospho-HER2 
 
The capture antibody was diluted to a working concentration of 0.8 µg/ml (EGFR) 
and 4.0 µg/ml (HER2) with PBS. The 96-well plates were coated with 100 µl of the 
diluted capture antibody. The plate was sealed and incubated overnight at room 
temperature. The capture antibody was aspirated vigorously and washed three times 
with wash buffer (0.05% Tween 20 in PBS, pH 7.2 – 7.4). The plate was blotted dry 
on clean paper towel then blocked for 1 – 2 hours at room temperature by adding 300 
µl of block buffer (1% BSA, 0.05% NaN3 in PBS, pH 7.2 – 7.4). The plate was 
aspirated and washed three times with wash buffer. A volume of 100 µl of each 
sample or standard, diluted in Diluent #12 (1% NP-40, 20 mM Tris (pH 8.0), 137 mM 
NaCl, 10% glycerol, 2 mM EDTA, 1mM activated sodium orthovanadate), was added 
to each well, sealed and incubated at room temperature for 2 hours. The plates were 
aspirated and washed three times with wash buffer. A volume of 100 µl of the diluted 
detection antibody (200 ng/ml) was added to each well, sealed and incubated for 2 
hours at room temperature. The plates were aspirated and washed three times with 
wash buffer. 100 µl of substrate solution was added to each well and incubated in the 
dark for 20 minutes at room temperature. 50 µl of stop solution was added to each 
well. To mix, the plate was gently tapped. The plate was read at a wavelength of 450 
nm.  
 
 
2.12. Pharmacokinetics studies 
 
2.12.1. Determination of free versus protein-bound epirubicin 
 
An aliquot of 1 ml of foetal calf serum, serum albumin or AAG was prepared and 
epirubicin was added to make a 2 µM solution. This solution was placed above the 
cellulose triacetate ultrafiltration membrane of the 20,000 Da Vivaspin 2 units 
(Sartorius; Cat #: VS02X1). The samples were centrifuged at 3200 x g for 20 minutes. 
The volume of the filtrate (filtered solution) was measured using a P1000 pipette and 
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made up to 1 ml. The remaining solution above the membrane was removed and the 
membrane was rinsed once with PBS. The final volume of solution above the 
membrane and the PBS containing the cake (protein/drug remaining on the surface of 
the membrane) was 1 ml. Samples were stored at -4oC for a maximum of 2 weeks. 
200 µl of each sample was extracted (see section 2.12.3.) and the quantity of 
epirubicin that was protein bound or free was determined using LC-MS analysis (see 
table 2.12.5.1 for mass spectroscopy parameters). 
 
Calculations: 
 
Formula 1: Amount of protein-free drug bound to the membrane. 
Membrane (ng) = Total (ng) – (retentate (ng) + filtrate (ng)) 
 
Formula 2: Percentage of protein-free drug. 
Free (%) = Filtrate (ng) + membrane (ng) × 100 
          Total (ng) 
 
Formula 3: Percentage of drug bound to protein. 
Bound (%) = retentate (ng) × 100 
  Total (ng) 
 
 
2.12.2. Cell Preparation 
 
Vented T25 flasks were seeded with 5 mls of 3 x 104 cells/ml cell suspension and 
incubated at 37oC overnight to allow cells attach.  
2.12.2.1. Accumulation assay:  
 
Method as published by Wall R., et al. [339]. Cells were exposed to 2 µM epirubicin or 
2.5 µM celecoxib, made-up in ATCC media containing 5% FCS, for 2 hours at 37oC. 
After 2 hours the media containing drug was removed and the cells were rinsed with 
sterile PBS. The cells were trypsinised and placed in extraction tubes. They were spun 
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for 3 minutes at 160 x g. The supernatant was removed and 1 ml of PBS was added. 
The cells were counted using the procedure described in section: 2.5.2 and the 
remaining cell suspension was centrifuged at 160 x g for a further 3 minutes. The 
supernatant was removed and the cell pellets were frozen for a maximum period of 2 
weeks. 
 
2.12.2.2. Efflux assay [339]: 
 
Method as published by Wall R., et al. [339]. Cells were exposed to 2 µM epirubicin or 
10 µM celecoxib, made-up in ATCC media containing 5% FCS, for 3 hours. After 3 
hours the media containing drug was removed, the cells were rinsed with warmed 
media and replaced with 5 mls of warmed media. At times 0, 30, 60, and 120 minutes 
cell pellets were prepared as described in section 2.12.2.1.  
 
 
2.12.3. Anthracycline cell-drug extraction procedure: 
 
2.12.3.1. Standards and solutions 
 
Method as published by Wall R., et al. [339]. Epirubicin (2 mg/ml) was purchased from 
Pfizer, Cambridge, MO, USA. The internal standard for epirubicin was daunorubicin 
(2 mg/ml). This was diluted to 1 µg/ml in MS grade water and protected from direct 
light prior to epirubicin extraction. For safe handling of all cytotoxic drugs see section 
(2.8). 
 
2.12.3.2. Extraction procedure 
 
Method as published by Wall R., et al. [339]. The frozen cell pellets were thawed in the 
dark. The pellets were resuspended in 200 µl MS grade water. Then 20 µl of 33% 
silver nitrate was added and the sample was vortexed. 200 µl of the internal standard, 
daunorubicin, was added, followed by 700 µl ice cold isopropanol, 100 µl ammonium 
formate buffer. This mixture was mixed well before 1400 µl chloroform was added 
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using a glass pipette. The extraction tubes were mixed using a Stuart Scientific (UK) 
blood mixer for 5 minutes, and then they were centrifuged for 5 minutes at 3200 x g 
(Thermo (Ireland)). The bottom organic layer (1.1 ml) was removed and placed in a 
glass vial. The vials were evaporated to dryness using a Genevac EZ-2 (Ipswich, UK) 
evaporator at ambient temperature, without light. The samples were reconstituted in 
30 μl of mobile phase with 20 μl injected automatically by the autosampler.  
The standard curve was prepared in the same manner as the cell pellets. A broad range 
of standards (10 ng/ml, 30, 50, 100, 300, 500 and 1000 ng/ml or 10, 50, 100, 500, 
1000, 3000, 5000 ng/ml) was prepared in MS grade water. 
 
2.12.3.3. Mobile phase preparation 
 
Method as published by Wall R., et al. [339]. To 720 ml of MS grade water, 720 µl of 
formic acid was added using a starpette. (Performed in a fume cupboard). The pH, 
which was about 2.5, was very carefully brought up to pH 3.2 using concentrated 
ammonium formate (300 mg/ml, made up in MS grade water). Finally, 280 mls of MS 
grade acetonitrile was added and the bottle was gently shaken to mix.  
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2.12.4. Celecoxib cell-drug extraction procedure 
 
2.12.4.1. Standards and solutions 
 
Celecoxib, valdecoxib and rofecoxib were purchased from Sequoia (UK). Prior to 
drug-cell extraction primary stocks of 0.5 mg/ml rofecoxib, valdecoxib and celecoxib 
were prepared in acetonitrile. A primary stock of 7.6 mg/ml celecoxib was prepared in 
DMSO for use in the accumulation and efflux assays. All coxibs were stored at room 
temperature until use.  
 
2.12.4.2. Extraction procedure 
 
The frozen cell pellets were thawed and resuspend pellet 200 µl MS grade water. An 
aliquot of 50 µl of rofecoxib or valdecoxib internal standard and 50 µl 0.01M 
ammonium formate pH 5 buffer was added. Finally, 1400 µl chloroform was added 
using a glass pipette. The extraction tubes containing the mixture was inverted on a 
Stuart Scientific (UK) blood mixer for 5 minutes and then centrifuged for 5 minutes at 
3200 x g (Thermo (Ireland)). The bottom organic layer was removed (1.1 ml) and 
placed in a glass vial. The vials were evaporated to dryness using a Genevac EZ-2 
(Ipswich, UK) evaporator at ambient temperature, without light. The samples were 
reconstituted in 30 μl of mobile phase with 20 μl injected automatically by the 
autosampler.  
The celecoxib standard curve was prepared in the same manner as the cell pellets. A 
broad range of standards (10 ng/ml, 30, 50, 100, 300, 500, 1000 and 2000 ng/ml) was 
prepared in MS grade water. 
2.12.4.3. Mobile phase preparation  
 
The pH of 350 ml 0.01 M formate buffer was reduced to pH 5.0 and 650 mls of 
acetonitrile was added. The mobile was gently shaken and allowed to settle. The 
method used for triplequad mass spectroscopy determination is modified from 
Satyanarayana U., et al. [375].  
 87
2.12.5. LC-MS (QQQ) analysis 
 
For all drugs, chromatographic separation was achieved using a Prodigy reverse phase 
column (5u ODS3 100A, 150 × 4.60mm, 5 µm) from Phenomemex, UK. The mobile 
phase used per drug is described above (sections 2.12.3.3. and 2.12.4.3.). The mass 
spectrometer was operated using an ESI source in the positive ion detection mode. 
The ionisation temperature was 350oC, gas flow rate was 16 L/min and nebulizer 
pressure was 50 psi. Nitrogen was used as the ionisation source gas and ultrapure 
nitrogen as the collision cell gas. Quantification was based on the integrated peak area 
as determined by the Masshunter Quantification Analysis software which quantitates 
the peak areas of the MRM transitions of each analyte. The conditions for ideal 
separation of each drugs is listed in table (2.12.5.1.) below. 
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Table 2.12.5.1.: The mobile phase, flowrate, column and autosampler temperatures, retention times and MRM transitions for the anthracyclines 
and NSAID’s (coxibs). 
 Epirubicin Daunorubicin Valdecoxib Rofecoxib Celecoxib 
Mobile phase (0.01M formic) 28% ACN, pH 3.2 28% ACN, pH 3.2 65% ACN, pH 5.0 65% ACN, pH 5.0 65% ACN, pH 5.0 
Flowrate (ml/min) 0.25 0.25 0.2 0.2 0.2 
Column temperature (oC) 45 45 20 20 20 
Autosampler temperature (oC) 4 4 4 4 4 
Retention time (mins) 9.5 ± 0.5 4.5 ± 0.5 3 ± 0.5 3.5 ± 0.5 6.5 ± 0.5 
MRM transition (m/z) 544 → 397 528 → 321 315 → 192 315 → 132 382 → 362 
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2.13. Determination of COX activity 
 
Cyclooxygenase (COX, also called Prostaglandin H Synthase or PGHS) is a 
bifunctional enzyme exhibiting both COX and peroxidase activities. The COX 
component converts arachidonic acid to a hydroperoxy endoperoxide (PGG2), and the 
peroxidase component reduces the endoperoxide to the corresponding alcohol (PGH2), 
the precursor of PGs, thromboxanes, and prostacyclins.1,2 It is now well established 
that there are two distinct isoforms of COX, namely COX-1 and COX-2. Cayman’s 
COX Fluorescent Activity Assay provides a convenient fluorescence-based method 
for detecting COX-1 or COX-2 activity in both crude (cell lysates/tissue homogenates) 
and purified enzyme preparations. The assay utilizes the peroxidase component of 
COXs. In this assay, the reaction between PGG2 and ADHP (10-acetyl-3,7-
dihydroxyphenoxazine) produces the highly fluorescent compound resorufin that can 
be analyzed using an excitation wavelength of 530-540 nm and an emission 
wavelength of 585-595 nm. The kit includes isozyme-specific inhibitors for 
distinguishing COX-2 activity from COX-1 activity. As described in the kit booklet 
(Cayman; COX fluorescent activity assay kit, Cat #: 700200). 
2.13.1. Lysate preparation 
 
Cells grown in 90mm tissue culture petri-dishes were collected using a cell scraper 
when confluency had reached about 90%. The cells, suspended in PBS, were counted 
and then centrifuged at 1,000 × g for 10 minutes at 4oC. The supernatent was removed 
and the appropriate volume of cold buffer (100 mM Tris-HCl, pH 7.5 containing 
protease inhibitors) was added to provide a cell suspension containing about 1 × 107 
cells/ml. The sample was pulsed 20 times using a sonicator and spun at 10,000 × g for 
15 minutes at 4oC. The supernatant was removed and stored on ice if performing the 
assay on that day. Otherwise, the sample was stored at -80oC (stable for up to one 
month). 
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2.13.2. Standard curve set-up 
 
A standard curve was carried out in order to obtain the optimum GAIN (optimal 
fluorescent detector setting) for the assay on that day. A volume of 20 µl was removed 
from the resorufin vial (provided in the kit) and diluted with 1.98 ml diluted assay 
buffer. Following a 1 minute incubation the plate was analysed using a fluorometer 
(Bio-tek, Synergy HT from Mason technologies using KC4 software) with an 
excitation wavelength of 530-540 nm and an emission wavelength of 585-595 nm The 
curve was prepared are described in table 2.13.2.1 below. 
 
Table 2.13.2.1.: The preparation of the resorufin standard curve. 
Tube Resorufin stock (µl) Assay buffer (µl) Final concentration (µM) 
A 0 1,000 0 
B 10 990 0.1 
C 20 980 0.2 
D 40 960 0.4 
E 80 920 0.8 
F 120 880 1.2 
G 160 840 1.6 
H 200 800 2 
 
2.13.3. COX activity assay procedure: 
 
This assay was performed according to the assay kit instruction (Cayman; COX 
fluorescent activity assay kit, Cat #: 700200). All samples were tested in duplicate 
wells. Each constituent of the assay was prepared as outlined in the manual provided 
with the assay kit. 
 
1. Standard wells – 180 µl of assay buffer was added to 10 ul of each resuforin 
standard, and read at excitation wavelength 530 – 540 and emission 
wavelength 585 – 595 after 5 minutes. The optimum GAIN was determined by 
setting the sensitivity to ‘auto’ and ‘scale to highest wells’.  
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2. COX positive control wells – 150 µl of the assay buffer was added to 10 ul 
heme, 10 µl fluorescent substrate and 10 µl sample. 
3. Sample wells – 160 µl of assay buffer was added to 10 µl heme, 10 µl 
fluorescent substrate and 10 µl sample. 
4. Sample background wells – 160 µl of assay buffer was added to 10 µl heme, 10 
µl fluorescent substrate and 10 µl sample. 
5. Inhibitor wells – 140 µl of assay buffer was added to 10 µl heme, 10 µl 
fluorescent substrate, 10 µl sample and 10 µl of either DuP-697 or SC-560. 
6. The reaction was initiated, only in the COX positive, sample and inhibitor wells, 
by adding 10 µl of Arachidonic acid solution. 
7. The plate was read after one minute using the same excitation and emission 
wavelengths as the standard curve and the GAIN determined by the standard 
curve. 
 
2.13.4. Calculating COX activity 
The average fluorescence for each standard was calculated and the zero value was 
subtracted from each standard. Using excel, resorufin (µM) (x-axis) versus 
fluorescence (relative units) (y-axis) graph was plotted, a trendline and equation of the 
curve was added. 
The average fluorescence for each sample was calculated and the background was 
subtracted. Using the equation of the curve from the standard curve the fluorophore 
concentration (µM) was calculated for each sample. To calculate the COX activity 
(nmol/min/ml) the follow equation was used: 
 
COX activity (nmol/min/107 cells) =    µM    × Sample dilution 
                    Minute 
Note: At 22oC, one unit of enzyme causes the formation of 1 nmol of fluorophore per minute. 
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2.14. Statistical Analysis 
 
Experimental in vitro data are presented as a mean ± standard deviations from three 
independent experiments, unless otherwise specified. For combination proliferation 
data where the three variables (i.e. drug 1, drug 2 and drug1 and 2 combined) had to 
statistically evaluated the difference in percentage proliferation between drug 1 and 
drug 2 (array 1) was paired against the difference between drug 1 and drug 1 and 2 
(array 2). Levels of significance from these data were calculated using student’s t test 
(two-tailed) (Excel ®, Microsoft). A p-value of less than 0.05 was considered 
significant in all statistical testing. 
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3.1. Screening of potential novel anti-cancer agents 
 
Multidrug resistance (MDR) proteins are expressed in a wide variety of tissue types, 
including, liver [42], gastrointestinal tract [35] and blood brain barrier, and help regulate 
the influx and efflux of substances required for normal cellular functioning [38] [39]. 
However, long-term treatment with chemotherapeutic drugs can lead to the over-
expression of the MDR proteins and the development of the MDR phenotype. This 
phenotype and enhanced expression can be a major cause of treatment failure for 
traditional and modern anti-cancer drugs that are effluxed by MDR transporter 
proteins.  
The search for agents that overcome this phenotype has been investigated for at least 
30 years. An extensive range of MDR modulators has been identified (listed in tables 
1.4.2.1, 1.4.3.1., 1.4.4.1, and 3.1.6.1.) and some of these have reached phase III of 
clinical trials [291] [180] [376]. However, the lack of improvement in outcome [291] [180] [376] 
and increased toxicity associated with the use of these agents [291] has hampered their 
entry into common clinical use. 
 
In this project, we investigated a broad range of novel compounds designed and 
synthesised in the NICB (sixty compounds) and Conway institute (Dublin) (one 
compound) as well as some agents currently undergoing or entering clinical trial. 
These agents were tested by a quick screen for their potential as P-gp and MRP1 
inhibitors and if an agent overcame resistance, further analysis took place. The in vitro 
models chosen for investigating this potential were DLKP and DLKP-A. The DLKP-
A cell line is a daughter cell line of DLKP, a poorly differentiated squamous non-
small cell lung carcinoma. The P-glycoprotein (P-gp) membrane pump is the main 
mechanism of multidrug resistance (MDR) in the DLKP-A cell line [369]. It highly 
over-expresses P-gp, while expressing very low levels of multidrug resistance protein 
1 (MRP1). DLKP, on the other hand, expresses low, yet highly active, MRP1 levels, 
while lacking the P-gp cell membrane transporter [337]. 
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3.1.1. Polyamine derivatives 
 
Polyamines are a group of organic compounds, with two or more primary amino 
groups, that are important in the regulation of gene expression, translation, cell 
proliferation, modulation of cell signalling, protein synthesis, and membrane 
stabilization in all known cell types [377] [378]. Adequate cellular polyamine levels are 
achieved by a careful balance between biosynthesis, degradation, and uptake of 
amines from the surrounding environment. Polyamines affect numerous processes in 
carcinogenesis. Increased polyamine levels are associated with increased cell 
proliferation, decreased apoptosis and increased expression of genes affecting tumour 
invasion and metastasis. Conversely, suppression/depletion of polyamine levels is 
associated with decreased cell growth [379], increased apoptosis and decreased 
expression of genes affecting tumour invasion and metastasis [380] [381]. Polyamines are 
often present at increased concentrations in tumour cells and tissues, for example, 
breast and colon cancer. 
Several hundred polyamine synthesis inhibitors have been developed over the past 20-
25 years with the main focus on decreasing cell growth [379]. However, the potential 
that these compounds could also inhibit MDR function has not been investigated. In 
this section, we used combination proliferation assay to investigate the possibility that 
spermine and 5 polyamine derivatives could inhibit the function of P-gp or MRP1 (for 
methodology see section 2.7.3. and 2.10.).  
The five polyamine compounds tested were less toxic in both cell lines compared to 
their spermine parent (refer to table 3.1.1.1). Spermine had the greatest growth 
inhibitory effect in the DLKP (IC50: 8 ± 1 µM) cell line. The PA1 structure is the most 
similar to spermine and had the greatest cytotoxic effect in both cell lines (10 ± 4 µM 
and 15 ± 2 µM). Spermine and four of the polyamine derivatives did not enhance the 
cytotoxicity of epirubicin in the DLKP cells, however, a mild increase was observed 
with spermine in the P-gp-expressing cell line, DLKP-A. The most toxic derivative, 
PA1, also slightly enhanced the anti-proliferative potential of the MRP1 and P-gp 
substrate, epirubicin, in both the DLKP and DLKP-A cell lines. This would suggest 
that PA1 maybe a weak modulator of both MRP1 and P-gp (see table 3.1.1.1 for 
details). 
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Table 3.1.1.1: The structure, molecular weight, IC50 values and enhancement of epirubicin cytotoxicity (combination result) by spermine and five 
polyamine derivatives in both the DLKP and DLKP-A cell lines. See graph 8.1.1.1. in section 8 for combaintion proliferation assays. 
Compound  Structure Molecular weight (Da) DLKP (µM) Cmb results DLKP-A (µM) Cmb results 
Spermine  
N N
H
H
N N
 
202 *8 ± 1 0 *<60 + 
PA1 
N
N N
H
H
N N
N
 
464 10 ± 4 + 15 ± 2 + 
PA2 F
F
N
H
N
H
N
O
O
F
F
O
F
F
 
565 *110 ± 10 0 74 ± 21 0 
PA4 
N
H
NH2
OF
 
218 *>200 0 *>200 0 
PA5 
N
N
O
O
O
O
 
356 34 ± 3 0 50 ± 40 0 
PA6 
N
N
F
F  
272 *>200 0 130 ± 20 0 
Key: Results presented above represent triplicate determinations carried out on separate days  
*:  single/double determination results   0: no change in epirubicin cytotoxicity  +: mild enhancement of epirubicin cytotoxicity 
>: greater than value presented  <: less than value presented 
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3.1.2. Resveratrol Analogues 
 
Resveratrol has been shown to prevent and slow the progression of a wide variety of 
in vitro disease models, including cancer, cardiovascular disease and ischaemic 
injuries. It also enhances stress resistance and extends the lifespan of various 
organisms from yeasts to vertebrates [382]. In vitro and in vivo studies have identified 
resveratrol as an effective candidate for cancer chemoprevention as it blocks each step 
in the carcinogenesis process [383]. These properties are mainly due to its antioxidant 
activity on molecular targets involved in tumour initiation, promotion and progression 
[384]. 
 
A major limitation of resveratrol is its metabolic stability in the body. In the hope of 
increasing resveratrol’s stability, toxicity and anti-MDR potential, our collaborators in 
the NICB, Dr. Frankie Anderson and Dr. Brian Moran, designed and synthesised a 
range of resveratrol derivatives. From this panel, a selection of analogues were tested 
for their anti-cancer toxicity and their potential to inhibit the function of P-gp and 
MRP1 (for methodology see section 2.7.3. and 2.10.).   
 
Resveratrol and its ten derivatives had the greatest anti-proliferative activity in the 
DLKP cell line (see table 3.1.2.1 for details). RF1 (7 ± 1 μM), RF3 (6 ± 0.3 μM), and 
RBM17 (<10 μM) had a similar toxicity to resveratrol (10 ± 2 μM), in the DLKP cells. 
Whereas RF2 (25 ± 5 µM), RF4 (21 ± 5 µM), RBM12 (>50 μM), RBM13 (39 ± 2 
μM), RBM14 (~50 μM), RBM15 (28 ± 4 μM) and RBM 16 (>50 μM) showed a 
decrease in cytotoxicity when compared to resveratrol in the DLKP cell line. 
Resveratrol (15 ± 3 μM) and RF1 (10 ± 2 μM) were the most potent anti-proliferation 
agents in the DLKP-A cell line. The 3,5-diacetyl analogue, RBM 14, and the 3,5-
amino acid salt, RBM16, had an IC50 value greater than 50 μM, as did the trans-
diamino stilbene RBM12, which lay beyond the range of this assay.  
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With regard to the MDR inhibitory status of resveratrol and its 10 analogues, 
resveratrol slightly increased the anti-proliferative potential of both MRP1 and P-gp 
substrate (epirubicin) while compound RBM15 caused a large enhancement of 
epirubicin toxicity in the P-gp expressing cell line, DLKP-A (see graph 3.1.2.1 and 
table 3.1.2.1. and 3.1.2.2. for details).   
In both the DLKP and DLKP-A cell lines, resveratrol improved epirubicin 
cytotoxicity (Epi 0.01 μM and Res 10 μM). The combination of any of the 10 
fluorinated resveratrol derivatives (10 μM) with the P-gp/MRP1 substrate, 0.01 μM 
epirubicin, resulted in no change in the anti-proliferative potential of epirubicin in the 
DLKP cells (see table 3.1.2.1.). Therefore, these compounds do not modulate the 
transporter function of MRP1.  
On the other hand, a change in the potency of 1.5 μM epirubicin in the DLKP-A cells 
was observed when combined with compounds RF1, RF2, RF4, RBM12, RBM13 and 
RBM14. Compared to resveratrol, RBM17 caused a similar enhancement of 
epirubicin in this cell line. In graph 3.1.2.1, 1.5 μM epirubicin caused a 37% decrease 
in proliferation, 10 μM RBM15, a ditrifluoroacetyl derivative, caused a 16% 
reduction in proliferation, however, and when they were combined they collectively 
reduced proliferation by 80%. This is a significant enhancement of the P-gp substrate 
cytotoxicity, which would suggest RBM15 is a P-gp modulator [385]. The data on the 
RF1 to RF4 compounds were also presented as a poster at the IACR conference in 
2006 and briefly discussed in the IACR newletter following the conference. 
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The combination of 3 resveratrol analogues with epirubicin on the DLKP-A cell line.
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Graph 3.1.2.1: The bar chart above illustrates the effect of the combination of 
resveratrol, RF3, RBM15 and RBM17 with epirubicin in the DLKP-A cell line. No 
DMSO or ethanol toxicity was experienced at these concentrations. The other six 
compounds were also tested but did not enhance the cytotoxicity of epirubicin in 
either the DLKP or DLKP-A cell lines. This graph is the result of a single 
determination. Significance of combination result relative to drugs alone is 
represented by * (p<0.05). Table 3.1.2.2 below depicts the percentage cell 
proliferation and standard deviations for this graph. 
 
Table 3.1.2.2: This table provides data for the combination of epirubicin with 
resveratrol and 3 of its analogues in the DLKP-A cell line. 
Compound Cell Proliferation (%) 
 Alone St Dev (%) Combination St Dev (%) 
Epirubicin 1.5µM 63 ±11   
Resveratrol 10µM 67 ±5 36 ±7.6 
RF3 10µM 85 ±5 56 ±12 
RBM15 10µM 84 ±0.7 19 ±7 
RBM17 10µM 87 ±5 46 ±12 
 
 
 
 
 
in 
* 
*
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Table 3.1.2.1: The structure, molecular weight, IC50 values and anti-P-gp/MRP1 activity of resveratrol and 10 resveratrol analogues in DLKP, 
and DLKP-A cell line. All IC50 results represent duplicate independent determinations. Combination assays were carried out with epirubicin in 
both cell lines (see graph 3.1.2.1 for illustration of these results). 
Compound  Structure Molecular weight (Da) DLKP (µM) Cmb result DLKP-A (µM) Cmb result 
Resveratrol 
HO
OH
OH
 
228 #10 ± 2 + #15 ± 3 + 
RF1 
F
F
O
O
 
274 7 ± 1 0 10 ± 2 0 
RF2 O
O
F
O
O
 
314 25 ± 5 0 19 ± 3 0 
RF3 F
F
OH  
232 6 ± 0.3 0 14 ± 2 0 
RF4 
OH
O
F
O
 
272 21 ± 5 
 
 
0 21 ± 2 0 
RBM12  
 
 
228 > 50 0 > 50 0  F
H2N
NH2
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Compound  Structure Molecular weight (Da) DLKP (µM) Cmb result DLKP-A (µM) Cmb result 
RBM13  
 
 
273 39 ± 2 0 Not soluble 0 
RBM14  
 
 
312 50 ± 5 + 50 ± 3 0 
RBM15  
 
 
408 28 ± 4Ψ 0 20 ± 10Ψ +++ 
RBM16  
 
 
401 >50 + >50 0 
RBM17  
 
 
 
567 >10 + 20 ± 10 + 
Key:  All IC50 results are representative of duplicate independent determinations.  
#:  triplicate independent determinations   Ψ: Duplicate independent determinations 0: no change in epirubicin cytotoxicity 
+: mild enhancement of epirubicin cytotoxicity   +++: large enhancement of epirubicin cytotoxicity 
F
H
N
HN
O
O
-O.+H3N
NH3+.O-
O
CF3
F3C
O
H
N
F
F
O
F
H
N
HN
O
O
F
H
N
HN
F3C
O
CF3
O
H
N
F
F
O
NH3+.O-
CF3
O
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3.1.3. Macrocyclic compounds 
 
Cyclic peptides, such as cyclosporine, and macrocycle compounds, tacrolimus, and 
sirolimus, are immunosuppressants used in organ transplantation and can also act as 
P-gp inhibitors [386]. Polycyclic alkaloids have also been reported to act as P-gp 
inhibitors, but because of their cytotoxicity or other intrinsic pharmacological effects, 
almost all of them have been proven to be unsuitable for clinical use as P-gp inhibitors. 
 
Due to the findings described above, six macrocyclic analogues (KG1 to KG6), 
designed and synthesised by Dr. Brian Deegan of the NICB, were investigated for 
their cytotoxicity and anti-MDR potential in two cells line, DLKP (MRP1-expressing) 
and DLKP-A (P-gp-expressing) (for methodology see section 2.7.3. and 2.10.). It was 
hoped that these ringed structures could additionally be designed to incorporate, and 
thus selectively delivery cytotoxic agents to cancer cells. A hydrolysis reaction would 
open the ringed structure producing MDR transporter pump modulators, therefore 
reducing the efflux of MDR substrates and thus enhancing their cytotoxicity.  
KG3 and KG4 mildly enhanced the anti-proliferative potential of the P-gp substrate, 
epirubicin, in the DLKP-A cell line (see table 3.1.3.5, graph 3.1.3.2 and table 3.1.3.2 
for details). These results were presented as a poster at the IACR conference in 2007. 
To determine whether the effect observed was due to the full macrocycle structure or 
a product of its hydrolysis, Dr. Deegan synthesised six further compounds (KG100 – 
KG105; see figure 3.1.3.1 for structure and sites of hydrolysis). These were also tested 
and three of the compounds had a similar effect on epirubicin cytotoxicity. KG103 
and KG104, had a greater effect on the anti-proliferative potential of epirubicin than 
KG3 or KG4 (see graph 3.1.3.2 and tables 3.1.3.2 and 3.1.3.5 for details). Further 
hydrolysis of these compounds was possible and six more derivatives were 
synthesised and tested. However, with these later derivatives no change in epirubicin 
cytotoxic was observed. This would suggest that the active hydrolysed products of 
KG3 and KG4 are KG103 and KG104. Later, Dr. Ewa Kowalska of the NICB, 
designed and synthesised 6 more macrocyclic derivatives. Of these, only KG405 
mildly enhanced the cytotoxic potential of epirubicin in the P-gp expressing cell line, 
DLKP-A. However, the effect was not significant. 
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Figure 3.1.3.1.: The structure of KG4 and the location of four sites of hydrolysis. 
Hydrolysis across 1 and 2 gives KG104 and KG101. Hydrolysis across 3 and 4 gives 
KG103 and KG101. Hydrolysis across 1 and 3 gives KG100 
 
 
KG100, KG101, KG102, KG105, KG200-KG206, KG408 and KG413 were found to 
be non-toxic (an IC50 above 50µM) in the DLKP-A cell line. KG411 (34µM) had the 
greatest growth inhibition followed by both KG103 (40 ± 18µM) and KG406 (40µM) 
and finally by KG104 (45 ± 11µM) in the DLKP-A cell line (see table 3.1.3.6 for 
details). For the DLKP cell line, five of the compounds tested were found to produce 
slight growth inhibition (see table 3.1.3.5 for details). KG413 (13 ± 3µM) was the 
most toxic followed closely by KG405 (19 ± 3µM) then KG411 (36µM), KG402 
(42µM) and finally KG406 (48µM) in the DLKP cell line. We noticed that KG103 
had a greater impact on the cell growth of DLKP-A compared to DLKP. We 
hypothesised that this might be due to the expression of P-gp in DLKP-A, therefore, 
we tested a small panel of other cell lines resistant due to P-gp over-expression. A549 
expresses MRP1, while its daughter cell line, A549-Taxol, expresses P-gp. H1299 
does not express P-gp while its paclitaxel-selected variant, H1299-Taxol, expresses 
low levels of P-gp. A difference in KG103 sensitivity between non-P-gp and P-gp 
expressing cell lines was not observed in A549 and H1299 cell lines and their variants 
(See graph 3.1.3.1 and table 3.1.3.1 for details).  
KG3, KG4, KG103 (see graph 3.1.3.2 and table 3.1.3.2 and 3.1.3.5 for details), 
KG104 (see graph 3.1.3.3 and table 3.1.3.3 for details), KG105 (see graph 3.1.3.2 and 
table 3.1.3.2 and 3.1.3.5 for details) and KG405 (see graph 3.1.3.4 and table 3.1.3.4 
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for details) moderately enhanced the anti-proliferative potential of epirubicin, and in 
many cases also docetaxel, in the P-gp overexpressing cell line, DLKP-A. These 
compounds were only active in the P-gp expressing cell line, DLKP-A. KG3 and KG4 
were the first macrocycles designed and synthesised for anti-cancer testing. 
Hydrolysis of the macrocycle KG3 produced non-macrocylic compounds KG100 to 
KG105. KG104 increased the cytotoxicity of epirubicin and docetaxel to the greatest 
extent in the P-gp expressing cell line, DLKP-A, at the lowest concentrations (see 
graph 3.1.3.2 and table 3.1.3.2 and 3.1.3.5 for details). But no change in the 
cyctotoxicity of the non-MDR substrate, 5FU, was observed suggesting KG104 effect 
is through P-gp modulation. Therefore, plans to investigate the mode of action by 
which KG104 overcame P-gp-mediated resistance were drawn up. Unfortunately, 
inconsistencies experienced with inter-batch solubility prevented this from being 
pursued (see section 8, graph 8.1.3.1 and table 8.1.3.1 for details). A number of 
attempts were made to dissolve the compound and while some worked, the solvent 
used actually interfered with normal P-gp function and therefore, work could not be 
continued (for details see section 8 graph 8.1.3.1 and table 8.1.3.1). This work was 
presented at the NICB conference in 2007. 
 
Despite the interesting findings with KG104, no work is planned for the future due to 
the inter-batch variation. 
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The IC50 values of KG103 on a panel of lung cell lines.
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Graph 3.1.3.1: The IC50 values of KG103 in a panel of lung cancer cell lines. No 
solvent vehicle (ethanol) anti-proliferative effects were experienced at the 
concentration used. Unless indicated (#) each bar is representative of triplicate 
independent determinations. The IC50 values and their standard deviations are 
presented in table 3.1.3.1 below. 
 
 
Table 3.1.3.1: The IC50 values of KG103 in a panel of lung cancer cell lines. All 
values represent triplicate independent determinations. # indicates duplicate 
independent determinations. 
IC50 DLKP DLKP-A A549 A549-T H1299 H1299-T 
KG103 
(µM) 
118 40 100 105# 100 95# 
stdev (%) ±2 ±18 ±8 ±21 ±6 ±50 
 
#
# 
in 
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The combination of epirubicin with a range of macrocyclic compounds on the DLKP-A 
cell line.
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Graph 3.1.3.2: The bar chart above illustrates the effect of the combination of 6 novel 
macrocyclic compounds with epirubicin in the DLKP-A cell line. No solvent vehicle 
(ethanol) anti-proliferative effects were experienced at the concentrations used. 
Significance of combination result relative to drugs alone is represented by * (p<0.05). 
Table 3.1.3.3 below depicts the percentage cell proliferation and standard deviations 
for this graph. 
 
 
Table 3.1.3.2: This table provides the combination data of epirubicin with 6 
macrocyline compounds in the DLKP-A cell line. 
Compounds Cell Proliferation (%) 
 Alone St Dev (%) Combination St Dev (%) 
Epirubicin 0.5µM 85 ±12   
KG3 100µM 82 ±3 59 ±6 
KG4 20µM 91 ±9 55 ±6 
KG103 20µM 90 ±5 11 ±7 
KG104 10µM 68 ±10 11 ±5 
KG105 40µM 100 ±4 54 ±9 
KG405 10µM 58 ±10 39 ±5 
 
 
in 
*
*
* *
*
*
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The combintion of KG104 with epirubicin, docetaxel and 5FU in the DLKP-A cell line.
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Graph 3.1.3.3: The bar chart above illustrates the effect of the combination of KG104 
with epirubicin, docetaxel and 5FU in the DLKP-A cell line. No adverse ethanol 
effects were observed at concentrations used. This graph is the result of triplicate 
independent determinations. Significance of combination result relative to drugs alone 
is represented by * (p<0.05). Table 3.1.3.4 below depict the percentage cell 
proliferation and standard deviations for this graph. 
 
 
Table 3.1.3.3: This table provides the combination data of epirubicin, docetaxel and 
5FU with KG104 on the DLKP-A cell line. 
Compounds Cell Proliferation (%) 
 Alone St Dev (%) Combination St Dev (%) 
KG104 10µM 68 ±10   
Epirubicin 0.5µM 83 ±4 11 ±5 
5FU 5µM 80 ±8 66 ±5 
KG104 20µM 60 ±8   
Docetaxel 0.005µM 95 ±3 11 ±0.7 
 
 
 
* * 
binati  
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The combination of KG405 with epirubicin, docetaxel and 5FU in the DLKP-A cell line.
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Graph 3.1.3.4: The bar chart above illustrates the effect of the combination of KG405 
with epirubicin, docetaxel and 5FU in the DLKP-A cell line. No adverse ethanol 
effects were observed at the concentration used. Significance of combination result 
relative to drugs alone is represented by * (p<0.05). Table 3.1.3.5 below depicts the 
percentage cell proliferation and standard deviations for this graph. 
 
 
Table 3.1.3.4: This table provides the combination data of epirubicin, docetaxel and 
5FU with KG405 on the DLKP-A cell line. 
Compounds Cell Proliferation (%) 
 Alone St Dev (%) Combination St Dev (%) 
KG405 10µM 58 ±10   
Epirubicin 0.5µM 85 ±0.3 39 ±5 
Docetaxel 0.005µM 94 ±0.5 52 ±7 
5FU 4µM 89 ±1.6 57 ±7 
 
 
 
 
* 
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Table 3.1.3.5: This table provides the compound structure, molecular weights, IC50 values and the level of epirubicin  cytotoxicity enhancement 
of 24 macrocyclic compounds in both the DLKP and DLKP-A cell lines. Unless otherwise indicated, all results represent a single determination. 
The combination proliferation assays that enhanced substrate cytotoxicity the greatest are presented in graph 3.1.3.2 and table 3.1.3.2.  
Compound Structure Molecular 
weight (Da) 
DLKP  
IC50 (µM) 
Cmb result DLKP-A  
IC50 (µM) 
Cmb result 
KG1 
O
O
O
O
O
O
O O
O O
 
569 N/A 0 N/A 0 
KG2 
O
O
O
O
O
O
O O
O O
 
569 N/A 0 N/A 0 
KG3 
O
O
O
O O
O
O
O
O
O
O O
 
504 N/A 0 N/A *+ 
KG4 
O
O
O
O
O
O
O O
O O
 
500 
 
 
 
 
 
N/A 0 
 
 
 
 
 
 
N/A *+ 
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Compound Structure Molecular 
weight (Da) 
DLKP  
IC50 (µM) 
Cmb result DLKP-A  
IC50 (µM) 
Cmb result 
KG5 
O
O
O
O
O
O
O O
O O
 
569 N/A 
 
 
0 N/A 0 
KG6 
O
O
O
O
O
O
O O
O O
 
569 N/A 0 N/A 0 
KG100 OH
O
OH  
154 N/A 0 > 120 0 
KG101 
HO OH
O O
 
132 N/A 0 > 140 0 
KG102 
O
O
O
OO
O  
266 
 
 
 
 
N/A 0 > 70 0 
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Compound Structure Molecular 
weight (Da) 
DLKP  
IC50 (µM) 
Cmb result DLKP-A  
IC50 (µM) 
Cmb result 
KG103 O
O
OH
O
O
HO  
405 118 ± 2 
 
0 #40 ± 18 #+++ 
KG104 OH
O
O O
O
OH
O O  
405 #88 ± 9 0 #45 ± 11 #Ψ++++ 
KG105 O
O
OH
O
O
HO  
348 N/A 0 > 50 ++ 
KG200  151 >250 0 >300 0 
KG201  195 >115 0 >230 0 
KG202  239 >95 0 >190 0 
KG203  284 >80 0 >160 0 
KG204  
 
 
210 
 
 
 
N/A 0 >210 0 
HO
O
O
OH
HO
O
O
O
OH
HO
O
O
O
O
OH
HO
O
O
O
O
O
OH
O O
O
O
O
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Compound Structure Molecular 
weight (Da) 
DLKP  
IC50 (µM) 
Cmb result DLKP-A  
IC50 (µM) 
Cmb result 
KG206  
 
 
312 N/A Not tested 
 
 
 
>145 0 
KG402 
O
O
OH
O
O
HO
OO
 
466 42 0 N/A 0 
KG405 
O
O
HO
O
O
OH  
459 #19 ± 3 0 #34 ± 4 #Ψ+ 
KG406 
O
O
HO
O
O
OH
N
 
455 48 0 40 0 
KG408 
O
HO
O
O
O
OH
O
 
418 
 
 
 
N/A Not tested 64 ± 20 0 
O
O
O
OO
O
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Compound Structure Molecular 
weight (Da) 
DLKP  
IC50 (µM) 
Cmb result DLKP-A  
IC50 (µM) 
Cmb result 
KG411 
O
HO
O
O
OH
O
 
457 36 0 34 0 
KG413 
O
HO
O
N
O
OH
O
 
455 13 ± 3 0 58 ± 15 0 
Key:   
N/A compound not tested  
#  triplicate independent determination 
Ψ combination proliferation assays of the test compound also carried out with docetaxel 
0 no change in cytotoxic potential of epirubicin 
+ mild enhancement of epirubicin cytotoxicity 
++ moderate enhancement of epirubicin cytotoxicity 
+++ large enhancement of epirubicin cytotoxicity 
++++ large enhancement of epirubicin at lowest concentration 
> greater than the value indicated 
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3.1.4. Metal agents 
 
Normally metal-based drugs, i.e. cisplatin, do not interact with multidrug resistance 
transport proteins (mentioned in section 1.0 in tables 1.4.1, 1.4.2, and 1.4.3). In this 
section, we determined if a titanium metal compound developed and synthesised by 
Dr. Matthias Tacke in the Conway Institute, UCD, was cytotoxic in MDR expressing 
cell lines (for methodology see section 2.7.3. and 2.10.). We chose two cell lines, 
DLKP and DLKP-A, for their expression of MRP1 and P-gp. Titanocene Y was 
selected from a panel of compounds. 
The cytotoxicity of Titanocene Y was moderate in both the DLKP (25 ± 3 µM) and 
DLKP-A (18 ± 4µM) cell lines. Titanocene Y did not enhance epirubicin cytotoxicity 
in either cell line. Therefore, at the concentrations used, Titanocene Y does not 
modulate P-gp or MRP1 pump function and these cells are not sensitive to it. No 
further work is planned in this area. 
 
Table 3.1.4.1.: This table provide the IC50 values and combination proliferation assay 
results for Titanocene Y in both the DLKP and DLKP-A cell lines. 
Compound 
(µM) 
DLKP Combination 
result 
DLKP-A Combination 
result 
Titanocene Y 25 ± 3 No additivity 18 ± 4 No additivity 
 
H3CO
OCH3
Ti
Cl
Cl
 
 
Figure 3.1.4.1.: The structure of Titanocene Y. The compound has a molecular 
weight of 482 Da. 
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3.1.5. Nano-particulate polymerised daunorubicin 
 
In this section, we investigated the potential that surrounding daunorubicin with a 
polymer, poly(butylcyanoacrylate), could assist distribution and/or overcome/evade 
MDR efflux pumps [387] [388]. The full compound was synthesised by polymerising n-
butylcyanoacrylate monomers in the presence of daunorubicin. To evaluate if this 
daunorubicin delivery system, which was designed and synthesised by our 
collaborators in DCU and the Conway institute, could evade P-gp and MRP1-
dependent efflux in vitro, we carried out straight proliferation assays (for 
methodology see section 2.7.) of daunorubicin, nano-particulated polymerised 
daunorubicin, daunorubicin plus the particulate/polymer, and the particulate/polymer 
in both the DLKP and DLKP-A cell lines. 
The straight proliferation assay of the polymerised daunorubicin particule in both the 
DLKP and DLKP-A cell line gave a similar toxicological response as unmodified 
daunorubicin (see table 3.1.5.1 for details). The particulate was less toxic than the test 
agents and the combination of daunorubicin with the particulate did not heighten the 
growth inhibition of daunorubicin (see table 3.1.5.1 for details). However, at high 
concentrations the encapsulation of daunorubicin reduced its potency in the P-gp 
overexpressing cell line, DLKP-A (see graph 3.1.5.1 for details). This work was 
published in Simeonova M., et al., [389]. 
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Figure 3.1.5.1.: The molecular structure of daunorubicin (M.W. 527.52 Da). 
Daunorubicin consists of a planar aglycon chromophore bearing an amino acid ring. 
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Graph 3.1.5.1.: The toxicity curves of daunorubicin (■), the nanoparticulate (▲), the nanoparticulate combined with daunorubicin (●) and the 
nanoparticulate encapsulating daunorubicin (  ) in the DLKP (A) and DLKP-A (B) cell lines. These graphs are the result of a single assay. For 
the IC50 of these curves please refer to table 3.1.5.1 below. 
 
Table 3.1.5.1.: This table provides the IC50 values of daunorubicin and its nano-particulate modified version in both the DLKP and DLKP-A cell 
lines. Concentrations used were calculated using the molecular weight of daunorubicin.  
Compound  DLKP  IC50 (µM) DLKP-A IC50 (µM) 
Daunorubicin 0.024 0.5 
Daunorubicin + Particulate 0.024 0.5 
Daunopart 0.026 0.8 
Particulate >0.05 >0.8 
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3.1.6. MDR down-regulation 
 
In this section, we investigated a range of small molecule agents that, according to the 
literature, modulate P-gp, MRP1 or BCRP expression. For this, we chose the lung 
cancer cell lines, A549, A549-Taxol, and DLKP-SQ/mitox. A549 expressed moderate 
levels of MRP1 and does not express P-gp or BCRP. A549-Taxol is the daughter cell 
line of A549 and was selected using paclitaxel (work carried out by Dr. Laura Breen 
[370]). A549-Taxol expresses moderate levels of P-gp but does not express MRP1 or 
BCRP. Both the A549 and A549-Taxol cell lines are moderately resistant due to the 
expression levels of their MDR proteins. DLKP-SQ/mitox is a squamous non-small 
cell lung carcinoma cell line that was selected from DLKP-SQ using mitoxantrone 
(work carried out by Helena Joyce of the NICB). DLKP-SQ/mitox does not express 
MRP1 or P-gp but expresses high levels of BCRP.   
The selection of these agents (listed in table 3.1.6.1 below) was based on the 
availability of information in the literature, i.e. biochemical data, known interactions 
with MDR pumps and existing availability for use in a clinical trial setting.  The doses 
used in this work are also presented in table 3.1.6.1 and fall below the maximum 
concentration achievable in the blood, with the exception of 10 µM celecoxib (2 µM) 
and 5 µM ibuprofen (2 µM).  These doses have been used in the literature and allow a 
direct comparison between the findings presented herein and those already published. 
The cells were exposed to each agent for 24 hours; allowing the drug enough time to 
alter protein expression (for methodology see section 2.11.). For agents that reduced 
MDR protein expression by more than 20%, they were brought forward for further 
analysis. This included examining the stability of the alteration in expression induced 
by the agents, the toxicity of the agents and their ability to overcome MDR-mediated 
resistance in co-treatment and pre-incubation proliferation assays (for methodology 
see section 2.11., 2.7.1., 2.7.2., and 2.7.3.). Over the next year, this body of work will 
be submitted for publication. 
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Table 3.1.6.1: Below is a list of agents known to alter MDR protein expression. 
Included in the table is a range of doses employed in the assay, the duration of 
exposure and summary of published findings for each agent. 
 
Class Drug Dose (µM) Exposure 
(hr) 
Summary effect on 
transporter 
TKI Lapatinib 0.3, 0.5, 1 24 P-gp [112] & BCRP 
[97] inhibitor 
 Erlotinib 0.3, 0.5, 1 24 P-gp [197] & BCRP 
[148] inhibitor 
 Gefitinib 0.3, 0.5, 1 24 P-gp & BCRP 
inhibitor [150] 
NSAID Sulindac 
(sulphide) 
0.5, 2, 5 24 ↓MRP1↑P-gp [171] 
[172] [173] 
 Celecoxib 0.5, 2, 10 24 ↓MRP1 [174]↓P-gp 
[160] 
 Ibuprofen 0.5, 2, 5 24 P-gp inhibitor [171]
 Indomethacin 0.4, 1, 2 24 ↓P-gp [96], MRP1 
[177] & BCRP [96] 
inhibitor 
Hsp 90 17-AAG 0.1, 0.5, 1 24 ↓P-gp [3] 
Other Elacridar 0.3, 0.5, 1 24 P-gp [191] & BCRP 
[193] inhibitor 
Key: 
↑ up-regulation of protein expression 
↓ down-regulation of protein expression 
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3.1.6.1. P-gp downregulation 
 
A549-Taxol was the P-gp expressing cell line chosen for this work. Figure 3.1.6.1 
outlines the P-gp (170 kDa) Western blots of A549-Taxol cells following a 24 hour 
exposure to each agent. β-actin (a 48 kDa house-keeping protein) was used as a 
control for protein loading and to show that the lysates were in good condition. 
For the lapatinib, erlotinib, gefitinib and elacridar-treated cells (lane 1 – 3) the bands 
from treated cells were bigger than the control/untreated (C) bands. This indicated that 
the P-gp protein expression was up-regulated in the presence of these agents. 
Densitometric analysis of these blots (which is presented as percentage change in 
table 3.1.6.2) supports these visual findings. These Western blots were not repeated as 
they did not qualify for further testing. Celecoxib, indomethacin and 17-AAG-treated 
cells (lane 1 – 3) showed a decrease in P-gp protein expression when compared to 
their control bands (C). Only the highest concentration of celecoxib (10 µM) 
downregulated the expression of P-gp. Indomethacin affected expression at 1 and 2 
µM but not with 0.4 µM. 17-AAG downregulated expression at 0.3, 0.5 and 1 µM. A 
60% decrease in expression occurred when the A549-Taxol cells were exposed to 1 
µM 17-AAG for 24 hours. The only small molecule agent that did not affect P-gp 
protein expression was ibuprofen. Densitometry was carried out on all the Western 
blots and is presented in table 3.1.6.2 in the form of percentage changes.  
Western blotting and densitometric analysis demonstrated that two small molecule 
agents, indomethacin and 17-AAG, noticably down-regulated the expression of P-gp. 
To identify if this down-regulation was maintained following removal of the drug 
after 24 hours, and if the concentrations used reduced cell proliferation, further 
Western blots were carried out, as well as short term proliferation assays.  
All concentrations of indomethacin down-regulated the expression of P-gp following 
a 24 hour exposure, however, this was not maintained once the drug was removed for 
24 and 48 hours (see figure 3.1.6.1.2.). A concentration of 1 µM 17-AAG down-
regulated the expression of P-gp in the A549-Taxol cells following a 24 hour 
exposure. This down-regulation was sustained for 24 and 48 hours in drug-free media 
(see figure 3.1.6.1.2.).  
In 6-well plates, with cells seeded at a density of 7 × 104 cells/ml, all concentrations 
were found to be non-toxic following a 24 hour exposure (see graphs 8.1.6.1.1.A and 
8.1.6.1.1.B for details). 
 120
Target Protein           Western blot    Summary effect 
C    1   2   3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.6.1.1.: The P-gp Western blots of A549-Taxol treated for 24 hours with a 
panel of agents listed in table 3.1.6.1. The drug concentrations used in this work are 
also presented in table 3.1.6.1. P-gp has a molecular weight of 170 kDa and the 
housekeeping protein, β-actin with a molecular of 48 kDa, used as a protein loading 
control.  Each sample was incubated at 37oC for 24 hours in ATCC media containing 
5% FBS. Control samples had no drug in their media. 40 µg of sample was loaded 
into each well. The positive control used was DLKP-A but is not included in these 
images (see figure 3.4.1.3. for P-gp expression). The densitometric analysis of these 
blots is represented in table 3.1.6.2. These Western blots are representative of 
duplicate or more independent determinations unless otherwise indicated (#). 
P-gp (170kDa) 
β-actin (48kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
↑ by Lapatinib after  24hrs# 
↑ by Gefitinib after 24hr# 
↑ by Erlotinib after 24hr# 
↓ by Celecoxib after 24hr 
↑ by Sulindac Sulphide after 24hr# 
↓ by Indomethacin after 24hr 
↔ by Ibuprofen after 24hr# 
↑ by Elacridar after 24hr# 
↓ by 17-AAG after 24hr 
Key:  
C: Control / untreated  ↑:         Protein expression up-regulation 
1: 1st drug concentration  ↓: Protein expression down-regulation 
2: 2nd drug concentration ↔: No change in protein expression 
3: 3rd drug concentration  #: Single replicate
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Table 3.1.6.1.2.: Percentage changes in the expression of P-gp in A549-Taxol cells 
following exposure to a range of agents (listed above) for 24 hours. These percentage 
changes were determined using densitometric analysis of Western blots carried out on 
lysates of the exposed A549-Taxol cells. The numbers 1-3 represent increasing 
concentrations of each agent which are listed in table 3.1.6.1.  
                                 Percentage change 
Drug panel  1st 
concentration 
2nd 
concentrations
3rd 
concentration
Lapatinib 40 130 130 
Erlotinib 170 200 160 
Gefitinib 200 140 90 
Celecoxib 0 -10 -20 
Sulindac S. -10 0 30 
Ibuprofen -20 20 0 
Indomethacin$ 0 -20 -50 
Elacridar 70 70 80 
17-AAG$ -20 -10 -40 
 
Key: 
$ Indicates successful candidates that were brought forward for testing stability in expression 
alteration, toxicity and proliferation assay. 
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Figure 3.1.6.1.2.: The P-gp Western blots of A549-Taxol treated for 24 hours with 
indomethacin or 17-AAG. Drug was removed after the 24 hour exposure and the cells 
were rinsed and fresh media was added. The drug concentrations used in this work are 
presented in table 3.1.6.1. Samples were taken 0 hours, 24 hours and 48 hours after 
drug removal. P-gp has a molecular weight of 170 kDa and the housekeeping protein, 
β-actin with a molecular of 48 kDa, used as a protein loading control. Each sample 
was incubated at 37oC for 24 hours in ATCC media containing 5% FBS. Control 
samples had no drug in their media. 40 µg of sample was loaded into each well. The 
positive control used was DLKP-A. These Western blots are the result of a single 
experiment and represent a trend over a period of 48 hours. 
 
 
 
 
 
 
 
 
 
 
Indomethacin 
P-gp 
β -actin 
17-AAG 
P-gp 
β -actin 
Key:  
C: Control / untreated  
1: 1st drug concentration  
2: 2nd drug concentration 
3: 3rd drug concentration
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Combination and scheduled proliferation assays: 
 
Using the two small molecule agents investigated in graph 8.1.6.1.1 (section 8) and 
figure 3.1.6.1.2, we examined if the down-regulation of P-gp protein could sensitise 
the A549-Taxol cells to the P-gp substrate, docetaxel. 
We found that indomethacin did not heighten the anti-proliferative potential of 
docetaxel in either the direct combination (5 ± 0.3 µM) or as a pre-treatment (9 ± 0.5 
µM) for docetaxel in the A549-Taxol cell line (see graph 3.1.6.1.1, 3.1.6.1.3 and table 
3.1.6.1.2. for details). All concentrations of indomethacin were non-toxic in both the 
combination and scheduled proliferation assays (see graph 3.1.6.1.1 and table 
3.1.6.1.2 for details). 
When the A549-Taxol cells were exposed to 0.3, 0.5 and 1 µM 17-AAG for 5 days, 
all concentrations were highly toxic (1-3% proliferation detected, see graph 3.1.6.1.2 
and table 3.1.6.1.2 for details). Therefore, when directly combined with docetaxel, no 
change in cell proliferation, compared to 17-AAG alone, was observed (see graph 
3.1.6.1.2. When the cells were exposed to 17-AAG for only 24 hours, and incubated 
for a further 4 days, the toxic effects were greatly reduced. A concentration 0.3 µM 
17-AAG allowed 49% (±18%), 0.5 µM 17-AAG allowed 43% (±18%) and 1µM 17-
AAG allowed 29% (±18%) cell proliferation (see table 3.1.6.1.2 for details). Using a 
24 hour pre-treatment method (scheduling proliferation assay), these concentrations 
reduced the IC50 of docetaxel, from 5 ± 0.4 µM to 0.7 ± 0.4 µM, 0.4 ± 0.2 µM and < 
0.07 µM (see graph 3.1.6.1.2.B, 3.1.6.1.3 and table 3.1.6.1.2 for details).  
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Graph 3.1.6.1.1.: The combination (A) and scheduling (B) assays of indomethacin 
and docetaxel (   ) in the A549-Taxol cell line. An IC50 curve of docetaxel combined 
or pre-treated with 0.5 (■), 1 (▲) and 2 µM (●) indomethacin over a 5 day period. 
The combination proliferation assay (A) is the combination of both drugs together on 
the cells at the same time. The 24 hour pre-treatment (B) is when the cells are exposed 
to indomethacin for 24 hours, removed and docetaxel is added for 4 days. Each graph 
is the result of a single assay with intra-day variation represented by error bars. 
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Graph 3.1.6.1.2.: The combination (A) and scheduling (B) assays of 17AAG and 
docetaxel (   ) in the A549-Taxol cell line. An IC50 curve of docetaxel when either co-
incubated or pre-treated with 0.3 (■), 0.5 (▲) and 1µM (●) 17AAG over a 5 day 
period. The combination proliferation assay (A) used the combination of both drugs 
together on the cells at the same time. In the scheduling proliferation assay (B) the 
cells are exposed to 17-AAG for 24 hours, removed and docetaxel added for 4 days. 
Each graph is the result of duplicate independent determinations and inter-day  
variation is represented by error bars. The IC50 of docetaxel alone, incombination and 
following a 24 hour pre-treatment are presented in graph 3.1.6.1.4. and table 3.1.6.1.2.
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Graph 3.1.6.1.3.: The IC50 values of docetaxel, alone and combined/scheduled with 
either indomethacin or 17-AAG, calculated using Calcusyn software. All values are 
the result of a duplicate determination. A star (#) indicates where the small molecule 
agent caused significant cytotoxicity alone. Table 3.1.6.1.2 outlines that percentage 
cell proliferation for each agent and the change in IC50 of docetaxel when combined 
or as part of a scheduled assay. 
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Table 3.1.6.1.2.: This table provides the percentage cell proliferation and the calculated average IC50 values (nM) of docetaxel for the duplicate 
combination and scheduled proliferation assays presented in graphs 3.1.6.2.1, and 3.1.6.2.2. These IC50 values are illustrated in graph 3.1.6.2.3. 
All results are due to duplicate independent determinations. 
Drug Combination assay 
Cell proliferation (%) 
Combination assay 
IC50 value 
Scheduling assay 
Cell proliferation (%) 
Scheduling assay 
IC50 values 
Docetaxel N/A 3.5 ± 1.5 N/A 7 ± 2 
Indomethacin 0.4 100 5 ± 0.3 100 9 ± 0.4 
Indomethacin 1 100 5 ± 0.3 100 9 ± 0.4 
Indomethacin 2 100 6 ± 0.3 100 8 ± 0.4 
17-AAG 0.3 2 ± 2 < 0.07 49 ± 18 0.7 ± 0.4 
17-AAG 0.5 1 ± 2 < 0.07 43 ± 18 0.4 ± 0.2 
17-AAG 1 2 ± 1 < 0.07 29 ± 18 < 0.07 
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3.1.6.2. MRP1 down-regulation 
 
As discussed in 3.1.7., A549 was the MRP1-expressing cell line chosen for this body 
of work. Figure 3.1.7.1 outlines the MRP1 (190 kDa) Western blots of A549 cells 
following a 24 hour exposure to each agent. β -actin (a 48 kDa house-keeping protein) 
was used as a control for protein loading and showed that the lysates were in good 
condition. 
 
For the erlotinib, gefitinib, ibuprofen and indomethacin-treated cells (lane 1 – 3) the 
bands of the treated cells were bigger than the control/untreated (C) bands. This 
indicated that the MRP1 protein expression was up-regulated in the presence of these 
agents. Densitometric analysis of these blots (which is presented as percentage change 
in table 3.1.7.2) supports these visual findings. These Western blots were not repeated 
as they did not merit for further testing. Lapatinib, celecoxib, sulindac sulphide and 
17-AAG-treated cells (lane 1 – 3) showed a decrease in MRP1 protein expression 
when compared to their control bands (C). Only the highest concentration of 
celecoxib (10 µM) downregulated the expression of MRP1. The only small molecule 
agent that did not affect MRP1 protein expression was elacridar. This Western blot 
was not repeated as it did not merit for further testing.   
Densitometry was carried out on all the Western blots and is presented in table 3.1.7.2 
in the form of percentage changes.  
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Target Protein    Western blot Summary effect 
   C    1     2    3    
 ↓ by Lapatinib after 24hr 
 
  ↑ by Erlotinib after 24hr# 
 
  ↑ by Gefitinib after 24hr# 
 
  ↓ by Celecoxib after 24hr 
 
   
 
  ↑ by Ibuprofen after 24hr# 
 
  ↑ by Indomethacin after 24hr# 
  
 ↑ by Elacridar after 24hr# 
 
 ↓ by 17-AAG after 24hr 
 
 
 
 
 
 
 
 
Figure 3.1.6.2.1.: The MRP1 Western blots of A549 treated for 24 hours with a panel 
of agents listed in table 3.1.7.1. The drug concentrations used in this work are 
presented in table 3.1.6.1. MRP1 has a molecular weight of 190 kDa and the 
housekeeping protein, β-actin with a molecular weight of 48 kDa, used as a protein 
loading control. Each sample was incubated at 37oC for 24 hours in ATCC media 
containing 5% FBS. Control samples had no drug in their media. 40 µg of sample was 
loaded into each well. The positive control used was 2008/MRP1 but is not shown 
(for proof of expression see figure 3.4.1.2.). The densitometric analysis of these blots 
is represented in table 3.1.7.2. These Western blots are the result of duplicate or more 
experiments unless otherwise indicated (#). 
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
Key:  
C: Control / untreated  ↑:         Protein expression up-regulation 
1: 1st drug concentration  ↓: Protein expression down-regulation 
2: 2nd drug concentration ↔: No change in protein expression 
3: 3rd drug concentration  #: Single replicate
↓ by Sulindac Sulphide after 24hr 
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Table 3.1.6.2.1.: Percentage changes in the expression of MRP1 in A549 cells 
following exposure to a range of agents (listed above) for 24 hours. These percentage 
changes were determined using densitometric analysis of Western blots carried out on 
lysates of the exposed A549 cells. The numbers 1-3 represent increasing 
concentrations of each agent which are listed in table 3.1.7.1.  
 
 Percentage change 
Drug Panel 1st 
concentration
2nd 
concentration
3rd 
concentration 
Lapatinib* -60 -80 -70 
Erlotinib 110 90 40 
Gefitinib 110 140 270 
Celecoxib 30 40 -20 
Sulindac Sulphide# 50 30 -40 
Ibuprofen 50 60 30 
Indomethacin -10 0 -10 
Elacridar 260 320 260 
17-AAG# -40 -60 -70 
 
Key: 
# Indicates successful candidates that were brought forward for testing stability in expression 
alteration, toxicity and proliferation assay. 
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Figure 3.1.6.2.2.: The MRP1 Western blots of A549 treated for 24 hours with 
lapatinib, sulindac sulphide or 17-AAG. Drug was removed after the 24 hour 
exposure and the cells were rinsed and fresh media was added. Samples were taken 0 
hours, 24 hours and 48 hours after drug removal. The concentrations used in this work 
are presented in table 3.1.6.1. MRP1 has a molecular weight of 190 kDa and the 
housekeeping protein, β-actin with a molecular weight of 48 kDa, used as a protein 
loading control. Each sample was incubated at 37oC for 24 hours in ATCC media 
containing 5% FBS. Control samples had no drug in their media. 40 µg of sample was 
loaded into each well. The positive control used was 20 µg of 2008/MRP1 but is not 
shown (for proof of expression see figure 3.4.1.2.). These Western blots are the result 
of duplicate or more independent Western blots unless otherwise indicated (#). 
 
 
 
 
 
 
Lapatinib MRP1 
β-actin 
MRP1 
β-actin 
Sulindac sulphide 
17-AAG MRP1 
β-actin 
Key: 
C: untreated 
1: 1st concentration of drug 
2: 2nd concentration of drug 
3: 3rd concentration of drug 
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Table 3.1.6.2.2.: Percentage changes in the expression of MRP1 in A549 cells 
following exposure to the selected small molecule agents (listed above) for 24 hours 
with samples taken 24 and 48 hours later (Western blots are preseted in figure 
3.1.6.2.2.). These percentage changes were determined using densitometric analysis of 
Western blots carried out on lysates of the exposed A549 cells. The numbers 1-3 
represent increasing concentrations of each agent which are listed in table 3.1.7.1.  
 
 Percentage change 
Treatment 1st concentration 2nd concentration 3rd concentration 
Lapatinib 0 hr 28 22 -100 
Lapatinib 24 hr -50 -44 -10 
Lapatinib 48 hr 209 -33 -10 
Sulindac S. 0 hr 29 -20 -60 
Sulindac S. 24 hr -20 -36 -62 
Sulindac S. 48 hr -45 -39 -80 
17-AAG 0 hr 19 -67 -93 
17-AAG 24 hr 51 45 16 
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Combination and scheduled proliferation assays: 
Using the two small molecule agents investigated in graph 8.1.6.2.1 (see section 8) 
and figure 3.1.6.2.2, we examined if the down-regulation of MRP1 protein could 
sensitise the A549 cells to the MRP1 substrate, vincristine. 
We found that the lapatinib combination with vincristine mildly decreased cell 
proliferation and therefore reduced the IC50 of vincristine from 12 ± 4 nM to 6 ± 4 nM 
(see graph 3.1.6.2.1, 3.1.6.2.4 and table 3.1.6.2.3 for details). In some cases, this 
potentiation can be attributed to the anti-proliferative potential of lapatinib itself 
(between 1 and 10 % growth inhibition, see table 3.1.6.2.3 for details). However, with 
the highest concentration of lapatinib (1 µM), the enhancement was slightly greater 
than could be attributed to either drug alone (see graph 3.1.6.2.1.A for illustration). 
This would suggest that lapatinib may mildly modulate MRP1. The use of lapatinib in 
the scheduling assay was less effective. When both replicates are integrated they 
indicate there is no effect on the IC50 value of vincristine (see graph 3.1.6.2.1.A, 
3.1.6.2.4 and table 3.1.6.2.3 for details). 
Sulindac sulphide had a moderate effect on the IC50 value of vincristine. It reduced the 
IC50 from 12 ± 4 nM to 8 ± 2 nM at the biologically achievable concentration of 2 µM 
(see graph 3.1.6.2.2.A, 3.1.6.2.4 and table 3.1.6.2.3 for details). While there was a 
very mild effect using the scheduling assay method, it was not as marked or 
statistically significant (see graph 3.1.6.2.2.A and B.).  The IC50 value remained close 
to 18 ± 2 nM.  
Due to the high cytotoxic nature of 17-AAG in these cells, a set of lower 
concentrations (0.02, 0.05 and 0.1 µM) were also tested. 17-AAG concentrations 
above 0.02 µM (35% cell proliferation) were highly toxic (0 – 8% cell proliferation). 
Therefore, in the combination proliferation assays no change in vincristine toxicity 
could be observed. However, the enhancement of vincristine cytotoxicity by 0.02 µM 
17-AAG was not due to MRP1 modulation but due to the anti-proliferative potential 
of 17-AAG alone.  The low concentrations employed were less toxic when exposed to 
the A549 cells for only 24 hours of the 5 day period. The doses in graph 3.1.6.2.3.B.1 
(0.03, 0.05 and 0.1 µM) had similar affects on growth inhibition (18, 22 and 26%), 
while the higher concentrations (0.3, 0.5 and 1 µM) in graph 3.1.6.2.3.B.2 inhibited 
cell proliferation by over 60% (see graph 3.1.6.2.3, 3.1.6.2.4 and table 3.1.6.2.3 for 
details). 
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Graph 3.1.6.2.1.: The combination (A) and scheduling (B) assays of lapatinib and 
vincristine (   ) in the A549 cell line. An IC50 curve of vincristine is combined or 
scheduled with 0.3 (■), 0.5 (▲) and 1µM (●) lapatinib over a 5 day period. The 
combination proliferation assay (A) is the combination of both drugs together on the 
cells at the same time. The scheduling proliferation assay (B) is when the cells are 
exposed to lapatinib for 24 hours, removed and vincristine was added for 4 days. Each 
graph is the result of a duplicate independent determinations with inter-day variations 
represented by error bars. Table 3.1.6.2.3 below provides the IC50 values calculated 
using calcusyn software. 
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Graph 3.1.6.2.2.: The combination (A) and scheduling (B) assays of sulindac 
sulphide and vincristine (   ) in the A549 cell line. An IC50 curve of vincristine is 
combined or scheduled with 0.5 (■), 2 (▲) and 5µM (●) sulindac sulphide over a 5 
day period. The combination proliferation assay (A) is the combination of both drugs 
together on the cells at the same time. The scheduling proliferation assay (B) is when 
the cells are exposed to sulindac sulphide for 24 hours, removed and vincristine is 
added for 4 days. Each graph is the result of a duplicate independent determinations 
with inter-day variation represented by error bars. Table 3.1.6.2.3 below provides the 
IC50 values calculated using calcusyn software. 
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Graph 3.1.6.2.3.: The combination (A.1 (low dose batch) and A.2. (high dose batch)) and scheduling (B.1. (low dose batch) and B.2 (high dose 
batch)) assays of 17AAG and vincristine (   ) in the A549 cell line. An IC50 curve of vincristine is combined (A.1.) or scheduled (B.1.) with 0.02 
(■), 0.05 (▲) and 0.1 µM (●) 17AAG over a 5 day period. An IC50 curve of vincristine is combined (A.2.) or scheduled (B.2.) with 0.3 (■), 0.5 
(▲) and 1µM (●) 17AAG over a 5 day period. The combination proliferation assay (A.1. and A.2.) is the combination of both drugs together on 
the cells at the same time. The scheduling proliferation assay (B.1. and B.2.) is when the cells are exposed to 17-AAG for 24 hours, removed and 
vincristine is added for 4 days. Each graph is the result of a single assay with intra-day variation represented by error bars. 
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Graph 3.1.6.2.4.: The IC50 values of vincristine calculated using Calcusyn software. All values are the average of two independent 
determinations and the standard deviations of this average is representated by error bars. A star (#) indicates where the small molecule agent 
caused significant cytotoxicity alone. IC50 values below 0.7 µM were not determined and are not presented in this graph. Table 3.1.6.2.3 below 
outlines percentage cell proliferation for each agents and the change in IC50 of vincristine when combined or as part of a scheduled assay. 
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Table 3.1.6.2.3.: This table provides the percentage cell proliferation and the calculated average IC50 values (nM) of vincristine for the duplicate 
combination and scheduled proliferation assays presented in graphs 3.1.6.2.1, 3.1.6.2.2 and 3.1.6.2.3. These IC50 values are illustrated in graph 
3.1.6.2.4. All results are due to duplicate independent determination. 
A549 Combination assay  
Cell proliferation (%) 
Combination assay 
IC50 (nM) 
Scheduling assay 
Cell proliferation (%) 
Scheduling assay  
IC50 (nM) 
Vincristine N/A 12 ± 4 N/A 18 ± 2 
Lapatinib 0.3µM 99 ± 9 8 ± 4 96 ± 1 19 ± 2 
Lapatinib 0.5 µM 92 ± 9 8 ± 4 99 ± 3 21 ± 4 
Lapatinib 1 µM 90 ± 8 6 ± 4 96 ± 4 19 ± 2 
Sul. Sulphide 0.5 µM 90 ± 1 9 ± 2 100 ± 1 21 ± 0.2 
Sul. Sulphide 2 µM 98 ± 2 8 ± 2 99 ± 1 17 ± 3 
Sul. Sulphide 2 µM 98 ± 1 5 ± 1 100 ± 1 18 ± 2 
17-AAG 0.02 µM $35 $< 0.7 $74 $6 ± 0 
17-AAG 0.05 µM $8 $< 0.7 $78 $5 ± 0 
17-AAG 0.1 µM $3 $< 0.7 $82 $5 ± 0 
17-AAG 0.3 µM $0.3 $< 0.7 $34 $< 0.7
17-AAG 0.5 µM $0.6 $< 0.7 $16 $< 0.7
17-AAG 1 µM $0 $< 0.7 $11 $< 0.7
Key:  
N/A: Not Applicable  $:  single determination  <: IC50 value lies below the figure indicated 
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3.1.6.3. BCRP down-regulation 
As discussed in 3.1.7., DLKP-SQ/mitox was the BCRP-expressing cell line chosen 
for this body of work. Figure 3.1.7.1 outlines the BCRP (72kDa) Western blots of 
DLKP-SQ/mitox cells following a 24 hour exposure to each agent. β -actin (a 48kDa 
house-keeping protein) was used as a control for protein loading and showed that the 
lysates were in good condition. 
For 2 and 5 µM sulindac sulphide-treated cells (lane 2 – 3) the bands were bigger than 
the control/untreated (C) bands. This indicated that the BCRP protein expression was 
upregulated in the presence of this agent. Densitometric analysis of these blots (which 
is presented as percentage change in table 3.1.8.2) supports this visual finding. This 
Western blot was not repeated as it did not merit for further testing. 
Gefitinib, indomethacin, elacridar and 17-AAG-treated cells (lane 1 – 3) decreased 
BCRP protein expression when compared to their control bands (C). For all 
concentrations of elacridar, gefitinib and indomethacin there was a 80 – 70% decrease 
in BCRP protein expression. 17-AAG had the greatest impact on BCRP protein 
expression in this cell line. There was a 50, 80 and 70% reduction in protein 
expression with 0.3, 0.5 and 1 µM exposures for 24 hours.  
A number of the small molecule agents had varying effect of on BCRP protein 
expression. For instance, 0.3 and 0.5 µM erlotinib decreased BCRP expression but 
increased it at 1 µM. The lowest concentration of celecoxib (0.5 µM) nearly tripled 
the BCRP expression but 10 µM decreased it (20% reduction). Ibuprofen caused a 
very similar reaction. A dose of 0.5 µM ibuprofen increased BCRP by 360% but 
increasing concentrations (2 and 5 µM) caused less of an increase (130% increase) to 
a decrease (20% decrease) in protein expression. Sulindac sulphide behaved in the 
opposite manner to both celecoxib and ibuprofen, with 0.5 µM there was a reduction 
(20% reduction) but 2 and 5 µM caused an increase (30 and 40% increase) in 
expression. Lapatinib, the final small molecule agent, presented a gradual decrease in 
BCRP expression. Densitometry was carried out on all the Western blots and is 
presented in table 3.1.7.2 in the form of percentage changes.  
 
Western blotting and densitometric analysis demonstrated that five small molecule 
agents, lapatinib, gefitinib, indomethacin, elacridar and 17-AAG, noticably down-
regulated the expression of BCRP. To identify if this down-regulation was maintained 
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following removal of the drug after 24 hours, and if the concentrations used reduced 
cell proliferation, further Western blots were carried out, as well as short term 
proliferation assays.  
When the DLKP-SQ/mitox cells were exposed to lapatinib for 24 hours in the 
biological replicate, lapatinib did not reduce the expression of BCRP (this was 
repeated a number of times). In fact, a slight increase was observed immediately after 
exposure as well as after a period of 24 and 48 hours in drug-free media (see figure 
3.1.6.3.2.).  
The reduction in BCRP expression following a 24 hour exposure to gefitinib was 
repeated and found to remain at the reduced level for 24 and 48 hours after drug 
removal.  
All concentrations of indomethacin caused a reduction in BCRP expression following 
a 24 hours exposure. Expression levels returned to normal with the lowest 
concentration after 24 hours in drug-free media and expression recovered for all 
concentrations after 48 hours in drug-free media (see figure 3.1.6.3.2 for details). In 
fact, BCRP expression increased slightly after 48 hours in drug-free media. 
A dose-dependent reduction in BCRP expression occurred following a 24 hours 
exposure to elacridar. Expression recovered after 24 and 48 hours in drug-free media 
(see figure 3.1.6.3.2.). 
The largest reduction in BCRP expression was caused by a 24 hour exposure to 
pharmacologically relevant concentrations of 17-AAG (0.3, 0.5 and 1 µM) (ref: 
www.rxlistcom). A mild restoration of expression was observed after 24 and 48 hours 
in drug-free media (see figure 3.1.6.3.2.).  
 
In 6-well plates, with cells seeded at a density of 7 × 104 cells/ml, all concentrations 
were found to be non-toxic following a 24 hour exposure (see section 8, graphs 
8.1.6.3.1.A, B, C, D and E). 
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Target Protein    Western blot Summary effect 
  C   1    2    3      
    ↓ by Lapatinib after 24hr 
 
    ↔ to ↓ by Erlotinib after 24hr# 
 
      ↓ by Gefitinib after 24hr 
 
     ↑ to ↓ by Celecoxib after 24hr# 
 
       ↑ by Sulindac S. after 24hr# 
 
      ↑ to↓ by Ibuprofen after 24hr# 
 
      ↓ by Indomethacin after 24hr 
     
       ↓ by Elacridar after 24hr 
 
      ↓ by 17-AAG after 24hr 
 
 
 
 
 
 
 
Figure 3.1.6.3.1.: The BCRP Western blots of DLKP-SQ/mitox treated for 24 hours with a 
panel of agents listed in table 3.1.8.1. The concentrations used in this work are presented in 
table 3.1.6.1. BCRP has a molecular weight of 70 kDa and the housekeeping protein, β-actin 
with a molecular weight of 48 kDa, used as a protein loading control. Each sample was 
incubated at 37oC for 24 hours in ATCC media containing 5% FBS. Control samples had no 
drug in their media. The positive control used was HL60/mxr (see figure 3.4.1.1.). The 
densitometric analysis of these blots is represented in table 3.1.8.2. Due to the level of BCRP 
expression in these cells only 4 µgs of protein was initially loaded but this was increased to 8 
µg (as seen in the indomethacin, elacridar and 17-AAG Western blots) in order to obtain a 
band consistency in the β-actin. These Western blots are representative of two or more 
independent biological replicates unless otherwise indicated (#). 
Key:  
C: Control / untreated  ↑:         Protein expression up-regulation 
1: 1st drug concentration  ↓: Protein expression down-regulation 
2: 2nd drug concentration  ↔: No change in protein expression 
3: 3rd drug concentration  #: represents single Western blots 
MRP1 (190kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP 70kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
 142
Table 3.1.6.3.2.: Percentage changes in the expression of BCRP in DLKP-SQ/mitox 
cells following exposure to a range of agents (listed above) for 24 hours. These 
percentage changes were determined using densitometric analysis of Western blots 
carried out on lysates of the exposed DLKP-SQ/mitox cells. The numbers 1-3 
represent increasing concentrations of each agent which are listed in table 3.1.8.1 
above.  
 Percentage Change 
Drug Panel 1st 
concentration
2nd 
concentration
3rd 
concentration 
Lapatinib# -30 -45 -45 
Erlotinib -20 -40 90 
Gefitinib# -20 -35 -25 
Celecoxib 170 0 -20 
Sulindac Sulphide -20 30 40 
Ibuprofen 360 130 -40 
Indomethacin# -40 -40 -30 
Elacridar# -35 -35 -40 
17-AAG# -50 -80 -70 
 
Key: 
# Indicates successful candidates that were brought forward for testing stability in expression 
alteration, toxicity and proliferation assay. 
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Figure 3.1.6.3.2.: The BCRP Western blots of DLKP-SQ/mitox treated for 24 hours 
with lapatinib, gefitinib, indomethacin, elacridar or 17-AAG. Drug was removed after 
the 24 hour exposure and the cells were rinsed and fresh media was added. The 
concentrations used in this work are presented in table 3.1.6.1. Samples were taken 0 
hours, 24 hours and 72 hours after drug removal. BCRP has a molecular weight of 72 
kDa and the housekeeping protein, β-actin with a molecular weight of 48 kDa, used as 
a protein loading control. Each sample was incubated at 37oC for 24 hours in ATCC 
media containing 5% FBS. Control samples had no drug in their media. 8 µg of 
sample was loaded into each well. The positive control used was 20 µg DLKP- 
SQ/mitox. These Western blots are representative of two or more independent biological 
replicates unless otherwise indicated (#). 
Lapatinib 
BCRP 
β-actin 
BCRP 
β-actin 
Gefitinib 
β-actin 
BCRP 
Indomethacin 
β-actin 
BCRP Elacridar 
17-AAG 
BCRP 
β-actin 
Key: 
C: untreated    2: 2nd concentration of drug 
1: 1st concentration of drug 3: 3rd concentration of drug 
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Combination and scheduled proliferation assays 
Using the five small molecule agents investigated in graph 8.1.6.3.1 (see section 8) 
and figure 3.1.6.3.2, we examined if the down-regulation of BCRP protein could 
sensitise the DLKP-SQ/mitox cells to the BCRP substrate, SN38. 
The use of lapatinib in straight combination and scheduling proliferation assays was 
highly successful. The IC50 value of SN38 in the combination assay dropped from 45 
± 7 nM to 1 ± 0.1 nM with only 0.5 µM lapatinib (see graph 3.1.6.3.1.A, 3.1.6.3.5 and 
table 3.1.6.3.2 for details). The scheduling assay was also very successful; it reduced 
the IC50 of SN38 from 60 ± 10 nM to 2 ± 0 nM with the amount of lapatinib (1µM) 
(see graph 3.1.6.3.1.B, 3.1.6.3.5 and table 3.1.6.3.2 for details). All concentrations of 
lapatinib caused less than 10% cell growth inhibition. 
Gefitinib was also highly effective in combination with SN38. A concentration of 
1µM gefitinib reduced SN38’s IC50 value from 45 ± 7 nM to 3 ± 0.7 nM (see graph 
3.1.6.3.2.A, 3.1.6.3.5 and table 3.1.6.3.2 for details). However, the scheduling assay 
was not as effective. The IC50 was reduced from 60 ± 10 nM to 41 ± 3 nM (see graph 
3.1.6.3.2.B, 3.1.6.3.5 and table 3.1.6.3.2 for details). The standard deviations for the 
scheduling proliferation assay IC50’s are such that the strength of these results is 
weakened considerably. All concentrations of gefitinib used, caused less than 5% cell 
growth inhibition. 
The pre-treatment of DLKP-SQ/mitox cells with indomethacin had no affect on the 
anti-proliferative potential of SN38. The presence of indomethacin did not heighten 
the cytotoxicity of SN38 in these cells. All concentration of indomethacin were non-
toxic (see graph 3.1.6.3.3, 3.1.6.3.5 and table 3.1.6.3.2 for details). All concentrations 
of indomethacin used caused less than 6% cell growth inhibition. 
Similar to lapatinib, the combination and scheduling proliferation assay of elacridar 
and SN38 on the DLKP-SQ/mitox cell line resulted in significant enhancement of 
SN38’s cytotoxicity. There was a dramatic reduction in the IC50 value of SN38 in both 
assay types. A concentration of 0.5 µM elacridar reduced the IC50 value of SN38 from 
45 ± 7 nM to 2 ± 0.6 nM (see graph 3.1.6.3.4.A, 3.1.6.3.5 and table 3.1.6.3.2 for 
details) when both drugs were simultaneously combined on this BCRP cell line. The 
same dose of elacridar (0.5 µM) had a near identical impact on the IC50 of SN38 in the 
scheduled proliferation assay; causing a reduction from 60 ± 10 nM to 3 ± 0 nM (see 
graph 3.1.6.3.4.B, 3.1.6.3.5 and table 3.1.6.3.2 for details).  
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 The last small molecule agent tested was 17-AAG. Due to the cytotoxicity of 17-
AAG on this cell line, DLKP-SQ/mitox, a lower set of concentrations (0.02, 0.05 and 
0.1 µM) were also tested. The presence of 0.05 and 0.1 µM 17-AAG dramatically 
enhanced the cytotoxicity of SN38; reducing its’ IC50 from 45 ± 7 nM to 12 ± 2 and 8 
± 3 nM. These concentrations of 17-AAG caused 3% and 23% cell growth inhibition. 
Concentrations above 0.1 µM were highly toxic alone and therefore the change in 
SN38s’ IC50 was solely due to this. All concentrations of 17-AAG were less toxic 
when exposed to the DLKP-SQ/mitox cells for only 24 hours of the 5 day period. The 
low concentrations of 17-AAG (0.02, 0.05, and 0.1 µM) caused less than 10% cell 
growth inhibition while the higher concentrations (0.3, 0.5 and 1 µM) resulted in 
broader inhibition (32, 38 and 63%). Similar to the combination proliferation assays, 
0.05 and 0.1 µM 17-AAG enhanced the anti-proliferative potential of SN38 (from 60 
± 10 nM to 44 ± 11 and 23 ± 3 nM) using the scheduling assay method. The 
concentrations 0.3, 0.5 and 1µM of 17-AAG also enhanced the cytotoxicity of SN38; 
from 60 ± 11 nM to 5, 1 and less than 0.7 nM.  
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Graph 3.1.6.3.1.: The combination (A) and scheduling (B) assays of lapatinib and 
SN38 (   ) in the DLKP-SQ/mitox cell line. An IC50 curve of SN38 is combined or 
scheduled with 0.3 (■), 0.5 (▲) and 1µM (●) lapatinib over a 5 day period. The 
combination proliferation assay (A) is the combination of both drugs together on the 
cells at the same time. The scheduling proliferation assay (B) is when the cells are 
exposed to lapatinib for 24 hours, removed and SN38 is added for 4 days. These 
graphs are the result of duplicate independent determinations with inter-day variation 
represented by error bars. Table 3.1.6.3.2 provides the IC50 values calculated using 
calcusyn software. 
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Graph 3.1.6.3.2.: The combination (A) and scheduling (B) assays of gefitinib and 
SN38 (   ) in the DLKP-SQ/mitox cell line. An IC50 curve of SN38 is combined or 
scheduled with 0.3 (■), 0.5 (▲) and 1µM (●) gefitinib over a 5 day period. The 
combination proliferation assay (A) is the combination of both drugs together on the 
cells at the same time. The scheduling proliferation assay (B) is when the cells are 
exposed to gefitinib for 24 hours, removed and SN38 is added for 4 days. These 
graphs are the result of duplicate independent determinations with inter-day variation 
represented by error bars.Table 3.1.6.3.2 provides the IC50 values calculated using 
calcusyn software. 
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Graph 3.1.6.3.3.: The combination (A) and scheduling (B) assays of indomethacin 
and SN38 (   ) in the DLKP-SQ/mitox cell line. An IC50 curve of SN38 is combined or 
scheduled with 0.4 (■), 1 (▲) and 2µM (●) indomethacin over a 5 day period. The 
combination proliferation assay (A) is the combination of both drugs together on the 
cells at the same time. The scheduling proliferation assay (B) is when the cells are 
exposed to indomethacin for 24 hours, removed and SN38 is added for 4 days. These 
graphs are the result of duplicate independent determinations with inter-day variation 
represented by error bars. Table 3.1.6.3.2 provides the IC50 values calculated using 
calcusyn software. 
 
 
 
DLKP-SQ/mitox: Combination proliferation assay
0
25
50
75
100
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18 0.2
SN38 (uM)
C
el
l P
ro
lif
er
at
io
n 
(%
)
SN38 (uM)
Indo 0.4uM
Indo 1uM
Indo 2uM
DLKP-SQ/mitox: Schedule proliferation assay
0
25
50
75
100
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18 0.2
SN38 (uM)
C
el
l P
ro
lif
er
at
io
n 
(%
)
SN38 (uM)
Indo 0.4uM
Indo 1uM
Indo 2uM
A. 
B. 
 149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3.1.6.3.4.: The combination (A) and scheduling (B) assays of elacridar and 
SN38 (   ) in the DLKP-SQ/mitox cell line. An IC50 curve of SN38 is combined or 
scheduled with 0.3 (■), 0.5 (▲) and 1µM (●) elacridar over a 5 day period. The 
combination proliferation assay (A) is the combination of both drugs together on the 
cells at the same time. The scheduling proliferation assay (B) is when the cells are 
exposed to elacridar for 24 hours, removed and SN38 is added for 4 days. These 
graphs are the result of duplicate independent determinations with inter-day variation 
represented by error bars. Table 3.1.6.3.2 below provides the IC50 values calculated 
using calcusyn software. 
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Graph 3.1.6.3.5.: The combination (A) and scheduling (B) assays of 17-AAG and SN38 (   ) on the DLKP-SQ/mitox cell line. An IC50 curve of 
SN38 is combined (A.1.) or scheduled (B.1.) with 0.02 (■), 0.05 (▲) and 0.1 µM (●) 17-AAG over a 5 day period.  An IC50 curve of SN38 is 
combined (A.2.) or scheduled (B.2.) with 0.3 (■), 0.5 (▲) and 1µM (●) 17-AAG over a 5 day period. The combination proliferation assay (A.1 
and A.2.) is the combination of both drugs together on the cells at the same time. The scheduling proliferation assay (B.1. and B.2.) is when the 
cells are exposed to 17-AAG for 24 hours, removed and SN38 is added for 4 days. Each graph is the result of a single assay with intra-day 
variation represented by error bars. Table 3.1.6.3.2 below provides the IC50 values calculated using calcusyn software.  
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Graph 3.1.6.3.6.: The IC50 values calculated using Calcusyn software. All values are the average of two independent determinations and the 
standard deviations of this average is representated by error bars. A star (#) indicates where the small molecule agent caused significant 
cytotoxicity alone. Table 3.1.6.3.2 outlines that percentage cell proliferation for each agents and the change in IC50 of vincristine when combined 
or as part of a scheduled assay.  
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Table 3.1.6.3.2.: This table provides the calculated average percentage cell proliferation for each agent alone and the IC50 values (nM) for the 
duplicate combination and scheduled proliferation assays presented in graphs 3.1.6.3.2, 3.1.6.3.3 and 3.1.6.3.4. These IC50s were calculated 
using calcusyn software. All values presented are the results of independent duplicate determinations plus and minus their standard deviations. 
DLKP-SQ/mitox Combination assay 
Cell Proliferation (%) 
Combination assay  
IC50 (nM) 
Scheduling assay 
Cell Proliferation (%) 
Scheduling assay  
IC50 (nM) 
SN38 N/A Ψ45 ± 7 N/A Ψ60 ± 10 
Lapatinib 0.3 µM 93 ± 4 2 ± 0.2 99 ± 0.4 4 ± 0.3 
Lapatinib 0.5 µM 96 ± 0.3 1 ± 0.1 99 ± 0.4 3 ± 0 
Lapatinib 1 µM 89 ± 6 < 0.7 95 ± 0.3 2 ± 0 
Gefitinib 0.3 µM 98 ± 1.4 8 ± 2 99 ± 0.3 51 ± 3 
Gefitinib 0.5 µM 97 ± 1.7 10 ± 8 95 ± 0.1 41 ± 3 
Gefitinib 1 µM 97 ± 2.3 3 ± 0.7 96 ± 1.3 41 ± 2 
Indomethacin 0.4 µM 100 ± 3 29 ± 7 96 ± 0.3 58 ± 7 
Indomethacin 1 µM 100 ± 4 31 ± 11 99 ± 0.7 60 ± 9 
Indomethacin 2 µM 95 ± 6 24 ± 3 98 ± 0.03 62 ± 7 
Elacridar 0.3 µM 99 ± 1 10 ± 12 99 ± 0.7 7 ± 0.4 
Elacridar 0.5 µM 98 ± 1 2 ± 1 100 ± 0.3 4 ± 0.2 
Elacridar 1 µM 90 ± 12 1 ± 1 96 ± 4 3 ± 0 
17-AAG 0.02 µM $102 40 ± 23 97 44 ± 7 
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DLKP-SQ/mitox Combination assay 
Cell Proliferation (%) 
Combination assay  
IC50 (nM) 
Scheduling assay 
Cell Proliferation (%) 
Scheduling assay  
IC50 (nM) 
17-AAG 0.05 µM $97 12 ± 2 99 44 ± 11 
17-AAG 0.1 µM $77 8 ± 3 90 23 ± 3 
17-AAG 0.3 µM $0 < 0.7 $68 $5 
17-AAG 0.5 µM $0 < 0.7 $62 $1 
17-AAG 1 µM $0 < 0.7 $37 $< 0.7 
Key: 
N/A not applicable 
Ψ Values are the average of 8 independent determinations 
$ Value are the result of a single assay determination..
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3.2. Cellular Pharmacokinetics of Epirubicin 
 
Two serum plasma proteins, serum albumin and α1-acid glycoprotein (AAG), are 
important transport proteins for the majority of cancer drugs. Albumin has the highest 
affinity for drugs with acidic or strong electronegative functional groups. Albumin has 
been shown to be crucial for the distribution, elimination and effectiveness of many 
conventional pharmaceuticals and anti-cancer drugs including anthracyclines and 
taxanes etc. [50] [390].  
Serum albumin is a highly soluble single polypeptide that is present in the plasma at 
an approximate concentration of 40mg/ml (600µM). AAG is a 40kDa protein present 
in the plasma at an approximate concentration of 0.8mg/ml (20µM). For a brief 
review on each plasma protein please refer to section 1.3.5 and 1.3.6. 
Protein-bound drug is generally considered to be too large to pass through most cell 
membranes to exert pharmacological actions and therefore, limits their cytotoxic 
potential. In 1998, Sham HL., et al, [60] found that plasma protein drug binding can 
reduce the in vitro potency of a compound, ABT-378 (a highly potent inhibitor of the 
human immunodeficiency virus protease), in the presence of exogenously added 
serum.  
 
3.2.1 Free versus Bound drug 
 
To determine if drug-protein binding was affected the accumulation of epirubicin in 
normal versus cancer cells, we first examined the levels of free versus bound 
anthracycline in solutions with or without the serum proteins, albumin and AAG. We 
selected a Vivaspin 2 ultrafiltration membranes with molecular weight cut off of 
20,000Da, supplied by Sartorius. Analysis indicated that the membrane material 
(cellulose triacetate) had high affinity for free epirubicin and this was taken into 
consideration when calculating the proportion of bound and unbound epirubicin. The 
formulae for calculating the amount of protein-free drug bound to the membrane, and 
the percentage of free and bound drug was described in section 2.12.1. with the 
extraction method described in section 2.12.3.2. 
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3.2.1.1. Free versus bound drug in solution containing serum proteins. 
 
In this section, we used membrane filters to separate out the free and bound drug in 
various solutions and in the presence of foetal calf serum, serum albumin or α1-acid 
glycoprotein (AAG). Initial testing demonstrated that the filter membrane material 
had high affinity for unbound epirubicin and this was exploited to allow calculation of 
the levels of free and bound epirubicin. 
As expected, we found that over 99% of epirubicin was free in solutions of water 
(UHP) and PBS, while 94% was free in cell growth media (ATCC). As depicted in 
graphs 3.2.1.1.2 and 3.2.1.1.3 increasing levels of FCS and serum albumin resulted in 
a concentration-dependent increase in the percentage of bound epirubicin (epirubicin 
binding to FCS increased from 6% up to 100% and from 6% to 80% in the presence 
of serum albumin). However, while an increase in epirubicin binding was observed in 
the presence of AAG (graph 3.2.1.1.4) the trend was not as dramatic (epirubicin 
binding increased from 6% to 14% in the presence of increasing levels of AAG). This 
was also expected as the concentrations of AAG used in this experiment are 
significantly lower than the concentrations of serum albumin.  
The concentrations of albumin and AAG were chosen to correlate with the amount 
present in serum, for example, 10% of FCS contains 40 mg/ml of albumin and 0.8 
mg/ml of AAG. The total (ng/ml) is the amount of epirubicin that was spiked into 
each solution. The retentate (ng/ml) is the bound epirubicin that remains above the 
membrane. The filtrate (ng/ml) is the free epirubicin that passed through the 
membrane without sticking to it while the membrane (ng/ml) is the amount of 
epirubicin that was not protein bound but that stuck to the membrane material. For an 
example of calculation working please refer to section 2.12.1. 
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The portion of free versus bound epirubicin in a range of medium.
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Graph 3.2.1.1.1.: Illustrates the proportion of free and bound epirubicin in solutions 
containing or lacking foetal calf serum (FCS). A concentration of 2 µM or 1.16 mg/ml 
of epirubicin was used in this experiment. This graph represents a single 
determination. The table below depicts the values (epirubicin ng) used to calculate the 
percentage of free and bound epirubicin in this graph. 
 
 
Table 3.2.1.1.1.: Raw data for the calculation of the percentage free versus bound 
epirubicin in a variety of solutions.  
Sample 
 
Total 
(ng) 
Retentate 
(ng) 
Filtrate (ng) Membrane 
(ng) 
Free 
(%) 
Bound 
(%) 
PBS 1160 3 453 704 99.7 0.3 
UHP 1160 9 1 1150 99.2 0.8 
UHP + 5 % FCS 1160 67 48 1046 94.2 5.8 
Cell growth media 1160 4 32 1124 99.7 0.3 
Cell growth media 
+ 5 % FCS 
1160 34 105 1021 97.0 3.0 
 
 
 
 
 
 
 157
Foetal Calf Serum
6 10
24
48
83
100
0
20
40
60
80
100
120
0 5% 10% 20% 50% 100%
Ep
iru
bi
ci
n 
(%
)
Bound (%)
 
Graph 3.2.1.1.2.: Illustrates the proportion of bound epirubicin in cell growth media 
in the presence of increasing levels of foetal calf serum (FCS). A concentration of 2 
µM or 1.16 mg/ml epirubicin was used. This graph represents duplicate intraday 
results. The table below depicts the values (epirubicin (ng)) used to calculate the 
percentage of free and bound epirubicin in this graph. 
 
Table 3.2.1.1.2.: Raw data for the calculation of free versus bound epirubicin, plus 
and minus their standard deviations (±), in cell growth media in the presence of 
increasing levels of foetal calf serum (FCS).  
Foetal calf 
serum 
Total (ng) Retentate 
(ng) 
Filtrate 
(ng) 
Membrane 
(ng) 
Bound 
(%) 
Free 
(%) 
0 % 1160 72 28 1060 6.2 ± 1 93.8 ± 1 
5 % 1160 115 76 969 9.9 ± 0 90.1 ± 0 
10 % 1160 284 207 669 24.5 ± 0 75.5 ± 0 
20 % 1160 555 246 359 47.8 ± 0 52.2 ± 0 
50 % 1160 959 196 4 82.7 ± 3 17.3 ± 3 
100 % 1160 1160 0 0 100 ± 13 0 ± 13 
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Serum Albumin.
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Graph 3.2.1.1.3.: Illustrates the proportion of bound epirubicin in cell growth media 
in the presence of increasing levels of albumin. A concentration of 2 µM or 1.16 
mg/ml epirubicin was used. This graph represents duplicate intraday results. The table 
below depicts the values (epirubicin (ng)) used to calculate the percentage of free and 
bound epirubicin in this graph. 
 
 
Table 3.2.1.1.3.: Raw data for the calculation of free versus bound epirubicin, plus 
and minus their standard deviations (±), in cell growth media in the presence of 
increasing levels of albumin. 
 
Albumin Total 
(ng) 
Retentate 
(ng) 
Filtrate 
(ng) 
Membrane 
(ng) 
Bound 
(%) 
Free 
(%) 
0 mg/ml 1160 72 28 1060 6.2 ± 1 93.8 ± 1 
2 mg/ml 1160 170 61 930 14.6 ± 1 85.4 ± 1 
4 mg/ml 1160 272 53 836 23.4 ± 0 76.6 ± 0 
8 mg/ml 1160 458 54 648 39.5 ± 1 60.5 ± 1 
20 mg/ml 1160 671 73 416 57.9 ± 2 42.1 ± 2 
40 mg/ml 1160 928 118 114 80.0 ± 3 20.0 ± 3 
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Graph 3.2.1.1.4.: Illustrates the proportion of bound epirubicin in ATCC media in the 
presence of increasing levels of α1-acid glycoprotein. A concentration of 2 µM or 1.16 
mg/ml epirubicin was used. This graph represents duplicate intraday results. The table 
below depicts the values (epirubicin (ng)) used to calculate the percentage of free and 
bound epirubicin in this graph. 
 
 
Table 3.2.1.1.4.: Raw data for the calculation of free versus bound epirubicin, plus 
and minus their standard deviations (±), in ATCC media in the presence of increasing 
levels of α1-acid glycoprotein. 
 
α1 acid-
glycoprotein 
Total 
(ng) 
Retentate 
(ng) 
Filtrate 
(ng) 
Membrane 
(ng) 
Bound 
(%) 
Free 
(%) 
0 mg/ml 1160 72 28 1060 6.2 ± 1 93.8 ± 1 
0.08 mg/ml 1160 50 44 1065 4.4 ±  0 95.6 ± 0 
0.1 mg/ml 1160 119 96 945 10.3 ±  2 89.7 ± 2 
0.5 mg/ml 1160 143 74 943 12.3 ±  1 87.7 ± 1 
0.8 mg/ml 1160 165 83 912 14.3 ±  0 85.7 ± 0 
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3.2.1.2. The effect of serum proteins on the uptake of epirubicin in normal 
mammalian epithelial cells and in breast and lung cancer cells. 
 
As outlined in section 3.2.1.1, the presence of AAG, and, particularly, albumin in 
serum affect the proportion of free and bound levels of epirubicin in cell culture 
medium. In this section, we studied the impact this binding had on the accumulation 
of epirubicin in normal human mammary epithelial cells (HMEC), and in a breast 
(MCF7) and a lung (DLKP) cancer cell lines. Methodology for this body of work is 
described in section 2.12.2., 2.12.2.1., and 2.12.3. 
 
We found that the presence of low levels of FCS had little impact on epirubicin 
accumulation in HMEC cells, while in the presence of 20%, 50% and 100% FCS 
there was a 3 fold decrease in drug accumulation. Little change was observed in the 
MCF7 cells with drug dissovled in medium containing 5%, 10% and 20% FCS but 
accumulation decreased in the presence of 50 % FCS and halved with 100% FCS 
compared to 0% FCS. On the other hand, there was a significant increase in 
accumulation of epirubicin in the presence of FCS in the DLKP cells. The 
accumulation peaked at 10% (4501 ± 590 ng/million cells) and remained higher in the 
presence of 100% FCS than 0% FCS.. A very similar trend was observed in all cells 
in the presence of serum albumin. This data is illustrated in graph 3.2.1.2.1 and in 
table 3.2.1.2.1. 
 
With low levels of albumin (2 mg/ml and 4 mg/ml) in the media a slight increase in 
drug accumulation occurred, while higher levels reduced the accumulation of 
epirubicin in the HMEC cells. Little change was observed with the MCF7 cells at 2 
mg/ml and 4 mg/ml of albumin but this accumulation decreased with 20mg/ml and 
almost halved with 40 mg/ml serum albumin. Similar to FCS, the presence of serum 
albumin significantly increased the accumulation of epirubicin in the DLKP cells. The 
accumulation peaked at 4mg/ml (3465 ± 917 ng/million cells) and did not drop to 
minimum drug accumulation with 40mg/ml of albumin in media (see graph 3.2.1.2.2 
and table 3.2.1.2.2.). These trends would suggest that the binding of epirubicin to the 
proteins in FCS and to serum albumin impact greatly on the accumulation of 
epirubicin in all three cell types. However, as demonstrated in section 3.2.1.1 with 
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levels of protein normally found in the plasma, the majority of epirubicin is bound to 
serum protein (100% FCS solution bound 100% of the epirubicin while 40mg/ml of 
albumin bound 80% of the epirubicin) while a much smaller proportion of epirubicin 
is bound to AAG (0.8mg/ml bound 14% of the epirubicin). The results in graph 
3.2.1.2.3 illustrate the affect the presence of AAG has on the acccumulation of 
epirubicin in the three cell types. In both the HMEC and DLKP cells there was a 
slight increase in the accumulation of epirubicin with low levels of AAG, however, 
this decreased at higher concentrations. Conversely, the accumulation doubled with 
the highest concentration of AAG in the MCF7 cells (see graph 3.2.1.2.3). This would 
suggest that AAG plays more complex role in cellular epirubicin accumulation. 
 
As serum deprivation has a negative impact on cell growth the toxicological 
consequences of these alterations could not be evaluated.  
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Graph 3.2.1.2.1.: This bar chart illustrates the accumulation of epirubicin in human 
mammary epithelial cells (HMEC) and in a breast (MCF7) and lung (DLKP) cell line 
in the presence of increasing levels of foetal calf serum (FCS). This graph represents 
triplicate intra-day results. The table below depicts the quantity of epirubicin 
(ng/million cells) accumulated in each sample.  
 
Table 3.2.1.2.1.: This table supplies the quantitative data for the accumulation of 
epirubicin in the presence of increasing levels of FCS in the three cell types. 
 
FCS (%) 0  5 10 20 50  100 
MCF7       
Epi (ng/106 cells) 6281 6012 7038 6539 4842 3270 
St dev ± 911 ± 842 ± 725 ± 1535 ± 711 ± 305 
DLKP       
Epi (ng/106 cells) 1025 2400 4501 4392 3393 2431 
St dev ± 529 ± 865 ± 590 ± 525 ± 286 ± 171 
HMEC       
Epi (ng/106 cells) 3150 3699 3663 1366 1358 1268 
St dev ± 184 ± 0 ± 1198 ± 238 ± 19 ± 190 
 
 
 163
Serum albumin
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Alb 0mg/ml Alb 2mg/ml Alb 4mg/ml Alb 8mg/ml Alb 20mg/ml Alb 40mg/ml
E
pi
ru
bi
ci
n 
(n
g/
m
ill
io
n 
ce
lls
)
MCF7
DLKP
HMEC
 
Graph 3.2.1.2.2.: This bar chart illustrates the accumulation of epirubicin in human 
mammary epithelial cells (HMEC) and in a breast (MCF7) and lung (DLKP) cell line 
in the presence of increasing levels of serum albumin. This graph represents triplicate 
intra-day results. The table below depicts the quantity of epirubicin (ng/million cells) 
accumulated in each sample.  
 
Table 3.2.1.2.2.: This table supplies the quantitative data for the accumulation of 
epirubicin in the presence of increasing levels of serum albumin in the three cell types. 
Albumin (mg/ml) 0 2 4 8 20 40 
MCF7       
Epi (ng/106 cells) 6281 7035 7231 6627 5000 4317 
St dev ± 911 ± 768 ± 447 ± 128 ± 362 ± 748 
DLKP       
Epi (ng/106 cells) 1025 2733 3465 2335 1907 1564 
St dev ± 529 ± 469 ± 917 ± 127 ± 244 ± 212 
HMEC       
Epi (ng/106 cells) 3150 4704 4137 3057 2669 1588 
St dev ± 184 ± 1228 ± 24 ± 389 ± 264 ± 394 
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Graph 3.2.1.2.3.: This bar chart illustrates the accumulation of epirubicin in human 
mammary epithelial cells (HMEC) and in a breast (MCF7) and lung (DLKP) cell line 
in the presence of increasing levels of α1-acid glycoprotein. This graph represents 
triplicate intra-day results. The table below depicts the quantity of epirubicin 
(ng/million cells) accumulated in each sample.  
 
Table 3.2.1.2.3.: This table supplies the quantitative data for the accumulation of 
epirubicin in the presence of increasing levels of α1-acid glycoprotein in the three cell 
types. 
AAG (mg/ml) 0 0.08 0.1 0.5 0.8 
MCF7      
Epi (ng/106 cells) 6281 6108 6714 8599 14011 
St dev ± 911 ± 1790 ± 1360 ± 2350 ± 2537 
DLKP      
Epi (ng/106 cells) 1025 2446 2318 2145 2670 
St dev ± 529 ± 281 ± 113 ± 185 ± 150 
HMEC      
Epi (ng/106 cells) 3150 4586 3770 3660 3131 
St dev ± 184 ± 495 ± 149 ± 1180 ± 286 
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3.3. Effect of tyrosine kinase inhibitors on the function and expression of 
epidermal growth factor receptors, EGFR and HER2, multidrug resistance 
transporter and cyclooxygenase proteins. 
 
3.3.1. TKI interference with EGFR and HER2 activity and heightened sensitivity 
to chemotherapeutic drugs. 
 
In this section, we investigated if inhibition of the activity and function of EGFR 
and/or HER2, with TKI’s (lapatinib, erlotinib and gefitinib), could sensitise breast 
cancer cells to chemotherapy (epirubicin and docetaxel). For this, we selected an 
HER2 over-expressing cell line that lacked EGFR (MDA-MB-453), a cell line with 
amplified levels of EGFR while lacking HER2 (MDA-MB-231) and finally a cell line 
that expressed both EGFR and HER2 at low levels (MCF7). Firstly, we carried out 
combination proliferation assays (see section 2.7.1 and 2.7.3) of lapatinib, erlotinib 
and gefitinib with epirubicin and docetaxel and finally ELISA immunoassays (see 
section 2.11.6 and 2.11.7.) to quantitate the effect of lapatinib on EGFR and HER2 
expression and activation levels.  
 
No decrease in cell proliferation was observed with the combination of lapatinib, 
erlotinib or gefitinib with epirubicin or docetaxel in the EGFR-overexpressing cell 
line, MDA-MB-231 (see graph 3.3.1.1 and table 3.3.1.1 for details), the HER2-
overexpressing cell line, MDA-MB-453 (See graph 3.3.1.2.A. and table 3.3.1.2 for 
further details) or the low EGFR/HER2 expressing cell line, MCF7 (see graphs 
3.3.1.3 A & B and table 3.3.1.3.). This would suggest that the three TKIs do not 
sensitise these TKI insensitive breast cell lines to the chemotherapeutic treatment of 
epirubicin or docetaxel.  
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Graph 3.3.1.1.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B:  ) and gefitinib (C:  ) on the MDA-MB-231 cell line (EGFR-
amplified cell line). Clinically relevant concentrations of both the chemotherapeutic 
agents and TKIs were tested alone and combined over a 5 day period. The bar chart is 
the result of triplicate experiments carried out on separate days. The table below 
depicts the percentage cell proliferation and standard deviations illustrated in this 
graph. 
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Table 3.3.1.1.: This table provides the percentage cell proliferation and standard 
deviations for graph 3.3.1.1.  
 Cell Proliferation (%) 
TKI (µM) 0 Stdev 
(%) 
0.3 Stdev 
(%) 
0.5 Stdev 
(%) 
1 Stdev 
(%) 
Lapatinib 100 ± 0 98 ± 1 99 ± 1 97 ± 2 
Lap + 0.005µM Epi 85 ± 6 87 ± 5 88 ± 5 84 ± 8 
Lap + 0.0005µM Doce 50 ± 12 50 ± 13 48 ± 13 47 ± 15 
Erlotinib 100 ± 0 96 ± 1 95 ± 3 95 ± 3 
Erlot + 0.005µM Epi 86 ± 6 82 ± 7 81 ± 8 73 ± 9 
Erlot + 0.0005µM Doce 50 ± 12 47 ± 11 46 ± 12 43 ± 12 
Gefitinib 100 ± 0 99 ± 12 99 ± 3 99 ± 0.2 
Gefit + 0.005µM Epi 88 ± 7 88 ± 3 88 ± 5 85 ± 7 
Gefit + 0.0005µM Doce 50 ± 8 51 ± 5 52 ± 6 50 ± 8 
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Graph 3.3.1.2.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B:  ) and gefitinib (C:  ) on the MDA-MB-453 cell line (HER2-
amplified cell line). Clinically relevant concentrations of both the chemotherapeutic 
agents and TKIs were tested alone and combined over a 5 day period. The bar chart is 
the result of triplicate experiments carried out on separate days. The table below 
depicts the percentage cell proliferation and standard deviations illustrated in this 
graph. 
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Table 3.3.1.2.: This table provides the percentage cell proliferation and standard 
deviations for graph 3.3.1.2 above.  
 Cell Proliferation (%) 
TKI (µM) 0 Stdev 
(%) 
0.3 Stdev 
(%) 
0.5 Stdev 
(%) 
1 Stdev 
(%) 
Lapatinib 100 ±0 87 ±7 86 ±7 83 ±10 
Lap + 0.02µM Epi 83 ±10 68 ±9 66 ±8 60 ±7 
Lap + 0.5nM Doce 84 ±16 71 ±6 68 ±8 62 ±6 
Erlotinib 100 ±0 100 ±2 101 ±3 103 ±5 
Erlot + 0.02µM Epi 87 ±4 90 ±3 90 ±2 90 ±1 
Erlot + 0.5nM Doce 95 ±8 96 ±8 98 ±9 98 ±9 
Gefitinib 100 ±0 98 ±1 99 ±1 96 ±5 
Gefit + 0.02µM Epi 84 ±8 86 ±7 89 ±7 87 ±6 
Gefit + 0.5nM Doce 96 ±7 95 ±10 94 ±9 94 ±10 
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Graph 3.3.1.3.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B:  ) and gefitinib (C:  ) on the MCF7 cell line (low EGFR/HER2-
expressing cell line). Clinically relevant concentrations of both the chemotherapeutic 
agents and TKIs were tested alone and combined over a 5 day period. The bar chart is 
the result of triplicate experiments carried out on separate days. The table below 
depicts the percentage cell proliferation and standard deviations illustrated in this 
graph. 
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Table 3.3.1.3.: This table provides the percentage cell proliferation and standard 
deviations for graph 3.3.1.3.  
 Cell Proliferation (%) 
TKI (µM) 0 Stdev 
(%) 
0.3 Stdev 
(%) 
0.5 Stdev 
(%) 
1 Stdev 
(%) 
Lapatinib 100 ±0 85 ±6 84 ±6 80 ±6 
Lap + 0.04µM Epi 55 ±5 40 ±2 37 ±1 32 ±1 
Lap + 4nM Doce 57 ±9 41 ±10 39 ±10 37 ±7 
Erlotinib 100 ±0 91 ±6 92 ±5 91 ±5 
Erlot + 0.04µM Epi 53 ±12 42 ±10 40 ±10 37 ±9 
Erlot + 4nM Doce 73 ±11 62 ±10 60 ±9 61 ±9 
Gefitnib 100 ±0 93 ±4 91 ±3 88 ±2 
Gefit + 0.04µM Epi 51 ±10 45 ±9 44 ±11 41 ±10 
Gefit + 4nM Doce 70 ±11 58 ±10 57 ±9 55 ±9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 172
3.3.4. Effect of tyrosine kinase inhibitors on COX protein expression and activity 
 
In this section, we considered the potential that lapatinib could affect the function and 
expression of the cyclooxygenase enzyme, COX-2 (see section 1.6.3. for review). We 
investigated the effect of four tyrosine kinase inhibitors (lapatinib, erlotinib, gefitinib 
and AG825) and the HER2 monoclonal antibody (trastuzumab) on the expression and 
activity of COX proteins (for methodology see section 2.11. and 2.13.). For this, we 
selected a human lung cell line, A549, which is known to express detectable levels of 
COX-1 and COX-2 protein. A549 also expresses low levels of EGFR and HER2 [97].  
 
We exposed the A549 cells to 2.5, 5, 7.5 and 10 µM lapatinib or AG825 and 0.25, 0.5, 
0.75 and 1 µM trastuzumab for 48 hours and ran Westerns blots to detect changes in 
the expression levels of COX-1 and COX-2 protein. We also evaluated the effect 10 
µM erlotinib and gefitinib had on the expression of COX-2 compared to lapatinib. We 
found that lapatinib, the dual EGFR/HER2 TKI, caused mild down-regulation of 
COX-1 expression levels (see figure 3.3.4.1 for details) but up-regulated COX-2 
protein expression (see figure 3.3.4.2 and table 3.3.4.1 for details). AG825, 
HER1/HER2 TKI, did not alter COX-1 or COX-2 protein expression (see figure 
3.3.4.1, 3.3.4.3 and table 3.3.4.1 for details). Trastuzumab, HER2 monoclonal 
antibody, up-regulated the expression of COX-1 but down-regulated the expression of 
COX-2 in the A549 cell line (see figure 3.3.4.1, 3.3.4.2 and table 3.3.4.1 for details).  
A panel of HER2-expressing cells lines, MDA-MB-453 (high HER-2-expressing and 
lapatinib insensitive), MCF7 (low EGFR/HER2-expressing and lapatinib insensitive) 
and BT474 (low HER-2-expressing and lapatinib sensitive), were also exposed to 
lapatinib, AG825 and trastuzumab (data not shown). However, COX-2 expression 
was not detected in either the untreated or treated cells. 
In figure 3.3.4.3, we exposed A549 cells to 10 µM lapatinib, erlotinib, gefitinib and 
celecoxib (COX-2 specific inhibitor) and found that erlotinib, gefitinib and celecoxib 
down-regulated the expression of COX-2 and only lapatinib up-regulated the 
expression of COX-2 in the A549 cells. 
Following a 48 hour exposure to 2.5 and 5 µM lapatinib, total COX activity was 
increased (from 8 nmol/min/107 to 13 and 15 nmol/min/107 cells) (graph 3.3.4.1.). 
This increase corresponded with an increase in COX-2 activity (from 2 nmol/min/107 
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to 4 and 7 nmol/min/107 cells) (graph 3.3.4.1.A). The higher concentrations of 
lapatinib (7.5 and 10 µM) returned total COX and COX-2 activity to normal levels. 
COX-1 activity was unaltered by lapatinib. All concentrations of AG825 mildly 
reduced COX-1 (from 7.5 nmol/min/107 cells to 6 nmol/min/107 cells) and COX-2 
(from 2 nmol/min/107 cells to 1 nmol/min/107 cells) activity and thus total COX (from 
9 nmol/min/107 cells to 7 nmol/min/107 cells) activity, following a 48 hour exposure 
(graph 3.3.4.1.B.). A same exposure to all concentrations of trastuzumab mildly 
reduced COX-1 (from 7.5 nmol/min/107 cells to 5 and 6 nmol/min/107 cells) and thus 
total COX activity (from 9 nmol/min/107 cells to 6 nmol/min/107 cells) (graph 
3.3.4.1.C.). Concentrations of 0.5, 0.75 and 1 µM trastuzumab also reduced COX-2 
activity (from 2 nmol/min/107 cells to 1 and 0.25 nmol/min/107 cells). COX-2 activity 
was unchanged in the presence of 0.25 µM trastuzumab (graph 3.3.4.1.C.).  
In the direct COX activity assay, DMSO (the solvent control for lapatinib) reduced 
COX activity. However, 10 µM of lapatinib increased COX-1 (from 4 nmol/min/107 
cells to 7 nmol/min/107 cells), COX-2 (from 3.5 nmol/min/107 cells to 7 
nmol/min/107 cells) and thus total COX activity (from 5 nmol/min/107 cells to 14 
nmol/min/107 cells) (graph 3.3.4.2.A.). Only the highest concentration of AG825 (10 
µM) reduced COX-1 (from 3.5 nmol/min/107 cells to 2.2 nmol/min/107 cells) and 
COX-2 (from 3.8 nmol/min/107 cells to 1.2 nmol/min/107 cells) activity (graph 
3.3.4.2.B.). Only the highest concentration of trastuzumab (1 µM) was tested and this 
reduced COX-1 (from 3.5 nmol/min/107 cells to 2.8 nmol/min/107 cells and COX-2 
(from 3.8 nmol/min/107 cells to 2.8 nmol/min/107 cells) active levels (graph 
3.3.4.2.B.). Celecoxib, a specific COX-2 inhibitor, was included as a control for this 
assay. As expected, 0.5 and 2 µM celecoxib only sufficiently inhibited COX-2 active 
levels (from 4 nmol/min/107 cells to 2.5 and 2 nmol/min/107 cells) while 10 µM 
celecoxib inhibited both COX-1 (from 5 nmol/min/107 cells to 3.5 nmol/min/107 
cells), COX-2 (from 4 nmol/min/107 cells to 2.8 nmol/min/107 cells) activity (graph 
3.3.4.2.C.) and total COX. 
 
To determine if a general COX inhibitor could sensitise lapatinib-insensitive breast 
cell lines to lapatinib we carried out combination proliferation assays (for 
methodology see section 2.7.1. and 2.7.3.) of a non-specific COX inhibitor, sulindac, 
with lapatinib in three breast cell lines. These cell lines were chosen for their growth 
factor receptor status. One cell line expresses high levels of HER2 (MDA-MB-453), 
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and other expresses high levels of EGFR (MDA-MB-231). Neither cells express 
COX-2 and the third cell line expresses low levels of both EGFR and HER2 (MCF7). 
COX-2 expression was not found in MDA-MB-453 or MCF7 (graph 3.3.4.3. and 
table 3.3.4.2.). 
 
The combination proliferation assay of sulindac with lapatinib, in the EGFR-
overexpressing cell line MDA-MB-231, resulted in no increased growth inhibition 
(see graph 3.3.4.3.A and table 3.3.4.2 for details). Neither drugs had inhibitory effects 
alone. However, there was a mild effect (of about 5%) coming into view with 15 µM 
sulindac and 1 µM lapatinib.  
 
When sulindac (non-specific COX inhibitor) and lapatinib (dual EGFR/ErbB2 
inhibitor) were combined in the HER2-overexpressing cell line, MDA-MB-453, it 
was clear that sulindac potentiated the anti-proliferative affect of lapatinib by up to 
33% (see graph 3.3.4.3.B and table 3.3.4.2 for details).  
 
Similar to the result observed in the MDA-MB-231 cells, sulindac did not enhance the 
anti-proliferative potential in the low EGFR/HER2-expressing cell line, MCF7 (see 
graph 3.3.4.3.C and table 3.3.4.2 for details). 
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   Target Protein       Western blot        Summary effect 
        
    0  2.5    5  7.5 10  µM     Tyrosine kinase inhibitor 
 
 
 
 
       
   0  0.25 0.5 0.75  1  µM     Antibody 
 
 
 
Figure 3.3.4.1.: COX-1 expression, by Western blotting, in the A549 cells following 
a 48 hour exposure to lapatinib, AG825 or trastuzumab. COX-1 has a molecular 
weight of 70 kDa and the housekeeping protein, β-actin with a molecular weight of 48 
kDa, was used as a protein loading control. The same concentration of DMSO was 
included in all lapatinib samples (including the untreated sample) equal to that of the 
10 µM concentration. A similar control for AG825 was not required as the levels of 
DMSO were less than 0.1%, while trastuzumab was in its clinical formulation. These 
Western blots represent a single determination. The concentrations used in the 
treatments are indicated in the legend above each band.  
 
 
 
 
 
 
 
↓ by Lapatinib after 48 hours 
↔ by AG825 after 48 hours 
↑ by Trastuzumab after 48 hours 
COX-1 (70kDa) 
COX-1 (70kDa) 
COX-1 (70kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
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Figure 3.3.4.2.: COX-2 Western blots for A549 cells treated with a range of 
concentrations of lapatinib, AG825 and trastuzumab for 48hrs. COX-2 has a 
molecular weight of 72 kDa and the housekeeping protein, β-actin with a molecular 
weight of 48 kDa, was used as a protein loading control. The same concentration of 
DMSO was included in all lapatinib samples (including the untreated sample) equal to 
that of the 10 µM concentration. A similar control for AG825 was not required as the 
levels of DMSO were less than 0.1%, while trastuzumab was in its clinical 
formulation. The lapatinib western were carried out in triplicate biological 
experiments and is represented in A, B and C. The concentrations used in the 
treatments are indicated in the key below the Westerns blots. This table all presents 
the densitometry results of these westerns. 
 
 
 
 
 
Lapatinib
-treated 
Trastuzumab-treated  
AG825-treated 
COX2 (72kDa)
COX2 (72kDa)
COX2 (72kDa)
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
Key: 
Lapatinib/AG825   Trastuzumab 
C:   Control / Untreated   C:   Control / Untreated 
1:    2.5 µM TKI   1:    0.25 µM Antibody 
2:    5 µM TKI   2:    0.5 µM Antibody 
3:    7.5 µM TKI   3:    0.75 µM Antibody 
4:    10 µM TKI   4:    1 µM Antibody
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Table 3.3.4.1.: Fold changes in the expression of COX-2 in A549 cells following 
exposure to a lapatinib, AG825 and trastuzumab for 48 hrs. These fold changes were 
determined using densitometric analysis of Western blots carried out on lysates of the 
exposed A549 cells. 
 
Sample C 1 2 3 4 
TKI dose (µM) 0 2.5 5 7.5 10 
Lapatinib    A 1 0.4 0.7 1.6 2.2 
Lapatinib    B 1 1.6 3.1 6.8 7.4 
Lapatinib    C 1 1.4 1.4 1.5 2.0 
AG825        1 0.9 0.9 1.5 0.9 
Antibody dose (µM) 0 0.25 0.5 0.75 1 
Trastuzumab    1 0.7 1.3 0.8 0.2 
 
 
 
 
         C     1      2     3     4     + 
 
 
 
 
 
Figure 3.3.4.3: The protein expression of COX-2 in A549 following 48hr treatments 
with 10 µM celecoxib, lapatinib, erlotinib, and gefitinib.  COX-2 has a molecular 
weight of 72 kDa and the housekeeping protein, β-actin with a molecular weight of 48 
kDa, was used as a protein loading control. Due to the low expression of COX-2 in 
this cell line, 40µg of protein was loaded. The positive control for COX-2 was 
2008/MRP1 (which we found to express COX-2 during a screening of a panel of cell 
lines, see section 3.4.1 and figure 3.4.1.4 for details). A technical replicate verified 
this result.  
 
 
COX2 (72kDA) 
α-tubulin (50kDA) 
A549 Key: 
C:   Control / Untreated 
1:   10µM Celecoxib 
2:   10µM Lapatinib 
3:   10µM Erlotinib 
4:   10µM Gefitinib 
+:    2008/MRP1  
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Graph 3.3.4.1.: The activity of total COX (navy), COX-1 (red) and COX-2 (green) in 
A549 cells following exposure to lapatinib (A), AG825 (B) or trastuzumab (C) for 48 
hours. The same concentration of DMSO was included in all lapatinib samples 
(including the untreated sample) equal to that of the 10 µM concentration. A similar 
control for AG825 was not required as the levels of DMSO were less than 0.1%, 
while trastuzumab was in its clinical formulation. A concentration of 10µM celecoxib, 
a specific COX-2 inhibitor, was included as a control and decreased COX-2 activity 
was established. These graphs are the result of duplicate inter-assay replicates. 
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Graph 3.3.4.2.: The activity of total COX (navy bar), COX-1 (red bar) and COX-2 
(green bar) in the A549 cell lysate in the presence of lapatinib (A), AG825 or 
trastuzumab (B) or celecoxib (C) for 48 hours. The same concentration of DMSO was 
included in all lapatinib samples (including the untreated sample) equal to that of the 
10 µM concentration. A similar control for AG825 was not required as the levels of 
DMSO were less than 0.1%, while trastuzumab was in its clinical formulation. Graphs 
A and C are the result of duplicate inter-assay replicates while B is the result of a 
single assay 
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Graph 3.3.4.3.: The combination of lapatinib (■) with sulindac (Δ and ●) in the 
EGFR-amplified (MDA-MB-231; A.), HER2-amplified (MDA-MB-453; B.) and low 
EGFR/HER2-expressing (MCF7; C.) cell lines. These graphs depict the proliferation 
combination assays of clinically relevant concentrations of lapatinib with the non-
specific COX inhibitor, sulindac, over a 5 day period. All results are representative of 
triplicate independent determinations unless otherwise indicated (Ψ). Significant 
changes between each drug alone and the combination of both drugs is indicated by * 
(p<0.05). Table 3.3.4.2 outlines the percentage cell proliferation and standard 
deviations for this graph. 
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Table 3.3.4.2.: This table provides data for the combination of lapatinib and sulindac in the MDA-MB-453 cell line (see graph 3.3.4.1.A, B and 
C). 
 
Cell line Agents Cell Prolfieration (%) 
 Lapatinib (µM) 0 StDev (%) 0.3 StDev (%) 0.5 StDev (%) 1 StDev (%) 
MDA-MB-231 Lapatinib  100 ±0 100 ±4 99 ±4 98 ±4 
 Lap + 8µM Sulindac 99 ±4 98 ±4 97 ±5 97 ±4 
 Lap + 15µM Sulindac 97 ±4 97 ±5 95 ±5 92 ±5 
MDA-MB-453 Lapatinib 100 ±0 90 ±3 87 ±5 83 ±6 
 Lap + 8µM Sulindac  95 ±2 84 ±3 77 ±3 68 ±7 
 Lap + 15µM Sulindac 96 ±1 78 ±4 73 ±5 62 ±6 
MCF7 Lapatinib 100 ±0 76 ±2 79 ±2 75 ±2 
 Lap + 2µM Sulindac 96 ±3 80 ±2 79 ±2 77 ±2 
 Lap + 10µM Sulindac 89 ±2 75 ±2 71 ±2 67 ±2 
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3.3.5. TKI-mediated modulation of MDR protein. 
 
In this section, we compared the efficacy of three tyrosine kinase inhibitors in 
overcoming resistance due to the amplified expression of multidrug resistance (MDR) 
transporter proteins (P-gp, MRP1 and BCRP). To date, a number of researchers have 
shown that lapatinib [97], erlotinib [198] and gefitinib [199] inhibit the function of the 
three transporters. However, none have compared their efficacy to overcome P-gp, 
MRP1 and BCRP-mediated drug resistance. 
We selected a panel of cell lines that express P-gp, MRP1 and/or BCRP followed by a 
panel of MDR substrates and non-substrates. With each proliferation assay a control 
was carried out. This control included the MDR substrate combined with that 
particular MDR specific inhibitor, to ensure the MDR protein, in the chosen models, 
were transporting as normal during each assay. 
 
Combination TKI – Cytotoxicity proliferation assays in P-gp-expressing cell models. 
Three P-gp-overexpressing models, NCI/Adr-res, A549-Taxol and H1299-Taxol, 
were chosen for their differing expression levels of the P-gp protein. NCI/Adr-res (an 
ovarian cell model) expresses very high levels of P-gp while A549-Taxol (lung cell 
line) expresses moderate levels and H1299-Taxol (lung cell line) expresses low levels. 
Two P-gp substrates were used in these proliferation assays, epirubicin and docetaxel.  
 
The combination proliferation assays of biologically-relevant concentrations of 
lapatinib in the ovarian P-gp-overexpressing cell line, NCI/Adr-res, significantly 
potentiated the cytotoxic effects of epirubicin and docetaxel (see graph 3.3.5.1.A and 
table 3.3.5.1.). Neither erlotinib nor gefitinib enhanced the anti-proliferative potential 
of epirubicin or docetaxel to the same degree as lapatinib in this cell line. However, 
when combined the total cell growth was reduced compared to each drug individually. 
This would suggest that erlotinib and gefitinib did not overcome P-gp-mediated 
resistance. However, lapatinib overcame P-gp-mediated resistance in this cell line.  
Similar to the combination findings of lapatinib with epirubicin and docetaxel in the 
NCI/Adr-res cell line, lapatinib potentiated the cytotoxic effects of both 
chemotherapeutic drugs in the moderately-expressing P-gp cell line, A549-Taxol (see 
graph 3.3.5.2.A. and table 3.3.5.2.). However, the combination proliferation assays 
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using clinically relevant concentrations of erlotinib and gefitinib showed potentiation 
of the cytotoxic effect of epirubicin and docetaxel in this cell line (refer to graph 
3.3.5.2 B and C and table 3.3.6.2).  
Once again, the combination proliferation assays of lapatinib in the low-expressing P-
gp cell line, H1299-Taxol, moderately potentiated the cytoxicity of epirubicin and 
docetaxel (see graph 3.3.5.3.A. and table 3.3.5.3.). However, this same trend wasn’t 
evident with erlotinib and gefitinib. The combination of epirubicin with both erlotinib 
and gefitinib had no effect on cell growth while only a very mild reduction was 
observed when docetaxel and erlotinib combination in this cell line (see graph 
3.3.5.3.B and C and table 3.3.5.3.).  
 
This data indicates that, compared to erlotinib and gefitinib, lapatinib is the most 
efficient at sensitising P-gp-overexpressing cells to P-gp substrate cytoxic agents. 
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Graph 3.3.5.1.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B: )  and gefitinib (C: ) in the NCI/Adr-res cell line. This 
proliferation assay combined clinically relevant concentrations of the TKI’s with 
epirubicin or docetaxel over a 5 day period. The bar chart is the result of triplicate 
experiments carried out on separate days. Significant changes between each drug 
alone and the combination of both drugs is indicated by * (p<0.05). Table 3.3.5.1 
below depicts the percentage cell proliferation and standard deviations for this graph. 
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Table 3.3.5.1.: Data for the combination of epirubicin or docetaxel with the three 
TKI’s in the NCI/Adr-res cell line. 
 Cell Proliferation (%) 
TKI (µM) 0 StDev 
(%) 
0.3 StDev 
(%) 
0.5 StDev 
(%) 
1 StDev 
(%) 
Lapatinib 100 ±0 96 ±7 89 ±8 82 ±10 
Lap + 0.5µM Epi 84 ±7 75 ±8 69 ±11 40 ±10 
Lap + 0.06nM Doce 82 ±10 65 ±7 49 ±9 20 ±4 
Erlotinib 100 ±0 95 ±3 92 ±3 85 ±6 
Erlot + 0.5µM Epi 84 ±5 78 ±11 76 ±2 70 ±11 
Erlot + 0.06nM Doce 80 ±6 74 ±3 69 ±4 62 ±5 
Gefitinib 100 ±0 95 ±4 93 ±5 89 ±6 
Gefit + 0.5µM Epi 79 ±9 73 ±4 70 ±6 64 ±7 
Gefit + 0.06nM Doce 78 ±6 70 ±9 71 ±5 65 ±6 
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Graph 3.3.5.2.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B:  ) and gefitinib (C:  ) in the A549-Taxol cell line. This 
proliferation assay combined clinically relevant concentrations of the TKI’s with 
epirubicin or docetaxel over a 5 day period. The bar chart is the result of triplicate 
experiments carried out on separate days. Table 3.3.5.2 depicts the percentage cell 
proliferation and standard deviations for this graph. 
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Table 3.3.5.2.: Data for the combination of epirubicin or docetaxel with the three 
TKI’s in the A549-Taxol cell line. 
 
 Cell Proliferation (%) 
TKI (µM) 0 StDev 
(%) 
0.3 StDev 
(%) 
0.5 StDev 
(%) 
1 StDev 
(%) 
Lapatinib 100 ±0 86 ±17 81 ±14 84 ±17 
Lap + 0.015µM Epi 69 ±10 43 ±16 41 ±13 31 ±14 
Lap + 0.5nM Doce 73 ±10 39 ±20 38 ±17 32 ±15 
Erlotinib 100 ±0 87 ±12 80 ±17 82 ±15 
Erlot + 0.02µM Epi 74 ±7 52 ±8 44 ±7 36 ±5 
Erlot + 0.5nM Doce 70 ±8 51 ±4 38 ±20 36 ±18 
Gefitinib 100 ±0 92 ±3 95 ±8 95 ±7 
Gefit + 0.015µM Epi 88 ±8 78 ±12 71 ±14 66 ±14 
Gefit + 0.5nM Doce 88 ±15 75 ±11 68 ±7 63 ±8 
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Graph 3.3.5.3.:  The combination of epirubicin (■) or docetaxel (Δ) with lapatinib 
(A:  ), erlotinib (B:  ) and gefitinib (C:  ) in the H1299-Taxol cell line. This 
proliferation assay combined clinically relevant concentrations of the TKI’s with 
epirubicin or docetaxel on the low P-gp-expressing lung cell line, H1299-Taxol, over 
a 5 day period. The bar chart is the result of triplicate experiments carried out on 
separate days. Significant changes between each drug alone and the combination of 
both drugs is indicated by * (p<0.05). Table 3.3.5.3 below depicts the percentage cell 
proliferation and standard deviations for this graph. 
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Table 3.3.5.3.: Data for the combination of epirubicin and docetaxel with the three 
TKI’s in the H1299-Taxol cell line. 
 
 Cell Proliferation (%) 
TKI (µM) 0 Stdev 
(%) 
0.3 Stdev 
(%) 
0.5 Stdev 
(%) 
1 Stdev 
(%) 
Lapatinib 100 ±0 97 ±1 101 ±8 102 ±11 
Lap + 0.06µM Epi 51 ±0 33 ±13 31 ±20 24 ±23 
Lap + 0.05nM Doce 75 ±5 36 ±5 31 ±9 28 ±19 
Erlotinib 100 ±0 90 ±11 78 ±17 84 ±11 
Erlot + 0.06µM Epi 45 ±3 50 ±12 45 ±12 47 ±12 
Erlot + 0.05nM Doce 75 ±12 62 ±14 53 ±21 42 ±11 
Gefitinib 100 ±0 105 ±7 99 ±1 106 ±8 
Gefit + 0.06µM Epi 48 ±14 54 ±4 56 ±1 53 ±5 
Gefit + 0.05nM Doce 78 ±14 81 ±12 74 ±15 73 ±11 
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Combination TKI – Cytotoxic proliferation assays in MRP1-expressing cell model. 
 
In this case, a cell line of ovarian origin with transfected MRP1 was chosen, 
2008/MRP1 [391]. The 2008/MRP1 cell line was chosen for its stability of MRP1 
expression, rapid growth and because no one had employed for such purposes 
previously. To determine if any effect observed was due to MRP1-inhibition a single 
substrate, epirubicin, and a non-substrate, docetaxel, were chosen. 
 
The combination proliferation assays of a clinically relevant concentration of 
docetaxel and epirubicin with lapatinib, erlotinib and gefitinib in the MRP1-
expressing ovarian cell line, 2008/MRP1, were comparable (see graphs 3.3.5.4.A, B 
and C and table 3.3.5.4 for details). Combined, no significant decrease in cell 
proliferation that would indicate the TKIs ability to overcome MRP1-mediated 
resistance was observed. However, compared to each individual drug alone the 
combination was more effective at reducing cell proliferation.  
 
This data suggests that these three TKI’s do not overcome MRP1-mediated resistance 
in the selected model. 
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Graph 3.3.5.4.: The combination of epirubicin (□) or docetaxel (▲) with the three 
TKI’s, lapatinib (A:  ), erlotinib (B:  ) and gefitinib (C:  ), in the 2008/MRP1 cell line. 
This proliferation assay involved the combination of a single concentration of 
epirubicin or docetaxel with the three TKI’s, in the MRP1-overexpressing cell line, 
2008/MRP1, over a 5 day period. This bar chart is the result of triplicate assays on 
separate days. Table 3.3.5.4 below depicts the percentage cell proliferation and 
standard deviations for this graph. 
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Table 3.3.5.4.: Data for the combination of epirubicin or docetaxel with lapatinib, 
erlotinib and gefitinib in the 2008/MRP1 cell line. 
 
 Cell Proliferation (%) 
TKI (µM) 0 StDev 
(%) 
0.3 StDev 
(%) 
0.5 StDev 
(%) 
1 StDev 
(%) 
Lapatinib 100 ±0 71 ±5 61 ±4 53 ±4 
Lap + 0.06µM Epi 66 ±3 48 ±4 42 ±4 32 ±6 
Lap + 0.5nM Doce 89 ±7 66 ±7 56 ±6 48 ±4 
Erlotinib 100 ±0 80 ±10 70 ±10 59 ±12 
Erlot + 0.06µM Epi 75 ±13 50 ±10 40 ±7 25 ±6 
Erlot + 0.5nM Doce 76 ±9 57 ±13 47 ±13 36 ±12 
Gefitinib 100 ±0 80 ±11 68 ±14 60 ±12 
Gefit + 0.06µM Epi 72 ±9 55 ±5 47 ±5 41 ±4 
Gefit + 0.5nM Doce 96 ±2 67 ±4 55 ±2 48 ±4 
 
 
Combination TKI – Cytotoxicity proliferation assays in a BCRP-expressing cell 
model. 
 
We compared the efficacy of the TKI’s to inhibit, and thus sensitise, BCRP-
expressing cells to BCRP substrate cytotoxic agents. The model chosen (DLKP-
SQ/mitox), has stable and high expression of BCRP and was developed in the NICB 
by Helena Joyce. Western blots demonstrated the presence of this protein in the cell 
line (see figure 3.4.1.1.).  
The substrate chosen for this work was SN38 (the active metabolite of irinotecan [373]). 
 
We found that all three TKI’s hugely potentiated the cytotoxicity of SN38 when 
combined in the DLKP-SQ/mitox cell line (see graph 3.3.5.5 and table 3.3.5.5 for 
details). Lapatinib caused the greatest effect, followed closely by erlotinib and finally 
gefitinib.  
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DLKP-SQ/mitox: Tyrosine Kinase inhibitors
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Graph 3.3.5.5.: The combination of SN38 with lapatinib (alone: ■, combined: □), 
erlotinib (alone: ●, combined: ○) or gefitinib (alone: ▲, combined: Δ) in the DLKP-
SQ/mitox cell line. This proliferation assay involved the combination of a single 
concentration of SN38 with the three TKI’s, in the BCRP-overexpressing cell line, 
DLKP-SQ/mitox, over a 5 day period. The bar chart is the result of a triplicate assays 
and all combination results are statistically significant when compared to each drug 
alone. Table 3.3.5.5 below depicts the percentage cell proliferation and standard 
deviations of this graph. 
 
 
Table 3.3.5.5.: Data for the combination of SN38 with three TKI’s, lapatinib, 
erlotinib and gefitinib in the DLKP-SQ/mitox cell line. 
 
 Cell Proliferation (%) 
TKI (µM) 0 StDev 
(%) 
0.3 StDev 
(%) 
0.5 StDev 
(%) 
1 StDev 
(%) 
Lapatinib 100 ±0 96 ±2 96 ±2 97 ±1 
Lap + 0.025µM SN38 96 ±6 2 ±1 1 ±1 1 ±1 
Erlotinib 100 ±0 97 ±4 96 ±4 96 ±4 
Erlot + 0.025µM SN38 97 ±3 16 ±13 4 ±3 3 ±2 
Gefitinib 100 ±0 96 ±4 96 ±4 96 ±4 
Gefit + 0.025µM SN38 97 ±3 31 ±35 9 ±9 3 ±3 
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3.3.6. The impact of short-term TKI exposure on protein expression levels of P-
gp, MRP1 and BCRP. 
 
In this section, we compared the extent, if any, to which the three TKI’s altered the 
expression of three multidrug resistant transporter proteins, P-gp, MRP1 and BCRP.  
For this we chose 3 cells lines each expressing one type of MDR protein. These cell 
lines were chosen for their levels of protein expression. We hypothesised that 
moderate transporter overexpression was likely to be amenable to increased and 
decreased expression.  
In this case, A549-Taxol (a lung cell line expressing P-gp), A549 (a lung cell line 
expressing MRP1) and DLKP-SQ/mitox (the BCRP expressing daughter cell line to 
DLKP-SQ, the non-small cell lung carcinoma cell line) were chosen. A549 was 
chosen for this section over 2008/MRP1 as it is easier to obtain a distinct protein band 
by Western blotting therefore allowing for better evaluation of the results. 
 
Following a 24 hr exposure to 0.3, 0.5 and 1 µM lapatinib, erlotinib or gefitinib, P-gp 
expression was increased from between 40% and 200% in the A549-Taxol cell line 
(see figure 3.3.6.1. and table 3.3.6.1 for details). The Western blots shown in figure 
3.3.6.1 are the result of a single determination, however similar findings have been 
replicated by two members of our group [197] [112]. 
Following a 24hr exposure to 0.3, 0.5 and 1 µM erlotinib or gefitinib the expression 
of MRP1 in the A549 cell line was up-regulated (see figure 3.3.6.2 and table 3.3.6.2. 
for details, result also replicated by another member of out group [197]). However, 
lapatinib had the opposite effect causing a 70% reduction in MRP1 protein expression 
compared to the control sample (see table 3.3.6.2. for details).  
The same exposure in the DLKP-SQ/mitox cells resulted in a less marked result (refer 
to figure 3.3.6.3 for details). Some down-regulation occurred in the 1st biological test 
of lapatinib but the replicate was not fully consistent with this. Erlotinib showed slight 
down-regulation at 0.3 and 0.5 µM but up-regulation with 1 µM (this was also 
replicated by another member of our group [112]). All concentrations of gefitinib 
reduced BCRP expression and this was confirmed in a biological replicate. The 
densitometry is presented in table 3.3.6.3. This table also includes the densitometry 
results for the replicate Western blots that are not presented in figure 3.3.6.3. 
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Effect of short-term TKI exposure on P-gp expression in the A549-Taxol cell line. 
 
 
           Target Protein          Western blot    Summary effect 
                     
 
 
 
 
 
 
  
Figure 3.3.6.1.: Western blots illustrating changes in P-gp (170kDa) expression 
following 24hr exposures to 0, 0.3, 0.5 and 1 µM lapatainib, erlotinib or gefitinib in 
the moderately-expressing P-gp lung cell line, A549-Taxol. The arrows (↑) indicate 
that the P-gp protein was upregulated compared to control sample. Each sample 
loaded contained 40 µgs protein. These Western blots are the result of a single 
experiment. Densitometric analysis was carried out on these Westerns and the fold 
changes compared to control/untreated protein bands and normalised to β-actin are 
presented in table 3.3.6.1 below 
 
Table 3.3.6.1.: Precentage changes in P-gp protein expression in the A549-Taxol 
cells following a 24 hr exposure to 0, 0.3, 0.5 and 1 µM lapatinib, erlotinib or 
gefitinib. These percentage changes were determined using densitometric analysis of 
Western blots carried out on lysates of the exposed A549-Taxol cells.  
 Percentage Change 
TKI (µM) 0 0.3 0.5 1 
Lapatinib 0 40 130 130 
Erlotinib 0 170 200 160 
Gefitinib 0 200 140 90 
 
 
 
0   0.3 0.5  1 Tyrosine Kinase Inhibitor (µM) 
P-gp (170kDa) 
P-gp (170kDa) 
P-gp (170kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
↑ by Lapatinib after 24 hours  
↑ by Erlotinib after 24 hours 
↑ by Gefitinib after 24 hours  
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Effect of short-term TKI exposure on MRP1 expression in the A549 cell line. 
 
           Target Protein          Western blot    Summary effect 
                                                        
        
 
 
 
 
 
  
Figure 3.3.6.2.: Western blots showing changes in expression of MRP1 (190kDa) 
following 24hr exposures to 0, 0.3, 0.5 and 1µM lapatainib, erlotinib or gefitinib in 
the moderately expressing MRP1 lung cell line, A549. The arrows (↑ / ↓) indicate that 
the MRP1 protein was upregulated/downregulated compared to control sample. Each 
sample loaded contained 40 µgs protein. These Western blots are the result of 
duplicate or more Western blots, unless otherwise indicated (#). Densitometric 
analysis was carried out on these Westerns and the fold changes compared to 
control/untreated protein bands and normalised to β-actin are presented in table 
3.3.6.2 below. 
 
Table 3.3.6.2.: Fold changes in the expression of MRP1 in A549 cells following 
exposure to 0, 0.3, 0.5 and 1µM lapatinib, erlotinib and gefitinib for 24hrs. These fold 
changes were determined using densitometric analysis of Western blots carried out on 
lysates of the exposed A549 cells.  
 
 Percentage Change 
TKI (µM) 0 0.3 0.5 1 
Lapatinib 1 -60 -80 -70 
Erlotinib 1 110 90 40 
Gefitinib 1 110 140 270 
 
 
 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
↑ by Erlotinib after 24 hours#  
↑ by Gefitinib after 24 hours#  
MRP1 (190kDa) 
MRP1 (190kDa) 
MRP1 (190kDa) 
↓ by Lapatinib after 24 hours  
0   0.3  0.5   1 Tyrosine Kinase Inhibitor (µM) 
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Effect of short-term TKI exposure on BCRP expression in the DLKP-SQ/mitox cell 
line. 
 
           Target Protein          Western blot    Summary effect 
                                                        
 
 
 
 
 
 
  
Figure 3.3.6.3.: These Western blots show changes in expression of BCRP (70kDa) 
following 24hr exposures to 0, 0.3, 0.5 and 1 µM lapatainib, erlotinib and gefitinib in 
the highly over-expressing BCRP lung cell line, DLKP-SQ/mitox. The arrows 
indicate that the BCRP protein is unchanged (↔) or downregulated (↓) compared to 
control sample. 4 µgs of sample was loaded to each well. These Western blots are the 
represent duplicate or more independent Western blots, unless otherwise indicated (#). 
Densitometric analysis was carried out on these Westerns and the fold changes 
compared to control/untreated bands are presented in table 3.3.6.3 below. 
 
Table 3.3.6.3.: Fold changes in the expression of BCRP in DLKP-SQ/mitox cells 
following exposure to 0, 0.3, 0.5 and 1 µM lapatinib, erlotinib and gefitinib for 24hrs. 
These fold changes (compared to the control/untreated samples) were determined 
using densitometric analysis of western blots carried out on lysates of the exposed 
DLKP-SQ/mitox cells. The westerns blots for lapatinib and gefitinib were carried out 
in duplicate and the densitometry for both blots is presented in this table. 
 Percentage Change 
TKI (µM) 0 0.3 0.5 1 
Lapatinib 1 -25 -45 -35 
Erlotinib 1 -20 -40 90 
Gefitinib 1 -20 -35 -25 
β-actin (48kDa) 
β-actin (48kDa) 
β-actin (48kDa) 
↔ by Lapatinib after  24hrs 
↔ to ↓ by Erlotinib after 24hr# 
↓ by Gefitinib after 24hr 
BCRP (70kDa) 
BCRP (70kDa) 
BCRP (70kDa) 
0   0.3  0.5   1 Tyrosine Kinase Inhibitor (µM) 
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3.4. Relationship between the COX-2 inhibitor, celecoxib, and expression and 
function of Multidrug resistant proteins. 
 
This work was presented as a poster at the IACR conference in 2009. Over the next 
year, this body of work will be submitted for publication. 
 
3.4.1. Cell Panel Characterisation 
 
The purpose of this section was to verify the MDR and COX status of a panel of cell 
lines that were to be used in combination proliferation assays, pharmacokinetic and 
protein studies. Initially, 40 µgs of each protein sample was loaded; however, 
differences in target protein expression required alterations in the amount loaded for 
some samples.   
 
Most cell lines gave the expected results with regard to their MDR status, i.e. DLKP-
A expressed high levels of P-gp but did not express MRP1 or BCRP, HL60/S did not 
express P-gp, MRP1 or BCRP, etc (see table 3.4.1.1. and figure 3.4.1.1 to 3.4.1.3 for 
details). One cell line did not express the protein expected. From previous work done 
in the NICB (by Alex Eustace), BCRP expression was expected in lane 9 (M14) of 
figure 3.4.1.1. Later, BCRP-specific combination proliferation assays confirmed a 
lack of BCRP expression in this cell line. 
 
Most cells in the body express COX-1, therefore it was not unexpected to find that 
every cell line in this panel expressed this protein (see table 3.4.1.1 and figure 3.4.1.4 
for details).  
 
However, expression of COX-2 was less common and the profile of this panel could 
not be predicted. Western blot analysis showed that 2008/MRP1 expressed very high 
levels of this protein while HL60/S and M14 expression was barely detectable (see 
table 3.4.1.1 and figure 3.4.1.5 for details).  
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Table 3.4.1.1.: Summary of the MDR and COX expression profile in the panel of cell 
lines used in this project. 
 
Cell model MRP1 P-gp BCRP COX-1 COX-2 
HL60/S - - - + + 
M14 - - - + + 
DLKP + - - + - 
2008/MRP1 +++ - - ++ +++ 
HL60/Adr ++ - - + - 
DLKP-A - +++ - + - 
H1299-T - ++ - ++ - 
HL60/mdr1 - +++ - +++ - 
DLKP-
SQ/mitox 
- - +++ + - 
HL60/mxr - - ++ + - 
Key: 
-  No protein detected 
+ Low protein expression 
++ Moderate protein expression 
+++ High protein expression 
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Panel Characterisation 
 
BCRP profiling: 
 
   1     2    3    4    5    6    7    8    9   10   11 
 
   
 
Figure 3.4.1.1.: The expression of BCRP in a panel of cell lines using the Western 
blotting technique. The positive control used in this blot was DLKP-SQ/mitox (lane 
11). Lanes 1 to 7 (HL60/s, DLKP, 2008/MRP1, HL60/Adr, DLKP-A, H1299-Taxol, 
and HL60/Mdr1) did not express BCRP while lane 8 (DLKP-SQ/mitox) and 10 
(HL60/mxr) expressed the protein. This Western blot is representative of duplicate 
independent determinations. Results are summarised in table 3.4.1.1. 
Combination proliferation assays confirmed these results (see section 3.4.2 for details). 
 
Western blot lane designation: 
1. HL60/S (40µg) 
2. DLKP (40µg) 
3. 2008/MRP1 (40µg) 
4. HL60/Adr (40µg) 
5. DLKP-A (40µg) 
6. H1299-Taxol (40µg) 
7. HL60/mdr1 (40µg) 
8. DLKP-SQ/mitox (10µg) 
9. M14 (50µg) 
10. HL60/mxr (10µg) 
11. Positive control; DLKP-SQ/mitox (5µg) 
 
 
 
 
 
BCRP (70kDa) 
β-actin (48kDa) 
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MRP1 profiling: 
 
  1     2     3    4   5    6   7     8     9   10  11 
 
 
 
Figure 3.4.1.2.: Expression of MRP1 in a panel of cell lines using the Western 
blotting technique. Lanes 1 and 5 to 10 (HL60/s, DLKP-A, H1299-Taxol, HL60/Mdr1, 
DLKP-SQ/mitox, M14 and HL60/mxr) did not express MRP1 while lane 3 
(2008/MRP1) and 4 (HL60/Adr) express the protein. Lane 2 (DLKP) had a very small 
amount and is barely evident. The positive control used in this blot is 2008/MRP1 and 
is located in lane 11. These results are summarised in table 3.4.1.1 above. This 
Western blot is representative of duplicate independent determinations. Results are 
summarised in table 3.4.1.1. 
Combination proliferation assays also confirmed these results (see section 3.4.2 for 
details).  
 
 
Western blotting lane designation: 
1. HL60/S (40µg) 
2. DLKP (40µg) 
3. 2008/MRP1 (10µg) 
4. HL60/Adr (40µg) 
5. DLKP-A (10µg) 
6. H1299-Taxol (40µg) 
7. HL60/Mdr1 (20µg) 
8. M14 (40µg) 
9. DLKP-SQ/mitox (40µg) 
10. HL60/mxr (40µg) 
11. Positive control; 2008/MRP1 (10µg) 
 
 
MRP1 (190kDa) 
β-actin (48kDa) 
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P-gp profiling: 
 
   1     2    3    4    5    6   7    8    9   10   11 
 
 
Figure 3.4.1.3.: Western blot show the expression of P-gp in a panel of cell lines. The 
positive control used in this blot is DLKP-A (lane 11). Lanes 1 to 4 and lane 8 to 10 
(HL60/s, DLKP, 2008/MRP1, HL60/Adr, DLKP-SQ/mitox, M14 and HL60/mxr) did 
not express P-gp while lane 5 to 7 (DLKP-A, H1299-Taxol and HL60/mdr1) 
expressed the protein. DLKP-A had the highest expression of P-gp, followed closely 
by HL60/mdr1 and to a much lesser extent H1299-Taxol. These results are 
summarised in table 3.4.1.1 above. This Western blot is representative of duplicate 
independent determinations. Results are summarised in table 3.4.1.1. Combination 
proliferation assays confirmed these results (see section 3.4.2 for details).  
 
Western blotting lane designation: 
1. HL60/S (40µg) 
2. DLKP (40µg) 
3. 2008/MRP1 (10µg) 
4. HL60/Adr (40µg) 
5. DLKP-A (10µg) 
6. H1299-Taxol (40µg) 
7. HL60/Mdr (20µg) 
8. M14 (40µg) 
9. DLKP-SQ/mitox (40µg) 
10. HL60/mxr (40µg) 
11. Positive control; DLKP-A (10µg) 
 
 
 
 
 
P-gp (170kDa) 
β-actin (48kDa) 
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COX profiling: 
                                                                                            
   1    2     3   4    5    6    7    8    9   10        
  
 
                              
    1    2   3    4    5    6    7    8    9   10   
  
  
 
Figure 3.4.1.4.: Western blots show the expression of COX-1 and COX-2 in a panel 
of cell lines. The COX-1 positive control used was a mouse heart extract purchased 
from Santa Cruz. COX-2 positive control is A549. As COX-1 is known to be 
expressed in most tissue types it is not unexpected to discover every cell line in this 
panel express COX-1. On the other hand, COX-2 is not constitutively expressed but 
has been found to be expressed or up-regulated in cancer cells. Out of this panel 
HL60/S (lane 1), M14 (lane 2) and 2008/MRP1 (lane 4) expressed detectable levels of 
COX-2. The COX-1 blot was carried in duplicate (A and B) and the COX-2 Western 
is the result of a single experiment (A). These results are summarised in table 3.4.1.1 
above. 
 
Western blot lane designation: 
1. HL60/S (40µg) 
2. M14 (20µg) 
3. DLKP (40µg) 
4. 2008/MRP1 (40µg) 
5. HL60/Adr (40µg) 
6. DLKP-A (40µg) 
7. H1299-Taxol (40µg) 
8. HL60/Mdr1 (40µg) 
9. DLKP-SQ/mitox (20µg) 
10. HL60/mxr (20µg) 
β-actin (48kDa) 
β-actin (48kDa) 
COX2 (72kDa) 
COX-1 (70kDa) 
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3.4.2. Effect of celecoxib on the inhibition of multidrug resistance transporter 
proteins. 
 
The use of NSAIDs in the clinic for cancer treatment has been suggested and some 
agents such as, sulindac, are currently undergoing clinical trials (for review see 
section 1.4.3). The purpose of this body of work was to clarify the true relationship 
between celecoxib and its effect on the three MDR transporters. We selected a panel 
of MDR-expressing cell lines, two substrates, two non-substrates and an inhibitor for 
each MDR transporter. The cell lines were chosen for having established, reliable 
expression of their MDR proteins. The two substrates that were chosen for each MDR 
pump were selected in order to rule out the possibility of interacting with other MDR 
pumps and other non-MDR mechanisms. For example, epirubicin and docetaxel were 
chosen for the P-gp combination assays as docetaxel is a substrate for P-gp but not for 
MRP1 or BCRP, however, eprubicin is a substrate for P-gp, MRP1 and one mutant 
form of BCRP. A non-substrate for each MDR pump was selected to demonstrate that 
any additivity observed was due to that particular MDR transporter and not another.  
 
Table 3.4.2.1.: Summary of the MDR cell lines, substrates, non-substrates and MDR-
inhibitors used in this project. 
MDR 
transporter  
Cell line Substrate Non-substrate MDR-inhibitor 
P-gp DLKP-A Epirubicin Cisplatin Elacridar 
 H1299-Taxol Docetaxel 5FU  
 HL60/mdr1    
MRP1 DLKP Epirubicin Docetaxel Sulindac Sulphide 
 2008/MRP1 Vincristine 5FU  
 HL60/Adr    
BCRP DLKP-SQ/mitox SN38 Vinblastine Elacridar 
 HL60/mxr    
Note: The relationship of each drug with the multidrug resistance transporter proteins was discussed in 
section 1.4 and in tables 1.4.1, 1.4.2 and 1.4.3 of the introduction. 
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Interaction of celecoxib with P-gp-mediated resistance 
 
As presented in section 3.4.1., the three P-gp expressing cell lines selected for this 
project were DLKP-A, H1299-Taxol and HL60/mdr1 (figure 3.4.1.3, table 3.4.2.1 and 
table 2.5.1 for for further details). The combination proliferation assays of epirubicin 
or docetaxel with celecoxib in the P-gp-overexpressing lung cell lines, H1299-Taxol 
and DLKP-A, demonstrated a moderate decrease in cell proliferation compared to 
celecoxib or the P-gp substrate alone. This effect only occurred with the highest 
concentration of celecoxib (10 µM). A milder effect was observed at biologically 
relevant concentrations (2 µM) (see graphs 3.4.2.1.A and B and table 3.4.2.1 for 
details). However, in graph 3.4.2.1.C1 and C2, the combination proliferation assays 
of epirubicin and doctaxel with celecoxib in the HL60/mdr1 cell line demonstrated no 
change in growth proliferation. No interaction was observed by the combination of 
celecoxib with cisplatin or 5FU on these cell lines.  
The decrease in cell proliferation observed with the P-gp substrates suggest that 
celecoxib overcomes P-gp-mediated resistance to a minor extent at biologically-
relevant concentrations. 
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Graph 3.4.2.1.: The combination of epirubicin (□), docetaxel (▲), cisplatin (×) or 
5FU (■) with celecoxib (  ) in the DLKP-A (A), H1299-Taxol (B) and HL60/mdr1 (C) 
cell lines. This proliferation assay involved the combination of one of 4 
chemotherapeutic agents with celecoxib on the high, low and moderately expressing 
P-gp cell line, DLKP-A, H1299-Taxol and HL60/mdr1, over a 5 day period. Graph 
3.4.2.1.A and B are the result of triplicate assays on separate days. Significant 
changes between each drug alone and the combination of both drugs is indicated by * 
(p<0.05). Graphs 3.4.2.1.C represents duplicate independent determinations Table 
3.4.2.1 below depicts the percentage cell proliferation and standard deviations for this 
graph. 
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Table 3.4.2.1.: The percentage cell proliferation and standard deviations for the combination proliferation assays of epirubicin, docetaxel, 
cisplatin and 5FU with celecoxib in the three P-gp expressing cell lines. This table is illustrated in graph 3.4.2.1. 
Cell line Agents Cell Prolfieration (%) 
 Celecoxib (µM) 0 StDev (%) 0.5 StDev (%) 2 StDev (%) 5 StDev (%) 10 StDev (%) 
DLKP-A Celecoxib 100 ±0 98 ±2 97 ±2 91  ±11 85 ±10 
 Cele + 1µM Epi 68 ±8 73 ±7 69 ±8 60 ±7 30 ±6 
 Cele + 0.5nM Doce 97 ±4 99 ±1 98 ±3 92 ±2 78 ±7 
 Cele + 1µM Cis 94 ±1 93 ±3 95 ±2 95 ±4 93 ±6 
 Cele + 5µM 5FU 94 ±2 97 ±0 97 ±2 94 ±0 84 ±0 
H1299-Tax Celecoxib 100 ±0 96 ±1 95 ±1 92 ±2 84 ±5 
 Cele + 0.02µM Epi 95 ±4 92 ±5 88 ±6 83 ±8 72 ±11 
 Cele + 1nM Doce 97 ±3 92 ±2 91 ±2 88 ±5 78 ±9 
 Cele + 0.3µM Cis 99 ±2 97 ±1 96 ±3 93 ±4 87 ±6 
 Cele + 0.3µM 5FU 99 ±2 96 ±1 95 ±1 92 ±3 86 ±5 
HL60/mdr1 Celecoxib  100 ±0 88 ±6 83 ±4 82 ±6 76 ±2 
 Cele + 0.2µM Epi 57 ±2 55 ±1 61 ±0 67 ±3 64 ±1 
 Cele + 0.07nM Taxt 90 ±6 88 ±4 82 ±7 82 ±2 75 ±15 
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Interaction of celecoxib with MRP1-mediated resistance 
 
As presented in section 3.4.1., the three MRP1-expressing cell lines selected for this 
project were DLKP, 2008/MRP1 and HL60/Adr (figure 3.4.1.2, table 3.4.2.1 and 
table 2.5.1 for further details). The combination proliferation assays of vincristine 
with celecoxib in all three MRP1-expressing cell lines, DLKP (A), 2008/MRP1 (B) 
and HL60/Adr (C1 and C2), gave a significant decrease in cell proliferation (see 
graphs 3.4.2.2.A, B, C1 and C2 and table 3.4.2.2. for details). The combination of 
epirubicin with celecoxib in the DLKP or 2008/MRP1 cell lines also had the same 
impact on cell growth. However, this combination caused no change in cell growth in 
the HL60/Adr cells. 
The combinations of docetaxel and 5FU with celecoxib had no heightened decrease in 
the cell proliferation of DLKP or 2008/MRP1 therefore adding weight to thefact that 
these cells do not express P-gp and that the enhanced toxicity of the MRP1 substrates 
by celecoxib is the results of celecoxib overcoming MRP1-mediated resistance.  
Graphs 3.4.2.2.A and B represent the average of three indepent determinations. Graph 
3.4.2.2.C1 and C2 are duplicates of each other and represent single independent 
determinations. Table 3.4.2.2 contains the percentage cell proliferation and standard 
deviations for graphs A, B and C in graph 3.4.2.2.  
 
In section 8, results for the combination assay of vincristine or epirubicin with 
celecoxib on the A549, moderately expressing MRP1, cell line are presented . This 
cell line does not express P-gp or BCRP [112]. The A549 cell line was included as it 
was later used to examine the effect of celecoxib on the expression of MRP1 (see 
section 3.4.3 for further details). The presence of celecoxib enhanced the anti-
proliferative potential of both MRP1 substrates, epirubicin and vincristine (see section 
8, graph 8.4.2.1 and table 8.4.2.1 for details). Therefore, celecoxib also overcomes 
MRP1-mediated resistance in the A549 cell line. 
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Graph 3.4.2.2.: The combination of epirubicin (□), vincristine (▲), docetaxel (×) or 5FU (■) with celecoxib (  ) in the DLKP (A), 2008/MRP1 
(B) and HL60/Adr (C1 and C2) cell lines. This proliferation assay involved the combination of one of 4 chemotherapeutic agents with celecoxib 
in very low, high and moderately expressing MRP1 cell lines, DLKP, 2008/MRP1 and HL60/Adr, over a 5 day period. Graph 3.4.2.2.A. and B 
are the result of a triplicate independent determinations. Significant changes between each drug alone and the combination of both drugs is 
indicated by * (p<0.05). Graphs 3.4.2.2.C1 and C2. were single day replicates. Table 3.4.2.2 below depicts the percentage cell proliferation and 
standard deviations for this graph. 
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Table 3.4.2.2.: The percentage cell proliferation and standard deviations for the combination proliferation assays of epirubicin, vincristine, 
docetaxel, or 5FU with celecoxib in the three MRP1-expressing cell lines. This table is illustrated in graph 3.4.2.2. 
Cell line Agents Cell Prolfieration (%) 
 Celecoxib (µM) 0 StDev (%) 0.5 StDev (%) 2 StDev (%) 5 StDev (%) 10 StDev (%) 
DLKP Celecoxib 100 ±0 94 ±3 90 ±4 85 ±5 67 ±11 
 Cele + 10 nM Epi 63 ±11 61 ±11 32 ±16 26 ±12 4 ±6 
 Cele + 1 nM Vinc 89 ±13 85 ±14 68 ±11 54 ±12 36 ±4 
 Cele + 0.5 nM Doce 85 ±8 87 ±8 81 ±5 73 ±8 59 ±11 
 Cele + 1.5 µM 5FU 93 ±5 93 ±3 87 ±4 83 ±5 66 ±10 
2008/MRP1 Celecoxib 100 ±0 98 ±2 99 ±1 99 ±1 97 ±1 
 Cele + 60 nM Epi 86 ±7 82 ±8 53 ±13 20 ±7 11 ±4 
 Cele + 20 nM Vinc 67 ±3 61 ±4 24 ±5 8 ±2 4 ±1 
 Cele + 0.5 nM Doce 95 ±7 94 ±7 95 ±7 95 ±8 90 ±14 
 Cele + 5µM 5FU 78 ±19 80 ±14 77 ±15 77 ±17 77 ±16 
HL60/Adr Celecoxib  100 ±0 95 ±2 93 ±6 93 ±5 88 ±5 
 Cele + 0.05µM Epi 93 ±3 94 ±2 93 ±2 92 ±4 88 ±4 
 Cele + 0.14µM Vinc 88 ±1 83 ±2 70 ±3 62 ±3 59 ±3 
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Interaction of Celecoxib with BCRP-mediated resistance: 
 
Two cell lines were used in this section; DLKP-SQ/mitox and HL60/mxr (see figure 
3.4.1.3, table 3.4.2.1 and table 2.5.1 for further details). The combination proliferation 
assay of SN38 with celecoxib in both cell lines, DLKP-SQ/mitox and HL60/mxr, 
gave a mild decrease in cell proliferation at the pharmacologically-relevant 
concentration of 2 µM and a much greater effect with 5 and 10 µM (see graphs 
3.4.2.3.A, and table 3.4.2.3 for details).   
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Graph 3.4.2.3.: Combination of SN38 (Δ) with celecoxib (●) in the DLKP-SQ/mitox 
(A) and HL60/mxr (B) cell lines. This proliferation assay involved the combination of 
one of 2 chemotherapeutic agents with celecoxib in very high and moderately 
expressing BCRP cell lines, DLKP-SQ/mitox and HL60/mxr, over a 5 day period. 
Graph 3.4.2.3.A. was the result of a triplicate assay on separate days. Graph 3.4.2.3.B. 
was single day assays. Significant changes between each drug alone and the 
combination of both drugs is indicated by * (p<0.05). Table 3.4.2.3 below depicts the 
percentage cell proliferation and standard deviations for this graph. 
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Table 3.4.2.3.: The percentage cell proliferation and standard deviations for the combination proliferation assay of SN38 with celecoxib in the 
two BCRP expressing cell lines. This table is illustrated in graph 3.4.2.3. 
 
Cell line Agents Cell Prolfieration (%) 
 Celecoxib (µM) 0 StDev (%) 0.5 StDev (%) 2 StDev (%) 5 StDev (%) 10 StDev (%) 
DLKP-SQ/mitox Celecoxib 100 ±0 99 ±2 97 ±2 98 ±2 97 ±2 
 Cele + 25nM SN38  91 ±3 90 ±3 79 ±13 35 ±13 9 ±10 
HL60/mxr Celecoxib 100 ±0 97 ±5 99 ±3 88 ±2 93 ±5 
 Cele + 12nM SN38 84 ±8 85 ±17 81 ±10 60 ±17 32 ±6 
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3.4.3. Effect of celecoxib on P-gp, MRP1, BCRP, COX1 and COX2 protein 
expression. 
 
We investigated the extent to which celecoxib altered the expression of three 
multidrug resistant transporter proteins, P-gp, MRP1 and BCRP, and the 
cyclooxygenase enxymes, COX-1 and COX-2. For this we chose 3 MDR cells lines, 
each expressing one type of MDR protein. In this case, H1299-Taxol (a lung cell line 
expressing P-gp), A549 (a lung cell line expressing MRP1) and DLKP-SQ/mitox (a 
non-small cell lung carcinoma expressing BCRP) were chosen. H1229-Taxol and 
A549 express moderate to low levels of P-gp protein and are therefore more 
representative of what would be found in vivo. Unfortunately, a stable moderately-
expressing BCRP cell line was not easily available so we chose DLKP-SQ/mitox 
(very high but stable expression of BCRP). The MRP1-transfected cell line, 
2008/MRP1, was chosen for the COX-1 work and A549 (a well known COX-2 
expressor) was used for the COX-2 protein expression work. All cells were exposed 
to 0, 0.5, 2 and 10 µM Celecoxib for 48 hours. 40 µg of protein was loaded for the P-
gp, MRP1, COX-1 and COX-2 westerns. 4 µgs (for A) and then 8 µgs (for B) of the 
DLKP-SQ/mitox protein lysate were loaded for the detection of BCRP.  
Following a 48hr exposure to 0.5, 2 and 10 µM celecoxib, the expression of P-gp in 
the H1299-Taxol cell line decreased slightly (see figure 3.4.3.1.i.A and B for details). 
Celecoxib caused a slight down-regulation of MRP1 at the highest concentration (10 
µM) but had no impact at biologically relevant concentrations (0.5 and 2 µM) (see 
figure 3.4.3.1.ii.A and B for the image). Variations in the expression of BCRP 
occurred following the exposure of DLKP-SQ/mitox to celecoxib for 48 hours. The 
lowest concentration (0.5µM) slightly increased expression while the highest 
concentration (10µM) reduced its expression (see figure 3.4.3.1.iii.A and B for 
images). 
 
COX-1 expression in the 2008/MRP1 cells was reduced with the highest 
concentration of celecoxib while there was little change in the expression of COX-2 
across the board in the A549 cells (see figures 3.4.3.1.iv.A and B and figure 3.4.3.1.v. 
A for images). 
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Effect of short-term celecoxib exposures on the P-gp, MRP1, BCRP, COX1 and 
COX2 expression in a panel of cell lines. 
(i.)      A                      B 
  1    2    3     4    1     2    3   4 
 
 
(ii.)     A                     B 
  1    2   3    4     1    2    3   4 
  
 
(iii.)     A                      B 
   1    2    3    4     1    2    3   4 
 
 
(iv.)     A                      B 
  1    2     3    4     1    2    3    4 
 
 
(v.)       A                     B 
   1    2    3     4    1    2   3    4 
 
 
 
Figure 3.4.3.1.: These images represent the Western blots for P-gp (i.: 170kDa), 
MRP1 (ii.: 190kDa), BCRP (iii.: 70kDa), COX-1 (iv.: 72kDa) and COX-2 (v.: 70kDa) 
expression following exposure to 0, 0.5, 2 and 10 µM celecoxib for 48 hours. Blots A 
and B are biological replicates of each MDR/COX protein. 40 µg of protein was 
loaded for the P-gp, MRP1, COX-1 and COX-2 Westerns. 4 µg’s (for A) and then 8 
µg’s (for B) of the DLKP-SQ/mitox protein lysate were loaded for the detection of 
BCRP. 
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3.4.4. Cellular pharmacokinetics of celecoxib in MDR-expressing cell models 
 
In this section, we investigated the pharmacokinetics of celecoxib in MDR-expressing 
cell lines. This work was carried out to establish the relationship of celecoxib to each 
MDR transporter pump. For example, is celecoxib a substrate for MRP1, P-gp and /or 
BCRP?  
 
We investigated the accumulation of celecoxib in the panel of cell lines (except for 
the suspension cells HL60/S, HL60/mdr1 and HL60/Adr). The cells were exposed to 
2.5, 5 and 10 µM celecoxib for 2 hours. 2008/MRP1 had the greatest accumulation 
where the level of celecoxib nearly reached 2782 ng/million cells (graph 3.4.4.1.). 
H1299-Taxol and DLKP-A, had maximum accumulations 2600 and 2375 ng/million 
cells. The maximum accumulation for the DLKP and HL60/mxr cells were 1231 and 
899 ng/million cells. The DLKP-SQ/mitox cells had the lowest accumulation (156 
ng/million cells).The difference in accumulation between all the cell lines may be due 
to a difference in cell size, MDR transport protein expression or permeability. 
 
We determined if celecoxib was a substrate for any of the MDR pumps. Using the 
lowest concentration of celecoxib (2.5 µM) we quantified the accumulation of 
celecoxib in the presence and absence of MDR inhibitors. For MRP1, 5 µM sulindac 
sulphide was used and for both P-gp and BCRP, 2.5µM elacridar was used. There was 
a 3-fold increase in celecoxib accumulation in the presence of sulindac sulphide (an 
MRP1 inhibitor) in both of the MRP1 cell lines, DLKP and 2008/MRP1 (see graph 
3.4.4.2.). There was no increase in celecoxib accumulation in the presence of elacridar 
in DLKP-A cells. Nevertheless, the other P-gp-expressing cell line, H1299-Taxol, 
experienced a 3 fold increase in celecoxib accumulation in the presence of the same 
dose of elacridar. The cells were pre-treated with the MDR inhibitor to determine if 
pre-treatment would enhance celecoxib accumulation to a greater extent than the 
direct combination of celecoxib with the MDR inhibitor (see graph 3.4.4.2 and table 
3.4.4.2. for details). The results were very similar; therefore pre-treating the cells with 
the MDR inhibitor did not enhance celecoxib accumulation to a greater extent then 
the co-incubation. A 2 fold increase resulted from the introduction of elacridar to both 
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of the BCRP-expressing cell lines, DLKP-SQ/mitox and HL60/mxr. This work 
suggests that celecoxib could be a substrate for MRP1, P-gp and BCRP. 
 
To confirm whether celecoxib is a substrate of the MDR transporter pumps, we 
carried out efflux assays in all cell lines. The cells were exposed to 10µM celecoxib 
for 3 hours. At this point the drug was removed and fresh media (± MDR inhibitor) 
was added. We found that celecoxib is rapidly effluxed from all cells. The presence of 
an MDR-inhibitor did not alter this. However, there was a slight decrease in the efflux 
of celecoxib from the DLKP cells in the presence of sulindac sulphide (see graph 
3.4.4.3.A). Yet, the effect is not observed with the 2008/MRP1 cells.  
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Graph 3.4.4.1.: Accumulation of celecoxib in two MRP1 (DLKP (  ) and 2008/MRP1 
(  )), P-gp (DLKP-A (■) and H1299-Taxol (□) and BCRP (DLKP-SQ/mitox (▲) and 
HL60/mxr (Δ)) expressing cell lines. This graph is the result of a triplicate intraday 
assay. 
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Graph 3.4.4.2.: This bar chart outlines the accumulation of 2.5µM celecoxib in the 
presence or absence of the appropriate multidrug resistance transport protein inhibitor 
in a panel of MDR-expressing cell lines. These accumulation assays involved the 
exposure of MRP1-expressing cell lines (DLKP and 2008/MRP1) to 2.5µM celecoxib 
alone and in combination with 5µM Sulindac sulphide (a known MRP1-inhibitor). 
This graph also depicts the accumulation of celecoxib in P-gp (DLKP-A and H1299-
Taxol) and BCRP (DLKP-SQ/mitox and HL60/mxr) expressing cell lines in the 
presence or absence of 2.5µM elacridar (a known P-gp and BCRP inhibitor). This bar 
chart is one of two independent determinations, with triplicate intra-day results. 
Significane differences (P < 0.05) between celecoxib accumulation alone and in the 
presence of a MDR-inhibitor in indicated by *. Table 3.4.4.2 below depicts the 
quantity of celcoxib (ng/million cells), the standard deviations and significance values 
for this graph. 
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Table 3.4.4.2.: Data for the accumulation of celecoxib (ng/million cells) in the presence or absence of the appropriate MDR-inhibitor in the 
MRP1, P-gp and BCRP cells. This table includes the standard deviation and significance (P<0.05) values for graph 3.4.4.2. 
Celecoxib 
(ng/million cells) 
Celecoxib Stdev Cele + 
Inhibitor
StDev P value Inhibitor 
pre-treat 
StDev P value 
DLKP 61 ±11 201 ±41 0.005 187 ±32 0.003 
2008/MRP1 434 ±146 1127 ±269 0.017 742 ±288 0.174 
DLKP-A 695 ±235 685 ±323 0.965 779 ±142 0.627 
H1299-Taxol 363 ±41 957 ±348 0.042 1219 ±666 0.09 
DLKP-SQ/mitox 106 ±42 200 ±46 0.061    
HL60/mxr 516 ±23 949 ±47 0.007    
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Graph 3.4.4.3.: The efflux of celecoxib in the presence (□) or absence (  ) of MDR-
inhibitors in MRP1 (A: DLKP and 2008/MRP1), P-gp (B: DLKP-A and H1299-Tax) 
and BCRP (C: DLKP-SQ/mitox and HL60/mxr) expressing cells. The cells were 
exposed to 10µM celecoxib for 3 hours. At this time celecoxib was decanted, the cells 
were rinsed with warmed PBS and replaced with warm media (± the MDR-inhibitor) 
and samples were extracted after 30, 60 and 120 minutes. These graphs are results of 
triplicate intra-day determinations and * denotes significant differences (P < 0.05) 
between celecoxib efflux in the presence and absence of the appropriate MDR-
inhibitor. 
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3.4.5. Effect of celecoxib on epirubicin accumulation in MDR-expressing cell 
lines. 
 
We investigated the effect of celecoxib on the pharmacokinetics of MDR substrates in 
a panel of MDR-expressing cell lines, to establish if celecoxib can directly inhibit the 
efflux of MDR substrates via their appropriate transporter pump. For example, a 
heightened epirubicin accumulation was observed when celecoxib was present in 
MRP1 or P-gp cells, therefore suggesting that celecoxib can inhibit pump function. 
The best methods to determine this are accumulation or efflux assays (for 
experimental details see section 2.12.2). For this assay, all cells were exposed to 2µM 
epirubicin (± MDR inhibitor) for 2 hours. At this time, the cells were removed from 
their flasks, washed, counted and prepared for drug extraction. 
 
Accumulation of epirubicin in the DLKP cells was higher than in the 2008/MRP1 
cells (see graph 3.4.5.1). When 0.5, 2 and 10µM celecoxib was introduced there was a 
1.3, 1.6 and 1.7 fold increase in epirubicin accumulation in the DLKP cells. Celecoxib 
had a greater impact on epirubicin accumulation in 2008/MRP1 cells. Fold increases 
of 1.3, 3.9 and 4.9 occured with the addition of 0.5, 2 and 10µM celecoxib (see graph 
3.4.5.1 and table 3.4.5.1.).  
As expected, there was very little accumulation of epirubicin in the DLKP-A cells. 2 
and 10µM celecoxib increased this accumulation by 1.5 and 2.3 fold. Celecoxib had a 
similar impact on epirubicin accumulation in H1299-Taxol cells. 2 and 10µM 
celecoxib increased accumulation by 2.2 and 2.5 fold (see graph 3.4.5.2. and table 
3.4.5.2.). 
Unexpectedly, we also observed an increase in epirubicin accumulation in the 
presence of celecoxib in the BCRP expressing cells, DLKP-SQ/mitox. The addition of 
0.5, 2 and 10µM celecoxib caused a 1.5, 1.7 and 1.5 fold increase in epirubicin 
accumulation (see graph 3.4.5.3. and table 3.4.5.3.). 
 
These results would suggest celecoxib directly inhibits all three MDR pumps. The 
greatest effect was seen in the MRP1-expressing cell line 2008/MRP1, followed by 
the P-gp expressing cells and finally the BCRP cells. This order of impact could be 
due to the degree of inhibition or to the affinity the pump has for the substrate.  
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Graph 3.4.5.1.: The accumulation of epirubicin, in the presence or absence of 
celecoxib, in the two MRP1-expressing cell lines, DLKP and 2008/MRP1. The bars in 
this graph represent the quantity (ng) of epirubicin accumulated per million cells. 
Significance relative to the 0 µM celecoxib is indicated by * (p value below 0.05). 
The value for each bar is located above the error bars. This bar chart represents two 
independent determinations with triplicate intra-day results. Table 3.4.5.1. below 
provide the fold increases in epirubicin accumulation and the p values for each sample. 
 
Table 3.4.5.1.: Data for the accumulation of epirubicin in the presence and absence of 
celecoxib in the DLKP and 2008/MRP1 cells. This table provides the fold changes 
and significance/P values for the cells exposed to both epirubicin and celecoxib 
relative to cells exposed to epirubicin alone. 
Cell line Celecoxib (µM) Fold change P value
DLKP 0 1.0 N/A 
 0.5 1.3 0.13 
 2 1.6 0.0003 
 10 1.7 0.002 
2008/MRP1 0 1.0 N/A 
 0.5 1.3 0.17 
 2 3.9 0.0008 
 10 4.9 0.002 
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Graph 3.4.5.2.: The accumulation of epirubicin, in the presence or absence of 
celecoxib, in the two P-gp expressing cell lines, DLKP-A and H1299-Taxol. The bars 
in this graph represent the quantity (ng) of epirubicin accumulated per million cells. 
Significance is indicated by * (p value below 0.05). The value of each bar is located 
above the error bars. This bar chart represents two independent determinations with 
triplicate intraday results. Table 3.4.5.2. below provide the fold increases in epirubicin 
accumulation and the p values for each sample. 
 
 
Table 3.4.5.2.: Data for the accumulation of epirubicin in the presence or absence of 
celecoxib in the DLKP-A and H1299-Taxol cells. This table provides the fold 
changes and significance values relative to 0µM celecoxib for graph 3.4.5.2. above. 
 
Cell line Celecoxib (µM) Fold change P values 
DLKP-A 0 1 N/A 
 0.5 1.6 0.06 
 2 1.5 0.02 
 10 2.3 0.001 
H1299-Taxol 0 1 N/A 
 0.5 1.2 0.58 
 2 2.2 0.04 
 10 2.5 0.03 
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Graph 3.4.5.3.: The accumulation of epirubicin, in the presence and absence of 
celecoxib, in the BCRP expressing cell line, DLKP-SQ/mitox. The bars in this graph 
represent the quantity (ng) of epirubicin accumulated per million cells. Significance is 
indicated by * (p value below 0.05). The value for each bar is located above the error 
bars. This bar chart represents two independent determinations with triplicate intraday 
results. Table 3.4.5.3. below provide the fold increases in epirubicin accumulation and 
the p values for each treatment. 
 
 
Table 3.4.5.3.: Data for the accumulation of epirubicin in the presence and absence of 
celecoxib in the DLKP-SQ/mitox cells. This table provides the fold changes and 
significance values for graph 3.4.5.3. above. 
 
Cell line Celecoxib (µM) Fold change P value
DLKP-SQ/mitox 0 1 N/A 
 0.5 1.5 0.09 
 2 1.7 0.009 
 10 1.5 0.010 
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General discussion 
Multidrug resistance (MDR) proteins are expressed in a wide variety of tissue types, 
including, liver [42], gastrointestinal tract [35] and blood brain barrier, and help regulate 
the influx and efflux of substances required for normal cellular functioning [38] [39]. 
However, long-term treatment with chemotherapeutic drugs can lead to the over-
expression of the MDR proteins and the development of the MDR phenotype. This 
phenotype and enhanced expression can be a major cause of treatment failure for 
conventional and modern anti-cancer drugs that are effluxed by MDR transporter 
proteins.  
The search for agents that overcome this phenotype has been investigated for at least 
30 years. An extensive range of MDR modulators has been identified (listed in tables 
1.4.2.1, 1.4.3.1., 1.4.4.1, and 3.1.6.1.) and some of these have reached phase III of 
clinical trials [291] [180] [376]. However, the lack of improved outcome [291] [180] [376] and 
increased toxicity associated with the use of these agents [291] has hampered their entry 
into common clinical use. 
There are a number of ways an agent can alter MDR expression and function: 
1. post-translational modification, such as inhibition of MDR phosphorylation 
which can prevent the efflux of its substrates (directly inhibiting its function) 
and/or prevent the intermediate MDR protein from returning to its original 
state, 
2. differences in affinity for the MDR protein can reduce and even prevent the 
efflux of anti-cancer agents by MDR transporter proteins. 
3. amplification of the MDR gene by SP1 (mdr1, MRP1), PXR (mdr1), NF-Y 
(mdr1), YB-1 (mdr1), p53 mutation (mdr1) and the activation NF-kappaB 
(mdr1) by down-stream signalling of the AKT signalling pathway, 
4. negative transcriptional regulation by a NF-KappaB/P63 and r-fos protein 
complex interaction with the CAAT region of the gene promoter and by c-jun 
and p-c-jun (JNK pathway affected by MEK/ERK pathway) 
5. post-transcriptional control such as the use of an alternative promoter (5’UTR), 
post-transcriptional destabilisation of MDR1 mRNA, and translational 
blockade of P-gp expression at the ribosomal level.  
In the past, a few functional inhibitors were tested in clinical trial [291] [180]. However, 
due to the lack of improvement in superior outcomes and toxicity, the focus shifted 
from inhibitors and competitive substrates to agents that could down-regulate or 
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eradicate MDR protein expression (by method 4 mentioned above). This shift in focus 
coincided with an increase in interest to identify an MDR modulator that could also 
inhibit oncoproteins (i.e. EGFR, HER2, COX-2, Hsp90) and cell signalling pathways 
(i.e. P13K/Akt, ERK/MEK) essential for tumour growth.  
One such agent, 17-AAG (Hsp90 inhibitor and P-gp protein down-regulater), showed 
significant anti-tumour activities against a broad spectrum of cancers in pre-clinical 
studies, with growing clinical trial information [reviewed in 392]. To date, the modulation 
of MDR by 17-AAG has not been investigated in clinical trials. 
The main aim of this project was to identify the optimum drug combination that 
would target multidrug resistance, oncoproteins and/or cell signalling pathways 
essential for tumour cell growth. For this, we compared the ability of COX, EGFR, 
HER2 and Hsp90 inhibitors to modulate MDR and determined their optimum 
treatment regimen. Also, we sought to identify a new MDR modulator by screening a 
panel of novel compounds derived from anti-cancer and cancer preventative agents as 
well as investigating a delivery system. The impact serum transport proteins have on 
the accumulation of epirubicin in normal and cancer cells in vitro was also evaluated.  
 
4.1. Screening of potential novel anti-cancer agents 
 
Despite the broad range of MDR modulators (anti-MDR agents), the search for better, 
safer, more efficient and less toxic modulators continues (reviewed in [393]). In this section, 
we tested a panel of 61 novel compounds, ranging from plant derivatives to metal 
agents, for anti-cancer and anti-MDR potential. These compounds (listed in table 
2.9.1.) along with other modern small molecule agents (listed in table 3.1.6.1.) that, 
according to the literature, interact with the MDR pumps (see section 1.4. for review 
on multidrug resistance), were tested for their anti-MDR potential. As described in 
section 2.10., the compounds were combined with MRP1 and P-gp substrates in non-
small cell lung carcinoma cell models, DLKP and DLKP-A (MRP1 and P-gp cell 
models [369]). The small molecule agents were tested (see section 2.7. and 2.11. for 
methodology) in the lung cell lines; A549 (MRP1 expressing), A549-Taxol 
(paclitaxel-selected P-gp expresser) and DLKP-SQ/mitox (mitoxantrone-selected 
BCRP expresser). 
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Four families of derivatives were tested along with a polymer vehicle for 
daunorubicin delivery. Two potential P-pg modulators were identified, RBM15, a 
fluorinated resveratrol derivative, and KG104, an open hydrolysed macrocycle.  
Nine small molecule agents were tested in P-gp, MRP1 and BCRP-expressing cell 
lines. 17-AAG was identified as a BCRP modulator. The majority of small molecule 
agents altered MDR protein expression. The level of MDR protein down-regulation 
was not significant enough to overcome resistance. However, with the range of small 
molecule agents tested, the optimum treatment regimen to overcome MDR in tumours 
was identified as the concurrent combination therapy of these small molecule agents 
with chemotherapeutic drugs that are effluxed by MDR transport proteins. This 
combination would enhance the cytotoxicity of the chemotherapeutic drugs and could 
increase survival rates and decrease mortality. 
 
4.1.1. Polyamine derivatives 
 
Polyamines are a group of organic compounds, with two or more amino groups, that 
are important in the regulation of gene expression, translation, cell proliferation, 
modulation of cell signalling, protein synthesis, and membrane stabilization in all 
known cell types [377] [378]. Adequate cellular polyamine levels are achieved by a 
careful balance between biosynthesis, degradation, and uptake of amines from the 
surrounding environment. Polyamines affect numerous processes in carcinogenesis. 
Increased polyamine levels are associated with increased cell proliferation, decreased 
apoptosis and increased expression of genes affecting tumour invasion and metastasis. 
Conversely, suppression/depletion of polyamine levels is associated with decreased 
cell growth [379], increased apoptosis and decreased expression of genes affecting 
tumour invasion and metastasis [380] [381]. Polyamines are often present at increased 
concentrations in tumour cells and tissues, for example, breast and colon cancer.  
Several hundred polyamine synthesis inhibitors have been developed over the past 30 
years. These drugs have focused on the key polyamine biosynthetic enzymes, 
catabolic enzymes, polyamine uptake, transport systems, and various downstream 
DNA, RNA, proteins, enzymes, and specific regulatory control systems. These 
inhibitors mainly concentrated on decreasing cell growth by inhibiting polyamine 
transport and synthesis. Selective inhibitors of the enzymes involved in polyamine 
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biosynthesis did not result in practically useful anti-cancer drugs [394] [395], but a 
selective inactivator of ornithine decarboxylase (ODC; an enzyme that partakes in the 
urea cycle), 2-(difluoromethyl) ornithine (DFMO) is currently being developed as a 
cancer chemopreventive agent [396]. For review see Marra M., et al. [154].  
Over 10 years ago, it was reported that 50 µM of a polymeric conjugate of spermine 
was shown to reverse P-gp-mediated resistance to doxorubicin, etoposide, vinblastine 
and paclitaxel in the MDR variants (Dx5 cells) of the human sarcoma cell line MES-
SA., [397]. Gosland MP., et al. [397], also suggested there may be a link between the 
polyamine influx pump and the P-gp efflux pump. This theory was confirmed by Aziz 
SM., et al. [398]. They suggest that functional polyamine transport may be required for 
P-gp transport activity and that increased expression of functional P-gp reduced 
polyamine transport in mdr1-transfected CHO cells. Since this time, there has been 
little work in the development of anti-MDR polyamine derivatives. In this section, we 
investigated the possibility that spermine and 5 polyamine derivatives might 
overcome P-gp and MRP1-mediated resistance in two non-small cell lung carcinoma 
cell lines, DLKP and DLKP-A (methodology described in section 2.7.1., 2.7.3. and 
2.10.).  
We found that, compared to spermine, the analogues were less toxic. The most toxic 
derivative was PA1; IC50 values of 10 ± 4 µM in the DLKP cell line and 15 ± 2 µM in 
the DLKP-A cell line (section 3.1.1., table 3.1.1.1.). A concentration of 5 µM PA1 
was the only analogue to interfere with the normal functioning of MRP1 and P-gp. 
This was shown by a mild enhancement of the anti-proliferative potential of 
epirubicin in MRP1-expressing, DLKP, and P-gp-expressing cell lines, DLKP-A 
(section 3.1.1., table 3.1.1.1.). This effect was very mild compared to the 42-fold 
reduction in doxorubicin resistance in the presence of 50 µM of a polymeric conjugate 
of spermine in the MDR variants (Dx5 cells) of the human sarcoma cell line MES-SA 
[399]. We noticed that spermine was significantly less toxic in the P-gp expressing cell 
line (section 3.1.1., table 3.1.1.1.). This was expected as spermine accumulation is 
lower in P-gp expressing cell lines compared to non-P-gp expressing parental cell 
lines [399]. This difference in sensitivity was eliminated by the modifications used to 
make PA1. Despite being a less effective P-gp modulator than the polymeric 
conjugate, its toxicity was independent of P-gp expression. There is no 
pharmacological data relating to the levels of this agent found in the blood. These two 
findings (MDR modulation and MDR independence) show that there may be potential 
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for the development of a polyamine derivative whose toxicity is independent of MDR 
expression while modulating MDR and still inhibiting polyamine production and/or 
transport. Future work in this field could involve polyamine transport studies to 
determine if PA1 alters influx or efflux of polyamines, synthesis of polyamines, 
expansion of the panel of P-gp expressing cell lines and their parental cell lines to 
determine if PA1 toxicity is independent of P-gp in multiple cell types, and 
modification of the PA1 structure with the aim of maintaining its MDR-independent 
toxicity while enhancing its toxicity and MDR modulation. 
 
4.1.2. Resveratrol Analogues 
 
Resveratrol is a polyphenol derived from nature and in vitro, has been shown to 
interfere with tumour initiation, promotion and progression. Research interest to date 
has been focused on cancer prevention and only slightly on its anti-cancer potential. 
Tolomeo M., et al. [400], found that resveratrol and other stilbenes overcame P-gp-
mediated Imatinib resistance in lymphoma cell lines (HL60 and K562 cell lines). 
However, a major limitation of resveratrol use is its in vivo metabolic stability. 
Therefore, in this section, the collaborating chemists (Dr. Frankie Anderson and Dr. 
Brian Morgan) developed and synthesised a range of fluorinated analogue in the 
hopes of improving its metabolic stability [401] as well as its cytotoxicity and anti-
MDR potential. We focused on MDR modulation and toxicity (methodology 
described in section 2.7.1., 2.7.3. and 2.10.). 
The RF1 and RF3 compounds were slightly more toxic than resveratrol, while 
RBM15 was the most effective compound at overcoming P-gp-mediated resistance 
(section 3.1.2, and table 3.1.2.1). A concentration of 10 μM of the ditrifluoroacetyl 
derivative (2 μM above levels of resveratrol achievable in plasma [402]), RBM15, 
caused a 15% decrease in cell growth alone, but enhanced the cytotoxicity of 1.5 μM 
epirubicin from 15% to 80% (section 3.1.2, graph 3.1.2.1., and table 3.1.2.2.). It was 
through the enhancement of epirubicin toxicity, in the DLKP-A cell line, that RBM15 
was identified as a potential P-gp modulator. The chemopreventive activity of 
resveratrol has been linked to its ability to block the NF-KappaB pathway through 
IkappaB kinase inhibition [403]. NF-KappaB is known to amplify the transcription of 
the mdr1 gene. Therefore, if RBM15 has the same mechanism of action, blocking 
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NK-KappaB activation could lead to the down-regulation in P-gp protein expression 
via eliminating the amplification of mdr1 gene transcription, thereby, sensitising P-
gp-mediated resistant cells to the cytotoxic effects of chemotherapeutic drugs. This 
RBM15 compound had a number of superior characteristics to the original resveratrol 
compound as it was less toxic and potentiated the cytotoxicity of the P-gp substrate, 
epirubicin, to a much greater extent than resveratrol did (section 3.1.2., graph 3.1.2.1, 
and table 3.1.2.2). However, RBM15 does not overcome P-gp-mediated resistance to 
the same degree as other P-gp-modulators, such as elacridar, lapatinib or cyclosporine 
A, but is less toxic than the P-gp modulators. Therefore, further investigations into 
RBM15’s MDR modulatory properties could be of interest. For example, expansion 
of the P-gp substrate chemotherapeutics panel as well as the panel of P-gp expressing 
cell lines (and not just lung cell lines) could be the first step. If these findings prove 
positive in many tumour types, a closer look at its effect on protein expression and 
alteration in pharmacokinetics of P-gp substrates in the presence of RBM15 would 
elucidate its mechanism of action. This body of work has shown that RBM15 does not 
overcome MRP1-mediated resistance (see section 8, graph 8.1.2.1.); however, its 
ability to overcome BCRP-mediated resistance has not been evaluated. A BCRP 
expressing cell line, which has been used successfully to demonstrate BCRP-
modulation by small molecule agents in this project, is the squamous lung cancer cell 
line, DLKP-SQ/mitox. This would be an ideal cell line to evaluate any BCRP 
modulation by RBM15. 
The cancer-preventative properties of resveratrol are still the main focus of 
researchers but its anti-cancer potential is beginning to emerge. This body of work is a 
step forward in bringing resveratrol closer to the clinic and was published by Moran 
BM., et al. [385]. However, significant work to examine bioavailability, toxicity and the 
anti-MDR potential of resveratrol is required before it can be considered seriously as 
an anti-cancer agent. 
 
4.1.3. Macrocycle compounds 
 
Macrocyclic compounds, such as cyclosporine A, are effective P-gp modulators in 
vitro [184] [404] [405], however, this drug did not improve the outcome of patients 
presenting the P-gp phenotype in phase II clinical trials [406] [399] (for further discussion 
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see section 3.1.3.). Despite increasing the AUC (area under the curve, drug level in 
the blood) of doxorubicin, etoposide and tenoside these macrocyclic agents were 
unsuitable for use in the clinic due to their undesirable side-effects. For example, 
cyclosporine’s side effects include nephrotoxicity [407].  
In this study, we tested a range of macrocyclic compounds for their toxicity and anti-
MDR potential in two cell lines, DLKP and DLKP-A (methodology described in 
section 2.7.1., 2.7.3. and 2.10.). No MRP1 modulation occurred with these 
compounds. The IC50 for all tested compounds, in both cell lines, was in the 
micromolar range (i.e. reasonably non-toxic) (section 3.1.3., and table 3.1.3.5.). A 
number of compounds enhanced the cytotoxic potential of epirubicin in the P-gp 
expressing cell line, DLKP-A. The combination proliferation assays of KG3, KG4, 
KG103, KG104, KG105 and KG405 with epirubicin (section 3.1.3, graph 3.1.3.2 and 
table 3.1.3.2), and in many cases also with docetaxel, resulted in a large reduction in 
DLKP-A cell proliferation (graph 3.1.3.3. and graph 3.1.3.4). KG3 and KG4 were the 
first macrocycles designed and synthesised by our collaborators for anti-cancer testing. 
We found that both of these agents overcame P-gp-mediated resistance in the DLKP-
A cell line. KG3 and KG4 have ether groups and are labile in aqueous solution. To 
determine if KG4 was broken down in the media and cells, our collaborators 
hydrolysed KG4 (see figure 3.1.3.1.) and we found that two of these hydrolysed 
compounds, KG103 and KG104 (graph 3.1.3.2), overcame P-gp-mediated resistance 
to a greater extent than the parent macrocycle, KG4. It was also hoped that the 
addition of the cytotoxic to the ether location on the closed KG3 or KG4 structure 
would improve drug delivery to the tumour, while hydrolysis of the compound inside 
the cell would release the cytotoxic drug and the KG metabolite would inhibit MDR 
transporter pumps.  
KG104 strongly potentiated the anti-proliferative effect of epirubicin in the P-gp 
expressing cell line, DLKP-A, at the lowest concentration. The mechanism of P-gp 
modulation by these KG compounds could be through direct functional inhibition as 
demonstrated by other macrocyclic compounds, such as cyclosporine A. Compared 
with a similar combination in the same cell line carried out by Heenan M., et al. [369], 
of 1.7 µM adriamycin and 1.6 µM cyclosporine A, KG104 was only slightly less 
effective at modulating P-gp but was less toxic. This result could be very interesting 
for potential use in the clinic but requires further investigation to determine its 
mechanism of action and side effects. However, variations in interbatch synthesis led 
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to inconsistencies in the solubility of this compound which became a seriously 
limiting issue (see section 8, graph 8.1.3.1 and table 8.1.3.1). Extensive synthesis and 
solubility investigations in to the materials and vehicles used took place, however, 
with no success. This issue is currently being investigated in the chemistry department 
in the NICB, DCU. 
 
4.1.4. Metal agents 
 
The development of drugs with a metal platinum core, such as cisplatin and 
carboplatin, has had huge impact on current cancer treatment therapies. However, the 
range of cancers that can be treated with these platinum drugs is limited and the 
development of other metal drugs is being investigated. Other complexes include, iron, 
cobalt, gold, titanium, ruthenium, and gallium. Many of these complexes are 
undergoing pre-clinical studies as well as phase I and II clinical trials. For example, a 
metallocene titanocene dichloride was active in a broad spectrum of cancerous tissues 
in pre-clinical studies and showed promising results in phase I clinical trial. In 40 
patients with refractory solid malignancies a lyophilized formulation of titanocene 
dichloride afforded two minor responses (in bladder carcinoma and in non-small cell 
lung cancer), the dose-limiting side effect was nephrotoxicity. For review see Ott I., 
and Gust R. [408]. 
Normally metal-based drugs, i.e. cisplatin, do not interact with multidrug resistance 
transport proteins (mentioned in section 1.0 in tables 1.4.1, 1.4.2, and 1.4.3). However, 
it was unknown if titanium based complexes can overcome multidrug resistance. In 
this section, we evaluated the potential that the Titanocene Y compound could 
overcome MRP1 and P-gp-mediated drug resistance in cancer cells. The cytotoxicity 
of Titanocene Y was moderate in both the DLKP (25 ± 3 µM) and DLKP-A (18 ± 4 
µM) cell lines (section 3.1.4, table 3.1.4.1 and for method see section 2.10.). These 
IC50 values are 10 times less toxic than other metal agents for example; cisplatin has 
an IC50 of 1.1 ± 0.24 µM in DLKP and 2.0 ± 0.17 µM in the DLKP-A cells [207]. As 
expected, the combination proliferation assay of Titanocene Y with epirubicin in both 
the DLKP and DLKP-A cell lines resulted in no alteration in cell proliferation 
(section 3.1.4. and table 3.1.4.1). Metallic agents, such as cisplatin or carboplatin, 
rarely interact with multidrug resistance proteins; therefore, this result was expected. 
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The modulation of MDR by this compound is no longer of interest. However, an 
interesting point arises from this data. The cytotoxic effects of the titanocene 
compound are independent of MDR expression, i.e. the presence P-gp or MRP1-
mediated drug resistance does not alter the compounds ability to reduce cell growth. 
Therefore, this type of compound could be significantly effective in tumours 
presenting the P-gp/MRP1 multidrug resistant phenotype. However, in these non-
small cell lung carcinoma cell lines this titanocene analogue would not be the first 
choice of treatment as cisplatin is more effective. Comparing the cytotoxicity of this 
compound to cisplatin or carboplatin in a wider variety of cancer types would 
evaluate its true value. Following on from this investigation, other aspects, such as 
pro-apoptotic properties, are currently being investigated by Professor Tache of the 
Conway Institute. 
 
4.1.5. Nano-particulate modified drugs 
 
The use of biocompatible and biodegradable polymer nano-particules to enhance 
anthracycline delivery and distribution [409] while reducing cardiotoxicity as well as 
evade P-gp-dependent efflux [387] [388] in vitro has given some promising results [396]. 
Evasion of MRP1-mediated resistance, using a similar delivery system, daunorubicin 
nano-sphere, occurred in a breast cell line, MCF7 [410]. In this section, we investigated 
the potential that surrounding daunorubicin with a n-butylcyanacrylate nano-particle 
could evade daunorubicin MDR-mediated resistance. We carried out proliferation 
assays (described in section 2.7.) of daunorubicin, nano-particle polymerised 
daunorubicin, daunorubicin plus the nano-particle, and the nano-particle without drug 
in both the DLKP and DLKP-A cell lines. We found that the modification of 
daunorubicin in this manner did not enhance its cytotoxicity (section 3.1.5. and table 
3.1.5.1). In fact, at high concentrations its potency was reduced in the P-gp-over-
expressing cell line, DLKP-A (graph 3.1.5.1). Other similar nano-particulates have 
been shown to evade P-gp-mediated efflux in a large number of cell lines and short-
term in vitro proliferation assays have shown an increase in the toxicity of the nano-
particulate polymerised daunorubicin [388] [411]. However, the nanoparticulate used was 
a polyalkylcyanoacrylate, which has many more carbons then the n-
butylcyanoacrylate, used in this project, which is limited to four carbons. The 
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difference in size could explain the lack of effect by the n-butylcyanoacrylate-
daunorubicin polymer in P-gp and MRP1-expressing cell lines.  However, the 
findings with this nano-particle discussed here are interesting, as there is strong 
evidence in favour of long-term retention of significant quantities of daunorubicin in 
the nano-particulate carrier in the cellular environment, if not within the cells 
themselves. The development of this type of system, remains an important goal for 
researchers working in the area of drug delivery. This body of work was published in 
Simeonova M., et al. [389]. 
 
4.1.6. MDR down-regulation 
 
To date, the most effective multidrug resistance (MDR) inhibitors have been 
functional inhibitors. While many of these have shown promise in vitro, no inhibitors 
have proven successful in the clinic. For example, PSC-833 (valspodar) alone or in 
combination with vincristine, doxorubicin, and dexamethasone (VAD) did not 
increase the progress-free survival period (7 months for VAD alone reduced to 4.9 
months for PSC-833 combined with VAD) [291] and when combined with cytarabine, 
daunorubicin and etoposide (ADE) it actually increased mortality (0% for ADE2 alone 
increased to 18% for ADE combined with PSC-833) [412] for multiple myeloma 
patients compared to VAD or ADE2 alone.  
In this section, our aim was to identify a panel of MDR modulators that down-
regulate the expression of MDR proteins while targeting other important signalling 
pathways and oncoproteins. We examined whether these small molecule agents 
caused the greatest anti-cancer outcome in combination (see section 2.7.2. for 
methodology) with chemotherapeutic drugs or as a pre-treatment (see section 2.7.3 for 
methodology) for the chemotherapeutic drugs. To the best of our knowledge an 
extensive study like this has not been carried out before. The selection of the small 
molecule agents was based on the availability of information in the literature, anti-
MDR status and availability for use in a clinical trial. The panel included tyrosine 
kinase inhibitors (TKI; lapatinib, erlotinib and gefitinib), non-steroidal anti-
inflammatory drugs (NSAID; celecoxib, sulindac sulphide, ibuprofen and 
indomethacin), an Hsp90 inhibitor (17-AAG) and an established MDR modulator 
(elacridar) (list summarised in table 3.1.6.1). Information published on the modulation 
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of MDR function and expression by these small molecule agents is summarised in 
section 1.4.5. The concentrations of the small molecule agents used for this work are 
equivalent and lower to their plasma AUC values (see section 1.4.5 and table 3.1.6.1. 
for details). 
To determine if the small molecule agents listed in table 3.1.6.1 affected the 
expression of P-gp, MRP1 or BCRP we exposed the cells to the small molecule 
agents for 24 hours and carried out Western blots using the cell lysates (for 
methodology see section 2.11.). Small molecule agents that reduced the MDR protein 
expression by more than 20% were selected for examination of the stability of this 
alteration (section 2.11.), toxicity and combination/scheduling proliferation assay 
(section 2.7.) testing. The expression stability and toxicity of the selected small 
molecule agents testing involved; exposing the cells to the small molecule agents for 
24 hours, removal of the drug and a further incubation of 24 and 48 hours in drug-free 
media. Western blotting was carried out on these lysates (section 2.11.) and the 
toxicity of the small molecule agents was evaluated using an end-point assay, PNP 
(section 2.7.2). Finally, the small molecule agents were either combined with MDR 
substrates (combination proliferation assay, see section 2.7.1.) or used as a pre-
treatment for the MDR substrate (scheduled proliferation assay, see section 2.7.2.). 
 
4.1.6.1. P-gp downregulation 
 
We found that pharmacologically relevant concentrations of lapatinib, erlotinib, 
gefitinib, elacridar and sulindac sulphide increased P-gp expression in the P-gp 
moderately-expressing cell line, A549-Taxol. Densitometric analysis of these Western 
blots supported the visual findings (figure 3.1.6.1.1 and table 3.1.6.1.2). Long-term 
treatment with agents that up-regulate P-gp expression could lead to the development 
and amplification of multidrug resistance in cancer and, therefore, reduce the 
effectiveness of chemotherapy in patients. No information is published on the affect 
erlotinib, gefitinib or elacridar have on P-gp protein expression. But the data suggests 
that drug treatment with these targeted therapies may affect drug resistance 
mechanisms resulting in tumours with a higher degree of drug resistance. Using 
ATPase activity assays, it has been shown that lapatinib [147], erlotinib [148] and 
gefitinib [97] are functional inhibitors of P-gp. Contrary to results presented here and 
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demonstrated by other members of our group, where P-gp was up-regulated in the 
presence of lapatinib, Dai CL., et al. [147], demonstrated that lapatinib does not effect 
the expression of P-gp protein at the transcriptional or translational level in 
doxorubicin selected MCF7 cells following exposure to similar concentrations for 48 
hours. However, this cell model was not developed using paclitaxel and was not a 
non-small-cell lung carcinoma cell line. Therefore, the effects observed here or in the 
publication may be cell line/tissue specific or due to a difference in the development 
in P-gp resistance. However, in agreement with our result, P-gp up-regulation with the 
same and higher concentrations of lapatinib [197] [112], erlotinib [112] and gefitinib [112] 
was reported by members of our group. Elacridar, which also up-regulated P-gp 
protein expression was found to inhibit P-gp-mediated resistance and increase 
intercellular accumulation while reducing efflux of rhodamine in acute leukemia and 
multiple myeloma cells lines RPMI 8226/Dox1, /Dox4, /Dox6 and /Dox40 compared 
to the wild-type 8226/S [191].  
The only small molecule agent which was tested and found not to affect P-gp protein 
expression was ibuprofen. 
Indomethacin and 17-AAG-treated A549-Taxol cells caused a decrease in P-gp 
protein expression at and below pharmacologically relevant concentrations (figure 
3.1.6.1.1 and table 3.1.6.1.2). Celecoxib also down-regulated P-gp protein expression 
but only at concentrations above levels achievable in the body. These results indicate 
that indomethacin, celecoxib and 17-AAG could reduce the degree of resistance 
caused by P-gp in these cells by reducing its expression at the cell membrane. This 
reduction in resistance could result in enhanced toxicity of chemotherapeutic drugs 
and thus, increase the rate of tumour cell kill during treatment resulting in increased 
survival and decreased mortality in the clinic. This also suggests that long-term 
treatment with these small molecule agents may not result in P-gp-mediated resistance 
in later tumours.  
With a closer look at down-regulation; we showed that indomethacin affected 
expression at 1 and 2 µM (20% and 50% reduction) but not at 0.4 µM in the A549-
Taxol cell line (figure 3.1.6.1.1 and table 3.1.6.1.2.). It is thought that indomethacin 
down-regulates P-gp protein expression through activation of c-jun N-terminal kinase 
[181]. However, Zrieki A., et al. [96], found that a 90% down-regulation in P-gp protein 
expression occurred in CaCo-2 cells following exposure to the same concentration for 
the same time period. A difference in the type and level of P-gp expression, culturing 
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conditions and handling may explain the discrepancy in the degree of effect between 
the two cell lines.  
The highest concentration of celecoxib (10 µM) down-regulated the expression of P-
gp by 20% (table 3.1.6.1.2). Celecoxib inhibits Akt activation which could also lead 
to inactivation of the NF-kappaB promoter [333] and thus reduction in P-gp protein 
expression.  Arunasree K.M. et al. [160], demonstrated a 50% decrease in P-gp 
expression in imatinib-resistant leukemic cells following a 24 hour exposure to 10 µM 
celecoxib but did not provide an explanation for its mechanism of action. Following a 
24 hour exposure to 0.3, 0.5 and 1 µM of the Hsp90 inhibitor, 17-AAG, down-
regulation of P-gp expression occurred in the A549-Taxol cell line, by 20%, 10% and 
40% (figure 3.1.6.1.1 and table 3.1.6.1.2). Katayama K., et al. [3], also observed a 
down-regulation in P-gp protein expression and found that it was caused by 17-AAG 
inhibiting the MAPK signalling pathway. However, they also found that 0.1 µM of 
17-AAG for 12 hours caused a 90% reduction in P-gp protein expression in colon 
cells (SW620 MDR selected) and breast cell lines (MCF7 and MDA-MB-231 MDR 
induced). The discrepancies in the degree of down-regulation by celecoxib and 17-
AAG presented here versus results published may be due to the difference in cell type, 
difference in the growth rate of the cells, expression levels of P-gp, the method of P-
gp induction or a difference in their dependence of signalling pathways for gene 
regulation, culturing conditions or handling.  To determine if the down-regulation by 
these small molecule agents is tissue or cell line specific, the small molecule agents 
should be tested, in the same manner, on a panel of P-gp expressing cell lines that 
originate from a variety of tissues.  
Indomethacin and 17-AAG had greatest effect on P-gp levels and were selected for 
further testing of their stability of down-regulation, toxicity and proliferation assays. 
The P-gp expression stability analysis showed that protein down-regulation by 
indomethacin recovered after 48 hours (figure 3.1.6.1.2) in a drug-free environment 
and that the concentrations were non-toxic under these conditions (see section 8, 
graph 8.1.6.1.1.A) (6-well plate with a cell seeding density of 7 ×104 cells/ml). On the 
other hand, the effect 17-AAG had on P-gp protein expression remained for a period 
of 48 hours following drug removal (figure 3.1.6.1.2). This may suggest that different 
mechanisms of down-regulation are caused by the two small molecule agents. The 
concentrations were also found to be non-toxic under these conditions (see section 8, 
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graph 8.1.6.1.1.B). Therefore, due to the sustained down-regulation of P-gp, 17-AAG 
was the best candidate for future work.  
Neither the co-treatment nor pre-incubation with indomethacin enhanced the anti-
proliferative potential of the chemotherapeutic drug (P-gp substrate), docetaxel (graph 
3.1.6.1.1). The expression of P-gp recovered once indomethacin was removed, 
therefore, restoring full P-pg expression and function. This would explain the lack of 
effect in the scheduled proliferation assay. These results indicate that even though 
indomethacin down-regulated the expression of P-gp protein it does not alter its level 
of activity in these cells. Therefore, when considering its use in the treatment of 
cancer it will not overcome P-gp-mediated resistance but could reduce the risk of P-
gp related resistance developing or amplifying in later tumours. Draper MP., et al. [413], 
also found that indomethacin did not inhibit the efflux of the P-gp substrate 
rhodamine 123 in the HL60/Vinc P-gp over-expressing cell line, however they did not 
look at protein expression. In contrast to both our results and Draper’s results, Zrieki 
A., et al. [96], demonstrated a decrease in both expression and activity of P-gp in Caco-
2 cells with the same concentrations. However, the degree of P-gp protein down-
regulation in their cell line was significantly higher and this may account for the lack 
of effect observed in our combination proliferation assays. The concentrations of 17-
AAG employed were extremely toxic in the combination proliferation assays (graph 
3.1.6.1.2.A). The difference in toxicity between the 6-well plates (toxicity study) and 
the 96-well plates (combination and scheduled proliferation assay) was due to the 
large reduction in cell density required for the 7-day proliferation assays in the 96-
well plates. While these concentrations were still very toxic in the scheduled 
proliferation assay, a toxicity curve for docetaxel in their presence was obtained 
(graph 3.1.6.1.2.B). This curve demonstrated that while 17-AAG may down-regulate 
P-gp protein expression (as shown in figure 3.1.6.2.1 and 3.1.6.2.2) it does not 
overcome P-gp-mediated resistance in this cell line (i.e. it doesn’t enhance the 
cytotoxicity of docetaxel, the P-gp substrate). The IC50 of docetaxel was decreased in 
its presence but this was more likely due to the joint anti-proliferative effects of both 
17-AAG and docetaxel and not due to P-gp modulation by 17-AAG. To date, the 
ability of 17-AAG to overcome P-gp-mediated resistance has not been investigated. 
For the scheduled proliferation assay, it would be expected that down-regulation of P-
gp protein with 1 µM 17-AAG would help overcome MDR. However, as described by 
Breen L., et al. [370], treatment with chemotherapeutic drugs such as docetaxel can 
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cause stress induction and thus up-regulation of P-gp expression, especially in this 
cell line as it is a taxane-selected cell line. Therefore, the docetaxel effect on P-gp 
expression could potentially override any down-regulation caused by 17-AAG. Also, 
the down-regulation and stability of down-regulation of P-gp by 17-AAG was only 
looked at in the absence of docetaxel. However, recovery of P-gp expression could 
have occurred rapidly in the proliferation assays due to the presence of docetaxel. 
Also, it has been shown that 17-AAG resistance could be due to heat shock response 
and the up-regulation of P-gp [414]. Providing further evidence of up-regulation of P-
gp following the removal of 17-AAG. Mechanistically, docetaxel induces apoptosis 
by promoting the phosphorylation and thus inactivation of bcl-2 [29], while 17-AAG 
down-regulates bcl-2 [414]. Down-regulation of bcl-2 prior to docetaxel exposure 
might initially slow docetaxel induced apoptosis. To date, the ability of 17-AAG to 
overcome P-gp-mediated resistance has been investigated only with regard to heat 
shock response. 
This evidence indicates that the co-administration or pre-treatment of 17-AAG or 
indomethacin with chemotherapeutic drugs, does not overcome P-gp-mediated and 
thus a clinical trial is not indicated. It also suggests that the optimal method for 
overcoming P-gp-mediated resistance does not lie in the down-regulation of its 
protein. 
 
In summary; five small molecule agents (lapatinib, erlotinib, gefitinib, sulindac 
sulphide and elacridar) up-regulated the expression of P-gp protein. This could have 
implications for their use in long-term treatment of cancer as they may induce or 
amplify drug resistance, due to P-gp activity, in secondary or advanced tumours. Two 
small molecule agents (indomethacin and 17-AAG) reduced the expression of P-gp in 
the A549-Taxol cell line at and below pharmacologically relevant concentrations. The 
affect of indomethacin on P-gp expression was not sustained once removed while 17-
AAG’s effects were maintained. Neither small molecule agent overcame P-gp 
mediated resistance in this cell line and should not be included in anti-P-gp clinical 
trials. 
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4.1.6.2. MRP1 down-regulation 
 
The regulation of MRP1 expression is not fully understood but tenuous links between 
transcription factors, nrf2, n-myc and c-myc (important in P13K pathway), and MRP1 
transcriptional regulation have been suggested. Hypoxic conditions increase the 
phosphorylation of ERK/MAPK and increase HIF-1 activity. These factors cause the 
up-regulation of MRP1. 
We found that up-regulation of MRP1 expression occurred in the A549 cells 
following a 24 hour exposure to erlotinib, gefitinib, ibuprofen, indomethacin and 
elacridar (figure 3.1.6.2.1 and table 3.1.6.2.1.). Long-term treatment with these agents 
could lead to the development and amplification of MRP1-mediated drug resistance in 
cancer and, therefore, reduce the effectiveness of chemotherapy in patients.  
We also found that four small molecule agents (lapatinib, celecoxib, sulindac sulphide 
and 17-AAG) down-regulated the expression of MRP1 protein in these cells (figure 
3.1.6.2.1 and table 3.1.6.2.1). Lapatinib (the dual EGFR/HER2 tyrosine kinase 
inhibitor), 17-AAG (the Hsp90 inhibitor), and celecoxib (COX-2 specific inhibitor) 
could potentially down-regulate MRP-1 expression by reducing the active levels of 
Akt and thus inactivation of n-myc or c-myc or by preventing the phosphorylation of 
ERK/MAPK. High concentrations of sulindac were shown to increase MRP1 protein 
expression due to n-myc [207], however, the down-regulation observed here may be 
due to lower, less non-specific effects of sulindac sulphide on transcription factors 
such as n-myc or c-myc. These results indicate that lapatinib, sulindac sulphide and 
17-AAG could reduce the degree of resistance caused by MRP1 in these cells by 
reducing it’s expression at the cell membrane. This reduction in resistance could 
result in enhanced toxicity of chemotherapeutic drugs and thus, increase the rate of 
tumour reduction during treatment resulting in increased survival and decreased 
mortality in the clinic. This also suggests that long-term treatment with these small 
molecule agents may not result in MRP1-mediated resistance in secondary or 
advanced tumours. 
With a closer look at down-regulation; a 20% decrease in MRP1 protein expression 
was caused by the highest concentration of celecoxib (10 µM, table 3.1.6.2.1). Kang 
HK., et al. [174], found that a 24 hour exposure to 5 µM celecoxib had no effect while 
50 µM decreased the expression of MRP1 protein in a COX-2 independent manner. 
This does not contradict our result as they did not use the same concentrations as 
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those used in this project (concentrations listed in table 3.1.6.1.). Celecoxib was not 
selected for further testing as the percentage reduction was not significant enough and 
the change only occurred at a concentration greater then that achievable in the body 
(about 2 µM [25]) (see section 1.4.5). For all concentrations of lapatinib, significant 
down-regulation of MRP1 protein expression occurred (between 80% and 60%) (table 
3.1.6.2.1). There are no publications in this area; however, this finding was replicated 
in the same cell line, with the same concentrations and experimental design by a 
member of our group, Dunne G., thesis [197]. Concentrations of 2 and 5 µM sulindac 
sulphide reduced MRP1 expression by 30% and 40%, while 17-AAG caused a 
reduction at all concentrations used (70% to 40%) (figure 3.1.6.2.1 and table 
3.1.6.2.1.). These are novel observations that have not previously been reported. As 
the MRP1 down-regulation by these small molecule agents was partially inconsistent 
with some publications or novel findings, it would be important to evaluate if their 
effect is cell/tissue specific. For this, expanding the panel of MRP1-expressing cell 
lines to include a wide variety of tissue types would be essential. 
The most efficient MRP1 protein down-regulator was lapatinib, followed closely by 
17-AAG and finally sulindac sulphide. As their effect on protein expression occurred 
below pharmacologically relevant concentrations (less than 1.5 - 3.8 µg/ml for 
lapatinib [25], 0.15 - 17 µM for 17-AAG [212] and 4 - 6 µg/ml for sulindac sulphide [25]) 
and was greater than 20%, all three small molecule agents were brought forward for 
examination of the stability of their expression alterations, toxicity and proliferation 
assays. 
The down-regulation of MRP1 by lapatinib, sulindac sulphide and 17-AAG was 
duplicated in biological replicates (figure 3.1.6.2.2.). However, after 24 hours MRP1 
expression recovered following the removal of lapatinib or 17-AAG. The down-
regulation caused by sulindac sulphide was stable for 48 hours following drug 
removal (figure 3.1.6.2.2). The concentrations were also found to be non-toxic under 
conditions in the 6-well plates (see section 8, graph 8.1.6.2.1). 
The concurrent combination and scheduling proliferation assays of lapatinib with 
vincristine (the MRP1 substrate) found little significant change (graph 3.1.6.2.1 A and 
B). There was a slight reduction in the calculated IC50 of vincristine (graph 3.1.6.2.4 
and table 3.1.6.2.3.) but this was more likely due to the combined anti-proliferative 
potential of lapatinib and vincristine rather than direct functional inhibition or protein 
down-regulation of MRP1. A partial recovery in MRP1 expression occurred after 
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lapatinib was removed for 48 hours therefore, partially restoring MRP1 expression 
and function. This would explain the lack of significant effect in the scheduled 
proliferation assay. These results indicate that even though lapatinib down-regulated 
the expression of MRP1 protein it does not alter its level of activity in these cells (also 
demonstrated by another member of our group). Or the down-regulation of MRP1 
protein expression caused by lapatinib could be negated by stress induced factors due 
to the presence of vincristine. Therefore, when considering its use in the treatment of 
cancer it will not overcome MRP1-mediated resistance but could reduce the risk of 
MRP1 related resistance developing or amplifying in secondary or advanced tumours. 
The lack of effect can be explained to some degree by work carried out by Collins D., 
[112], who demonstrated, using ATPase assays, that lapatinib was a poor activator and 
inhibitor of MRP1 and does not overcome MRP1-mediated resistance to epirubicin in 
the A549 cell line [97]. Another MRP1 down-regulator, sulindac sulphide (the active 
metabolite for sulindac), caused very little toxicity itself and still reduced the IC50 of 
vincristine in the combination proliferation assay (graph 3.1.6.2.2.A, graph 3.1.6.2.4 
and table 3.1.6.2.3). This was expected as it was previously shown to overcome 
MRP1-mediated resistance in these cell lines [337] [172]. Whether down-regulation of 
MRP1 protein was involved is unclear. However, a slight drop in the IC50 of 
vincristine was observed in the scheduled proliferation (graph 3.1.6.2.2.B, graph 
3.1.6.2.4 and table 3.1.6.2.3). As the down-regulation of MRP1 protein expression 
was sustained for 48 hours following sulindac sulphide removal, the slight 
enhancement in vincristine cytotoxicity could potentially be due to this sustained 
down-regulation. To determine if this theory holds, MRP1 protein stability studies in 
the presence of vincristine would be required. The down-regulation of MRP1 protein 
expression by sulindac sulphide could reduce the efflux of chemotherapeutic drugs 
and thus improve their efficacy. The fact that the down-regulation of MRP1 is 
partially sustained following drug removal could have therapeutic implications. Not 
only could it overcome MRP1-mediated resistance but it could also prevent the 
induction or amplification of MRP1 by chemotherapy treatment in the clinic. In fact, 
combination of this non-specific COX inhibitor with another MRP1 substrate, 
epirubicin, has given promising results in xenograft models and is currently 
undergoing randomised melanoma phase II clinical trial [173].  
When exposed to the cells for 5 days, all concentrations of 17-AAG were extremely 
toxic (graph 3.1.6.2.3.A and table 3.1.6.2.3). The difference in toxicity between the 6-
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well plates (toxicity study) and the 96-well plates (combination and scheduled 
proliferation assay) was due to large reduction in cell density required for the 7-day 
proliferation assays in the 96-well plates. Therefore, a lower set of concentrations was 
employed for the combination and scheduling proliferation assays. However, no 
protein expression studies were carried out with these concentrations. A concentration 
of 0.02 µM 17-AAG allowed a 35% cell growth and it was this combination, with 
vincristine, that suggested that 17-AAG does not overcome MRP1-mediated 
resistance (graph 3.1.6.2.3.A). The drop in vincristine IC50 by their combination was 
due to the combined anti-proliferative potential of 17-AAG and vincristine and not 
due to changes in MRP1 protein expression (as protein expression was not effected 
with the higher concentration of 0.3 µM 17-AAG) or functional level by 17-AAG 
(graph 3.1.6.2.3.A and table 3.1.6.2.3). The lower concentrations of 17-AAG 
employed (0.02, 0.05 and 0.1 µM) were significantly less toxic (26%, 22% and 18% 
cell proliferation) when the cells were exposed to the drug for 24 hours of that 5 day 
period (scheduled proliferation assay) (graph 3.1.6.2.3.B). These concentrations 
caused a decrease in the IC50 of vincristine (graph 3.1.6.2.4 and table 3.1.6.2.3). In the 
scheduled proliferation assay with vincristine, the higher concentrations (0.3, 0.5 and 
1 µM) resulted in over 60% growth inhibition but also reduced the overall cell 
proliferation. The toxicity of 0.5 and 1 µM 17-AAG were too high to evaluate. 
However, 0.3 µM was slightly less toxic but the reduction in the IC50 of vincristine 
can solely be attributed to the combined anti-proliferative potential of 17-AAG and 
vincristine and not due to MRP1 function or expression (no reduction in MRP1 
expression occurred with this concentration) inhibition by 17-AAG. These 
combination and scheduled proliferation assay results indicate that 17-AAG does not 
overcome MRP1-mediated resistance. Therefore, when considering their use as part 
of cancer treatment in the clinic, they would not alter MRP1-mediated resistance but 
could help prevent the amplification or induction of MRP1 transporter proteins caused 
by chemotherapeutic drugs.  
Of the three small molecule agents tested, sulindac sulphide was the only agent to 
overcome MRP1-mediated resistance in the A549 cell line and this only occurred in 
concurrent combination proliferation assays with vincristine. The combination 
proliferation assay result was not unexpected as sulindac is known to overcome 
MRP1-mediated resistance [337]. This body of work demonstrates that while all small 
molecule agents alter the expression of MRP1, the down-regulators, with the 
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exception of sulindac sulphide, do not overcome MRP1-mediated resistance. It also 
indicates that when using protein down-regulation as a mechanism of overcoming 
MDR in both in vitro and in vivo systems, a continuous exposure to the modulator is 
required to maintain the alteration. It also implies that lapatinib, sulindac sulphide and 
17-AAG could be of therapeutic benefit in preventing the amplification or induction 
of MRP1 transporter proteins in cancer treated with chemotherapeutic drugs.  
   
In summary; at and below pharmacologically relevant concentrations, five small 
molecule agents (erlotinib, gefitinib, ibuprofen, indomethacin and elacridar) up-
regulated the expression of MRP1 in the A549 cell line. This could have implications 
for their use in long-term treatment of cancer as they may induce or amplify drug 
resistance due to MRP1 activity in secondary or advanced tumours. Three small 
molecule agents (lapatinib, sulindac sulphide and 17-AAG) down-regulated MRP1 
protein expression, at and below pharmacologically relevant concentrations. 
Expression levels recovered following removal of 17-AAG or lapatinib. The 
regulatory effect of sulindac sulphide was stable for 48 hours. 17-AAG or lapatinib 
did not enhance the cytotoxicity of the MRP1 substrate, vincristine, through 
modulation of MRP1. Sulindac sulphide, which is also a non-specific COX inhibitor, 
overcame MRP1-mediated resistance when combined with the chemotherapeutic drug 
but its MRP1 inhibition was not sustained when absent. Therefore, these results 
indicate that only the concurrent combination of sulindac sulphide with MRP1 
chemotherapeutic substrates is worth pursuing as an anti-cancer therapy. It also 
reveals that even with a 70% reduction of MRP1 protein expression, MRP1-mediated 
resistance is persistent or still susceptible to up-regulation by vincristine. Therefore, 
as reduction in MRP1 protein did not result in a reduction in MRP1-mediated 
resistance, two possible options remain for overcoming MRP1-mediated resistance; a. 
not partial but total elimination of MRP1 protein expression which would hopefully 
negate the stress induced effects of chemotherapeutic drugs, or, b. direct functional 
inhibition. 
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4.1.6.3. BCRP down-regulation 
 
Little is known about the regulation of BCRP at the mRNA or protein level. However, 
a link between increased presence of porphyrin and heme in the cell leading to 
increase activated reactive oxygen species (ROS) and thus, increased BCRP protein 
expression has been suggested. BCRP expression is also up-regulated by heat shock 
response and the hypoxia-inducible transcription factor complex HIF-1 [138]. Also 
inactivation of the P13K/Akt pathway causes the translocation of BCRP from the 
apical surface of the membrane to the intracellular compartment. However, the 
physiological implications of this have not been established. 
The cell line used in the section of the project was the mitoxantrone selected 
squamous lung cell line, DLKP-SQ/mitox, developed by Helena Joyce of the NICB, 
DCU. 
 By Western blotting (section 2.11.), we found that up-regulation of BCRP protein 
expression occurred in the DLKP-SQ/mitox cells following a 24 hour exposure to 
sulindac sulphide (figure 3.1.6.3.1). To date, up-regulation of BCRP is known to 
occur through increased activated reactive oxygen species, heat shock response or up-
regulation of the transcription factor complex HIF-1. As the method for determining 
alterations in BCRP expression by the panel of small molecule agents is not under 
hypoxic condition (HIF-1) it can be theorised that up-regulation caused by sulindac 
sulphide is the result of increased ROS activity. This up-regulation of BCRP 
expression by sulindac sulphide implies that, use of this small molecule agent in the 
clinic could result in the amplification or induction of BCRP expression and thus, 
reduce efficacy of some chemotherapeutic drugs in secondary or advanced tumours. 
The up-regulation of BCRP by sulindac sulphide has not been explored previously in 
the literature.  
A number of small molecule agents gave mixed results. For example, 0.3 and 0.5 µM 
of erlotinib slightly reduced BCRP expression, whereas, 1 µM increased BCRP 
expression in the DLKP-SQ/mitox cells. Celecoxib and ibuprofen both increased 
BCRP expression with low concentrations but decreased it with higher concentrations 
(figure 3.1.6.3.1 and table 3.1.6.3.1). These mixed results may be explained by the 
nature of MDR proteins and the specificity of small molecule agents over a broad 
concentration range. As the concentration of the small molecule agent increases in the 
cell its activities become less specific which could inadvertently induce a stress 
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response, inhibit or stimulate proteins, signalling pathways or transcription factors 
that regulate MDR protein expression and function. Due to the unstable regulation of 
BCRP protein expression by these small molecule agents they were not selected for 
further analysis. 
Within the 24 hour exposure time, five small molecule agents down-regulated the 
expression of BCRP, in the DLKP-SQ/mitox cell line (figure 3.1.6.3.1 and table 
3.1.6.3.1). These small molecule agents included (and in the order of efficacy); 17-
AAG, lapatinib, indomethacin, elacridar and finally gefitinib. For each small molecule 
agent, concentrations used were well below and at the pharmacologically relevant 
levels (see section 1.4.5 for concentrations). They reduced BCRP protein expression 
by more than 20% in this cell line. It would be expected that the down-regulation in 
BCRP protein expression, by these small molecule agents, would reduce the efflux of 
BCRP substrates from BCRP-expressing cell lines. Therefore, enhancing the 
cytotoxic potential of these substrates resulting in increased cell death and improving 
treatment outcome. While others have demonstrated regulation of BCRP protein 
expression and mRNA levels, little is known to explain negative regulation of BCRP 
transcription, post-transcription, translation and post-translational modifications. 
17-AAG caused a 50% decrease in protein expression with only 0.3 µM and to date, 
this not been published. The same concentration of lapatinib reduced BRCP 
expression by 40% (figure 3.1.6.3.1. and table 3.1.6.3.1.). However, Dai CL., et al. 
[147], found that lapatinib does not affect BCRP mRNA or protein expression levels. 
However, Dai CL., et al. [147], used a transfection induced colon cell line and even 
though the concentrations and exposure times are similar to those used in this project, 
a difference in tissue type, mutant/wild type and expression levels may explain the 
difference between their results and findings presented in this thesis. Concentrations 
of 0.3 and 0.4 µM of elacridar and indomethacin reduced expression by 30% (figure 
3.1.6.3.1 and table 3.1.6.3.1). To date there are no publications stating the effect of 
elacridar on the expression of BCRP. The indomethacin result does not agree with 
Zrieki A., et al. [96]. They showed that exposure to 0.4 µM indomethacin for 24 hours 
increases BCRP expression by 10-40% in the colorectal cell line (CaCo-2). This 
disparity may be due to the expression of wild type BCRP in the CaCo-2 cells and the 
suspected expression of mutant BCRP in the DLKP-SQ/mitox cells (see section 1.4.4 
for more details on amino acid substitution). Finally, gefitinib reduced expression by 
50% at a concentration of 0.5 µM (figure 3.1.6.3.1 and table 3.1.6.3.1). There are no 
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publications to exemplify similar conditions; however, Meyer Zu Schwabedissen HE, 
et al. [170], suggested that anti-EGFR agents (such as gefitinib) could potentially 
reduce BCRP protein expression as they found that EGF stimulates BCRP expression. 
As the down-regulation by these small molecule agents was partially inconsistent with 
some publications, it would be important to evaluate if their effect is cell/tissue 
specific. The full panel of down-regulators were selected for further analysis as they 
reduced BCRP-expression by more than 20% and were well within biologically 
relevant concentrations. As summarised in table 3.1.6.1, none of the publications 
indicate that these agents alter BCRP protein expression.   
Biological repetition of these Western blots (figure 3.1.6.3.2) generated results which 
were inconsistent with the lapatinib and elacridar BCRP protein down-regulation 
previously observed (figure 3.1.6.3.1). In these Western blots, it was clear that the two 
small molecule agents up-regulated the expression of BCRP. However, the down-
regulation caused by gefitinib and 17-AAG, which is novel, was replicated and 
maintained for 48 hours following drug removal (figure 3.1.6.3.2). The effect by 
indomethacin was also replicated and maintained for 24 hours after the drug was 
removed. However, full recovery was achieved after 48 hours in a drug-free 
environment. For all five small molecule agents, the concentrations used were non-
toxic under the described conditions (6-well plates seeded with 7 × 104 cells/ml) (see 
section 8, graph 8.1.6.3.1).  
The next step in testing involved combination and scheduling proliferation assays (for 
methodology see section 2.7.1 and 2.7.2). In the combination proliferation assays, 
lapatinib, gefitinib, elacridar and 17-AAG caused a significant reduction in the IC50 of 
SN38 (graph 3.1.6.3.6 and table 3.1.6.3.2). This was expected for lapatinib [147] [97], 
gefitinib [150] and elacridar [415] as they were shown to functionally inhibit BCRP using 
ATPase activity assays. It is unclear if down-regulation of the BCRP protein 
expression influenced the small molecule agent’s ability to overcome BCRP-mediated 
resistance. Lapatinib caused the greatest effect, followed by elacridar, gefitinib and 
finally 17-AAG. The degree by which these agents overcame BCRP-mediated 
resistance was substantial and could have significant implications in the treatment of 
BCRP-mediated resistant tumour. Their combination with BCRP substrate could 
significantly enhance the cytotoxic potential of the BCRP substrate, therefore 
increasing cell kill and improve treatment outcome. For the scheduled proliferation 
assay of 17-AAG, the higher concentrations (0.3, 05 and 1 µM) were extremely toxic 
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in these cells (graph 3.1.6.3.5.A.2). The difference in toxicity between the 6-well 
plates (toxicity study) and the 96-well plates (combination and scheduled proliferation 
assay) was due to large reduction in cell density required for the 7-day proliferation 
assays in the 96-well plates. However, the lower concentrations (0.02, 0.05 and 0.1 
µM) were much less toxic but their effect on BCRP expression was not established. 
However, it was evident from the toxicity curves that 17-AAG modulates BCRP 
either through direct functional inhibition or reduction in protein expression (graph 
3.1.6.3.5.A1, graph 3.1.6.3.6 and table 3.1.6.3.2). No literature could be found 
suggesting that 17-AAG modulates BCRP expression or function. Of all the small 
molecule agents tested in the combination and scheduled proliferation assays, 
indomethacin was the only one unable to overcome BCRP mediated resistance. At 
concentrations of 0.4, 1, and 2 µM, indomethacin was the only small molecule agent 
not to potentiate the cytotoxicity of SN-38 (graph 3.1.6.3.3.A, 3.1.6.3.3.B, 3.1.6.3.6 
and table 3.1.6.3.2). As discussed in the P-gp down-regulation discussion, this 
inconsistency could be due to the stress induced BCRP expression (via ROS) by 
chemotherapeutic drugs such as irinotecan [416]. This combination proliferation assay 
results agrees with Nozaki Y., et al. [176], who found that 1 µM had no inhibitory 
effect on BCRP function, but 10 µM caused a 30% decrease in activity in human 
kidney slices. Therefore, it is possible that the concentrations of indomethacin used in 
this experiment were too low to induce an effect, however, it also suggests that down-
regulation of BCRP protein expression by indomethacin is not an effective method of 
overcoming BCRP-mediated resistance. Despite its inability to overcome BCRP-
mediated resistance, its ability to decrease BCRP protein expression still has a 
therapeutic benefit. The use of indomethacin might prevent the induction or 
amplification of BCRP in tumours treatment with chemotherapy. 
Upon removal of lapatinib, elacridar, gefitinib or 17-AAG after a 24 hours pre-
treatment (scheduling proliferation assay) the cytotoxic potential of SN-38 was still 
greatly enhanced (graph 3.1.6.3.1.B, 3.1.6.3.2.B., 3.1.6.3.4.B, 3.1.6.3.5.B, 3.1.6.3.6 
and table 3.1.6.3.2.) As both lapatinib and elacridar regulation of BCRP protein 
expression was inconsistent (figure 3.1.6.3.2), the modulatory effect on BCRP could 
be due to a consequence of lasting BCRP functional inhibition, the presence of 
lapatinib in the cells 48 hours after removal even though it is a BCRP substrate (as 
described by our group in Dunne G., thesis [197]) or due to a change in protein 
expression. Conversely, 17-AAG’s down-regulation of BCRP protein expression was 
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stable for 48 hours (figure 3.1.6.3.1 and 3.1.6.3.2.), but whether the potentiation of 
SN38 (graph 3.1.6.3.6) was due to protein down-regulation or direct and persistent 
functional inhibition has yet to be established (method involving exposure of the cells 
to 17-AAG for 24 hours, removal 17-AAG followed by the addition of various 
concentration of SN38. BCRP protein expression would be monitored over a 72 hour 
period to determine if SN38 reversed the down-regulation of BCRP by 17-AAG). The 
scheduling proliferation assay with gefitinib as the pre-treatment small molecule agent 
was much less effective compared to the combination proliferation assays (graph 
3.1.6.3.2.A and 3.1.6.3.2.B). SN38 cytotoxicity was still enhanced but to a much 
lesser extent. This could be due to the down-regulation of BCRP protein in the first 24 
hours or to mild sustained inhibition of BCRP function. This work also indicates that 
when using protein down-regulation as a mechanism of overcoming MDR in both in 
vitro and in vivo systems, a continuous exposure to the modulator is required to 
maintain the alteration. Of all the small molecule agents tested in BCRP-expressing 
cell lines, lapatinib was the most effective at overcoming BCRP-mediated resistance 
which caused a huge reduction in cell growth. This has significant therapeutically 
potential as lapatinib is also a dual EGFR/HER2 tyrosine kinase inhibitor [417] and P-
gp functional inhibitor [418]. Therefore, tumours presenting multiple MDR, as well as, 
amplified EGFR/HER2 phenotypes could benefit greatly from the combination of 
lapatinib with chemotherapeutic drugs (that are P-gp and/or BCRP substrates).  
 
In summary; one small molecule agent (sulindac sulphide) up-regulated the 
expression of BCRP protein while three small molecule agents (erlotinib, celecoxib 
and ibuprofen) caused up-regulation and down-regulation depending on their dose.  
These small molecule agents provide the potential for the induction and amplification 
of BCRP transporter protein expression in secondary or advanced tumours treated 
with them. Three small molecule agents (indomethacin, gefitinib and 17-AAG) 
consistently reduced the expression of BCRP in the DLKP-SQ/mitox cell line. For 
both gefitinib and 17-AAG, this down-regulation was sustained following drug 
removal but the effect by indomethacin recovered within 48 hours. Initially, two other 
small molecule agents, lapatinib and elacridar, down-regulated BCRP protein 
expression but these effects were not reproducible. However, when compared to the 
down-regulators, both small molecule agents had a greater impact on BCRP-mediated 
resistance in both co-treatment and pre-incubation proliferation assays. Gefitinib and 
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17-AAG were highly effective when combined with the chemotherapeutic drug but 
upon removal their anti-MDR potential was significantly reduced. This may suggest 
that 17-AAG does not only down-regulate BCRP protein expression but also inhibits 
its function. Therefore, once 17-AAG was removed, in the pre-treatment proliferation 
assays, its functional inhibitory effects on BCRP are significantly reduced but 17-
AAG still overcomes BCRP-mediated resistance due to down-regulation of BCRP-
protein expression. These small molecule agents could be of significant interest in the 
treatment of BCRP expressing tumours as not only do they overcome BCRP-mediated 
resistance but they could also prevent the amplification or development of BCRP. 
To date, there are no clinical trials investigating BCRP modulation by lapatinib but 
results presented in this project suggest it could be beneficial. Phase I and II clinical 
trials of gefitinib with irinotecan (a BCRP substrate) in patients with advanced 
fluoropyrimidine-refractory colon cancer have been completed but gefitinib did not 
appear to add substantial efficacy to irinotecan [419]. There is a phase II clinical trial 
combining 17-AAG and irinotecan in solid tumours [420] however, their focus was on 
down-regulating checkpoint kinase 1 (Chk1) and not on overcoming BCRP-mediated 
resistance which is commonly induced in solid tumours. Therefore, the result of this 
clinical trial could be interesting considering we identified 17-AAG as a BCRP 
modulator. A pharmacological study (phase I clinical trial) was completed for the 
combination of elacridar with topotecan [421]. 
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Key take-home points from MDR down-regulation experiments: 
1. 17-AAG modulates BCRP expression and overcomes BCRP-mediated 
resistance. 
2. Drugs can dynamically effect MDR protein expression 
3. A single drug can differentially alter the expression of MDR proteins; 
therefore, understanding mechanisms of regulations for each MDR protein is 
important.  
4. For the small molecule agents tested, combination therapy is the optimum 
treatment regimen. 
5. Full and permanent eradication of MDR protein expression that is stable in the 
presence of chemotherapeutic drugs is essential when considering a 
combination or pre-treatment schedule.  
6. Agents can be inhibitors, down-regulator and up-regulators of MDR 
transporter proteins. 
7. When using protein down-regulation as a mechanism of overcoming MDR in 
both in vitro and in vivo systems, a continuous exposure to the modulator is 
required to maintain the alteration. 
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4.2. Cellular Pharmacokinetics of Epirubicin 
 
The distribution and elimination of intravenously and orally administered anti-cancer 
drugs are influenced by biological factors such as multi-drug resistance transporter 
proteins and serum transport proteins. Serum transport proteins, such as serum 
albumin and α1-acid glycoprotein (AAG) play a major role in the distribution, and 
thus efficacy, of anti-cancer agents by binding and transporting them through the 
circulatory system [48].  Albumin is crucial for the distribution, elimination and 
effectiveness of drugs such as digoxin, NSAIDs [49], midazolam, warfarin, thiopentone, 
tamoxifen, digitoin and anti-cancer drugs such as, anthracyclines [50] and taxanes etc. 
[50] [51]. AAG also plays an important role in the transport and delivery of many drugs. 
In a solution containing 50 µM AAG, 31% of a fixed concentration of epirubicin was 
bound [59]. Chassany O., et al. [59], also stated that 61 – 94% of epirubicin was bound 
to a solution containing 40 mg/ml of albumin. However, the impact of this binding on 
epirubicin transport, availability to the cell and the length of time spent in the body 
has not been investigated. On reaching the cell, the accumulation of these protein 
bound drugs is dependent on the molecular size of the protein, level of serum 
transport protein binding and the phenotype of the cancer cells. 
In this study, we investigated the role that two serum proteins (serum albumin and α1-
acid glycoprotein) play in the accumulation of epirubicin in both normal and cancer 
cells. While the binding affinity of serum albumin and AAG to anthracyclines has 
been investigated, the impact of this binding on drug accumulation has never been 
explored. In vitro, varying levels of FCS are required for culturing different types of 
cancer cells. This body of work was undertaken to characterise the impact of varying 
levels of FCS on the cytotoxic potential of anti-cancer drug in difference cancer cells.  
As expected, over 99% of epirubicin was free in a solution of water (UHP) or PBS, 
while 94% was free in cell growth media (ATCC) (graph 3.2.1.1.1 and for method see 
section 2.12.1). The decrease in free drug in cell culture media may be due to the 
presence of sugars and salts altering the pH and potentially have a small effect on 
drug solubility. Use of cell growth media without proteins resulted in varying levels 
of drug accumulation in the three different cell types. The largest drug accumulation, 
of 6281 ± 911 ng/million cells, was found in the MCF7 cells, followed by 3150 ± 184 
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ng/million cells in the normal HMEC cells and finally 1025 ± 529 ng/million cells in 
DLKP cells (graph 3.2.1.2.1, table 3.2.1.2.1 and see method section 2.12.2.1.). 
The introduction of low levels of FCS or albumin increased epirubicin accumulation 
in all cells types (graph 3.2.1.2.1, 3.2.1.2.2 and 3.2.1.2.3 and method in section 2.12.). 
However, above 20% FCS, and the equivalent 8 mg/ml albumin, and with less then 
60% of free epirubicin, the level of epirubicin accumulation reduced in all cells (graph 
3.2.1.2.1, 3.2.1.2.2. and table 3.2.1.2.1., 3.2.1.2.2.). The proportion of bound 
epirubicin at this point was 48% in FCS (graph 3.2.1.1.2. and table 3.2.1.1.2) and 40% 
in albumin (graph 3.2.1.1.3 and table 3.2.1.1.3). At 100% FCS or 40 mg/ml serum 
albumin (with 0 to 20% free epirubicin), the level of epirubicin accumulation was 
halved, compared to 0% FCS or 0 mg/ml albumin, in the MCF7 and HMEC cells 
(graph 3.2.1.2.1, 3.2.1.2.2. and table 3.2.1.2.1., 3.2.1.2.2.). However, with the highest 
concentration of FCS, drug accumulation in the DLKP cells was double (2431 ± 171 
ng/million cells) that of cell growth media without proteins (1025 ± 529 ng/million 
cells) (graph 3.2.1.2.1 and table 3.2.1.2.1). But with the equivalent concentration of 
albumin (40 mg/ml) the accumulation was only slightly higher (1564 ± 212 ng/million 
cells) (graph 3.2.1.2.2. and table 3.2.1.2.2). With 100% FCS, 100% of epirubicin was 
bound while 80% was bound in the presence of 40 mg/ml serum albumin. This 
accumulation data suggests that low levels of FCS and serum albumin aid epirubicin 
entry into the cells while higher levels restrict entry to these cells. This reduction in 
accumulation could be due to the protein sequestering the drug so it’s not free to enter 
the cell. In the case of DLKP, the presence of FCS or serum albumin heightened 
epirubicin accumulation across the board. This may be due to a difference in tissue 
type, membrane drug permeability or protein influx pumps (expression of OATP’s, 
etc.). Pharmacologically, this body of work indicates that serum albumin and the 
protein cocktail in serum do not differentially alter the accumulation of epirubicin in 
normal or cancer cells. The level of epirubicin-protein binding correlates with 
Chassany O., et al. [59], who used HPLC with fluorescent detection to discover that 
61 – 94% of epirubicin, was bound to a solution containing 40 mg/ml of albumin. 
However, no publications have investigated the effect drug-protein binding has on 
drug accumulation in the cell. 
At levels found in the body (0.08 mg/ml up to 0.8 mg/ml (20 µM)) only 6% to 14% of 
epirubicin was bound in the presence of AAG (graph 3.2.1.1.4, table 3.2.1.1.4 and 
method in section 2.12.1). This correlated with results described by Chassany O., et al. 
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[59], using HPLC with fluorescent detection, there was a 31% reduction of free 
epirubicin in the presence of 50 µM AAG. With the lowest level of AAG (0.08 mg/ml) 
epirubicin accumulation doubled in the DLKP cells (from 1025 ± 529 to 2670 ± 150 
ng/million cells) and only slightly increased (from 3150 ± 184 to 4586 ± 495 
ng/million cells) in the HMEC cells (graph 3.2.1.2.3., table 3.2.1.2.3 and method 
2.12.2.1). MCF7 cells demonstrated the most dramatic epirubicin accumulation in the 
presence of AAG (graph 3.2.1.2.3 and table 3.2.1.2.3), which did not occur in the 
presence of FCS or albumin. In the presence of 0.8 mg/ml AAG, the accumulation of 
epirubicin increased 2-fold from 6281 ± 911 to 14011 ± 2537 ng/million cells in these 
cells. As drug-protein binding was very low even with the highest concentration of 
AAG, this could suggest that delivery of epirubicin by AAG is a more efficient 
compared to serum albumin. Therefore, one would expect that the presence of AAG 
in FCS would result in improved delivery and greater accumulation. However, in this 
case the level of AAG may be low in serum, while the levels of serum albumin would 
be set at 40 mg/ml and therefore, the binding of serum albumin to the cell membrane 
could not only inhibit the accumulation of albumin bound drug but also AAG bound 
drug . There are some disease states where the levels of AAG increase (280-fold) to 
the same levels as serum albumin. This can occur as a result of an acute inflammatory 
response and neoplasia. Inflammation has been linked with tumour initiation, 
promotion and progression [422] [423]. This project dealt with normal or non-
inflammatory response levels of AAG. However, to determine the true impact of 
AAG on anthracycline accumulation, further pharmacokinetic studies using levels up 
to 280-fold higher need to be carried out. Other avenues, such as identifying the true 
impact serum proteins have on the efficacy of epirubicin could also be investigated. 
Apoptosis assays carried out in DLKP, MCF7 and HMEC cells in presence of varying 
levels of FBS, serum albumin and α1-acid glycoprotein in serum-free media over a 3 
day period would evaluate this. Also to investigate whether serum albumin and/or 
AAG levels in patients correlate with outcome would also be of great interest as it 
could potentially identify a patient sub-population that would respond better to 
anthracycline treatment. There has been very little research published on this area. 
The only article relating anthracycline-AAG binding was published by Chassany O., 
et al. [59]. The level of AAG used in their publication is more than double the highest 
concentration of AAG used in this project. However, their results demonstrate that 
epirubicin binding to AAG is low. 
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In summary, FCS and albumin bind free epirubicin. This binding aids epirubicin 
accumulation at low protein concentrations but hinders it at high protein 
concentrations. This is most likely due to bound drug being sequestering by the 
protein and unable to pass into the cell. AAG, at low levels found in blood under 
normal conditions, does not bind a lot of epirubicin but causes a 2-fold increase in the 
accumulation of epirubicin in all three cell lines. These serum proteins do not alter the 
availability of epirubicin for normal cells any differently than they do for the cancer 
cells.  
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4.3. Effect of tyrosine kinase inhibitors on the function and expression of 
epidermal growth factor receptors, EGFR and HER2, multidrug resistance 
transporter and cyclooxygenase proteins. 
 
The epidermal growth factor receptor (EGFR) family (for review see section 1.5.) is 
composed of cell surface receptors with tyrosine kinase functionality that are involved 
in the regulation of cellular proliferation, survival and differentiation during 
development, tissue homeostasis, and tumourigenesis of epithelial cells. Activation of 
these receptors leads to stimulation of signal transduction pathways including 
phosphtidylinositol 3’-kinase (P13K/Akt/mTOR), Erk1/2 mitogen-activated protein 
kinase (MAPK) and Jak/Stat. HER2 over-expression or amplification occurs in a third 
of breast tumours and confers an aggressive clinical course, worse survival and is 
responsible for a quarter of all cancer-related deaths in women [215]. The outcome of 
these highly aggressive tumours has markedly improved with the development of 
anti-HER2 therapies. For example, the combination of trastuzumab with docetaxel in 
HER2 metastatic breast cancer patients resulted in better response (60% vs. 34%), 
increased survival (31.2 vs. 22.7 months), increased disease-free response (11.7 vs. 
6.1 months) and longer duration of response (11.7 vs. 5.7 months) compared to 
docetaxel alone [217]. EGFR over-expression is found in many tumour types, such as 
lung, colon, kidney and head and neck carcinoma, which are mostly resistant to 
conventional chemotherapy [424]. Anti-EGFR, small molecule agents have been 
identified and several are now approved for treatment of late stage, advanced cancers 
[425]. We examined three such small molecule inhibitors, lapatinib (a dual EGFR and 
HER2 inhibitor), erlotinib and gefitinib (both specific EGFR inhibitors). We 
compared the efficacy of lapatinib, erlotinib and gefitinib, to sensitise EGFR/HER2-
amplified breast cancer cell models to the chemotherapeutic agents, epirubicin and 
docetaxel (for methodology see section 2.7.1., 2.11. and for results see section 3.3.1.). 
As many tumours, such as breast, lung and colon, co-express EGFR/HER2, MDR and 
COX-2, we also compared the efficacy of lapatinib, erlotinib and gefitinib to 
overcome P-gp, MRP1 and BCRP-mediated resistance (see sections 2.7.1., 2.11., and 
3.3.5.) aswell as determining their effect on COX expression and function (see 
sections 2.7.1., 2.11., 2.13., and 3.3.4).  
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Using combination proliferation assays (described in section 2.7.1), there were no 
alterations in cell proliferation when the three TKIs were combined with epirubicin or 
docetaxel in the EGFR-amplified cells (MDA-MB-231) (graph 3.3.1.1 and table 
3.3.1.1), in HER2-amplified breast cancer cells (MDA-MB-453) (graph 3.3.1.2 and 
table 3.3.1.2) or in the moderately-expressing EGFR/HER2 breast cell model (MCF7) 
(see graph 3.3.1.3 and table 3.3.1.2.). This is surprising as sensitivity lapatinib 
decreased the active levels of both EGFR and HER2 (pEGFR and pHER2) in both 
lapatinib sensitive and insensitive breast cell lines [426].. Furthermore, in the clinic a 
HER2 inhibitor, trastuzumab, increased the benefit of first-line chemotherapy in 
metastatic breast cancer that overexpress HER2 [216]. Their combination resulted in a 
longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher 
rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of 
response (median, 9.1 versus 6.1 months; P<0.001), a lower rate of death at 1 year 
(22% versus 33%, P=0.008), longer survival (median survival, 25.1 versus 20.3 
months; P=0.01), and a 20% reduction in the risk of death. Therefore, this data 
provides biological rationale for the lack of clinical efficacy with lapatinib when used 
in EGFR or dual EGFR/HER2 over-expressing breast cancer patients.  
 
By immunoblotting, Sakai K., et al. [390], demonstrated that 2 µM of gefitinib reduced 
phosphorylated (activated) EGFR levels in 293(W) cells transfected with wild-type 
EGFR. In invasive human bladder cells lines, Wallerand H., et al. [351], also 
demonstrated this effect by gefitinib using Western blotting techniques. There is no 
data to show the same for either erlotinib but it would be expected that erlotinib 
would have the same effect on pEGFR and that lapatinib would affect both pEGFR 
and pHER2. By ELISA (see section 2.11.6.) preliminary results indicate that lapatinib 
has no affect on the active levels of EGFR (see section 8, graph 8.3.2.1. and table 
8.3.2.1.A.) but decreases HER2 activation levels (see section 8, graph 8.3.3.1 and 
table 8.3.3.1.A) at 24 hours and had little impact at 48 and 72 hours. As the effect was 
only observed for 24 hours it suggests that the effect on HER2 activity by lapatinib is 
only short term. The preliminary pHER2 result correlates with Zhang D., et al. [1], 
who demonstrated a reduction in pHER2 in BT-474 and SK-BR-3 breast cell lines 
following a 24 hour exposure to 0.1 and 1 µM lapatinib (using Western blotting 
techniques). However, the pEGFR result does not correlate with their result. This may 
be due to a difference in cell line, culturing techniques and handling. There are no 
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publications demonstrating pEGFR reduction in the MDA-MB-231 cell line. The 
positive controls for this experiment were MDA-MB-453 and MDA-MB-231 cells 
exposed to the EGF ligand for the same time periods as lapatinib. Sakai K., et al. [390], 
showed that short term exposure to the EGF ligand had little effect on EGFR 
expression in 293(W) cells transfected with wild-type EGFR, while Zhang D., et al. [1], 
also observed little change in EGFR protein expression but an increase in its 
phosporylated active form in BT-474 and SK-BR-3 breast cell lines. We also found 
that EGF had little effect on HER2 expression and only moderately increased its 
active state (see section 8, graph 8.3.3.1 and table 8.3.3.1.B). This has not been 
reported in the literature. This data helps explain why lapatinib did not sensitise the 
EGFR over-expressing cell line (MDA-MB-231) to epirubicin or docetaxel and 
instead why it sensitised the HER2 amplified cell line (MDA-MB-453) to the 
chemotherapeutic drugs.  
 
Several studies reported that COX-2 (an enzyme involved in the PGE2 pathway) 
production occurs along side EGFR activation [338] and HER2/HER3 
heterodimerisation [340] [342]. COX-2 activity produces PGE2 which in turn rapidly 
phosphorylates EGFR and triggers ERK2. Therefore, it is thought that through 
PGE2’s activity, which leads to the transactivation of EGFR and promotion of the Akt 
pathway, that COX2 causes an increase in tumour cell number and thus, volume as 
well as changes in morphological architecture and organisation [359]. Targeting EGFR, 
Gadgeel SM., et al. [327], showed that both erlotinib and gefitinib down-regulate the 
expression of COX-2 in the non small cell lung carcinoma cell lines, H1650 and 
H1781. In some cases, the combination of COX-2 inhibitors (celecoxib/NS-398) with 
erlotinib or gefitinib increased apoptosis in non-small cell lung carcinoma cell lines 
[362] and decreased cell number, tumour size and number in colorectal xenograft 
tumours in mice [324]. As both EGFR and HER2 have been linked with COX-2 
production and COX2 activity has been linked with the transactivation of EGFR, a 
COX inhibitor (i.e. sulindac/celecoxib) could potentiate the pro-apoptotic of a dual 
EGFR/HER2 inhibitor (i.e. lapatinib). Therefore, in this section, we investigated the 
effect lapatinib has on the expression and activity of COX in the COX-1, COX-2, 
EGFR and HER2 expressing squamous lung cell line, A549 (for methodology see 
section 2.11. and 2.13. and for results see section 3.3.4.).  
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Firstly, we examined the effect a 48 hours exposure to each TKI (lapatinib, erlotinib 
and gefitinib) had on COX-2 protein expression in the A549 cell lines. We included 
10 µM celecoxib as a negative control. We found that, as expected, erlotinib, gefitinib 
and celecoxib down-regulated COX-2 protein expression in the A549 cells (figure 
3.3.4.3.). However, when compared to the EGFR-specific TKI’s, erlotinib and 
gefitinib, lapatinib (the dual EGFR/HER2 TKI) had the opposite effect. It caused a 
large increase in COX-2 protein expression (figure 3.3.4.3.). As COX-2 protein 
expression was only increased following exposure to the dual EGFR/HER2 inhibitor 
and not by the EGFR-specific inhibitors, it is clear that the lapatinib-mediated up-
regulation of COX-2 protein is independent of its EGFR tyrosine kinase inhibitory 
activity.  
To determine if lapatinib up-regulated COX-2 protein expression through its HER2 
inhibitory activity, we exposed the A549 cells to increasing concentrations of 
lapatinib, AG825 (HER1/2 TKI) and trastuzumab (HER2 antibody) and examined 
changes in COX-2 protein expression by Western blotting. We found that lapatinib 
consistently upregulated COX-2 protein expression while the HER1/2 TK inhibition, 
AG825, did not alter COX-2 protein expression (figure 3.3.4.2.). This indicates that 
COX-2 up-regulation by lapatinib is not through its HER2 tyrosine kinase activity. 
We also found that 0.75 and 1 µM trastuzumab down-regulated COX-2 protein 
expression (figure 3.3.4.2.). This also indicates that COX-2 up-regulation by lapatinib 
is not due to HER2 inhibition. Therefore, lapatinib-mediated up-regulation of COX-2 
protein expression is independent of its EGFR/HER2 tyrosine kinase activity. 
To establish whether the up-regulated COX-2 protein expressed by lapatinib was 
functionally active, we carried out COX activity assays on A549 protein lysates that 
were exposed to lapatinib for 48 hours prior to extraction. As a control, we included 
AG825 and trastuzumab treated A549 cell lysate. We found that A549 cells, when 
exposed to 2.5 and 5 µM lapatinib for 48 hours, up-regulated COX-2 protein 
expression and also increased its activity (graph 3.3.4.1.A.). This was mirrored by an 
increase in total COX activity (graph 3.3.4.1.A.). However, while 7.5 and 10 µM of 
lapatinib up-regulated COX-2 protein expression it did not alter COX-2 activity. This 
may suggest that concentrations of lapatinib below 5 µM stimulate COX-2 
transcription and thus protein synthesis while concentrations above 5 µM interfere 
with post-transcription or translational modifications, thus rendering the new protein 
inactive.  
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As the up-regulation of COX-2 protein expression and activity by lapatinib has not 
been investigated before, a closer look into the signalling pathway, their down-stream 
transcription factors and effect on post-translational modifications, such as 
phosphorylation and folding, would be of considerable interest. Also, as the lapatinib-
mediated COX-2 stimulation has only been studied in the A549 cell line, we do not 
know if the effect is cell specific, tissue specific or common in all COX-2 expression 
cancer cells. Also, as the concentrations used in this project were above achievable 
serum concentrations, repeating this study at lower concentrations would be essential 
to determine if the up-regulation of COX-2 by lapatinib would have consequences in 
the clinic, such as increased angiogenesis, metastasis or resistance to apoptosis. 
Interestingly, Huber LC., et al. [272], also looked at the effect of lapatinib on COX-2 
expression and activity. However, they looked at it from a different perspective. They 
stimulated rheumatoid arthritis synovial fibroblasts with cytokines and pro-
inflammatory mediators (TNFα, IL-1B and EGF ligand) which increased COX-2 
mRNA and protein expression (quantified by ELISA). This increase was abrogated by 
the addition of 5 and 10 µM of lapatinib and the TKI also reduced PGE2 production. 
In our system (the A549 cells), COX-2 expression occurs naturally and does not 
require induction/stimulation from external factors. To determine if the discrepancy in 
results is due to experimental design and type of COX-2 expression, the introduction 
of TNFα, IL-1B or EGF to proliferating A549 cells and examining any changes 
lapatinib has on this enhanced COX-2 would be important. 
Incidentally, we also found that following a 48 hour exposure to the HER1/2 TKI, 
AG825 (graph 3.3.4.1.B.), and the HER antibody, trastuzumab (graph 3.3.4.1.C.), the 
activity of COX-2 in the A549 cells was more than halved. This provides further 
evidence to indicate that the stimulation of COX-2 expression and function by 
lapatinib was independent of its EGFR/HER2 TKI activity.  
Work so far has demonstrated that, following a 48 hour exposure to lapatinib, COX-2 
expression and function is increased significantly but the mechanism of action of this 
effect is not through tyrosine kinase inhibition of EGFR or HER2. At this stage, we 
examined the ability of lapatinib to directly stimulate COX-2 activity. We also 
included AG825, trastuzumab and celecoxib in this assay. To do this assay, we 
extracted untreated A549 lysate and included increasing concentrations of lapatinib 
into the assay plate. Before undertaking the assay we assessed whether lapatinib or its 
vehicle would interfere with the assay. Lapatinib has very little fluorescence (an 
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emission wavelength of 350-550 nm) even in strong organic solvents (as 
demonstrated by Dr. Brian Trummer, Department of Pharmaceutical Sciences, 
University at Buffalo) and therefore would not interfere in the assay. An excitation 
wavelength of 530 – 540 nm and emission wavelength of 585 – 595 nm were used to 
read the assay plates. Also, the lapatinib vehicle used was DMSO, and according to 
the assay manual, low levels of DMSO do not interfere with the assay. In this section, 
we found that lapatinib directly stimulated COX-2 activity readings in the A549 lysate 
(graph 3.3.4.2.A.). While AG825, trastuzumab (graph 3.3.4.2.B.) and celecoxib 
(graph 3.3.4.2.C.) directly inhibited COX-2 activity. Once again lapatinib stands apart 
from the HER2 TKI and antibody. The lapatinib-mediated COX-2 stimulation could 
lead to increased angiogenesis, metastasis, resistance to apoptosis and increased cell 
growth. However, it is unclear if other inhibitory activities of lapatinib would counter 
the increased COX-2 activity. Also, the concentrations of lapatinib used in this work 
are above pharmacologically relevant concentrations. Therefore, further investigations 
with lower concentrations would help determine if lapatinib-mediated COX-2 
stimulation has therapeutic implications. 
In summary, after short-term exposure, lapatinib up-regulates COX-2 protein and 
activity. It also directly stimulates COX-2 activity.  
Finally, we examined whether lapatinib, AG825 or trastuzumab affected COX-1 
expression and function aswell as directly interacting with COX-1. We found that 
with the highest concentration of lapatinib COX-1 protein expression was slightly 
reduced (figure 3.3.4.1.). AG825 had no effect on COX-1 expression (figure 3.3.4.1.) 
while 0.5, 0.75 and 1 uM of trastuzumab up-regulated COX-1 protein expression 
(figure 3.3.4.1.). Using the COX fluorescent activity assay, we found that a 48 hour 
exposure to lapatinib, AG825 or trastuzumab had little effect on COX-1 activity. 
Lapatinib had no effect, while both AG825 and trastuzumab slightly reduced COX-1 
activity (graph 3.3.4.2.A, B and C.). Once again, lapatinib stands apart from the 
HER2 TKI and antibody. The highest concentration of lapatinib stimulates COX-1 
activity while the highest concentration of AG825 and trastuzumab directly 
suppressed COX-1 activity (graph 3.3.4.2.B and C.). All the data combined indicates 
that lapatinib directly stimulates COX-1 activity but, following exposure to lapatinib 
for 48 hours, did not alter COX-1 protein expression of activity. AG825 had no effect 
on COX-1 protein expression but slightly decreases its activity directly and after a 
short-term treatment. Trastuzumab up-regulates COX-1 protein expression but 
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inhibits its activity directly and following short-term treatment. As COX-1 expression 
has been linked with early stage tumourigenesis (in HCC patients) [290] the use of 
lapatinib for preventing or reducing tumour progression might not therefore be 
recommended. However, as the concentrations of lapatinib used in this section are 
above pharmacologically relevant concentrations, these experiments require repeating 
with lower lapatinib concentrations to determine if lapatinib, at therapeutically 
achievable levels, would stimulate COX-1. On the other hand, the trastuzumab 
concentrations used are pharmacologically relevant and would be capable of 
inhibiting COX-1 activity in these cells, and therefore, trastuzumab could inhibit a 
factor that is potentially involved in tumour initiation/progression. There are no 
publications demonstrating the effects of lapatinib, AG825 or trastuzumab on COX-1. 
It has been demonstrated that breast tumours can co-express COX-2, EGFR, HER2 
and in many cases MDR transport proteins. As we have shown that lapatinib increases 
COX-2 expression and activity, we considered the implications of this on cell growth 
and apoptosis. We wanted to determine if sulindac, a non-specific COX inhibitor, 
could enhance the anti-proliferative potential of lapatinib in breast cell lines by 
reducing COX activity in these cells. We selected a panel of breast cell lines that were 
sensitive and insensitive to lapatinib and, while determining their COX-2 status, we 
carried out combination proliferation assays with both drugs. We found that sulindac 
could not sensitise the mild EGFR/HER2-expressing cell line, MCF7 (graph 
3.3.4.3.(C) and table 3.3.4.2.), or the EGFR-amplified cell line, MDA-MB-231 (graph 
3.3.4.3.(A) and table 3.3.4.2.), to lapatinib. But sulindac mildly sensitised the HER2-
amplified breast cell line, MDA-MB-453, to lapatinib (graph 3.3.4.3.(B) and table 
3.3.4.2.). However, in the meantime, we discovered that our panel of lapatinib 
sensitive and insensitive breast cell lines did not express COX-2. Therefore, even 
though a slight sensitisation of the HER2-expressing cell line, MDA-MB-453, 
occurred, the positive finding did not support the original hypothesis as this cell line 
does not express COX-2.  
These novel results suggest that the effect of lapatinib on COX-2 is independent of its 
EGFR/HER2 targeted therapy activity. As COX-2 promotes angiogenesis, metastasis, 
cell proliferation and inhibit apoptosis (all negative outcomes for cancer treatment), 
the implications that lapatinib stimulates COX-2 could be detrimental in the clinic 
especially when combined with chemotherapeutic drugs that are already known to 
simulate COX-2 expression following long-term treatment. The combination of 
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lapatinib and a chemotherapeutic drug along with a NSAID/coxib would be worth 
serious consideration. We would also need to determine if the effect of lapatinib on 
COX-2 is cell specific by expanding testing to other COX-2 expressing cell lines, 
such as HL60, M14 and 2008/MRP1.  
 
A number of anti-HER2 and anti-EGFR agents have been found to inhibit the 
function of multidrug resistant transporter proteins, such as P-gp and BCRP 
(discussed in section 1.4.5.). In this study, we compared the ability of the three 
tyrosine kinase inhibitors (lapatinib, erlotinib and gefitinib) to overcome (see section 
2.7. for combination proliferation assay method) and alter the expression (see section 
2.11. for Western blotting method) of P-gp, MRP1 and BCRP.  
In three P-gp expressing cell lines (NCI/Adr-res, A549-Taxol and H1299-Taxol), 
lapatinib potentiated the anti-proliferative effects of two P-gp substrates (epirubicin 
and docetaxel) (graph 3.3.5.1.(A), 3.3.5.2.(A) and 3.3.5.3.(A)). Dai C-L., et al. [147], 
had similar findings in mdr1-transfected breast cell lines (MCF7 and S1) using 
combination proliferation assays. Using ATPase assays, they also showed that 
lapatinib directly inhibited the transport function of P-gp. Similar work by Collins 
D.M. et al. [97], in lung cancer cell lines also correlates with this finding. However, in 
two of three P-gp-expressing cell lines (NCI/Adr-res and H1299-Taxol (graph 
3.3.5.1.(B&C) and 3.3.5.3.(B&C))), erlotinib and gefitinib did not overcome P-gp-
mediated resistance. This does not correlate with Shi Z., et al. [148], who demonstrated 
that erlotinib sensitises the P-gp expressing colchicine-selected human epidermoid 
carcinoma cell line, KB-3-1, to P-gp substrates. Also, the gefitinib result does not 
correlate with work published by Yanase K., et al. [150], who found that 0.3 and 3 µM 
of gefitinib could sensitise an mdr1-transfected human myelogenous leukemia, K562, 
cell line to vincristine. Erlotinib (bar a mild affect with docetaxel in the H1299-Taxol 
cell line) and gefitinib did not inhibit P-gp function in these cells using the same 
combination proliferation assays employed in this thesis. The difference in results 
may be due to method of resistance selection/transfection or cell type. Comparing 
these results, lapatinib sensitises these P-gp expressing cell lines to the greatest extent. 
This finding is partially supported by ATPase assay results published by our group 
(Collins DM., et al. [97]), where lapatinib caused the greatest reduction in activated P-
gp ATPase followed by erlotinib and finally gefitinib. All the TKIs caused an increase 
in the P-gp protein expression following a 48 hour exposure (figure 3.3.6.1.). 
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Contrary to our findings, Dai CL., et al. [147], found that lapatinib did not affect the 
mRNA or protein expression levels of P-gp in doxorubicin-selected MCF7 cells 
following exposure to similar concentrations for 48 hours. However, using the same 
cell line, similar drug concentrations and technique as used in this thesis, Collins DM., 
Thesis [112] demonstrated the same changes in protein expression presented in this 
thesis.  
As all TKI’s up-regulate the expression of P-gp, there is an increased risk that long-
term treatment with the TKI’s could amplify or induce P-gp protein expression and 
thus, P-gp-mediated resistance. This implies that the MDR phenotype could be 
presented in secondary or advanced tumours and would require consideration in 
treatment design. Lapatinib, below pharmacologically relevant concentrations, 
effectively overcame P-gp-mediated resistance, leading to an increased toxicity of the 
P-gp substrate chemotherapeutics, epirubicin and docetaxel. The inhibition of P-gp 
activity by lapatinib has two potential clinical applications, firstly sensitising P-gp-
mediated multidrug resistance tumours to substrate chemotherapeutics and secondly 
improving the bioavailability of orally administered P-gp substrate anti-cancer agents. 
These results would suggest that the combination of lapatinib with epirubicin or 
docetaxel warrants clinical investigation in cancer. 
 
In the transfected MRP1 cell line, 2008/MRP1, the three TKI’s did not enhance 
MRP1 substrate toxicity or overcome resistance (graph 3.3.5.4 and table 3.3.5.4.). 
This correlates with a number of publications: (a) Yanase K., et al. [150], demonstrated 
this with gefitinib in MRP1-transfected human epidermoid carcinoma cells, KB-3-1,  
and (b) Collins D.M. et al. [97], found that lapatinib, erlotinib and gefitinib did not 
sensitise the endogenously expressing MRP1 lung cell line, A549, to epirubicin. With 
regard to MRP1 protein expression we found that the dual EGFR/HER2 TKI, 
lapatinib, had the opposite effect on MRP1 protein expression relative to erlotinib and 
gefitinib (figure 3.3.6.2.). Both erlotinib and gefitinib up-regulated MRP1 protein 
expression while lapatinib down-regulated it (also shown by Dunne G., Thesis [197]). 
Even though lapatinib down-regulated MRP1 protein expression it did not sensitise 
the A549 cells to epirubicin. This would not be unexpected, as work carried out by 
Collins D., [112] demonstrated, using ATPase assays, that lapatinib was a poor 
activator and inhibitor of MRP1. Also difference in MRP1 expression caused by 
lapatinib could be negated by stress response induced by the presence of vincristine. 
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The mechanism by which lapatinib down-regulated MRP1 protein expression has not 
been elucidated, however, from the proliferation combination assay discussed in this 
section, it is clear that this down-regulation does not alter the sensitivity to the MRP1 
substrate, epirubicin. This finding has not been published in the literature. 
The three TKI’s do not overcome MRP1-mediated multidrug resistance, however, 
both erlotinib and gefitinib up-regulate MRP1 protein expression. Therefore, long-
term treatment with erlotinib or gefitinib could amplify or induce MRP1 protein 
expression and thus, resistance to MRP1 substrate chemotherapeutic drugs including 
the anthracyclines or vincristine. However, this acquired resistance would not change 
the anti-proliferative potential of erlotinib or gefitinib. On the other hand, lapatinib 
down-regulates MRP1 protein expression and therefore lapatinib could suppress the 
subsequent development of MRP1-mediated resistance in tumours.  
 
The greatest effect of the three TKIs occurred when combined with the BCRP 
substrate, SN-38, in the BCRP-expressing mitoxantrone-selected squamous lung cell 
line, DLKP-SQ/mitox (graph 3.3.5.5 and table 3.3.5.5.). With 0.3 µM lapatinib, 0.5 
µM erlotinib and 0.5 µM gefitinib the anti-proliferative potential of SN-38 was 
increased from 4% to greater than 90%. Lapatinib caused the greatest effect, followed 
closely by erlotinib and finally gefitinib. In pre-clinical studies, a number of 
publications have shown enhanced sensitivity to BCRP substrates by lapatinib, 
erlotinib or gefitinib. However, a comparison between the three agents has never been 
published. Dai CL., et al. [147], sensitised the mitoxantrone-selected colon cell line, S1-
M1-80, to topotecan and mitoxantrone with concentrations between 0.6 and 2.5 µM 
lapatinib. Using erlotinib, Shi Z., et al. [148], sensitised the flavopiridol-selected breast 
cell line, MCF7-BCRP, to mitoxantrone in combination proliferation assays. In 
combination proliferation assays, Yanase K., et al. [150], reversed BCRP-mediated 
resistance in human myelogenous leukemia (K562/BCRP), BCRP-transduced murine 
lymphocytic leukemia (P388-BCRP) and in the endogenous BCRP expressing human 
colon (HT-29) cancer cell lines with gefitinib. They also demonstrated an increase in 
substrate accumulation in the presence of gefitinib and indicated that the agent may be 
a functional inhibitor of the BCRP transporter protein (using ATPase assays).  
The effect observed on BCRP protein expression by the three TKI’s differed 
according to their concentrations (figure 3.3.6.3.). Down-regulation with lapatinib 
occurred; however, a biological repeat was not fully consistent. Dai CL., et al. [147], 
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showed that lapatinib does not affect the mRNA or protein expression levels of BCRP 
in a BCRP-transfected colon cell line. In our hands, the expression of BCRP was up-
regulated with low concentrations of erlotinib but down-regulated at the higher 
concentration of 1 µM erlotinib. These mixed results may be explained by the nature 
of MDR proteins and the specificity of TKIs over a broad concentration range. As the 
concentration of the TKIs increases in the cell its activities become less specific 
which could inadvertently induce a stress response, inhibit or stimulate proteins, 
signalling pathways or transcription factors that regulate MDR protein expression and 
function. All three TKI’s significantly overcame BCRP-mediated resistance. This was 
expected for lapatinib [147] [97], erlotinib [148] and gefitinib [150] as they were shown to 
functionally inhibit BCRP using ATPase activity assays. Lapatinib caused the greatest 
effect, followed by erlotinib and finally gefitinib. The degree by which these TKI’s 
overcame BCRP-mediated resistance was substantial and could have significant 
implications in the treatment of BCRP-mediated resistant tumour. Their combination 
with BCRP substrate could significantly enhance the cytotoxic potential of the 
substrate, therefore increasing cell kill and improving treatment outcome. 
 
In summary, lapatinib sensitised both HER2-expressing cell lines, MDA-MB-453 
and MCF7, to chemotherapy treatment and overcame P-gp and BCRP mediated 
resistance to the greatest extent. However, lapatinib did not affect EGFR-expressing 
cells, while erlotinib inhibited both EGFR and BCRP to a greater extent than gefitinib. 
Thus, the use of lapatinib combined with P-gp substrates, such as epirubicin or 
docetaxel, or BCRP substrates, such as irinotecan, might decrease cell growth in 
tumours presenting an HER2 and/or MDR phenotype. Lapatinib may also enhance 
COX-2 expression and activity, therefore combining lapatinib with a COX-2 inhibitor 
could reduce tumour cell proliferation, angiogenesis, and metastasis and reduce the 
risk of later tumours presenting amplified levels of COX-2. The up-regulation of 
COX-2 protein expression and activity by lapatinib is not due to inhibition of EGFR 
and/or HER2. The combination of erlotinib or gefitinib with BCRP substrates, and 
potentially with a coxib, in EGFR+, BCRP+ and COX-2+ cells could be beneficial as 
many solid tumours co-express BCRP and COX-2 due to the hypoxic environment 
inside the tumour mass. Also introducing a coxib, such as celecoxib (also an MRP1 
inhibitor), into the combination would aid reduce the risk of the angiogenesis and 
metastasis. These combinations could have long term benefits in the treatment of 
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tumours commonly presenting intrinsic or acquired multidrug resistance, such as lung, 
digestive tract, lung, haemotopoeitic stem cells and brain tumours. In addition, these 
combinations might also prove beneficial in reducing solid tumour mass as BCRP [215] 
and COX-2 [428] expression is known to be upregulated in hypoxic conditions 
(observed in the solid tumours of ovarian, small-cell lung carcinoma, ewing sarcoma 
and prostate cancer).  
There are no clinical trials investigating the anti-MDR potential of lapatinib. However, 
the anti-cancer properties presented in this project provide strong backing to support 
moving forward to animal models and potentially clinical trial. Erlotinib has not 
reached anti-MDR clinical trials but the pharmacokinetics erlotinib-mediated BCRP 
inhibition was investigated in Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type 
mice [229]. They found that erlotinib is actively transported by P-gp and BCRP in vitro 
and the lack of P-gp/BCRP significantly increased the blood plasma concentration of 
both i.p. and p.o. administered erlotinib in mice [198]. Phase I and II clinical trials of 
gefitinib with irinotecan in patients with advanced fluoropyrimidine-refractory colon 
cancer have been completed but gefitinib did not appear to add substantial efficacy to 
irinotecan [419]. This combination did not result in increased side-effects (grade 3-4). 
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4.4. Relationship between the COX-2 inhibitor, celecoxib, and expression and 
function of Multidrug resistant proteins. 
 
Active components of the inflammatory response (COX-1 and COX-2 and their major 
metabolites) involved in tumour progression are frequently up-regulated in many 
cancer types. For review on this area see section 1.6. COX-1 is constitutively 
expressed in a wide variety of tissues and was been found to be over-expressed in 
breast [263], prostate [264], cervical [265] and ovarian [267] cancer. COX-2 on the other 
hand, is not detected in the majority of normal tissue but up-regulated in 80-90% of 
colorectal cancer [273], and is also commonly up-regulated in gastric [274], lung [275], 
prostate [264], breast, ovarian [276] [277], liver, bladder, osteosarcoma, melanoma [278] and 
bone cancer.  PGE2, a major metabolite of COX-2, has been shown to promote cell 
growth, inhibit apoptosis [239], increase angiogenesis [193] and enhance cell motility and 
adhesion [241] in vitro. COX-2 over-expression has been tentatively linked with poor 
prognosis, decreased survival and increased risk of re-occurrence in colorectal [286], 
ovarian [277] [287] and breast cancers [288]. 
   
A number of publications link COX-2 expression with multidrug resistance. For 
example, induced-COX-2 expression resulted in the enhancement in P-gp expression 
and functional activity in rat glomerular mesangial cells [326] and the breast cancer cell 
line, MCF7[328]. For review see section 1.6.3. and Sorkin A. [327]. Zatelli MC., et al. 
[175], provided evidence to support the hypothesis that the selective COX-2 inhibitor, 
NS-398, can prevent and reduce the development of the chemo-resistance phenotype 
in breast cancer cells by inhibiting P-gp function. Celecoxib, another selective COX-2 
inhibitor, induced apoptosis by down-regulating the expression of COX-2 and P-gp 
via a mechanism involving the Akt pathway. Recently, Mazzanti R., et al. [429], 
restored apoptosis by inhibiting P-gp with celecoxib. They found that P-gp was 
involved in the HGF/MET autocrine loop which leads to increased Bcl-2 and mTor 
levels, inhibition of eIF2α, resistance to apoptosis, progression of cell cycle.  
 On the other hand, Kang HK., et al. [174], showed that MRP1 expression was not 
necessarily due to the presence of COX-2, as induced COX-2 expression in the human 
H460 lung carcinoma cell line did not cause enhancement in MRP1 expression. Of 
further interest, they also showed that induced COX-2 expression did not increase P-
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gp expression, suggesting that the P-gp up-regulation observed may not be true for all 
cells/tissue types. In human colorectal CaCo-2 cells, 6 µM naproxen [96], 0.4 µM 
indomethacin heptyl ester [96] and 10 µM nimesulide [96] reduced the expression and 
function of the P-gp pump. Puhlmann U., et al. [330], showed that doxorubicin-induced 
MDR1 over-expression was down-regulated by the COX-2-preferential inhibitor, 
meloxicam, in both HL-60 and primary AML blasts with subsequent improvement of 
cytostatic efficacy of doxorubicin. They suggested that the mechanism of P-gp down-
regulation could be due to meloxicam directly inhibiting transcription factors, NF-
KappaB and AP-1, which are known to positively regulate mdr1 transcription. For 
review on this area see section. 1.4.5., 1.6. and 1.6.3. 
 
In this study, we established the effect celecoxib (above and below pharmacologically 
relevant concentrations) had on three multidrug resistance pumps, P-gp, MRP1 and 
BCRP. Firstly, we identified a panel of cell lines that only expressed one MDR 
protein (see section 3.4.1.). For example, DLKP-A expressed P-gp but does not 
express MRP1 or BCRP. Similar to finding published by Arunasree  KM., et al. [160], 
where they showed that 10 µM celecoxib exposure for 24 hours down-regulated the 
expression of P-gp in the imatinib-selected K562 lymphoma cell line, we found that 
with the same concentration of celecoxib with the same exposure time, that celecoxib 
slightly down-regulated the expression of P-gp in the paclitaxel-resistant lung cell line, 
H1299-Taxol (see figure 3.4.3.1.(i) and for method see section 2.11.). The 
pharmacological studies revealed that celecoxib is a paclitaxel selected-P-gp substrate 
and inhibitor of both doxorubicin and paclitaxel selected P-gp. Accumulation of the 
P-gp substrate, epirubicin, increased in the presence of celecoxib at and above 
pharmacological concentrations in both cell lines (graph 3.4.5.2., table 3.4.5.2. and for 
method sees section 2.12.2.1.), while the P-gp inhibitor, elacridar, increased celecoxib 
accumulation in the same cell line (graph 3.4.4.2 and table 3.4.4.2.). This would 
suggest that celecoxib inhibits the transport function of P-gp and is effluxed by P-gp. 
An increase in celecoxib accumulation in the presence of elacridar did not occur in the 
DLKP-A cells, which is most likely due to the extremely high expression levels of P-
gp in this cell line. Celecoxib was rapidly effluxed from both cell lines even in the 
presence of a functional inhibitor (graph 3.4.4.3.(B) and method in section 2.12.2.2.). 
This is most likely due to the expression of other mechanisms of efflux or 
experimental design. Keeping the pharmacological results in mind, it is not surprising 
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to find that celecoxib only slightly potentiated the anti-proliferative potential of two 
P-gp substrates, epirubicin and docetaxel, at and above pharmacologically relevant 
concentrations. This was observed in two of the three P-gp-expressing cell lines in our 
panel (graph 3.4.2.1., table 3.4.2.1. and method in section 2.7.1.). The inconsistency, 
for one of the cell lines, may be due to small nucleotide polymorphisms (SNP) 
differences [42] between the two drug selected-resistant cell lines and the transfected-
resistant cell line.  
 
Over-expression of MRP1 [349] and COX-2 but not P-gp [338] is frequently observed in 
lung cancers and has been associated with poor prognosis. Therefore, the second 
multidrug resistance protein we studied was MRP1. We found that only 10 μM 
celecoxib slightly reduced MRP1 expression (figure 3.4.3.1.(ii)). Partially consistent 
with these findings published work in this area found no alteration in MRP1 
expression with 5 μM but an 80% decrease in expression with 50 μM celecoxib in the 
same cell line, A549 [174].  
The pharmacological data strongly suggest that celecoxib inhibits the function of the 
MRP1 transporter protein. Celecoxib accumulation was increased 2 and 3 fold in the 
presence of sulindac sulphide, an MRP1 inhibitor, suggesting celecoxib may also be 
an MRP1 substrate (graph 3.4.4.2. and table 3.4.4.2.). However, contradicting with 
this point, the efflux of celecoxib occurred rapidly in the presence and absence of the 
MRP1 inhibitor (graph 3.4.4.3.(A)). There was a slight reduction in efflux at 60 
minutes and 120 minutes in the presence of sulindac sulphide in the DLKP cells but 
not in the 2008/MRP1 cells. This may be due to the low levels of MRP1 expression in 
the DLKP cells. This contradiction may, in part, be due to slow inhibition of MRP1 
by sulindac sulphide, but this fact has not been investigated. Looking at the efflux 
curve for shorter durations, between 0 and 30 minutes, would be the optimal method 
to determine if celecoxib is a substrate. Concentrations of 2 and 10 μM celecoxib 
increased the accumulation of the MRP1 substrate, epirubicin, in both of the MRP1-
expressing cell lines, DLKP and 2008/MRP1 (graph 3.4.5.1.). In this case, the effect 
was 3 fold greater in the 2008/MRP1 cells compared to the DLKP cells. This 
significant increase (p = 0.008 and 0.002) in epirubicin accumulation was 2 fold 
greater than the effect observed in the P-gp-expressing cells. To date, publications in 
this area demonstrated that 50 and 100 μM celecoxib increases doxorubicin 
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accumulation following a 16 hour pre-treatment and enhances doxorubicin sensitivity 
in the A549 cells after 48hrs [174]. In this project, the dose of celecoxib used is at 
levels achievable in the blood which is 5 to 10 times lower than used by Kang HK., et 
al. [174], therefore, this work stands apart from their experiments. The pharmacological 
data indicates that celecoxib may be a weak substrate and is a direct functional 
transport inhibitor of MRP1. Therefore, it was not unexpected to find that celecoxib 
significantly enhanced the cytotoxicity of the two MRP1 substrates (epirubicin and 
vincristine) in all three MRP1-expressing cell lines (graph 3.4.2.2., table 3.4.2.2. and 
also see section 8, graph 8.4.2.1 and table 8.4.2.1.). Celecoxib did not alter the 
cytotoxicity of the two MRP1 non-substrates, docetaxel and 5FU, thus re-enforcing 
the statement that celecoxib overcomes MRP1-mediated resistance and that the 
mechanism of action is most likely through functional inhibition of the MRP1 
transporter protein. Also, the enhancement in substrate cytotoxicity, during the 
combination proliferation assays, by celecoxib was significantly greater in the MRP1-
expressing cells compared to the P-gp-expressing cells. As the anti-proliferative 
enhancement was observed at and below pharmacologically relevant concentrations 
and the cellular pharmacokinetic assays were conducted over 3 hours, the mechanism 
by which celecoxib overcomes MRP1-mediated resistance is unlikely to be through 
protein down-regulation (figure 3.4.3.1.(ii)) as protein down-regulation only occurred 
above pharmacologically relevant concentrations and over longer time periods. 
Therefore, this novel finding indicates that celecoxib is a functional inhibitor and 
weak substrate of MRP1 and thus overcomes MRP1-mediated resistance. The degree 
of inhibition by celecoxib in the MRP1-expressing cell lines was significantly larger 
than compared that of the P-gp-expressing cell lines. The inhibition of MRP1 activity 
by celecoxib has two potential clinical applications, firstly sensitising MRP1-
mediated multidrug resistance tumours to substrate chemotherapeutics, and secondly, 
improving the bioavailability of orally administered MRP1 substrate anti-cancer 
agents. These results would suggest that the combination of celecoxib with epirubicin 
or vincristine warrants clinical investigation in cancer. 
 
In 2008, Surowiak P., et al.  [329], studied the correlation of COX-2, P-gp, MRP1 and 
BCRP expression in non-small cell lung carcinoma (NSCLC) in a cohort of 32 
patients. They discovered that even though there was a very strong correlation 
between COX-2, P-gp and BCRP expression it had little prognostic value for 
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predicting outcome. However, this strong correlation prompted us to investigate the 
potential that celecoxib could additionally cause inhibition of BCRP-mediated drug 
resistance. Therefore, we carried out the same list of experiments as with P-gp and 
MRP1 in two BCRP expressing cell lines, DLKP-SQ/mitox (mitoxantrone-selected) 
and HL60/mxr (BCRP-transfected). Celecoxib had a mixed impact on BCRP protein 
expression (see figure 3.4.3.1.(iii)). At low levels, it appeared to increase expression, 
while at higher concentrations, BCRP protein expression was reduced. These mixed 
results may be explained by the nature of MDR proteins and the specificity of 
celecoxib over a broad concentration range. As the concentration of the small 
molecule agent increases in the cell its activities become less specific which could 
inadvertently induce a stress response, inhibit or stimulate proteins, signalling 
pathways or transcription factors that regulate MDR protein expression and function. 
Elacridar, a highly effective P-gp and BCRP functional inhibitor, caused a 2 fold 
increase in celecoxib accumulation in DLKP-SQ/mitox (p<0.05) and HL60/mxr 
(p>0.05) cells (see graph 3.4.4.2.). Once again celecoxib was promptly effluxed from 
both BCRP-expressing cell lines within 30 minutes (graph 3.4.4.3.). However, 2 μM 
celecoxib enhanced epirubicin accumulation by 1.7 fold (P = 0.009) in the DLKP-
SQ/mitox cells (graph 3.4.5.3. and table 3.4.5.3.). The BCRP mutation status of this 
cell line is unknown, the enhanced accumulation of epirubicin in the presence of 
celecoxib could suggest that this cell line expresses the BCRP mutant form (see 
section 1.4.4.). This would suggest that celecoxib is also a weak substrate and 
inhibitor of BCRP. The combination proliferation assay of celecoxib and SN-38 
confirmed this statement (graph 3.4.2.3. and table 3.4.2.3). At and above 
pharmacological concentrations (2 µM), celecoxib heightened the anti-proliferative 
potential of SN-38 in both of the BCRP-expressing cell lines, DLKP-SQ/mitox and 
HL60/mxr (graph 3.4.2.3. and table 3.4.2.3). Combining the protein expression work, 
the pharmacological data and the proliferation assay results, it is clear celecoxib is a 
weak substrate and inhibitor of BCRP at the pharmacological concentration of 2 μM 
and is a weak substrate, inhibitor and protein down-regulator at the higher 
concentration of 10 μM. This finding has not been noted in existing literature.  
MDR inhibition by celecoxib was the greatest in MRP1-expressing cell lines, 
followed closely by BCRP-expressing cell lines and to a much lesser extent by the P-
gp-expressing cell lines. The inhibition of BCRP activity by celecoxib has two 
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potential clinical applications, firstly sensitising BCRP-mediated multidrug resistance 
tumours to substrate chemotherapeutics and secondly improving the bioavailability of 
orally administered BCRP substrate anti-cancer agents. These results would suggest 
that the combination of celecoxib with irinotecan warrants clinical investigation in 
cancer. 
 
In summary, celecoxib maybe a weak substrate of MRP1 and BCRP and inhibits the 
function of MRP1 and BCRP in these cell lines. Celecoxib is also a weak substrate 
and inhibitor of P-gp but not at pharmacologically relevant concentrations. 
The uptake of celecoxib is heightened in the presence of the appropriate MDR 
inhibitor in all cell lines. Celecoxib slightly down-regulated MDR protein expression 
at 10 μM but this did not occur at achievable serum concentrations. The drug was 
rapidly removed from all cells within 30 minutes and increased MDR substrate 
accumulation in all cell lines. MDR substrate accumulation in the presence of 
celecoxib is particularly large in MRP1-expressing cells. Celecoxib enhanced the 
cytotoxic potential of MRP1 substrates the greatest extent, followed by BCRP and 
finally P-gp substrates. This evidence indicates that the combination of celecoxib with 
MRP1 or BCRP substrate chemotherapeutic drugs could potentially decrease tumour 
growth through direct pump inhibition and possibly through substrate competition. 
Tumours previously treated for prolonged periods with a traditional chemotherapy 
presenting MRP1 or BCRP phenotype along with COX-2 over-expression might be 
the best target for such therapy. The rationale behind this combination of traditional 
chemotherapy and the selective COX-2 inhibitor is further supported by the fact that 
chemotherapy itself induces COX-2 expression.  
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4.5. Overall summary and conclusion: 
 
Pharmacokinetics of Epirubicin 
• Serum transport proteins alter epirubicin accumulation in cancer and normal cells. 
• Low levels of serum albumin and FCS aid epirubicin accumulation, but high 
levels hinder epirubicin accumulation. 
• α1-acidic glycoprotein (AAG) enhances the accumulation of epirubicin to the 
greatest extent.  
• Serum proteins do not alter epirubicin accumulation differently in normal versus 
cancer cells. 
Screening of potential novel anti-cancer agents 
• Cytotoxicity of the polyamine derivative, PA1, and the titanium compound, 
Titanocene Y, are independent of P-gp expression and activity in the DLKP-A cell 
line. 
• The fluorinated resveratrol derivative, RBM15, and the hydrolysed macrocyclic 
compound, KG104, overcome P-gp-mediated resistance in the DLKP-A cell line. 
MDR downregulation 
• Drugs dynamically alter MDR protein expression and understanding the pathways 
and transcription factors they inhibit or stimulate can help predict their effect. 
• The use of small molecule agents to overcome MDR-mediated resistance is most 
effective in combination with MDR substrate cytotoxics. 
• 17-AAG overcomes BCRP-mediated resistance and down-regulates its protein 
expression. 
• As previously published; lapatinib, gefitinib, 17-AAG and elacridar overcome P-
gp and BCRP-mediated resistance and could improve the bioavailability of orally 
administered. 
• Sulindac sulphide overcame MRP1-mediated resistance. 
• Agents can be inhibitors, down-regulator and up-regulators of MDR transporter 
proteins. 
• When using protein down-regulation as a mechanism of overcoming MDR in both 
in vitro and in vivo systems, a continuous exposure to the modulator is required to 
maintain the alteration. 
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Interactions of TKI activity  
• Lapatinib sensitises HER2-expressing cells to chemotherapy in the presence or 
absence of EGFR expression in breast cancer cell lines. 
• Lapatinib up-regulates the COX-2 protein expression and activity while also 
directly stimulating COX-2 activity in A549 cells. Its activity is independent of 
EGFR/HER2 tyrosine kinase inhibition. 
• Lapatinib overcomes P-gp-mediated resistance to a greater extent than erlotinib or 
gefitinib. 
Celecoxib interaction with MDR 
• Celecoxib is a weak substrate for MRP1, BCRP and P-gp. 
• Celecoxib down-regulates the expression of MRP1 and P-gp above plasma 
concentrations. 
• Celecoxib inhibits MRP1 the greatest, followed closely by BCRP and to a much 
lesser degree P-gp, below plasma concentrations.  
 
Considering novel results reported in this thesis, a number of drug combinations, 
which could potentially be therapeutically beneficial in the clinic, for targeting 
multiple oncoproteins and cell signalling pathway come to light: 
• The concurrent combination of lapatinib and celecoxib or sulindac with a P-
gp, MRP1 or BCRP chemotherapeutic substrate. This targets P-gp, MRP1, 
BCRP, COX-2 and HER2. 
• The concurrent combination of erlotinib and celecoxib or sulindac with P-gp, 
MRP1 or BCRP chemotherapeutic substrate. This targets P-gp, MRP1, BCRP, 
COX-2 and EGFR. 
• The concurrent combination of gefitinib and celecoxib or sulindac with a P-gp, 
MRP1 or BCRP chemotherapeutic substrate. This targets P-gp, MRP1, BCRP, 
COX-2 and EGFR. 
• The concurrent combination of 17-AAG with irinotecan or another BCRP 
substrate.  
• The concurrent combination of 17-AAG, lapatinib, celecoxib/sulindac with a 
P-gp, MRP1 or BCRP chemotherapeutic substrate. This targets all three MDR 
transporter proteins, COX-2, HER2 as well as heat shock protein 90. 
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Conclusion 
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5.1. Novel Compounds 
 
Sixty one novel compounds were tested for their anti-cancer and anti-MDR potential 
in the two non-small cell lung carcinoma cell lines, DLKP and DLKP-A. 
 
The polyamine compounds did not overcome MRP1 and P-gp-mediated drug 
resistance in the DLKP and DLKP-A cell lines. 
 
The ditrifluoroacetyl resveratrol derivative, RMB15, and the open hydrolysed 
macrocycle compounds, KG104, are potentially modulators of P-gp, as shown in the 
DLKP-A cell line and could be therapeutically important. 
 
The metallic agent, Titanocene Y, did not enhance the cytotoxic potential of MRP1 or 
P-gp cytotoxic substrates in the DLKP or DLKP-A cell lines. It has similar toxicity in 
both cell lines. Titanocene Y’s cytotoxicity is independent of MDR expression which 
could be of significant therapeutic relevance similar to that of other metal-based anti-
cancer agents. 
 
Encapsulation of daunorubicin with a nano-particulate polymer was unsuccessful at 
evading pump-mediated efflux from MRP1 and P-gp-expressing cell models, DLKP 
and DLKP-A. However, there is strong evidence in favour of long-term retention of 
significant quantities of daunorubicin in the nano-particulate carrier in the cellular 
environment, if not within the cells themselves. This is of particular interest to 
researchers in the area of delivery development.   
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5.2. MDR down-regulation 
Indomethacin and 17-AAG down-regulated the expression of P-gp in the A549-Taxol 
cell line but do not overcome P-gp-mediated resistance. Lapatinib, erlotinib, gefitinib, 
sulindac sulphide and elacridar up-regulate P-gp protein expression. 
 
Lapatinib, sulindac sulphide and 17-AAG down-regulate MRP1 protein expression in 
the A549 cell line. MRP1 expression recovers following removal of lapatinib or 17-
AAG. MRP1 protein reduction by sulindac sulphide is sustained for 48 hours. 
Sulindac sulphide overcame MRP1-mediated resistance in combination proliferation 
assays but not in scheduled proliferation assays. Lapatinib and 17-AAG did not 
overcome MRP1-mediated resistance. Erlotinib, gefitinib, ibuprofen, indomethacin 
and elacridar up-regulate MRP1 protein expression. 
 
Gefitinib, indomethacin and 17-AAG down-regulate the expression of BCRP in the 
DLKP-SQ/mitox cell line. Down-regulation by gefitinib and 17-AAG is sustained for 
48 hours following drug removal and both agents overcome BCRP-mediated 
resistance in the combination and scheduled proliferation assays. Indomethacin down-
regulation recovered within 48 hours and it did not overcome BCRP-mediated 
resistance. Lapatinib and elacridar did not down-regulate the expression of BCRP but 
significantly overcame BCRP-mediated resistance in both the combination and 
scheduled proliferation assays. Sulindac sulphide up-regulated BCRP protein 
expression while erlotinib, celecoxib and ibuprofen up- and down-regated BCRP 
protein expression depending on their concentration. 
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Key take-home points from MDR down-regulation experiments: 
8. 17-AAG down-regulates BCRP protein expression and overcome BCRP-
mediated resistance. 
9. Drugs can dynamically effect MDR protein expression 
10. A single drug can differentially alter the expression of MDR proteins; 
therefore, understanding mechanisms of regulations for each MDR protein is 
important.  
11. For the small molecule agents tested, combination therapy is the optimum 
treatment regimen. 
12. Full and permanent eradication of MDR protein expression that is stable in the 
presence of chemotherapeutic drugs is essential when considering a 
combination or pre-treatment schedule.  
13. Agents can be inhibitors, down-regulator and up-regulators of MDR 
transporter proteins. 
14. When using protein down-regulation as a mechanism of overcoming MDR in 
both in vitro and in vivo systems, a continuous exposure to the modulator is 
required to maintain the alteration. 
 
 
5.3. Pharmacokinetics of epirubicin 
 
FCS and albumin causes a dose dependent reduction in free epirubicin. At low protein 
levels the binding epirubicin with FCS or serum albumin enhance epirubicin 
accumulation but high protein levels hinder epirubicin accumulation in all cell types. 
Binding to α1-acid glycoprotein also enhances epirubicin accumulation in all cell 
types. Therefore, serum albumin and α1-acid glycoprotein improve the availability of 
epirubicin to both normal and cancer cells. The true impact of AAG on anthracycline 
accumulation requires further investigating using AAG levels up to 280-fold higher.  
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5.4. Tyrosine kinase inhibitors 
 
Lapatinib sensitises HER2 over-expressing cells to chemotherapy in the presence or 
absence of EGFR expression. Lapatinib slightly increases HER2 expression but 
reduced its active levels and does not alter EGFR expression or active levels. 
Lapatinib up-regulates the expression and function of COX-2 and down-regulates the 
expression of COX-1 protein but up-regulates its activity. This action is independent 
of EGFR and HER2 TKI inhibition but more likely due to the non-specific activities 
of lapatinib. Further work is needed to evaluate the possibility that COX inhibitors 
could sensitise breast cell lines to lapatinib. Lapatinib increases P-gp and BCRP 
protein expression and overcomes P-gp and BCRP-mediated resistance in the A549-
Taxol and DLKP-SQ/mitox cell lines. Compared to erlotinib and gefitinib, lapatinib is 
the most potent inhibitor of P-gp and BCRP. 
 
Erlotinib sensitises moderately-expressing EGFR/HER2 cells to chemotherapeutic 
drug to a greater extent than either lapatinib or gefitinib. Erlotinib down-regulates 
COX-2 protein expression. Erlotinib up-regulates the expression of P-gp, MRP1 and 
BCRP and in the DLKP-SQ/mitox cell line, overcomes BCRP-mediated resistance.  
Gefitinib down-regulates the expression of COX-2 and BCRP while up-regulating the 
expression of P-gp and MRP1. Gefitinib significantly overcomes BCRP-mediated 
resistance.  
 
5.5. Celecoxib overcomes MDR resistance. 
 
Pharmacological and proliferation assays indicate that celecoxib is a weak substrate 
and inhibitor of P-gp, MRP1 and BCRP. Celecoxib strongly overcomes MRP1 and 
BCRP-mediated resistance. Celecoxib also overcomes P-gp-mediated resistance but 
only non-pharmacologically relevant concentrations. Celecoxib reduces P-gp, MRP1 
and BCRP protein expression at a concentration of 10 µM. Lower doses have no 
effect on their expression levels. The concurrent use of celecoxib with an MRP1 or 
BCRP substrate chemotherapeutic drug could be of value for the treatment of many 
tumours present multiple phenotypes (co-expression of COX-2 and MDR) and also 
because long-term treatment with chemotherapy often increases COX-2 expression. 
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Future plans 
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6.1. Modulation of Multidrug resistance 
 
• Perform Western blotting to determine changes in P-gp expression, 
combination proliferation assays, P-gp substrate pharmacokinetic studies and 
ATPase assays to establish the nature of P-gp modulation by RBM-15 and 
KG104.  
 
• The effects of RMB-15 and KG104 on the ATPase activity of other drug 
transporters, i.e. BCRP, MRP-2, 3 and 4, to develop a transporter profile. 
 
• To expand on design and characterisation of the nano-particle polymer and to 
perform detailed in vitro examinations with other tumour cell lines and in vivo 
examinations on systemic drug toxicity of the new formulations. 
 
• Perform Western blotting including more time points to determine changes in 
BCRP expression, combination proliferation assays with more substrates, 
BCRP substrate pharmacokinetic studies, confocal imaging of substrate 
accumulation and ATPase assays to establish the nature of BCRP modulation 
by 17-AAG. 
 
• Identify a small molecule agent that causes full and stable eradication of MDR 
protein expression for pre-treatment schedule.  
 
6.2. Pharmacokinetics of epirubicin 
 
• Determine the amount of epirubicin bound to 280-fold higher α1-acid 
glycoprotein and accumulation assays to show its affect on the availability of 
epirubicin to the normal and cancer cells. 
 
• To determine if serum albumin and α1-acid glycoprotein affect the cytotoxicity 
of epirubicin, carry out apoptosis assay with DLKP, MCF7 and HMEC cells in 
presence of varying levels of FBS, serum albumin and α1-acid glycoprotein in 
serum-free media over a 3 day period.  
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• To identify, a possible link between serum albumin/α1-acid glycoprotein blood 
levels and patient outcome following anthracycline treatment. Check the levels 
of serum albumin, and anthracyclines in patient’s blood samples. 
 
6.3. Tyrosine kinase inhibitors 
 
• Further combination proliferation assay of the three tyrosine kinase inhibitors 
with a broader range of chemotherapeutic drugs in a larger panel of EGFR and 
HER2-amplified breast cell lines.  
 
• Pharmacokinetics studies to determine if serum protein levels alter the 
availability of tyrosine kinase inhibitors to cancer cells. 
 
• Determine if A549 cells produce TNFα, IL-1B or EGF in culture, and if the 
addition of TNFα, IL-1B or EGF to proliferating A549 cells changes the affect 
of lapatinib on this enhanced COX-2.  
 
• Determine if a lapatinib-selected cell line expresses COX-2. Examine whether 
celecoxib can prevent COX-2 induction. Identify changes in the MDR and 
invasive status, including MMP production. Check for senescence. 
 
6.4. Celecoxib, the MDR modulator 
 
• COX activity assays, in the presence of celecoxib, on lysates that have been 
treated with lapatinib for 48 hours.  
 
• Combination proliferation assays of lapatinib with celecoxib in breast cell 
models with induced (transfected) COX-2 expression, that are sensitive and 
insensitive to lapatinib.   
 
 285
• Determine if the enhancement of P-gp substrate cytotoxicity by celecoxib is 
due to P-gp inhibition or induction of apoptosis via P-gp involvement in the 
HGF/MET autocrine loop.  
 
• The effects of celecoxib on the ATPase activity of MRP1, P-gp or BCRP, to 
conclusively determine if celecoxib is a functional inhibitor or substrate of 
these MDR transporter proteins. 
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8.1. Screening of potential novel anti-cancer agents 
 
8.1.1. Polyamine derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 8.1.1.1.: The combination proliferation assays of spermine (A and B) or PA1 
(C and D) with varying concentrations of epirubicin in the DLKP (A and C) and 
DLKP-A (B and D) cell lines. This graph is the result of a single determination. 
 
8.1.2. Resveratrol Analogues 
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Graph 8.1.2.1.: The combination of resveratrol or RBM15 with the MRP1 substrate, 
epirubicin, in the DLKP cell line (MRP1 expressing cell line). The bar chart is the 
result of a single assay. 
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8.1.3. Macrocycle compounds 
KG104 instability testing
0
20
40
60
80
100
120
E
pi
 0
.5
uM
K
G
10
4 
10
uM
or
ig
in
al
K
G
10
4 
25
uM
 n
ew
ba
tc
h
K
G
10
4 
10
uM
 n
ew
ba
tc
h 
in
15
%
tw
ee
n/
et
ha
no
l
et
ha
no
l
15
%
 tw
ee
n/
et
ha
no
l
D
M
S
O
C
el
l P
ro
lif
er
at
io
n(
%
)
Alone
Combination
 
Graph 8.1.3.1: Cell proliferation associated with different KG104 batches, ethanol, 
DMSO and 15% tween80/ethanol (v/v) with epirubicin in the DLKP-A cell lines. This 
graph is the result of a single assay. Table 8.1.3.6 below depict the percentage cell 
proliferation and standard deviations for this graph. 
 
Table 8.1.3.1: This table provides the combination data of epirubicin with a range 
KG104 batches and their vehicles. 
Compounds Cell Proliferation (%) 
 Alone St Dev (%) Combination St Dev (%) 
Epirubicin 0.5µM 90 ±5   
KG104 10µM original 98 ±3 21 ±2 
KG104 25µM new batch 97 ±3 52 ±6 
KG104 10µM new batch in 
15%tween/ethanol 
97 ±2 22 ±0.8 
Ethanol 100 ±5 99 ±3 
15% tween80/ethanol 99 ±2 20 ±5 
DMSO 100 ±2 100 ±1 
 
KG104 variability in toxicity findings 
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8.1.6. MDR down-regulation 
8.1.6.1. P-gp downregulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 8.1.6.1.1.: The short-term treatment with A549-Taxol cells to indomethacin 
(A) or 17-AAG (B). The cells (at a density of 5×104 cells/ml) were exposed to each 
drug for 24 hours and the cell proliferation was determined at this point (0 (  )), 24 (■) 
and 48 hours (Δ) later. Each graph is the result of a single assay. 
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8.1.6.2. MRP1 down-regulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 8.1.6.2.1.: The short-term treatment of A549 cells with lapatinib (A), sulindac sulphide (B) or 17-AAG (C). The cells (at a density of 
5×104 cells/ml) were exposed to each drug for 24 hours and the cell proliferation was determined at this point (0 (  )), 24 (■) and 48 hours (Δ) 
later. Each graph is the result of a single assay. 
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8.1.6.3. BCRP down-regulation 
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Graph 8.1.6.3.1.: The short-term treatment of DLKP-SQ/mitox cells with lapatinib (A), gefitinib (B), indomethacin (C), elacridar (D) or 17-
AAG (E). The cells (at a density of 5×104 cells/ml) were exposed to each drug for 24 hours and the cell proliferation was determined at this 
point (0 (  )), 24 (■) and 48 hours (Δ) later. Each graph is the result of a single assay. 
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8.3. Effect of tyrosine kinase inhibitors on the function and expression of 
epidermal growth factor receptors, EGFR and HER2, multidrug resistance 
transporter and cyclooxygenase proteins. 
8.3.2. EGFR and phospho-EGFR protein quantification by ELISA 
 
In section (3.3.1.) we found that lapatinib had no effect on the toxicity of epirubicin or 
docetaxel in the EGFR, HER2 or dual EGFR/HER2 expressing breast cell lines. In 
this section and in section 8.3.3., we quantified the effect lapatinib had on the 
expression and activation levels of EGFR and HER2/ErbB2. Quantitation employed 
ELISA assays. The EGFR and pEGFR ELISAs were carried out on MDA-MB-231 
cell lysates while the ErbB2 and pErbB2 ELISAs were carried out on MDA-MB-453 
cell lysates. The MDA-MB-231 cells were exposed to lapatinib (2.5, 5 and 10 µM), 
EGF (10, 50 and 100 ng/ml) and DMSO (0.5 and 1 %) for 48 hours. 
 
In the EGFR-amplified MDA-MB-231 cell line, we found that lapatinib had no effect 
on EGFR expression or active levels at 12 hours but caused a slight increase in both at 
24 and 48 hours (see graph 8.3.2.1.A and table 8.3.2.1.A). Lapatinib’s control, DMSO, 
caused no changes in EGFR expression or active levels at 12 and 24 hours but a slight 
increase at 48 hours (see graph 8.3.2.1.C and table 8.3.2.1.C).  
EGF slightly decreased EGFR expression but greatly increased levels of 
phosphorylated EGFR (i.e. activity levels). The greatest increase in activation was 
seen after 12 hours (graph 8.3.2.1.B and table 8.3.2.1.B). 
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Graph 8.3.2.1: This set of graphs show the levels of EGFR and phosphor-EGFR in 
the MDA-MB-231 cell line following exposure to the tyrosine kinase inhibitor, 
Lapatinib (A), the EGFR ligand, EGF (B) and as a control, DMSO (C) for 12hrs (  ), 
24hrs (■) and 48hrs (Δ).  The data is representative of duplicate intraday results. The 
tables below provide the raw data illustrated in these graphs.  
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Table 8.3.2.1.A: This table outlines the expression levels of EGFR (pg/µg Total 
Protein) and pEGFR (pg/µg Total Protein) in MDA-MB-231 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of lapatinib. This data is illustrated in 
graph 8.3.2.1.A. 
 
Lapatinib (µM) 
12hr EGFR (pg/µg 
Total Protein) 
StDev pEGFR (pg/µg 
Total Protein) 
StDev 
0 575 ±65 1475 ±71 
2.5 457 ±10 1387 ±159 
5 491 ±15 1325 ±106 
10 559 ±42 1463 ±53 
24hr     
0 826 ±73 713 ±53 
2.5 995 ±52 788 ±194 
5 925 ±71 763 ±88 
10 864 ±27 763 ±18 
48hr     
0 551 ±11 575 ±106 
2.5 590 ±6 613 ±18 
5 549 ±2 650 ±71 
10 620 ±25 1038 ±124 
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Table 8.3.2.1.B: This table outlines the expression levels of EGFR (pg/µg Total 
Protein) and pEGFR (pg/µg Total Protein) in MDA-MB-231 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of EGF. This data is illustrated in 
graph 8.3.2.1.B. 
 
EGF (ng/ml) 
12hr EGFR (pg/µg 
Total Protein) 
Stdev pEGFR (pg/µg 
Total Protein) 
Stdev 
0 605 ±81 1850 ±0 
10 507 ±8 4200 ±0 
50 525 ±17 6450 ±106 
100 499 ±62 6275 ±247 
24hr     
0 490 ±21 1575 ±141 
10 490 ±44 2213 ±159 
50 450 ±12 4388 ±124 
100 410 ±12 4100 ±283 
48hr     
0 358 ±50 2013 ±159 
10 286 ±10 2013 ±230 
50 370 ±60 3250 ±106 
100 298 ±12 3588 ±124 
 
 322
Table 8.3.2.1.C: This table outlines the expression levels of EGFR (pg/µg Total 
Protein) and pEGFR (pg/µg Total Protein) in MDA-MB-231 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of DMSO. This data is illustrated in 
graph 8.3.2.1.C. 
 
DMSO (%) 
12hr EGFR (pg/µg 
Total Protein) 
Stdev pEGFR (pg/µg 
Total Protein) 
Stdev 
0 575 ±65 1475 ±71 
0.5 501 ±10 1638 ±53 
1 423 ±15 1563 ±265 
24hr     
0 826 ±73 712 ±53 
0.5 823 ±27 575 ±0 
1 759 ±48 650 ±0 
48hr     
0 551 ±12 575 ±106 
0.5 588 ±10 925 ±71 
1 721 ±60 900 ±0 
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8.3.3. ErbB2 and phospho-ErbB2 protein quantification by ELISA 
 
As discussed in section 3.3.2 above, in this section we assessed the impact lapatinib 
had on the expression and activation levels of ErbB2.  
 
The presence of lapatinib in MDA-MB-453 ErbB2-overexpressing cells resulted in a 
slight increase in ErbB2 expression and moderate decrease in its active level (graph 
8.3.3.1.A and table 8.3.3.1.A.). DMSO caused a slight decrease at 12 and 24 hours but 
increased expression at 48 hours (graph 8.3.3.1.C and table 8.3.3.1.C). Similar to 
lapatinib, DMSO caused a slight decrease in the activity levels of ErbB2 and any 
effect at 48 hours can be eliminated by large error bars. However, the decrease in 
activity caused by lapatinib at 12 and 24 hours was greater than that of DMSO but no 
change at 48 hours. 
 
EGF caused a slight increase in ErbB2 expression at 48 hours and activity at 12 and 
24 hours. However, at 48 hours there was a sharp drop in pErbB2 present (graph 
8.3.3.1.B and table 8.3.3.1.B.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 324
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 8.3.3.1: This set of graphs show the levels of ErbB2 and phosphor-ErbB2 in 
the MDA-MB-453 cell line following exposure to the tyrosine kinase inhibitor, 
Lapatinib (A), the EGFR ligand, EGF (B) and as a control, DMSO (C) for 12hrs (  ), 
24hrs (■) and 48hrs (Δ).  The data is representative of duplicate intraday results. The 
tables below provide the raw data illustrated in these graphs.  
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Table 8.3.3.1.A: This table outlines the expression levels of ErbB2 (pg/µg Total 
Protein) and pErbB2 (pg/µg Total Protein) in MDA-MB-453 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of lapatinib. This data is illustrated in 
graph 8.3.3.1.A. 
 
Lapatinib treatment (µM) 
12hr ErbB2 (pg/ug 
Total Protein) 
StDev pErbB2 (pg/ug 
Total Protein 
StDev 
0 134 ±35 1925 ±912 
2.5 147 ±18 930 ±85 
5 259 ±71 840 ±0 
10 259 ±35 1370 ±311 
24hr     
0 172 ±17 2115 ±304 
2.5 222 ±53 2095 ±262 
5 297 ±53 2730 ±240 
10 334 ±0 1390 ±141 
48hr     
0 309 ±35 1795 ±856 
2.5 496 ±17 2175 ±120 
5 509 ±35 1935 ±134 
10 397 ±17 2370 ±651 
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Table 8.3.3.1.B: This table outlines the expression levels of ErbB2 (pg/µg Total 
Protein) and pErbB2 (pg/µg Total Protein) in MDA-MB-453 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of EGF. This data is illustrated in 
graph 8.3.3.1.B. 
 
EGF Treatment (ng/ml) 
12hr ErbB2 (pg/µg 
Total Protein) 
StDev pErbB2 (pg/µg 
Total Protein) 
StDev 
0 147 ±18 1525 ±714 
10 122 ±18 1955 ±474 
50 147 ±18 2165 ±573 
100 134 ±0 2065 ±191 
24hr     
0 159 ±0 775 ±64 
10 209 ±0 1080 ±651 
50 134 ±0 1320 ±721 
100 134 ±35 1560 ±891 
48hr     
0 159 ±35 1875 ±64 
10 222 ±18 1385 ±262 
50 247 ±18 805 ±7 
100 234 ±2 1195 ±148 
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Table 8.3.3.1.C: This table outlines the expression levels of ErbB2 (pg/µg Total 
Protein) and pErbB2 (pg/µg Total Protein) in MDA-MB-453 following a 12hr, 24hr 
and 48hr exposure to increasing concentrations of DMSO. This data is illustrated in 
graph 8.3.3.1.C. 
 
DMSO Control (%) 
12hr ErbB2 (pg/µg 
Total Protein) 
StDev pErbB2 (pg/µg 
Total Protein) 
StDev 
0 134 ±35 1925 ±912 
0.5 84 ±35 1650 ±948 
1 97 ±53 1455 ±615 
24hr     
0 172 ±17 2115 ±304 
0.5 84 ±35 2135 ±332 
1 172 ±53 1985 ±78 
48hr     
0 309 ±35 1795 ±856 
0.5 509 ±0 2170 ±750 
1 409 ±35 2015 ±559 
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8.4. Relationship between the COX-2 inhibitor, celecoxib, and expression and 
function of Multidrug resistant proteins. 
 
8.4.2. Effect of celecoxib on the inhibition of multidrug resistance transporter 
proteins. 
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Graph 8.4.2.1.: Combination of epirubicin (□) or vincristine (VNC; ▲) with 
celecoxib (  ) in the A549 cell line. This proliferation assay involved the combination 
of one of 2 chemotherapeutic agents with celecoxib in a moderately expressing MRP1 
cell line over a 5 day period. This graph is the result of a single determination with 
standard deviations, for that day, presented as error bars. Statistically significant 
(p<0.05) results are indicated by (*). Table 8.4.2.1 below depicts the percentage cell 
proliferation and standard deviations for this graph.  
 
 
Table 8.4.2.1.: The percentage cell proliferation and standard deviations for the 
combination proliferation assays of epirubicin or vincristine with celecoxib in the 
MRP1-expressing cell lines, A549. This table is illustrated in graph 8.4.2.1. 
 Cell Proliferation (%) 
Celecoxib (µM) 0 StDev 
(%) 
0.5 StDev 
(%) 
2 StDev 
(%) 
5 StDev 
(%) 
10 StDev 
(%) 
Celecoxib 100 ±0 99 ±0 97 ±0 96 ±0 86 ±2 
Cele + 10nM Epi 90 ±2 89 ±1 72 ±7 53 ±3 36 ±2 
Cele + 1nM Vinc 69 ±5 68 ±7 33 ±4 22 ±5 13 ±6 
 
*
*
**
* *
 β-actin (48kDa) 
Abbreviations 
 
17-AAG  17-(Allylamino)-17-demethoxygeldanamycin 
5-Fu   5-Fluorouracil 
AAG   α1-acid glycoprotein 
ABC   ATP-Binding Cassette 
ADE   Absorption, distribution and elimination 
ADE2   Cytarabine, daunorubicin and etoposide combination 
ADP   Adenosine Diphosphate 
ADR   Adriamycin 
AML   Acute myeloid leukemia 
ATCC   American Tissue Culture Collection 
ATP   Adenosine Triphosphate 
AUC   Area under the curve 
BCA  ` Bicinchoninic Acid 
BCRP   Breast Cancer Resistance Protein 
BSA   Bovine Serum Albumin 
cDNA   Complementary DNA 
CIN   Cervical intraepithelial neoplasia 
COX   Cyclooxygenase 
COX-1/-2  Cyclooxygenase-1/-2 
C.P.M.   Counts Per Minute 
DMEM   Dulbecco’s Minimum Essential Medium 
DMFO   2-(difluoromethyl) ornithine 
DMSO   Dimethyl Sulfoxide 
DNA    Deoxyribonucleic Acid 
DOX   Doxorubicin (adriamycin) 
EDTA   Ethylene diamine tetracetic acid 
EGFR   Epidermal growth factor receptor 
ELISA   Enzyme-linked Immunosorbant Assay 
ERK   Extracellular signal-Regulated Kinase 
ET   Endothelin 
FCS   Fetal Calf Serum 
FDA   Food and Drug Administration 
GIT   Gastorintestinal tract 
GSH   Glutathione 
HBV   Hepatitis B  
HCV   Hepatitis C 
HCL   Hydrochloric Acid 
HCC   Hepatocellular carcinoma 
HGF   Hepatocyte growth factor 
HEPES   4-(2-hydroxyethyl)-piperazine ethane sulphonic acid 
HPLC   High Performance Liquid Chromatography 
Hsp90   Heat shock protein 90 
IC50   Inhibitory Concentration 50% 
ICG   Indocyanine Green 
IgG   Immunoglobulin 
IL   Interleukin 
IMS   Industrial Methylated Spirits 
JNK   Jun N-terminal Kinase 
kDa   Kilo Daltons 
MAPK   Mitogen Activated Protein Kinase 
MDR   Multi-Drug Resistance 
MEM   Minimum Essential Medium 
MgCl2   Magnesium Chloride 
Mitox   Mitoxantrone 
MRP   Multidrug Resistance-associated Protein 
MMP   Metalloproteinase 
mRNA   Messenger RNA 
MW   Molecular Weight 
N/A   Not appliacble 
NaCl   Sodium Chloride 
NBF   Nucleotide binding folds 
NaHCO3  Sodium Bicarbonate 
NaOH   Sodium Hydroxide 
NF-Y   Nuclear factor Y (transcription factor) 
NSAID   Nonsteroidal anti-inflammatory drug 
NSCLC Non-small cell lung cancer 
OCD ornithine decarboxylase 
OD   Optical Density 
P450   Cytochrome P450 
PAGE   Polyacrylamide Gel Eletrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PG   Prostaglandin 
P-gp   P-glycoprotein 
P13K   Phosphatigylinositol 3-kinase  
PMSF   Phenylmethanesulphonyl Fluoride 
RNA   Ribonucleic Acid 
ROS   Reactive oxygen species 
RT-PCR  Reverse Transcriptase-PCR 
SD   Standard Deviation 
SDS   Sodium Dodecyl Sulphate 
siRNA   Small interfering RNA 
SP1   Member of the SP/KLF transcriptor factor family  
STAT   Signal transducers and activators of transcription protein 
TBS   Tris Buffered Saline 
TEMED  N, N, N’, N’-Tetramethyl-Ethylenediamine 
THF   Tetrahydrofuran 
TKI   Tyrosine kinase inhibitor 
TM   Transmembrane  
Tris   Tris(hydroxymethyl)aminomethane 
TXA   Thromboxanes 
UTR   Untranslated region 
UHP   Ultra high purity water 
VAP   Vincristine, doxorubicin, and dexamethasone combination 
Vp   Verapamil 
VEGF   Vascular endothelial growth factor 
PDGFR  Platelet-derived growth factor receptor 
PXR   Pregnance X receptor 
YB-1   Y box 1 
